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7Abstract
Use of medicines is the commonest intervention in healthcare.  Information about an
individual’s medication use over their lifetime, managed as a coherent whole but
presented appropriately for context, is central to providing good quality care.
Considerable investment continues to be made in specifying the information
structures underpinning electronic health systems to provide clinicians with patient
information to support care provision, yet medication errors continue to occur at
unacceptable rates.  At the same time, the quantity of healthcare information - which
includes medication information – is increasing, and there is growing interest in
“secondary uses” of this, particularly to support clinical research.   Unfortunately, for
both primary and secondary uses, the requirements for the data elements that are
needed for medication information are poorly specified, despite a variety of major
national and international initiatives and effort.  The process for population of those
data elements with high quality, consistent, trustworthy information that can be
presented to the use cases efficiently and clearly is even more poorly specified.
By gathering requirements from processes within clinical research alongside the
requirements from the processes of patient care, an integrated data element view of
a patient’s medication use over their lifetime has been described; this is termed the
patient’s Medication Profile. Examination of the care processes that provide the data
to populate that integrated view elicits the method and rules for the realisation of the
Medication Profile. These together are provided in a formally scoped fully specified
information model which defines the data elements of the Medication Profile (the
static model) and the processes and rules to instantiate it (the dynamic model).
The Medication Profile, populated with data based on the rules and processes of the
dynamic model, is evaluated against test scenarios to assess its success to support
use cases from both clinical care and clinical research.  This evaluation indicated
that the model provided both sufficiency of information coverage and clarity in the
information presented.
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Chapter 1: Introduction
This chapter presents the background and rationale for the thesis.  It provides an
initial overview of the situation with regard to information - and specifically electronic
health record information - about a patient’s medications, about the use of this
information for patient care and about the secondary uses of this information in
clinical research, and from this demonstrates why this work to formally define a
Medication Profile is necessary and valuable.  This leads into the description of the
Aims and Objectives of the thesis in Chapter 2.
Everyone uses medicines
In the provision of healthcare, the administration of one or more medicines is the
commonest intervention used in the care of patients; a prescribed medicine is the
most frequent treatment provided for patients in the United Kingdom’s National
Health Service1. In addition to medicines prescribed as treatment for or prophylaxis
of symptoms or conditions, almost all surgical interventions use medicines in the
process of managing the patient through the procedure, whether in anaesthesia, in
analgesia, and/or in prophylaxis or treatment of infection. Many diagnostic
investigations use medicines either as part of the investigative process, for example
contrast media used in imaging investigations and/or in the care of the patient during
the process, for example in sedation for endoscopic procedures. Almost every
member of the population has received at least one vaccination with a medicinal
product and most people have received courses of vaccines at various points in their
lifetime. Patients themselves are increasingly encouraged to take some
responsibility for their own health, which may include purchase and administration of
medicines without requiring prescription and in some cases without reference to the
advice of a healthcare professional. Almost everyone in the world has used a
medicine at some point in their life, and is likely to do so again in their future.
A cradle to grave record of medication information
In addition to the increasingly widespread use of medicines, the delivery patterns for
healthcare are also changing rapidly.  Patients are no longer cared for by one or two
primary care professionals who are familiar with all aspects of their care – including
their medication.  Care is now delivered in many different ways, through multi-
disciplinary care teams in different care settings, through out-of-hours facilities and
in situations without any direct contact such as telemedicine. Patients themselves
are mobile: travelling widely for business, pleasure, and maybe even migrating
considerable distances between locations with the seasons (the so called
‘snowbirds’). The information about the use of medicines by an individual (the basic
data of what, when, why, how much, for how long) is therefore likely to be recorded
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in a variety of disparate places throughout (possibly multiple) healthcare services.
This information is rarely if ever brought together into a comprehensive and cohesive
set of information about the medication of an individual a patient.
This truly complete and coherent set of medication information appears to be
somewhat challenging to compile and maintain.  Various initiatives have been
undertaken to date and are reviewed fully in a later chapter; these have concentrated
on various forms of recent (i.e. recently comprehensive) history, although without
defining such concepts formally and without a documented foundation in the
evidence on safety or quality of care. This limited view carries risk, since it is clear
it will miss a considerable amount, particularly about immunisation, the majority of
which occurs in the early years of life.  The ideal is to have information about the
lifetime use of medicines as a true longitudinal whole. In the UK, where every baby
has a vitamin K medicine administered within moments of their birth, clearly such a
record must cover the ‘cradle to the grave’.
Without this comprehensive and coherent medication record, it is hard for healthcare
professionals to provide high quality and safe ongoing care for a patient.  Without
the full picture, preventable adverse drug reactions become harder to avoid2, it is not
possible to ascertain whether drug interactions are likely, whether treatment side
effect profiles may be overlapping, or to judge the success or otherwise of a previous
exposure to a medicine or class of medicines.
The risks of continuing without this comprehensive and coherent medication record
are so great it is difficult to comprehend why the situation continues.  One concerning
estimate is that that around 150 deaths occurred as a result of medication errors in
England and Wales in the year of 20013, another is that errors in prescribing have
been estimated to cost £400million in the UK annually; this is equivalent to the cost
of running four district general hospitals4. The FDA state that medication errors
cause at least one death every day and injure approximately 1.3million people
annually in the United States5, at an estimated cost of at least $3.5billion6. Every
year nearly 10,000 people are reported to have experienced serious adverse
reactions to drugs in the NHS7.  Yet the behaviour of the medicines themselves is
largely predictable, so many adverse reactions could be avoided or minimised by
healthcare professionals having access to good information about both the medicine
and the context of its use in the individual patient.  This context includes the patient’s
medication history, and particularly, the medicines they are currently using and the
justification for those8.  However unfortunately, it has been estimated that
medications are accurately recorded for as few as 5.3% of patients9.
21
Requirements from patient care and electronic
health records
There has been and continues to be much local, national and international emphasis
on designing, building, populating and maintaining electronic health records (EHRs)
for patients, to improve the quality of the care that they receive.
National initiatives include:
 the NHS in England, through the National Programme for Information
Technology (NPfIT) and its successors, Connecting for Health (CfH)10 and the
Health and Social Care Information Centre11
 in the USA, through Healthcare Information Technology Standards Panel
(HITSP)12 and the ‘Meaningful Use’ initiative for electronic health records
which flows from the American Reinvestment & Recovery Act (ARRA)13
 in Australia, through the National eHealth Transition Authority (NeHTA)14
 in the Netherlands, through NICTIZ (Nationaal ICT Instituut in de Zorg)15
 in Singapore, through the Ministry of Health and Holdings (MOHH16) and
 in European Commission initiatives such as epSOS (European Patients Smart
Open Services)17
All of these initiatives have within them a focus on the prescribing and/or recording
of medication information, highlighting the central importance of medication
information in the development of eHealth services and acknowledging its centrality
to the delivery of safe, high quality and cost-efficient patient care.
Within these initiatives, the concepts of ‘medication history’, ‘past medication’ and
‘current medication’ are often used but rarely if ever defined, either informally or
formally as information concepts. For example, the Integrated Care Records Service
Output-Based Specification from NHS England18 has a concept of a ‘Patient
Medication Profile’ to which information may be added by the patient, the patient’s
practitioner, or through uploads from pharmacy fulfilment files (dispensing records)
[311.17.1].  This profile may be edited (additions, changes and deletions) and
reviewed by authorised users [311.17.7-9].  From this profile, an application is
required to create a ‘dynamic list of medications (current and past) for the patient,
which may be filtered, sorted and grouped by the user’ [311.17.6].  So although this
specification has a clear requirement for the concepts of ‘current and past medication
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information’ to be available for a user, there is no definition of exactly what these
concepts are, or where or how to find or generate them.
The ASTM Standard Specification for Continuity of Care Record (CCR)19 is a little
better in its descriptions.  It is one of the most detailed specifications of its type,
describing itself as a patient health summary standard.  It has been developed by a
significant range of stakeholders in the domain, based in the US.  It claims to be a
‘core data set of the most relevant administrative, demographic, and clinical
information facts about a patient’s healthcare, covering one or more healthcare
encounters’ [page 8].  This aims to provide the means by which one healthcare
practitioner, system, or setting can aggregate together all of the pertinent data about
a patient and share it with another practitioner, system, or setting, to support the
ongoing care of that patient.  Its data set includes a summary of the patient’s health
status (for example, problems, medications, and allergies), some information about
their insurance plan(s), and any care plan(s). It contains a significant amount of detail
about medications, most particularly in its section 5.1.2.9, which deals with a
patient’s current medications and pertinent medication history.  This section states
that: ‘at a minimum, the currently active medications should be listed, with an entire
medication history as an option, particularly when the CCR is used for
comprehensive data export’; however, no definition or even description is given for
what ‘currently active medications’ actually consist of.
The terms ‘current medication’ and ‘past medication history’ have for many years
been regularly used in the common parlance of clinical practice, for example in
admission and referral correspondence, where ‘current medication’ is listed, along
with ‘previous medication (history)’ in order to provide some relevant information
about the patient’s current and possibly previous treatments. These two concepts,
the latter being described as ‘relevant previous medications’ are the two sub-
headings in the Medication record section of the Royal College of Physicians
approved Hospital admission record: headings and definitions20.  However, in the
formal literature search supporting this thesis, it was confirmed that these concepts
have had very little formal investigation or definition.  Clearly, pragmatic definitions
do exist in order that various aspects of clinical applications can function at all, in
particular for medication decision support. For example, one national general
practice computer system defines current medication as ‘all currently authorised
repeat prescriptions and any acute prescriptions generated in the last six months’21.
In an era of evidence based practice and with health informatics being a formal
discipline both academically and professionally, a lack of formal definition for such
critical concepts should not continue.
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In addition, either as part of the development and implementation of EHR
applications or as standalone systems, the use of information technology to support
the medication process (prescribing, dispensing and administration) in all sectors of
care is growing, with the aim of  improving the quality (safety, efficacy and value for
money) of medicines use1.    The increasing use of decision support is very welcome.
However, without access to the relevant supporting clinical information about the
patient, and in particular the comprehensive and cohesive information about the
medication the patient is already using, has used in the past, and which they may
have access to in the foreseeable future, the decision support that is integral to
support a safer medication process22 cannot function to its full potential23. The
availability of that comprehensive and cohesive information in a clear, robust,
standardised and useable format is therefore critical to this quality improvement for
medication use in patient care, yet the definition of what this actually consists of
remains unclear and without that clarity it cannot be provided.
Requirements for secondary uses – clinical research
In recent years, there has been a growing interest in exploiting the rich source of
data that EHR systems could provide for so-called secondary uses: clinical research,
public health, epidemiology and health service management; if and when suitable
privacy and ethical considerations are fully respected.  This naturally includes
medication information, as well as information about diagnoses, procedures and
investigations.  This interest is currently expressing itself in a large number of
projects that are developing models and policies to effectively utilise this longitudinal
data from cohorts of patients.  The following are examples of these projects; each
has a multi-million dollar/euro budget and multi-year time-span.
 EHR4CR (focus on using EHRs to support four scenarios  that are current
bottlenecks in clinical research)24
 TRANSFoRm (focus on translating knowledge from research into clinical
practice, and data from clinical practice into formal studies – particularly in
primary care)25
 OMOP (focus on using EHR data to detect and monitor safety risks for existing
medicinal products)26
 EURECA (focus on re-use of EHR data in clinical trials)27
 SALUS (focus on using EHR in pharmacovigilance)28
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The proliferation of these projects intimate that there are substantial challenges to
be overcome in order to extract the value from this data for clinical research, public
health or service management most effectively.   These challenges include the
incompatibility of the standards used in healthcare and in research, particularly in
terms of their purpose and therefore their models, and the patchy implementation of
these standards. It is clear that there urgently needs to be a formally documented
evidence-based set of information requirements, and particularly the medication data
elements, that should be available to clinical research from EHRs.
Clinical research, as opposed to the broader term of medical research, is defined as
‘studies for the formal assessment of the utility, impact, or other pharmacological,
physiological, or psychological effects of a medicinal product, procedure, process,
or device on a human, plus all associated regulatory artefacts required for or derived
from this effort, including data specifically associated with post-marketing adverse
event reporting’.  This definition is derived from the definition of the domain of the
BRIDG model29 and used in particular because it references the artefacts of clinical
research, such as protocols and the eligibility criteria they contain, and it explicitly
references post-marketing adverse event reporting, which is a large part of the
process of pharmacovigilance.  Within clinical research, currently used standards
focus on the syntactic structuring or formatting of study data in its collection
(CDASH30), presentation for submission (SDTM31) and presentation for analysis
(ADaM32).  These standards are not semantic standards whose aim would be to
ensure the preservation of meaning of the data across time and space such that it
can be exploited to support multiple use cases.
Clinical research is more than the management of study data.  There are processes
that occur before a study can be conducted that are concerned with developing the
study protocol and recruiting subjects into studies, and processes that must continue
after formal studies have concluded, to continue to monitor the safety of the
medication.  There are several specific processes where information about the
administration of medicinal products to individual patients or to cohorts of patients is
of value.  These include in the authoring of a Clinical Development Plan (CDP), in
the patient recruitment process (both for protocol feasibility testing and in the actual
recruitment of individual sites and subjects), in the gathering of clinical information
for a subject throughout a study (the so-called clinical report form (CRF) process),
and in safety assessment – the pharmacovigilance process.  Two of these processes
(the study feasibility/patient recruitment process and the pharmacovigilance
process) are examined in detail in this thesis to ascertain the requirements they place
on the information held in a patient’s Medication Profile.  These two processes have
been selected as there is evidence that there are issues within these that better
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medication information would help to solve, and very pragmatically because the raw
material for the examination is available, either through personal contact (from the
EHR4CR project24, see below) or in the public domain.  Examination of other
processes would be equally valuable, but currently out of scope for this thesis due
to resources both of time and availability of materials: formal CDPs are relatively new
constructs33 and as such a representative set is not available for study; CRFs are
proprietary both to each study and to each organisation that conducts the study.
However, relating to this latter, a specification for data elements used in the
submission of raw clinical trial data, the Study Data Tabulation Model (SDTM)31,
does exist and its content has been included in the pharmacovigilance work, as
explained in that part.
Various strategies are being adopted in order to minimise study delays and ever-
increasing costs due to problems with patient recruitment, and there are various
development projects underway including several of those mentioned above that are
investigating the use of EHR data in clinical research, and particularly in protocol
feasibility studies and patient recruitment support.  These developments involve the
use of clinical data warehouses or registries against which queries derived from
study eligibility criteria are run.  As presented in Chapter 5 (1), a review of eligibility
criteria showed that a significant proportion include medication information and
therefore the importance of this type of data being available to query.
At the opposite end of the clinical research spectrum is pharmacovigilance, the
ongoing process to evaluation the safety of medicines. Pharmacovigilance is a multi-
stranded process and the various strands are reflected in the World Health
Organisation’s definition of pharmacovigilance as: ‘The science and activities
relating to the detection, assessment, understanding and prevention of adverse
effects or any other drug-related problem’34 [page 1].  Detection in this context
includes the gathering of adverse event information, including events that occur
within clinical trials (which may be in the pre-or post-marketing authorisation periods)
or by spontaneous reporting by patients, carers or clinicians in the post marketing
authorisation period, or by active surveillance of health records.  The assessment of
information gathered to gain the requisite understanding of adverse drug events is
complex; finding that a medicinal product is responsible for a particular adverse
event has been likened to finding a needle in a haystack35.  The process usually
involves significant analysis of vast amounts of data, both from the adverse events
themselves and comparison with one or more background datasets which are
sometimes taken directly from general healthcare and sometimes from a larger
adverse event database, as adverse events must be differentiated from normal
clinical events. Having gained an understanding of a medication adverse event, this
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understanding should be translated into prevention of (further) adverse events by a
set of actions, which may include altering recommended dosage regimens, adding
contra-indications, special precautions or warnings for use or, in severe cases, by
withdrawing the medicine from use.
The concept of pharmacovigilance and the management of medication adverse
events has recently been broadened to include adverse events that are not related
to the pharmacology or pharmaceutics of the medicinal product but which are caused
by external factors related to the medicinal product, such as issues with the
packaging or labelling of the product.  An example of this is the case where an
adverse event occurs due to incorrect dose quantity being administered; on analysis
it might be found that the description of the strength of the medicine on the packaging
lacks the necessary clarity36.
Adverse drug reactions have an enormous economic cost, in terms of the direct costs
to the healthcare system of treating the adverse events, in the loss of revenues
if/when a medicinal product must be prematurely withdrawn from the market and in
terms of any litigation arising from inadequate safety information for the sponsoring
pharmaceutical company. One large UK-based observational study from 2004 found
an adverse drug reaction prevalence of 6.5% with a projected cost to the health
services of managing these reactions being £466m37.  This same study points out
that much of the research in this area of setting a rate for adverse drug events is
over 20 years' old, and expresses the authors' disappointment that their findings
show that the prevalence has not decreased with time and understanding. There
have been many other studies and systematic reviews of studies into the prevalence
of adverse drug reactions; one of the most recent of these reviews found an overall
average of approximately 5.3% of hospital admissions were associated with adverse
drug reactions, with lower rates for children and higher rates for elderly patients38.
In terms of lost revenues and litigation costs, when rofecoxib (Vioxx, Merck) was
withdrawn in 2004, its loss was expected to reduce the company's profit by around
20%39 and one observer estimated legal costs to be between $12 billion and $38
billion40.  When Bayer withdrew celecoxin (Baycol, Lipobay), one report suggested
losses of between €600m and €650m41. There are also the less tangible but none
the less real costs of loss of confidence in the company and in the sector that follow
such a withdrawal.  Therefore managing the safety of medicinal products through
pharmacovigilance is extremely important, both for the health of individuals and
populations, and for the economic health of the pharmaceutical industry.
The backbone of pharmacovigilance remains the collection of data about adverse
events as they are suspected of occurring.  Various forms for clinicians and the
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general public to use to report suspected adverse events have been authored by the
agencies responsible to governments for the safety of medicinal products, and these
can be taken as providing a set of requirements for the actual data elements deemed
to be of use in pharmacovigilance.  Currently, this data must be gathered together
and provided to the form by the reporter, but in the future, if the enabling technology
and security/permissions were in place, it could be obtained directly by interrogation
of the relevant electronic health record, particularly for the medication information.  It
is imperative therefore, that the medication information that is available from EHRs
and their medication records supports the data elements that pharmacovigilance
requires, ensuring the ongoing safe use of medicines.
A high quality comprehensive and cohesive
Medication Profile
It is clear that high quality comprehensive and cohesive medication information is a
vital component of electronic health records, for use in the provision of care to
individuals and also for secondary use of that information in clinical research to
promote better and safer medication development for the future.  It is also clear that
there is no evidence based formal definition of what that high quality comprehensive
and cohesive medication information should explicitly be, what it should contain and
how it should be maintained. Humans have an innate ability to perceive and
understand within their framework of culture and experience that computers cannot
have.  However, this ability is itself shaped by our own individual representation or
mental map of our world (called ‘schema’ in psychology) which varies due to both
internal and external factors. So to use of concepts such as ‘current medication’ or
‘previous medication (history)’ that are essentially formally undefined and therefore
open to interpretation, even amongst humans with similar professional training, is of
concern. Of yet greater concern is that computers cannot ‘intuit, they cannot make
assumptions and act on these. Even the most sophisticated reasonersa running on
ontologic structures can only provide logical extensions to their existing knowledge,
which must be represented in quite sophisticated patterns in order to for the reasoner
to perform. The healthcare environment, both human and machine, cannot continue
to make guesses as to what is or what is not within a patient’s medication record,
and therefore how that content should be managed.  It must be systematically
reviewed from many perspectives in order to provide as comprehensive a picture as
possible, which is then formally defined and described.
a A “reasoner” is a piece of software that is able to infer logical consequences from
a set of asserted facts or axioms, as presented to it by an ontology
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This thesis will demonstrate that, by investigating and gathering requirements from
the process of clinical research alongside the requirements from the process of
patient care and blending these requirements together, an integrated view of how a
patient’s medication should be recorded in healthcare systems, from beginning to
end, can be produced. This formal definition of the gold standard comprehensive
cradle to grave Medication Profile, if and when it would be implemented within
systems, provides the solid foundation from which to conduct the safe and high
quality performance of the processes of patient care and clinical research. Clinicians
and the decision support systems that assist them would have the full set of
information they need to optimally manage the medication process for each patient,
and in particular to prevent those errors that continue to occur in patient care due to
the lack of this information. Clinical research would have the full set of information
it needs to optimally test protocols and select patients for study recruitment, and to
monitor the ongoing safety profile of medications in use through pharmacovigilance.
Having such a gold standard Medication Profile would also avoid the costly re-
specification that continues to be seen in the national and international e-health
initiatives and allow resources to be channelled to improving the actual
implementation, so that the benefits of this high quality comprehensive and cohesive
Medication Profile can be realised.
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Chapter 2: Aims and Objectives
Overall Aim
The aim of the thesis is to develop a formal specification for a patient’s
comprehensive and cohesive Medication Profile that, when implemented, can meet
the evidence based requirements placed upon it to support high quality care for that
patient, whilst also providing information to support valuable secondary use cases in
clinical research for the wider community.
Objectives
In order to achieve this aim, the following objectives were set:
 To specify the information (data elements) needed for the Medication Profile
to function effectively to support the use cases, alongside the evidence for
their validity, and processes for the population of those data elements
o for the provision of safe high quality care to the individual patient
 through record keeping
 through the various processes that are undertaken in medication use,
and the decision support that assists these processes
o for secondary uses in clinical research
 for protocol feasibility testing and patient recruitment
 for pharmacovigilance
 To investigate, define and validate the scope or boundary of the Medication
Profile
 To collate the gathered requirements into a cohesive set that transcends the
limitations of individual healthcare cultures and practices
 To formally define the gathered data element requirements and their
management through space and time using informatics best practice, to
produce an information model with both static and dynamic and rules-based
components, and therefore to give a complete formal domain information
model of the Medication Profile
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o Because of the fundamental nature of the medication concepts being
examined, this definitional work should provide value even in contexts
where there are not electronic medication information systems to
implement them
 To undertake an evaluation of the formal domain information model defined
above by developing some test scenarios which reflect the instantiation of
various aspects of the model (using the dynamic processes to populate the
static elements) to be submitted to a range of reviewers for evaluation and to
provide a report of the consolidated response to that evaluation
In addition to the objectives outlined above, this work aims to meld together the
academic discipline of a thesis, with literature review and investigation and analysis,
with the practical and formal discipline of the informatics/systems development
process.  This includes using informatics methods such as static and dynamic
information models described using the Unified Modelling Language (UML2)
standard42 from the Object Management Group, and a formal description of rules-
based information management processes, in such a way as to produce something
that is truly evidence-based but practically implementable in the development of the
healthcare systems of tomorrow.
The objectives focus on gathering requirements from two specific areas, but in doing
so this by definition excludes others.  Two areas that, like clinical research, are
secondary users of medication information and from which requirements could have
been gathered if time were unlimited are pharmacoepidemiology and
pharmacoeconomics.  These disciplines rely heavily on pooled data from
populations and in that sense will have similar requirements to those from protocol
feasibility testing in clinical research.
Thesis Structure
 Introduction: setting the context for the research
 Aims, Objectives, Structure
 Literature Review: formally investigating, documenting and discussing what
is already known in the domain for the definition and maintenance of a
Medication Profile
 General Methodology: description of the overarching method of research.
Note that supplementary method details and supplementary relevant literature
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are provided within each of the Requirement chapters, so that the context of
each requirements area is coherently presented
 Requirements from Patient Care: investigation, description and discussion
of the requirements for Medication Profile information for the provision of high
quality patient care:
o Patient Care Record specifications
o Safe Medication Processes and Decision Support
 Requirements from Clinical Research: investigation, description and
discussion of the requirements for Medication Profile information from the
clinical research process:
o Patient Recruitment and Protocol Feasibility Testing
o Pharmacovigilance
 Consolidated Results Summary: Presentation of the consolidated results of
the investigations, which form the formal requirements for the Medication
Profile model
 Scoping the Boundary of the Medication Profile: investigation, description
and discussion of the various types of products whose use the Medication
Profile should encompass
 The Medication Profile Model: presentation of the formal domain information
model (static and dynamic – data elements and business processes) that
form, populate and maintain the Medication Profile to meet the requirements
from patient care and clinical research
 Evaluation of the Medication Profile Model: investigation, description and
themed discussion of an evaluation of the Medication Profile model by a range
of users, based on a set of test scenarios
 Overall Discussion of the Research: a review and critique of the findings of
the research in terms of the fulfilment or otherwise of the aims and objectives,
and including Recommendations for future work and further research
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Figure 1: Diagrammatic Representation of Thesis Structure
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General Methodology
The literature review confirmed that although the concept of a ‘Medication Profile’ is
used widely, there is little if any formal definition of this is and what this should
contain.  This deficit exists in terms of the types of products whose usage information
should be included, in the data elements describing the use of those products by the
patient, and in how that data element information should be managed over time using
the medication process and the activities that it contains.  This latter is particularly
given that use of medications is often a long-term activity.  The objectives below
therefore aim to address this deficit.
Objective 1: Investigate and document the requirements
The first objective of the thesis was to investigate and document the specific
information required for the Medication Profile to function effectively to support the
use cases, alongside the evidence for their validity.  Requirements gathering is a
formal process which is part of business analysis and which seeks to document what
is needed for a system to function in a safe and useful way.  There are a variety of
requirements gathering and requirements validation techniques that can be
employed, including workshops, prototyping (user centred design), questionnaires,
process observation etc.  However, all of these produce opinion-based or context-
based requirements, not least because their primary aim is usually to produce a
system that the users accept and will want to use.  But, when designing a system
whose primary function is to store and manage data and to then provide that data in
meaningful display to users or to another system in response to specific queries,
opinion as to what that data should be or how it should be managed is not enough.
One of the best known hierarchies of evidence is that produced, and most recently
revised in 2009, by the Centre for Evidence-Based Medicine43 is the ‘Levels of
Evidence’; this states that ‘expert opinion without critical appraisal’ is the lowest (of
5) levels of evidence.  Therefore, a more robust requirements gathering exercise
than the usual user/opinion focussed business analysis must be undertaken.  The
search for and gathering of the requirements of a Medication Profile to serve both
patient care and clinical research was conducted by:
1. Examining a set of specifications from national and international health record
and summary care record development projects and programmes for their
requirements for medication related information.  By examining a set of
specifications and amalgamating the results, the vagaries of cultural practice
and individual expert opinion are reduced, giving a set of generic requirements
to support patient care
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2. Examining the various medication focused processes that occur in the
provision of healthcare to patients, and the medication information
requirements for systems that provide decision support to these processes to
ensure their quality and safety.  Unfortunately, much of the detailed
information for such processes is commercially confidential; however the
author is able to leverage many years’ experience of working in this area, both
nationally and internationally, to document these requirements
3. Examining a set of eligibility criteria from a range of protocols for recently
undertaken clinical studies for their requirements for medication related
information.  By examining a set of criteria and amalgamating their results, an
overall view of the requirements for the types and patterns of medication
information is produced that would be applicable for all clinical trials, and
which, if the information in patients’ Medication Profiles were available to
match those patterns, would be specifically useful to support patient
recruitment and protocol feasibility testing
4. Examining a set of pharmacovigilance reporting forms from a number of
national medicines regulatory agencies for their requirements for medication
related information to support suspected adverse reaction reports.  Again by
examining a set of forms, the vagaries of different cultures are reduced to give
a generic set of requirements which need to be captured, and therefore which
should be available from individual patient’s Medication Profiles
Objective 2: Define the scope of the Medication Profile
The second objective of the thesis was to investigate and document the scope of the
Medication Profile, to set a boundary around the types of things that a Medication
Profile system should contain.  Although medicinal products are tightly defined based
on regulation, there are types of products that could be considered as on the margins
of this; for example, the few types of products that in the past have been categorised
as medicinal products but which now are managed as medical devices.  Having
clarity with regard to whether information about the use of the types of borderline
products is included in the Medication Profile is important in order to fulfil the overall
aim of producing a robust information model of the domain.   This product boundary
is defined by:
 examining each of the different types of medicinal products and each of the
borderline product types
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 documenting these, with supporting regulatory definitions from international
standards where available
 documenting the roles such products play in the medication process and how
and where they play them
From this, each product type can be ruled within the scope of the domain covered
by the Medication Profile, or out of that scope.
Objective 3: Collate the requirements superset
Having undertaken the requirements gathering from the individual areas under
study, these are collated together to produce a cohesive superset of requirements
that transcends the limitations of individual healthcare cultures and practices and
transcends the individual areas of practice. This superset is then subjected to a
weighting exercise to give a relative sense of overall priority and importance of the
individual requirements within the overall.   This provides the summarised
requirements to go forward into the modelling process.
Objective 4: Develop a Domain Information Model for the
Medication Profile
The objective of the modelling process is to formally define the data elements from
the requirements gathering process described above and to define a management
process for these to robustly maintain their value to the use cases through space
and time.  This was undertaken using informatics best practice, to produce a domain
information model for the Medication Profile system consisting of
 static models – using classes, attributes and relationships to describe the data
elements of the domain
 dynamic models – describing the business processes that occur in the domain
and the different patterns of how these processes can relate together
 rules-based components – describing the logic of how to populate the static
models using information as it is generated by the different business
processes that occur
Objective 5: Evaluate the Domain Information Model using
test cases
The final objective was to evaluate the outworking of the formal domain
information model by applying it to produce some test scenarios.  This was
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undertaken by creating storyboards for some imaginary individual patients and
clinicians who are involved in a set of scenarios that reflect the original use cases
of providing safe patient care using medication and in supporting clinical
research and pharmacovigilance.  These evaluation scenarios contain exemplar
displays of relevant sections of the patient’s Medication Profile, populated with
data from the processes described in the storyboards, which reflect the data
elements and processes in the Model, and with the data managed using the
rules described in the Model.  A set of questions accompanied each scenario,
inviting reviewers to evaluate whether the information presented in the sections
of Medication Profile was accurate given the storyboard and acceptable to fulfil
the use case as described in the scenario.  The set of scenarios were then
distributed, with a covering letter, to a range of reviewers from those healthcare
professions most intimately involved with the medication process (doctors,
nurses and pharmacists) working in both patient care and clinical research, and
to a range of health informatics professionals with medication management
experience, who may or may not have originally been healthcare professionals.
An opportunity to provide general comments on the scenarios was also provided.
The responses and comments from the evaluations were collated together and
the general themes identified.  These were then examined for their validation or
otherwise of the model of the Medication Profile.
Biographic details of the author
In addition to the writing of this thesis, the author has extensive experience in the
field of health informatics and particularly in medication information.  This
experience, which is particularly relevant to the information present in the second
part of chapter 5, where little information is present in the public domain, includes:
 10 years working in the Knowledgebase Services department of First
DataBank44, a leading provider of medicines decision support systems (data
and algorithms), culminating in leading the department
 15 years working as a consultant in informatics including
 a 5 year project with the British National Formulary45 to transform their paper
publication into a knowledgebase for active decision support
 a 3 year (ongoing) project with the Irish Pharmacy Union46, working as a
consultant for the redevelopment of the Product File to support Irish
healthcare processes, and redevelopment of the decision support provided
with the Product File
 a 4 year project to develop the international standard for identification of
medicinal products for the national and international regulatory agencies
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These roles included responsibility for the following:
 The editorial policies that governed the data collection and/or data
management
 The structures within the information model, terminology model or
knowledgebase that hold the data to allow it to be used most effectively
in processes and algorithms
 The logic that governs the processing and/or algorithms that use the data
and provide further information
 The implementation guidance for deployment of the systems within
clinical care and/or clinical research
 The testing of implementations to ensure their correct functioning
In addition, the author has spent 20 years working in international standards bodies
to develop standards and specifications for medicines and medicines related
processes.  These bodies are:
 Health Level 7 (HL7)47,
 ISO TC 21548 (specifically WG6 Pharmacy and Medicines and WG2
Systems and Device Interoperability)
 IHE – Integrating the Healthcare Enterprise – Pharmacy domain49
In working to develop the standards and specifications in the organisations above,
various skills and expertise are needed, including understanding of how the different
healthcare cultures (legal, ethical, regulatory and practical aspects) of different
nations affect the
 medication processes that need to be supported
 business architectures that the processes and systems need to work
within
 data structures that must be populated and shared
 communications that need to flow
Having gained that understanding, standards and specifications are developed that
define and describe the same things in the same way whilst respecting and
supporting the national and regional differences as appropriate.
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Chapter 3: Literature Review
Introduction and initial investigation
As a precursor and in preparation to undertaking a comprehensive literature review,
an initial investigation into the use and understanding of the term ‘medication profile’
as used in the literature was undertaken.  This initial keyword search found that the
term was used extensively, often in very clinically focussed studies of a disease area,
to generically describe ‘information about a patient’s medication use’50,51,52,53. Rarely
was any formal definition of what the term actually meant given either explicitly or
implicitly, confirming the need for the research and informing the full search strategy.
The detail of this initial investigation is described in Appendix 1.
Methodology and search strategy
Scope of the search
The search strategy used the two most appropriate citation databases for this
domain: MEDLINE54 and EMBASE55 (the latter having a slant towards drug therapy,
research and pharmacovigilance)56, using the OVID tooling.  EMBASE covers
approximately 2700 journals that are not within scope of MEDLINE, but are likely to
have information about a ‘Medication Profile’, as can be seen from the significant
differences in search returns for the two databases given below.
Specialist citation databases such as PsychINFO57, concentrating on psychology
and the behavioural and social sciences, and CINAHL58 (Cumulative Index to
Nursing and Allied Health Literature) were not used.  These have a precise focus on
their particular areas of practice and therefore it is not expected that they will cover
medication summary information topics, and it is unlikely that data element definition
and requirements for management of data elements for medication would be within
their remit. Whilst it is possible that there might be description of medication
information requirements that are specific to these specialist areas that would not be
present in the more general clinical literature, the probability of this based on the
evidence from the general searches was deemed to be too small for the effort that
would have been required and the time resource available. Regional citation
databases such as IndMED59 and LILACS60 were not searched due to
resource/access constraint and English language focus for this work.
The searches, which were revised and updated in January 2016, covered all In-
Process and Other Non-Indexed Citations from 1946 to January 2016, with no other
search filters applied.
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Search terms
A thesaurus of search terms was developed, focused on the terms used to describe
medication information for a patient as found to be associated with describing a
‘medication profile’ in the initial literature review and using the search term matching
in the search databases.
Keyword search terms
This thesis uses the term ‘medication’ consistently and exclusively, because it
closely links to the formally defined regulatory concept of ‘medicinal product’ with its
therapeutic intent.  It avoids the negative connotations that can be associated with
the term ‘drug’ (as in misuse of substances for so called recreational purposes).
However, the keyword search used both ‘medication’ and ‘drug’; this is because
unfortunately there is no single term applied consistently in the literature, as the
search results confirm.  When combined with the qualifiers of ‘past’ and ‘current’, the
terms ‘drug’ and ‘medication’ appear to have been used in indexing synonymously
as the number of hits for each was identical, as was an ‘and’ search for the
combination of these terms.
Table 1: Keyword search terms
Medication profile Drug profile
Medication record Drug record
Medication history Drug history
Medication histories Drug histories
Current medication Current drugs
Past medication Past drugs
Controlled Vocabulary Tree search terms - MEDLINE
Although nominating the most appropriate index terms should maximise the
likelihood of retrieving relevant publications, the accuracy of the search, for example
in MEDLINE, critically depends upon how those terms are semantically indexed and
organised within the database itself.  MEDLINE uses the Medical Subject Heading
(MeSH)61 system to produce its controlled vocabulary for assisted searching.  The
terms described above were entered and the maps offered by the search engine
were evaluated.  A significant number of the search maps offered were not well
related to or just too general for the topic (e.g. the keyword map for ‘medication
profile’ includes the controlled terms of ‘aged’, ‘middle aged’ and ‘computers’).
Others were condition specific and therefore unhelpful (e.g. the keyword map for
‘current medication’ gives the controlled terms of ‘aged’, ‘middle aged’,
‘adult’, ’asthma’, ‘migraine disorders’, ‘endocarditis bacterial’, ‘heart defects,
congenital’, ‘antipsychotic agents’, ‘angiotensin-converting enzyme inhibitors’ and
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‘hypoglycaemic agents’).   The selection of MeSH terms for searching was therefore
informed by those mapped terms that appeared helpful (such as ‘Drug Prescription’,
mapped to ‘medication profile’) and was augmented by studying the MeSH hierarchy
and scope statements directly to find any additional concepts of relevance.  For
example, although ‘Drug Prescription’ was a mapped search term as discussed
above, its scope statement: ‘The use of DRUGS to treat a DISEASE or its symptoms.
One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER’ is too
broad to be useful to the objectives of the literature search focussing on the
perception and definition of a Medication Profile.  Similarly, although the term
‘Medical Records Systems, Computerized’ and its accompanying scope statement
of ‘Computer-based systems for input, storage, display, retrieval, and printing of
information contained in a patient's medical record’ is in some senses appropriate,
the term is too broad to be useful; the focus needs to be specifically on the
‘medication’ part of a patient’s overall health record.   Unfortunately, the scope for
the narrower term ‘Clinical Pharmacy Information Systems’ covers ‘Information
systems, usually computer-assisted, designed to store, manipulate, and retrieve
information for planning, organizing, directing, and controlling administrative
activities associated with the provision and utilization of clinical pharmacy services’
and clearly focuses on organisational activities for service provision and use rather
than the clinical information needed to provide those services, which would include
the patient’s Medication Profile.
The term ‘Medicine’ was also investigated in the MeSH controlled vocabulary.  The
scope statement for the term is ‘The art and science of studying, performing research
on, preventing, diagnosing, and treating disease, as well as the maintenance of
health’.  This statement includes a note, which adds ‘medicine only as a field,
profession or discipline: differentiate from DELIVERY OF HEALTH CARE where the
patient is emphasized; very general; it is divided broadly into experimental medicine
( = BIOMEDICAL RESEARCH) & CLINICAL MEDICINE, a specialty devoted to the
diagnosis & management of human patients; / legislation & jurisprudence =
LEGISLATION, MEDICAL or JURISPRUDENCE or FORENSIC MEDICINE; LEGAL
MEDICINE see FORENSIC MEDICINE is also available’.  The children of the term,
of which there are many, realise that scope statement in that they are all types of
specialities within the discipline of medicinal practice such as ‘Disaster Medicine’,
‘Preventative Medicine’, ‘Internal Medicine’, ‘Military Medicine’, ‘Sports Medicine’
‘Reproductive Medicine’, ‘Tropical Medicine’ and ‘Traditional Medicine’.  There is no
sense that the controlled term has any association with ‘medicine’ as a product used
for therapeutic effect.  There were, however, two intriguing terms as children of the
parent term ‘Medicine’ that merited some further investigation: ‘Herbal Medicine’ and
‘Medicine chest’.  The scope statement for the former is ‘The study of medicines
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derived from botanical sources’ and as such relates to the disciplines of
pharmacology and pharmacognosy rather than health informatics.  The scope
statement for the latter is ‘Boxes in which physicians kept their drugs and other
medications, medical instruments and supplies, manuals, etc. As a carrying case or
convenient storage receptacle, or a kind of portable pharmacy, the medicine chest
was indispensable to the itinerant physician. The chest was usually larger and
sturdier than a doctor's kit or bag. NOTE: do not confuse with the modern medicine
cabinet: may be used for doctor's bags’; so it is clear that this child search term is
describing a storage entity for medicinal products and instruments/supplies rather
than a health informatics topic concerned with recording information about the
administration of medicinal products to patients, although quite how that manages to
be a child concept (i.e. a specialisation) of the parent ‘Medicine’ concept is unclear.
The terms that after definitional review were selected for the controlled vocabulary
search are shown diagrammatically in their relative position in the MeSH hierarchy,
in two separate drawings (Figures 2 and 3), one from each of the two top level
concepts that are the parents for all the search terms; the terms selected for use in
the search are shown in bold type.  Terms that were considered but not included as
search terms are shown in italics.  The table that follows provides the formal MeSH
definitions of the terms selected for the search term thesaurus.
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Therapeutics
Analytical, Diagnostic and Therapeutic Techniques and Equipment
Drug Therapy
Inappropriate Prescribing
Medication Errors
Medication Reconciliation
Near Miss, Healthcare
Polypharmacy
Deprescription
Self Medication
Investigative Techniques
Epidemiologic Methods
Data Collection
Records as Topic
Medical Records
Medical Records Systems, Computerized
Electronic Health Records
Diagnosis
Diagnostic Techniques and Procedures
Medical History Taking
Drug Prescriptions
Figure 2: MeSH Term Tree from the parent concept Analytical, Diagnostic and
Therapeutic Techniques and Equipment
44
Health Services Administration
Health Care
Organization and Administration
Patient Care Management
Medication Systems
Medication Reconciliation
Medication Systems, Hospital
Pharmacy Administration
Drug Utilization
Drug Utilization Review
Medication Reconciliation
Medication Therapy Management
Quality of Health Care
Quality Assurance, Health Care
Potentially Inappropriate Medication List
Utilization Review
Concurrent Review
Drug Utilization Review
Health Services Facilities, Manpower and Services
Health Services
Pharmaceutical Services
Preventative Health Services
Drug Information Systems
Clinical Pharmacy Information Systems
Prescriptions
Electronic Prescribing
Health Education
Health Literacy
Patient Medication Knowledge
Community Health Services
Community Pharmacy Services
Health Facilities
Health Facility Administration
Hospital Administration
Hospital Departments
Pharmacy Service, Hospital
Figure 3: MeSH Term Tree from the parent concept Healthcare
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Table 2: MeSH controlled vocabulary search terms and their scope statements
MeSH Term MeSH Scope Statement
Inappropriate Prescribing The practice of administering medications in a manner that poses more risk than benefit, particularly where safer alternatives
exist
Medication Errors Errors in prescribing, dispensing, or administering medication with the result that the patient fails to receive the correct drug or
the indicated proper drug dosage
Medication Reconciliation The formal process of obtaining a complete and accurate list of each patient's current home medications including name,
dosage, frequency, and route of administration, and comparing admission, transfer, and/or discharge medication orders to that
list. The reconciliation is done to avoid medication errors
Deprescription Directions written to discontinue use of PRESCRIPTION DRUGS in order to reduce unnecessary and/or excessive medications
(see POLYPHARMACY), DRUG SIDE EFFECTS and ADVERSE DRUG REACTION
Drug Utilization The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes
drug stockpiling, and patient drug profiles
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Table 2 (cont.): MeSH controlled vocabulary search terms and their scope statements
MeSH Term MeSH Scope Statement
Drug Utilization Review Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical
appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be
done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug
utilization review is mandated for Medicaid programs beginning in 1993
Medication Therapy
Management
Assistance in managing and monitoring drug therapy for patients receiving treatment for cancer or chronic conditions such as
asthma and diabetes, consulting with patients and their families on the proper use of medication; conducting wellness and
disease prevention programs to improve public health; overseeing medication use in a variety of settings
Potentially Inappropriate
Medication List
A list, criteria, or screening tool designed to improve PATIENT SAFETY by determining an individual's exposure to potentially
inappropriate drugs. They are designed to prevent MEDICATION ERRORS by INAPPROPRIATE PRESCRIBING. Analysis for
a list includes factors such as DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND
ADVERSE REACTIONS; AGE FACTORS; GENDER; and existing medical conditions
Patient Medication
Knowledge
Patient health knowledge related to medications including what is being used and why as well as instructions and precautions
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Controlled Vocabulary Tree search terms - EMBASE
EMBASE has its own controlled vocabulary tree (Emtree) for assisted searching that
is different from MEDLINE. As with MEDLINE, the set of search terms that match to
the keyword search terms include those that are not well related to or just too general
for the topic (e.g. in EMBASE the keyword map for ‘medication profile’ includes the
controlled terms of ‘patient’, ‘pharmacy’ and ‘nilotinib’ (a specific immunomodulatory
agent)).  Other matched search terms were condition specific and therefore unhelpful
(e.g. the keyword map for ‘drug record’ includes the controlled terms of ‘acute heart
infarction’, ‘college’ and ‘cataract’).  The EMBASE search term scope statements
contain only a list of all the terms that are covered by the search term (i.e. its children
in the hierarchy); there is no formal textual definition of the search term provided.
This severely limits the value of the controlled vocabulary as a search tool for the
purpose of finding additional literature focused on the concept of a Medication
Profile.  In view of this, tree search terms from EMBASE were deemed to offer no
additional value to this literature search.
Comment on Search Terms
The MeSH and EMBASE search terms demonstrate the confusion that persists in
the definition of the vital concept of a patient’s Medication Profile. Whilst it is not
relevant to this thesis to conduct a full critique of the search terms provided by these
two fundamental research databases, it is relevant to comment that their lack of rigor
and consistency in term definition is perpetuating the problem of a clear
understanding of the concept of a patient’s Medication Profile throughout all aspects
of healthcare.
An example of the issues can be seen in the scope for the MeSH term ‘Drug
Utilization’, which is defined as ‘The utilization of drugs as reported in individual
hospital studies, FDA studies, marketing, or consumption, etc. This includes drug
stockpiling, and patient drug profiles’ where, it might be assumed ‘patient drug
profiles’ might refer to the concept of a patient’s longitudinal record of medication
use, i.e. their Medication Profile.  But there is, unfortunately, room for ambiguity;
‘patient drug profiles’ might equally refer to the concept of the information provided
to support the use of a medicinal product in clinical care: the Summary of Product
Characteristics in Europe or the Product Label in North America. The child concept
of ‘Drug Utilization’, ‘Drug Utilization Review’, is scoped as ‘Formal programs for
assessing drug prescription against some standard. Drug utilization review may
consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes.
Review is usually retrospective, but some analysis may be done before drugs are
dispensed (as in computer systems that advise physicians when prescriptions are
48
entered). Drug utilization review is mandated for Medicaid programs beginning in
1993’.  Within this scope there is no mention, nor even a hint of the requirement for
a patient Medication Profile, unless one accepts the implicit requirement that clinical
appropriateness cannot be assessed without the overall medication context that the
Profile provides.
Another example is the term ‘Potentially Inappropriate Medication List’ which looked
very promising as a search term and as such has been included in the search
thesaurus.  However, the scope statement is disappointing: ‘A list, criteria, or
screening tool designed to improve patient safety by determining an individual's
exposure to potentially inappropriate drugs. They are designed to prevent
medication errors by inappropriate prescribing. Analysis for a list includes factors
such as dose-response relationship, drug; drug-related side effects and adverse
reactions; age factors; gender; and existing medical conditions’.  Although the scope
explicitly states ‘existing medical conditions’ as being an important factor in
preventing medication errors it does not mention existing or past medication use.
Similarly the term ‘Medication Systems, Hospital’ which is scoped as ‘Overall
systems, traditional or automated, to provide medication to patients in hospitals.
Elements of the system are: handling the physician's order, transcription of the order
by nurse and/or pharmacist, filling the medication order, transfer to the nursing unit,
and administration to the patient’ does not mention anything about the facility to or
importance of storing and then sharing any of the information from the core
medication processes of prescribing, dispensing and administration that the system
is required to perform, even though it does explicitly mention the somewhat clinically
less important process of medication transportation.
Although both ‘drug’ and ‘medication’ appear in the MeSH and EMBASE controlled
vocabulary, the term ‘drug’ is only used in those terms with longstanding and widely
used application (‘Drug Information Systems’, ‘Drug Utilization’ and ‘Drug Utilization
Review’), although the term ‘Drug Therapy’ is a major heading, probably due to its
longstanding position within Therapeutics.  Further confusion appears in that various
authors have used the term ‘medication profile’ to describe the characteristics of a
medicinal product itself, yet had their articles matched to more clinically focussed
search terms.  Two have been picked out as exemplar: one focussing on information
for clinicians such as pharmacology, pharmacokinetic properties, efficacy, and
tolerability62 and the second on information of interest and consideration to patients
in order to ascertain their treatment preferences: time on the market, dose frequency,
side effect list63. Several authors used the concept of a ‘medication profile’ to mean
something closer to either a drug utilisation profile (the pattern of medicines from a
particular therapeutic group used in a particular cohort of patients) or to a medication
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regimen – a set of medications used together for a particular indication. French et
al64 applied the concept of a ‘medication profile’ to a cohort of patients when
investigating the use of medication by blast victims.  The concept was one of a drug
utilisation profile for the cohort; how many patients used medicines from the
particular therapeutic classes in a particular time frame post injury. The study did
also use the term ‘profile’ when describing medication for individual patients too.
Another study65 applied the term to a drug utilisation profile for a cohort of patients,
whilst investigating syncope and comparing cardiovascular medication use and
central nervous system medication use between groups.  Reichelmann et al66 used
the concept of a medication profile as the set of medications used to optimise
symptom management in palliative care.
If the conduct of a good systematic search of the literature is not routinely achievable
and comparatively reproducible on a regular basis, it is impossible to track and
harmonise development in this critical domain. For this thesis, having built a
thesaurus of search terms as rigorously as possible based on the hierarchies and
definitions, it has been necessary to review the large number of retrieved results
from their application quite extensively to find the literature that is truly relevant to
the area of study.
Method for reviewing the selected papers
After de-duplication, title and abstract screening was undertaken on the papers
retrieved through the above search strategy, to arrive at the final set of papers to be
studied in detail.  These were examined to elicit their contribution to the description
of, population of and requirements for a Medication Profile.  Based on the initial
investigation, it was clear that although the literature in this area appears extensive,
close examination shows that not to be the case and therefore a methodological
review or quantitative examination would not be as valuable as a narrative
discussion.  The discussion of the papers examined was structured around themes
from the papers themselves, which were assembled during the initial reading
process:
 Systematic reviews in the domain
 The ‘gold standard medication list’ and medication reconciliation
 Medication information in transfer of care
 Personal medication records
 Data sources for medication information
 Medication systems and medication information
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Results
Keyword search terms
The following gives the number of papers found (total and de-duplicated) for each of the keyword search processed through MEDLINE and EMBASE.
Table 3: Number of papers found in keyword searches
Keyword Search MEDLINE
TOTAL
MEDLINE
Duplicates
Resolved
MEDLINE
ONLY
Duplicates
Resolved
EMBASE
TOTAL
EMBASE
Duplicates
Resolved
EMBASE
ONLY
Duplicates
Resolved
BOTH BOTH
Duplicates
Resolved
Medication profile 137 133 15 231 225 107 118 118
Drug profile 221 211 12 492 484 285 200 199
Medication record 89 85 7 181 173 95 81 78
Drug record 19 18 0 28 27 9 18 18
Current medication 551 551 61 1024 987 497 490 490
Past medication 28 25 1 64 61 37 27 24
Medication history 840 836 102 1698 (1701) 1657 923 738 734
Medication histories 269 269 22 458 436 189 247 247
Drug history 825 825 111 1390 1356 642 714 714
Drug histories 167 161 27 224 214 80 137 134
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Note that although when run as a full search, the total for ‘Medication history’ in
EMBASE was 1701 articles, but due to institutional limits this full set could not be
accessed; all divisions used always returned a total of 1698 articles, so this is given
as the pragmatic total returned by the search query.
The number of papers in the search ranged from manageable numbers for some
search terms such as ‘past medication’, to very high numbers such as for ‘medication
history’, a pattern mirrored in both databases.  To develop a more focused set of
results for further investigation, the search terms were combined in a Cartesian
square using the ‘AND’ operator.  The results are presented in the table below.
Whilst there were one or two very useful sets of hits in combination with the
‘medication history’ and ‘medication histories’ search term in both databases, many
of the other combinations gave either a very small number or nothing at all.  This re-
enforced the sense that the searching and indexing in this domain is less than ideal
in supporting systematic evaluation of the literature for the concept of a Medication
Profile.
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Table 4: Number of papers found in keyword search combination (‘AND’ operator)
EMBASE
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Medication profile 2 1 1 3 0 5 3 0 0
Drug profile 1 1 0 1 0 1 0 0 0
Medication record 1 0 0 3 0 7 2 4 0
Drug record 0 0 0 0 0 0 0 0 0
Current medication 2 0 2 0 3 22 9 4 4
Past medication 0 0 0 0 3 16 1 1 0
Medication history 3 0 3 0 9 3 137 23 5
Medication histories 3 0 1 0 3 0 69 6 3
Drug history 0 0 0 0 1 1 8 3 22
Drug histories 0 0 0 0 0 0 2 1 9
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Controlled Vocabulary Tree search terms
As discussed above, search using selected controlled vocabulary terms was only sensible to do with search terms from MEDLINE, selected as described.
The results of this are given below, accompanied by the specific sub-set exclusions that were applied to the search.
Table 5: Number of papers found for the MeSH controlled vocabulary search (MEDLINE)
MeSH Term Search MEDLINE TOTAL Exclusions
Inappropriate Prescribing 489 History: Legislation & Jurisprudence; Statistics & Numerical Data; Veterinary
Medication Errors 6626 Legislation & Jurisprudence; Veterinary
Medication Reconciliation 192 Statistics & Numerical Data; Organization & Administration
De-prescriptions 6
Drug Utilization 3532 Legislation & Jurisprudence; Statistics & Numerical Data; Organization & Administration
Drug Utilization Review 585 Legislation & Jurisprudence; Statistics & Numerical Data; Organization & Administration
Medication Therapy Management 297 History; Legislation & Jurisprudence; Statistics & Numerical Data; Organization & Administration
Potentially Inappropriate Medication List 3
Patient Medication Knowledge 13 Statistics & Numerical Data; Organization & Administration
To focus the search more appropriately, particularly for the MeSH controlled terms with a large number of hits, pairings of the terms were combined using
the ‘AND’ operator using a Cartesian square pattern and the results shown below.
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Table 6: Number of papers found for the MeSH controlled vocabulary search combination (‘AND’ operator) (MEDLINE)
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Inappropriate
Prescribing
Medication Errors 34
Medication
Reconciliation 7 71
De-prescriptions 2 0 0
Drug Utilization 24 37 1 0
Drug Utilization
Review 14 30 7 0 16
Medication Therapy
Management 1 20 6 0 3 2
Potentially
Inappropriate
Medication List
0 0 0 0 1 0 0
Patient Medication
Knowledge 0 1 1 0 0 0 1 0
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Results summary
The results of the three searches, the keyword searches from MEDLINE and
EMBASE and the controlled vocabulary search from MEDLINE, with each search
having the AND operator applied using the Cartesian square pattern, were combined
and de-duplicated.  This gave 128 papers from the MEDLINE keyword search, 290
from the EMBASE keyword search and 279 from the MEDLINE controlled
vocabulary search, such that a set of 697 papers and articles were assembled. This
initial set of the 697 papers was screened by title, reducing it to 281 papers.  These
were then screened by abstract, selecting those relevant to the exploration of the
perception and definition of medication information for a ‘Medication Profile’ and its
value to healthcare, and in particular what the data objects in it are/should be, the
use cases it must support and how ‘current medication’ and ‘medication history’
relate to or within it.  This abstract screening provided a final set of 59 papers to be
reviewed.  A diagrammatic representation of this process is shown in the flow
diagram below.
Figure 4: Flow diagram of paper selection for review
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Discussion of the Literature
Systematic reviews and general discussion
Firstly, and following on from the challenges encountered in the literature searching
itself which have been described above, it is noteworthy that there are extremely few
systematic reviews of medication management and particularly the informatics of
medication management in the literature, and those that do exist demonstrate the
difficulty in finding relevant literature through searching.  A review by Bayoumi et al67
initially found 813 citations for a systematic review of medication reconciliation
processes, but these were reduced to just 5 to actually review.  A study by Kostas et
al68 also on the topic of medication reconciliation found 746 citations, but these were
reduced to 35 and then to only 19 when constrained on their main focus of ‘older
patients’.  This study described the concept of a ‘best possible medication history’
(BPMH) as a basis from which to conduct medication reconciliation process.   Kostas
and team describe a BPMH as a ‘comprehensive list of prescription and non-
prescription medications used by patients, which incorporates all available
information sources, including patients’ medication lists, prescription vials, outpatient
records, pharmacy records (and phone call if necessary) and patient interview,
among others’.  They list eight possible types of sources of data to populate that list:
1) medication histories, which involved patient-generated information, including
patient interviews, often in combination with other sources (e.g. prescription bottles
and outpatient pharmacy); 2) hospital orders, which included inpatient and discharge
medication orders; 3) medication  administration records, which included inpatient
drug administration records; 4) inpatient medical records, which included admission
histories and physicals, progress notes and discharge summaries; 5) outpatient
medical records, which included primary care notes and medication lists in outpatient
medical records; 6) outpatient prescriptions or pharmacy records, which often
included references to the patient’s actual medication bottles or phone calls to
pharmacies; 7) home reviews, which included a visit to the patient’s home; and 8)
the patient’s own list, which included a patient-supplied, written medication list.  The
review concentrated on the types of data sources used to collate a BPMH, not the
data elements that would comprise it, although implicitly, since omission of dosage
form and route information was taken as a ‘discrepancy’ one can assume that these
two data elements are indeed components of it.  The review concludes that there is
currently an absence of a gold standard medication list, which is a challenge, and
that the literature on the topic remains deficient.
A review by Hogan-Murphy et al69 looking more broadly at medication management
systems and their implementation found 2566 references through searching, but
these were reduced to 5 for actual inclusion.  That review stated that two of the
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studies had demonstrated that electronic systems had improved access to a
patient’s drug history and that it was ‘easier to alter patient’s drug list’ but there was
no definition of what those concepts (drug history or patient’s drug list) actually meant
in terms of the data elements to be provided.     A similar lack of definition was found
in a scoping review by Bassi et al70 that sought to identify studies that were using
information technology in medication reconciliation and determine how this is used
to facilitate the process.  Although this review looked at systems and functionality
ranging from medication information sharing using e-mail through to managing
medication safety by use of decision support tools, there was a marked absence of
any description of actual medication data elements used or required by the systems
or functionality.
Halapy and Kertland71 wrote a general discussion of problems with medication
histories (although the concept of ‘medication history’ itself is not defined in detail).
They used focus groups to study the topic from the perspective of the patient and
the healthcare professional. Patients were found to be unanimous in their opinion
that all healthcare professionals caring for them should have access to complete
medication histories to provide high quality care and expressed no reluctance to
have that information available.  Patients themselves knew they needed to be able
to provide information about their medication to healthcare professionals, otherwise
it might compromise the care being provided to them, and they used a variety of
methods to achieve that: lists (either handwritten or computer generated) or bringing
the actual medicines themselves.  Patients were supportive of the use of information
technology to achieve this goal of having their medication information available, and
‘some form of a central computerised solution was suggested frequently, such as a
single network listing medications captured through the patient’s (health insurance)
number, a smart card for electronic records, or some other mode of recording
medications in patients’ hospital records’.  Healthcare professionals all agreed that
accurate medication histories were important and they did provide a list of data
elements that could be included: names of medications, indications, directions for
use, and duration of therapy; they also described scope, to include both prescription
and non-prescription medications.   In this study, healthcare professionals suggested
that some other types of information, which have been explicitly excluded in this
research, would be useful in a medication history and these included allergy and
adverse reaction information and insurance eligibility.  The authors noted that
patients and health care professionals both agreed that recording medication history
information in electronic databases, to facilitate appropriate sharing of information
among health care providers, was an important process.  They also noted that an
electronic system would improve availability of information about a patient’s
medication, particularly out of routine hours, and would help to address concerns
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about inaccuracy or incompleteness of medication history.  This reinforces the
motivation for this research, to provide an evidence based static and dynamic
information to populate and maintain that database of medication information (in a
sense a synonym for the Medication Profile) in a comprehensive, high quality and
consistent manner.
Introducing the gold standard medication information
concept
The concept of ‘best possible’ or a ‘gold standard’ when related to concepts such as
medication history or medication list or current/active medication list to give the
concept of a ‘gold standard medication list’ that does appear frequently in the
literature, although rarely with a formal definition.  The process that is used to obtain
what is described as the best possible or a gold standard tends to form the focus of
study, usually in the context of finding a baseline from which to conduct a medication
reconciliation process, rather than defining the information elements that provide the
structure to hold the gold standard information.  Both are important, but focussing on
one to the exclusion of the other means that the foundations are unbalanced and
any construction is at risk.
The gold standard medication list and medication reconciliation
Medication reconciliation itself as a process does have a formal definition: it is ‘a
process of identifying the most accurate list of all medications a patient is taking—
including name, dosage, frequency, and route—and using this list to provide correct
medications for patients anywhere within the health care system’72.  It its goal is also
articulated: ‘to improve patient safety by minimizing errors that could harm
patients’73, and stated in more detail as ‘complete, accurate, and current medication
information for all patients and everyone involved in their care by seeking to prevent
omissions, duplications, dosing errors, and potential adverse interactions among a
person’s medications’. However, it is acknowledged that this is not as easy as it
sounds.  In March 2010, the Joint Commission issued a statement that noted that
many organisations had struggled to develop and implement effective and efficient
processes to achieve the recommended standards for medication reconciliation and
therefore they temporarily suspended the requirement.  And as of July 2011, rather
than being a separate Patient Safety Goal, medication reconciliation was brought
under the umbrella of the National Patient Safety Goal #374, Improving the safety of
using medications.  This requires that organisations maintain and communicate
accurate medication information and also that they undertake to compare the
medication information the patient brought to the hospital with the medications
ordered for the patient by the hospital in order to identify and resolve discrepancies.
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To do medication reconciliation effectively requires the development of an accurate
list, which must therefore be complete, of all medications a patient is currently taking,
then, as described by Feldman et al75, updating the list and repeating the comparison
and reconciliation process whenever medication changes are made.  It also includes
communicating the reconciled list to all appropriate clinicians, especially to the next
provider of care, and providing the list and effectively communicating its contents to
the individual and the individual’s family caregivers.  This essence of having
complete and accurate data about medications available to all, including the patient
and carers to improve safety, is articulating part of the heart of this research.  It also
highlights the urgent need for the research, since apart from the statement about
‘including name, dosage, frequency, and route’, there are no formal definitions of
exactly the data that should be involved, of what ‘currently taking’ truly means and
indeed what the scope is for ‘complete’.  Implicitly, ‘all medications’ can be assumed
to include those beyond simply prescribed medications, as further elucidated by
Steeb and Webster76 in their work on optimising medication reconciliation, where
they described a medication list to include ‘all medications as defined by accrediting
organizations such as the Joint Commission, including, at a minimum, prescription
medications; sample medications; vitamins and nutraceuticals; over-the-counter
(OTC) drugs; complementary and alternative medications; radioactive medications;
respiratory therapy–related medications; parenteral  nutrition; blood derivatives;
intravenous solutions (plain or with additives); investigational agents; and any
product designated by the Food and Drug Administration as a drug’. They provided
a definition for their concept of a medication list as ‘a record of current medications
that an individual carries across the continuum of care to stimulate conversation
between the individual and his or her health care providers regarding the patient's
current medications’.   Unfortunately, they did not provide a definition for the qualifier
of ‘current’, and although they stated that they felt that there was inadequate
standardisation of the data elements of the medication record, they did not offer any
view as to what that standard set of data elements should be.  There was a clear
sense from Steeb and Webster that, in their culture and practice (the United States
in 2012) the holder of this list should be the patient, as they saw fundamental barriers
to incorporating this list into the patient’s health record that only legislation and
regulation would overcome.
Back in 2004, Collins et al77 started looking at the gold standard and noted that
previously, researchers had assumed the gold standard medication history to be the
medication information from the patient at the time, but they felt there were problems
with this assumption. These included that patients cannot always recall all the
information about their medication currently (names, dosage instructions) and that
patients who are intentionally non-compliant with a regimen may be reluctant to
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express this. The study confirmed earlier research that showed that physician-
acquired medication histories contained inaccuracies and that pharmacist-
conducted medication histories are likely to be more accurate, in that they identify a
greater proportion of the medicines patients are taking.  It also highlighted that the
patient’s health record should have clearer and more complete medication
information. Although Collins et al concluded that there was indeed no gold
standard medication history available and therefore further work was needed, even
at this early stage there is a mismatch in definition and understanding which
pervades the domain and makes solid progress difficult.  This study implicitly
assumes the concept of a gold standard medication history to be what others might
actually term a current medication (list) since it is concerned with the medication of
the patient at this point in time, not in times past.
Nearly 10 years and much research later, and focusing in a particular clinical area,
Prins et al78 also concluded that there still is no gold standard for obtaining an
accurate medication history, either in terms of the structure of that history or in terms
of the process to gather it.  Their research compared information about the use of
medications at home for older patients admitted to a psychiatric hospital and found
it to be different from that recorded in the usual process for over three quarters of
patients, with nearly a quarter of patients suffering clinical consequences as a result
of the differences. It is therefore vital that these concepts are at last properly and
formally defined using best informatics practice to support the provision of clinical
care.
Fitzgerald79, writing an article on the importance of an accurate drug history in the
prevention of medication errors, gave quite a broad scope for what he considered
the medication history should be, not simply as a list of a patient’s medication and
the associated dosage information but also to include additional but related
information such as information about adherence to therapy, previous
hypersensitivity reactions and adverse effects, noting that these latter were often
poorly documented in patient records and particularly on medication charts. Ryan
et al80 studied the concept of correctness of medication information, such that the
medications reported for the patient are indeed the ones the patient is taking, with
no falsely included medications.  Completeness of the information was also
examined, stating that medication name, dose (quantity) and frequency (of
administration) should always be included for each reported medication.  In this
study, if medication information was both correct and complete it was deemed to be
accurate.
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Medication information in transfer of care
Much of the available information in the literature about description of medication
information comes from studies that have concentrated on particular points of
transition in the care process, as a different set of healthcare professionals take
responsibility for the care of the patient and need information, particularly medication
information, to provide that care safely and well.
Medication information at transfer into secondary care (admission)
The transition into secondary care, either directly or through an emergency
department, is a particular focus in the literature.  This is because more than half of
all hospital medication errors occur at the interfaces of care, with over one-quarter
of all hospital prescribing errors attributed to incomplete medication histories
obtained at the time of admission81. An early systematic review by Tam et al82, which
initially found 343 potentially relevant studies but which finally reviewed just 22,
looked at admission to hospital and the errors in ‘medication history’ that were
occurring.  This study found significant heterogeneity in methods/sources used to
obtain the comprehensive medication histories, but gave no detail of either the
definition of the period that a history might cover, nor the data elements that
comprised those histories other than by implication from the error types.  These
included incorrect dose (quantity), (product) strength, (dosage) frequency and errors
of omission or commission in the inclusion or otherwise of particular medicinal
products in the listing.  Similarly, an early study from Andersen et al83 looked at a
patient’s medication history on admission to a medical ward, but based on the
description that these were ‘the medications that the patients are reporting to
consume or the medications that they keep at home’ this is really a concept that
should be termed the patient’s current medication.  This study, and a similar one by
Rees et al84 which was also looking at discrepancies in drug history on admission to
a medical unit, had comparable findings to that of Prins discussed above, in that it
found that approximately 70% of the patients had some sort of discrepancy in their
medication list.
A study by Kaushal et al85 was a qualitative assessment of the use of a model health
information exchange project for a network of emergency departments in which
claims data from pharmacy benefit managers (PBMs) were made available at the
point of care to clinicians in emergency departments, to provide information on
patients’ medications.  Although the information provided was felt to improve
clinicians’ knowledge of patients' medications, they did not believe it decreased the
time required to obtain a medication list from which to continue to provide care.  The
authors felt this mismatch of value was probably due to a belief that the source
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information was incomplete, particularly since psychiatric and HIV medications, mail
order medications and medications dispensed in other countries were not included.
The study also noted that any system providing medication information at the point
of care needs to be carefully designed and implemented, especially into the
workflow.
This theme of use of the patient’s medication information in the workflow was also
studied by Vawdrey et al86, using a coded, longitudinal medication list known as the
‘Outpatient Medication Profile’ (OMP).   This study acknowledged that, in their
context, there was no gold standard medication list.  Although it might be assumed
the OMP could become that gold standard, there was a strong sense that further
analysis was necessary to assess the validity of that, and also to explore the
possibility of synchronising data with external pharmacy information and other data
sources.  This study is one of very few that describe any sense of a longitudinal
record of medication use for an individual patient, or to note explicitly the use of
coded data elements within that record.
A study by Cohen et al87 on the availability of medication information for elderly
patients to support the initial interventions made by physicians in the emergency
department concluded that even if the names of medications a patient may have
taken immediately before arrival at the emergency department were available, a
complete list of the patient’s medications with details of the dosage, route, and
frequency of medications was unlikely to be provided.  They felt that these elements,
accurately supplied, would be very valuable to support the initial interventions
necessary during the initial period of acute stabilization.   Another study that focussed
on medication reconciliation in the emergency department context was that by de
Winter et al88; this was a quantitative analysis of discrepancies in medication
histories obtained in that emergency care context which found a 59% discrepancy
rate (against a reported rate in other studies ranging from 10% to 96%).  Whilst no
explicit list of the data elements for which discrepancies were measured was
provided, the statement that ‘correct dose, frequency and route of administration
were responsible for the greatest number of discrepancies’ implies that these data
elements were considered, as well as omission or commission of the medicinal
product itself.   At the other end of the age spectrum, Dersch-Mills, Hugel, and
Nystrom89 looked at medication information on admission for paediatric patients, a
cohort that generally does not require much medication therapy, and in their study
just under a quarter of patients took no medications at all, and approximately half
took no prescribed medications.  This study used the concept of a best possible
medication history against which to calculate completeness, and although the
content of this was not explicitly stated, it can be gathered by implication from the
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completeness scoring system, which had one scoring point for each of: the name of
the medication, the dose (amount per dose), and the frequency of dosing, with
complete correctness being three points or a 100% score.    The scope of the best
possible medication history was also implicit, in that the study noted ‘the informed
interviewer consistently included over-the-counter products, herbal products, and
vitamins, in addition to prescription medications, in her questioning’.
Owusu-Ankomah et al90 investigated the overlooking of various types of medicines
when documenting a patient’s medication on admission to an acute medical unit.
This omission is important because incomplete medication histories at the time of
admission account for approximately 27% of hospital prescribing errors and increase
the risk of drug interactions. Use of over-the-counter complementary and alternative
medicines in particular is poorly documented at hospital admission and prescribed
drugs that are commonly overlooked included oral contraceptive medications, β-
adrenoceptor agonist inhalation products and topically administered medicines such
as steroid, antihistamine or emollient products. The authors suggested that reasons
for poor documentation may include lack of time or perceived lack of importance of
these medications and concluded that lack of documentation of non-prescribed
medications and overlooked medicines may result in omission of indicated
treatments or failure to predict interactions or correctly identify adverse events.
Fitzsimons, Grimes and Galvin91 also observed that ideally, pre-admission
medication lists (in their terms, ‘PAMLs’ or ‘GS-PAML’ (gold-standard PAML,
equivalent to Pippins ‘gold standard’ medication list described below) should not
merely list the medications prescribed or dispensed to the patient, but reﬂect what
the patient was actually using prior to admission, taking into account not just non-
prescribed medications, but also any known non-compliance with any medication
regimen.   In their study, only 17% of PAMLs had no discrepancy when compared to
the GS-PAML, constructed by amalgamation and reconciliation of various
information sources including general practice referral letters, community pharmacy
and where appropriate, nursing home information.  Their conclusion was that this
high discrepancy rate illustrates the complexity of the problem of identifying the
patient’s actual (current, pre-admission) medication use and medication history (no
definition given).  They also noted that their ﬁnding that the community pharmacy
provided information most frequently in agreement with the GS-PAML was
inconsistent with ﬁndings from the UK, where the GP was identiﬁed as the most
accurate source, adding yet more evidence to the need for formal definition of how
to structure and manage this information in this safety critical area.
In terms of internal transfer within an institution such as a hospital, Lee et al92 showed
that clinically significant medication discrepancies occur commonly at the point of
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internal hospital transfer of patients. Their conclusion was that a ‘structured,
collaborative, and clearly defined medication reconciliation process is needed’ to
prevent such transfer discrepancies and therefore to reduce the risk of patient harm.
They did not, however, postulate as to what that structure and clear definition might
be.
Dharas and Dean Franklin93 investigated the information that patients themselves
contributed at a point of transfer of care, by comparing and contrasting patients
admitted for elective surgery and through emergency medication admission.
Overall, 63% of patients contributed information about their regular medication (no
definition of regular was given), but it was noted that those admitted electively
contributed more than those admitted as an emergency, and particularly those
admitted through the accident and emergency department.  This points to the clear
requirement for a Medication Profile to be available to all, especially to support
unscheduled care.   In a similar vein, Dooley, van de Vreede and Tan94 studied the
accuracy of a patient-completed questionnaire for medication history used in a pre-
admission surgical assessment and found that it was inaccurate in four out of five
patients.  This study also used the concept of a gold standard for the patient’s
medication history, but other than stating that this was the pharmacist’s assessment
of the patient’s medication, no other description of that gold standard was provided.
Medication information in shared care (outpatients)
The availability and accuracy of medication information has also been studied in
outpatient clinics, a context which could be described more as a situation of shared
care than of a transfer of care.   Ashjian et al95 studied medication information at a
haematology/oncology outpatient clinic, finding the medication information
discrepancy rate to be similar to other studies, at 88% of patients’ records.  This
study was clear in that it explicitly described the scope of patient’s medication list (to
include prescription and non-prescription products, including herbal and dietary
supplements) and was also explicit about some of the data elements examined (drug
(description), dose (quantity), route, frequency and indication).   Pasetka et al96 also
studied medication history in an outpatient oncology setting; no detail of their
definitions is given but their conclusion was that approximately a third of patients in
this medication critical area of practice did not have a documented medication history
of any type.
Seden, Back and Khoo97 also reviewed medication history information in an
outpatient clinic setting, again for a medication critical speciality: human
immunodeficiency virus (HIV) treatment.  Their focus was identification of drug-drug
interactions, which they acknowledge relies upon having a comprehensive and
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current medication history.  No definition of this or of the data elements it should
contain was given, but the understanding that a range of non-prescription
medications such as herbal medicines, vitamins or supplements and so-called
recreational drugs may impact anti-retroviral therapy indicates that the scope of their
medication history concept would include these products.   In the United Kingdom,
Darley, Bell and Pammi98 also investigated communication specifically related to HIV
treatment, particularly between primary and secondary care environments and the
NHS England Summary Care Record99 (SCR), which is intended to provide patient
information to support better care for patients across care boundaries.   Less than a
quarter of patients (23%) had a mention of their anti-retro-viral (ARV) therapy on their
SCR, less than 10% of patients’ SCR had complete ARV information. In contrast,
just over half of the hospital records had all current medication listed, including all
ARV.  The findings of this study are in many senses extremely disappointing, given
that the SCR explicitly includes medication information as a priority100 (possibly its
only priority currently).  This highlights the need for this research to provide not just
the data element definition but also the dynamic model of processes and rules for
population of the data elements, to make initiatives such as the SCR for medication
actually work in reality.
Another study in a (preoperative) clinic setting, by Lee and Nishimura et al101 found
discrepancies in 94% of patients’ personal medication lists, with further analysis
noting that polypharmacy was a significant factor in increasing the likelihood of
inaccuracy in medication information.   This study did describe its data elements: the
name, dose (quantity), and frequency were included, but there is no mention of route
of administration as a data element.  The scope was described as including all
prescription and non-prescription medications or dietary supplements.
Personal medication records
Most of the situations described so far have focussed on one or more medication
lists being managed by one or more types of healthcare professional, either with or
without the support of information management systems.  The literature also
describes the concept of a personal medication record, a record of medication
information that is held and managed by the patient themselves, for example as
described by Burns102 as part of an overall medication therapy management service.
This service has five core elements, of which four are relevant to the management
of medication information for an individual: medication therapy review (MTR),
management of a personal medication record (PMR), development and execution of
a medication-related action plan (MAP), documentation and follow-up; with the fifth
being actual intervention and/or referral.  This work by Burns is unusual in that it
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provides good description of what it expects in the (personal) medication record, both
in terms of scope (all prescription and non-prescription medications, herbal products,
and other dietary supplements) and in terms of the data elements: for each
medication, name and dosage instructions for use, indication, start/stop date and
any special instructions.  It also requires information about the healthcare
professional responsible for that medication.   Because the focus is on the provision
of an overall medication therapy management service, various other information was
required in the record, including allergy/adverse reaction information and metadata
about when the PMR was updated and by whom.   Even more unusually, there is
some sense of the management of this record over time to keep the record current
and accurate, although this is, possibly unreasonably, delegated to the patient.  The
patient is instructed to update the PMR each time they receive a new medication
(prescription or non-prescription or herbal product) or has a current medication
discontinued or a medication has a dosage instruction or other regimen change.
However, there was the sense that ideally, the pharmacist, physician or other health
care professional should actively assist the patient with the management of the PMR.
The author concludes that widespread use of the PMR would support uniformity of
information provided to all healthcare professionals and therefore improve the care
they provided to patients yet because it is patient held and managed, it is not tied to
any particular provider’s system or specification, and could be used by all.  Given
the other research in this area, this is undoubtedly true, but no healthcare culture
has yet successfully implemented and had widespread uptake of a patient managed
medication record, despite several large initiatives including GoogleHealth103
(cancelled end of 2011) and Microsoft HealthVault104.  But the sentiments, and
particularly the explicit description of the nature of the scope and components of the
record are very much what this research is focussing on.
There have been some smaller research-led initiatives in the area of personal
medication records.  Zeng, Bodenreider and Nelson105 describe a stand-alone web-
based application called MyMedicationList that was provided by the US National
Library of Medicine as an initial trial of something that could also be integrated as a
medication module within a PHR (personal health record system), not least because
of its standards base.  MyMedicationList was composed of the data elements from
the ASTM Continuity of Care Record19 and was implemented through the Continuity
of Care Document (CCD) standard, to provide human readability as well as computer
process-ability, and as such can be argued to have a defined and standardised
dataset, at least within the US healthcare culture.  The authors argue that this means
that it is ‘semantically complete’ and rich enough to represent all medication
information, including medication name, interval (start/stop time), quantity,
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frequency, patient instruction, indication, available generic substitute of a branded
drug, prescriber and supplier.
Multiple data sources for a gold standard medication list
The theme of the multiple data sources that might or might not contribute to a gold
standard medication list is one that many have looked at.  Pippins et al106 looked at
what they considered to be all available sources of information, including subject and
family/caregiver interviews, prescription pill bottles, outpatient electronic medical
records, previous hospital discharge orders, outpatient providers, and outpatient
pharmacies in order to develop a pre-admission medication history.  The data
elements that they collected from this set of sources were not listed explicitly, but
can be implied by looking at the types of discrepancies that they noted.  These
included dose per administration (dose quantity), since to have ‘100mg bid’ instead
of ‘200mg bid’ was considered a discrepancy; dose frequency, since to have ‘100
mg bid’ instead of ‘100 mg tid’ was also considered a discrepancy, and indeed the
authors explicitly state that to have ‘100 mg bid’ instead of ‘200 mg qd’ (or ‘od/once
daily’ in UK/Europe) would be a discrepancy in dose and frequency even though the
total daily dose is the same.  Route of administration information and substitution
information (whether it is appropriate to exchange a medication for a different one
within the same therapeutic class) were collected.
Kramer et al107 used four different sources of information, home medication proﬁle
report, home medication reconciliation report, discharge medication reconciliation
report, and patient discharge medication proﬁle, and sought to use information
technology to integrate these sources into a system to generate forms to support
and to report the results of the medication reconciliation process on admission.
These forms were then placed in the patient’s notes or given to the patient on
discharge.  Although no explicit description of the data elements collected was given,
the copies of the forms provided showed that in addition to the full medicinal product
name, dose quantity, route of administration and dose frequency were collected, and
an additional ‘Comments’ space looked to be regularly used to describe the
indication for the medication.
Karkov et al108 also undertook to investigate the number and type of discrepancies
between four medication sources and to assess their potential clinical signiﬁcance
to the patient, in a very small study (9 patients) undertaken on patients admitted to
hospital with hip fracture. The four sources were the patients themselves, the Danish
Personal Electronic Medication Proﬁle (PEM)109 that records all prescriptions
dispensed to a patient, the general practitioner and the in-home care provider.   In
this study, a discrepancy was deﬁned as any disagreement or omission of
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information between the four sources mentioned concerning name, form, strength
and dose for each medication with which the patient is being treated, therefore
implicitly providing what the study considered to be the component data elements
for the gold standard.
Phansalkar et al110 also addressed the fragmentation of medication information
across the healthcare domain, and the difficulties that this poses.  They examined
various sources and their qualities, concluding that each source had both positives
and negatives in terms of their contribution to a gold-standard medication list (in their
case, for use at admission to hospital).    Information directly from patients and/or
their carers may not always be accurate but it is likely to be the most comprehensive
in scope (going beyond prescription medications) and may also reveal adherence
issues. Medication information obtained from an EHR system in secondary care
may provide greater detail on the dosage instructions for the medication, but have
no sense of whether the patient has actually had the prescription supplied and is
therefore using the medication. Pharmacy dispensing databases, either directly or
via insurance claims provide objective information on medication supply, but may
not have all the dosage instructions information. The conclusion, not unnaturally,
was that the gold-standard medication list is likely to be obtained by a combination
of all sources, but the study gave no indication as to how that combination should be
undertaken.
Similarly to the National Library of Medicines’ MyMedicationList, Simonaitis et al111
have also looked at the Continuity of Care Document standard as a vehicle to share
medication history information to primary care clinicians.   Three different sources
for medication information were queried, one providing dispense information, and
two providing dispense information indirectly through insurance claims.   Using the
structures in the CCD, the following information was extracted and provided back to
prescribers: the medication name (as the RxNorm112 Clinical Drug Name), the
dosage instructions (no individual components described), the quantity dispensed
and the date dispensed, which pharmacy dispensed it and also who prescribed it
(name).  The information was found to be helpful to the primary care clinicians and
complemented medication information that they already had, by adding to it.  The
researchers in this study started to describe – although not to attempt to solve - some
of the issues of a dynamic model for populating medication information, such as
when a change is made for a patient to move from lisinopril 10mg tablets to 20mg
tablets, is this a new medication or a continuation of an existing one? They also
investigated how to recognise two different reports of the same medication process
from two different sources.
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Medication systems and the gold standard medication list
There have been several studies on various aspects of information technology in
supporting the gold standard medication list.
Some of these studies have investigated particular local or national initiatives: one
of these is the study by Price et al113 from Canada, which used the term adopted in
this thesis, that of Medication Profile and although it did not provide a clear and
formal definition of the term, it appears that it was intended to mean the patient’s
current medication list (no definition of currency was given).  The study itself
extracted patient medication profiles from a provincial repository of dispensing
information (the PharmaNet system) and compared them to a Best Possible
Medication Histories (BPMH) gathered by pharmacist led patient interview.   The
study found that most of a patient’s medications were listed on their Medication
Profile, but discrepancies were occurring because of a missing ‘current’ flag, with
insulin, salbutamol and codeine being most frequently discrepant in this manner.
Discrepancies in dose (quantity) or dose frequency accounted for a further quarter
of recorded discrepancies, followed by discontinued medications still being listed as
current, and inaccuracies in route of administration information.  So although no data
element components were formally described for the Medication Profile, these are
implicitly understood to be included, with the discontinuation information being
equivalent to a ‘medication course ceased date’.   Over-the-counter medications
were rarely described in the PharmaNet system, relying as it does on dispensing
information, but specialist clinic medications (such as anti-retrovirals) and other
hospital dispensed medications were also missing.   The authors concluded that
using a system providing dispensing information only is insufficient for completing a
medication history, a term that was itself undefined yet clearly different in the authors’
minds from that of medication profile, and they suggested that information from other
health records must be incorporated to generate a Best Possible Medication History
(BPMH).
Another Canadian study by Fernandes et al114 also looked at the use of a provincial
database of prescription information, which was provided through a system called
the drug profile viewer (DPV).  Note that, similarly to the other Canadian study by
Price et al, this study also used the concept of a profile that is formally undefined,
but appears to be similar to the Medication Profile concept used in this research.
The premise of the study was that the DPV information could add value (quality and
efficiency) to a BPMH, and from the results, which found that discrepancies in the
BPMH were significantly reduced after the introduction of information from the DPV,
the premise was found to be supported.
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Tulloch and Evans115 also studied a provincial database of dispensing records in the
Canadian healthcare culture, the Pharmaceutical Information Program (PIP) from
the Saskatchewan Drug Plan and its use in providing a drug profile for patients
admitted to hospital, particularly to support medication reconciliation on admission.
Similar to other Canadian provincial medication databases, information about
hospital medications, cancer medications, tuberculosis medications, investigational
medications, over-the-counter medications and herbal products are not covered.
The focus of the study was to compare the PIP profile to a BPMH, obtained by a
pharmacist on admission.   Similarly to the study by Price et al above, this study by
Tulloch and Evans found most discrepancies occurred because of medications being
wrongly categorised in the PIP profile.  This was most particularly medication being
incorrectly given the status of inactive (the discrepant medication was listed on the
4-month PIP history in 88 (87%) of the 101 cases of this discrepancy, but incorrectly
appeared as inactive in 49 (49%) cases).  Differences in description of the dosage
instructions and medications missing from the PIP profile were the next most likely
discrepancies.   The differences in dosage instructions had the consequence of
affecting adherence calculations, especially where active status was calculated
based on dispensing date and dosage regimen; in this culture, the dispensing
pharmacy must enter the number of days’ supply for each medication, which is often
based on a best guess for usage.  The authors also noted that dispensing date might
be different from the date that the patient actually retrieved the medication from the
pharmacy, or the date at which they commenced using that supply.    This study has
started to tackle the dynamic modelling of information in the domain, looking at how
dynamic information components, particularly status, should be populated and starts
to document the problems in this area that must be overcome to provide a fully
defined and formally managed high quality comprehensive Medication Profile for
each patient.
Although most of the research in this section originates in North America, the issues
are global; an investigation in Taiwan by Lee et al116 also used information from a
medication usage database from a national insurance source to provide a baseline
list against which to work.  Unfortunately, there was no description of the actual data
elements taken from the database and brought into the list.
In each of the studies above, the information flow was unidirectional and at a single
point in time, from the provincial dispensing database to the user of the information
at the point of admission to hospital care.  A study by Remen and Grimsmo117 from
Norway looked at a situation where there are several versions of medication
information available in an EHR application from different sources, external (e.g. in
referral communications) and internal (e.g. from past episodes in hospital).  Their
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investigation found that clinicians were searching for up-to-date information about
the patient’s medication use, expressing a marked preference for limited and
summarised medication information to be available in emergency situations. They
postulated that this would be best obtained from a record of recently dispensed
prescriptions, which in effect is exactly what the Canadian studies had been using in
their unidirectional and single-point-in-time information flow from the provincial
dispensing databases.
Bell et al118 studied the views of a panel of technical experts in relation to the concept
of medication history (RxH) obtained from health insurance claims data, in the
context of electronic prescribing.  They looked particularly at the need for an accurate
medication history for prescribing decision support, especially in a healthcare culture
of distributed care with a single patient having multiple prescribers.  It was noted that
some vendors of prescribing decision support systems admitted to having given up
on reconciling medication history data from multiple sources and used only the
prescription data originated on their software for alerting. Others were matching
using more complex reconciliation, based initially on codes (the National Drug Code
- NDC) and failing that, using text string matching for medication names, but with
inconsistent success.  One vendor was quoted as saying: ‘In order for medication
history to be used effectively, it should be available in a consistent manner for the
majority of the patients being managed by a provider or practice. In areas of scarce
PBM (Pharmacy Benefits Management) coverage, for example, providers do not find
this information useful even when available’.   There was an overall sense from the
panel that the current information structures are likely to be adequate, but the value
of the medication history information is undermined by its inconsistent availability
and by problems with its usability, particularly in terms of reconciliation from different
sources.   Crossen et al119 also studied this same RxH concept from a physician’s
perspective, reporting that this group found the RxH information to be inaccurate or
incomplete and therefore they continued to rely on patients to provide medication
information to support their care.    It was felt that unless medication information can
be offered to prescribers in their systems consistently and reliably, it was actually of
little value.  The authors concluded that the remedy for the root cause of inaccurate
and incomplete medication information was to have standardisation for the
information, and it is exactly these issues, of consistency of both structure and
population of that structure that this research is aiming to address.
Elliott et al120 also studied prescriber’s opinions of a system to provide medication
information based on dispensing information into an electronic health record system.
Overall, the majority of respondents to the survey felt that the information provided
was useful, particularly when wanting information to assess adherence and to
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support a medication reconciliation process. All of the respondents felt that in order
to be useful in clinical practice, medication information needed to be both complete
and accurate, underlining the need for the gold standard Medication Profile to be
made available to all to support high quality delivery of care to patients, as proposed
by this research.
Given some of the issues described above with collecting and sharing data and
particularly data about ARV medication, some functionality developed by Cushman
et al121 is particularly interesting.  This was a web-based application to create and
then display ARV medication histories (only).   Patients and clinicians reviewed
medication use together at each clinic visit using the tool, which also included
medication images to facilitate obtaining accurate information.  The authors stated
that this gathered data was subject to quality control checks, particularly to confirm
clinically unlikely regimens, but they provided no information as to the data elements
or algorithms used to do this.   Implicitly, there is also a sense of a dynamic model
underpinning the application, although again it is not described, because the raw
data is dynamically transformed into medication instances (where a medication
instance is an uninterrupted period of use for a particular drug) which can then be
displayed graphically by the application.  This type of display is only possible when
the dynamic (process) model from which to manage the information has been
described within the system.  The authors anticipate that the use of the tool would
improve the accuracy and efficiency of medication data collection (in the clinics).
Zhu and Cimino122 acknowledged what much of the literature has demonstrated: that
a system that accurately presents medication information that has been obtained
from the range of different data sources that manage medication and which properly
deals with changes in medication use over time, to provide clinicians with reliable
summary of patient medication information at the point of care and in real time,
should reduce errors and improve quality of and patient safety; indeed the heart of
the motivation for this research. From this foundation, they performed an evaluation
of a prototype application that provided a visualisation of a patient’s medication
information in a set of timelines, using open source software called Timeline, working
as a complementary application in an overall EHR system. A web-based tool
collected medication lists from various sources including clinic notes, admission
notes and discharge summaries, the outpatient medication order entry system and
the inpatient pharmacy system.   The core data elements used in this tool were
medication name, dose (quantity), route (of administration), frequency, data source,
context, prescription time, start time, stop time, and usage status. Unfortunately, to
generate the gold-standard medication information required a significant amount of
human intervention in order to be presented in the Timeline application; two experts
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read each information record individually and produced the overall amalgamation.  It
is therefore clear that the system design did not address management of a dynamic
model such that accurate amalgamated information could be generated
automatically using logic rules.  The authors did conclude that their work had great
potential, and that it would be feasible to implement a medication summarisation tool
into clinicians’ daily practice.  Unfortunately, the focus of their future work appeared
to be improving the graphical user interface rather than investigating further and
more accurate generation of medication information; this is likely to seriously hinder
the value of their work as the level of human intervention required to generate the
gold-standard medication information seems insupportable in the wider world.
Again working alongside the main functionality of an EHR, Wolver and Aggarwal123
investigated views about and use of what they termed the External Medication
History (EMH) to support electronic prescribing.  There is no detail as to what the
EMH actually contained in terms of scope or data element components; the work
focussed on patients’ and healthcare professionals’ views of its value.  The authors
found the EMH was used to check compliance, to confirm or reconcile dosage
instructions information and to confirm that the most up to date medications were on
the patient's medication profile within the EHR, which raises questions as to where,
if anywhere, a gold standard medication profile would be available for a patient in
their healthcare environment.  There is an implicit sense from the patient survey that
the EMH was actually primary care dispensing information, since patients stated that
they ‘knew their providers could see if they were filling their medications’, and as
such, the environment for this study is similar to the several Canadian studies
discussed above.
Duran-Garcia et al124 looked at the role of information technology to bring together
the information needed to produce a best possible medication history from multiple
and fragmented data sources, including primary care prescription information,
discharge prescriptions, outpatient prescriptions and patient interview.  Yet again,
the actual data elements that would be necessary to form that best possible
medication history, or to maintain it over time, were not described.
Whilst the majority of studies have shown an improvement in medication information
quality with the use of information technology, Schnipper et al125 noted that, although
the quality and availability of medication information had improved in their study due
to the introduction of a medication reconciliation improvement process, after the
introduction of an electronic medication record as part of an EMR system, medication
information discrepancies actually increased in number at admission.  They felt this
was because the system itself had disrupted the medication reconciliation process
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and made medication information harder to document.  They advised that any
introduction of the use of information technology must be managed carefully so as
not to reduce data quality, even in the interim.
Stoop et al126 looked at the information technology of medication information from a
different perspective: that of the social and political environment in which the system
is developed, implemented and used by healthcare providers.  The Dutch OZIS
system, which provides shared access to the patient’s medication (dispensing) data,
has been accepted because, they hypothesise, its introduction coincided with
increasing need for medication information to provide high quality pharmaceutical
care out of hours and to a range of patients not necessarily within their usual practice.
This different perspective is not part of the heart of this thesis, but any
implementation of the information models from this thesis should be mindful of the
conclusions from Stoop et al, that the success or failure of information technology in
health care is just as much about the social and political context in which the system
is used as it is about the ‘intrinsic value’ of the system itself.
Finally, a study by Lesselroth et al127, published in a journal specialising in
methodology, was interesting in that its objectives included developing an in-depth
understanding of the workflow and information flow in admission medication
reconciliation; in other words, a dynamic model for the process.  From this they
looked to design medication reconciliation support technology using a combination
of software development methodologies such as rapid-cycle prototyping and human-
centred design (also known as user centred design).  However, despite the authors
stating these objectives, documenting their use of tools such as storyboards and
concentrating on the process, no formal process or data element models appear to
have been to be described, and although a proof of concept application was
developed, the authors reported it did suffer from usability issues.   This study is
particularly interesting to this research work, which aims to blend together the formal
software development paradigms, such as the use of analysis tools from the Unified
Modelling Language and Business Process Modelling Notation with the academic
discipline of a thesis, since in some senses this study by Lesselroth seemed to take
a similar approach.
Conclusion
Although there is a wealth of literature available that acknowledges the critical value
of an individual’s medication information (both history and current use) in order to
provide safe and effective ongoing care to patients, and a wealth of studies
describing methods to collect and share medication information, there is a dearth of
literature that formally describes any of the key concepts or informatics components
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that are needed to provide correct, complete and accurate medication information
for patients, either for their own care or for wider secondary uses such as clinical
research.  The formal definition of a high quality comprehensive and cohesive
Medication Profile for use in the provision of care to individuals and also for
secondary use of that information in clinical research to promote better and safer
medication development for the future is therefore urgently required.
Key literature findings that have directed this research
 Many studies have emphasised the importance of a consolidated and
reconciled medication list derived from multiple sources to underpin the safe
use of medicines in patients, especially at points of transfer of care or in
shared care environments
 The phrases ‘current medication’ and ‘medication history’ are frequently used
to describe a medication list or medication record and are often even given
the qualifier of ‘best possible’ or ‘gold standard’ but they are almost never
defined and never justified
 Several studies have reported that issues with identifying ‘current medication’
are a major source of medication discrepancies
 Studies that have attempted to consolidate medication lists from multiple
sources have found this to increase the overall quality of the medication
information but have found the process to be resource intensive; this implies
that a scalable and computable approach to integrating medication
information sources is needed and may improve patient safety
 Few studies that have designed systems to capture, communicate, integrate
or reconcile medication have been explicit about the details (data items) that
were used
 Few studies have addressed any of the issues regarding maintenance of
population of data elements over time or the processes that might be used  to
support this within a system, other than to repeat a reconciliation process at
every transfer of care
 Many studies have noted that the scope of the medication list, the inclusion or
otherwise of prescription and non-prescription medication and related
healthcare products, is a key issue in terms of discrepancies of information;
none have addressed this issue of scope directly
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 Few studies have addressed the issue of how to record and share changes in
therapy, especially when these changes do not affect the main therapeutic
intent (e.g. dosage instructions changes)
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Chapter 4: Requirements for the Medication Profile
from Patient Care
Part 1: Electronic Health Records and Electronic
Patient Summaries
Introduction
As healthcare computing has developed and health informatics has matured as a
discipline, a ‘holy grail’ has emerged: the specification for the delivery of an electronic
comprehensive longitudinal cradle-to-grave documentation of an individual person’s
health and wellbeing, available at all times to inform and support all healthcare
professionals that provide care for that individual; the Electronic Health Record
(EHR).  This chronicle of a person’s health status and the interventions made to
support that status would be ordered and presented in such a way as to be most
useful for all those supporting that person by the provision of health care to them.
Within an EHR, all information about the medications, including immunisations, that
a person has received, is receiving or is planned/scheduled to receive would be
present as a section, providing a ‘Medication Profile’ for that patient.
One of the key goals of a central electronic health record is that it should be
semantically interoperable128.  This means it should be able to share its information
with any and all other systems used by the healthcare professional, be they critical
support systems such as artificial ventilation systems, investigative or monitoring
systems such as x-ray systems, electrocardiograms, medication systems, care
record systems (medical, nursing or ancillary such as physiotherapy or dietetics) and
systems providing report information such as laboratory systems. Semantic
interoperability is a widely used phrase in health informatics to indicate that systems
are able to share information in such a way as the meaning of the information is
usefully and accurately preserved through both time and space; information entered
in system A at time point X can be shared with system B at some later time and the
meaning of that information remains the same129.  In the medication domain,
semantic interoperability would be demonstrated by the prescribing section of a
general practitioner’s care record system sharing its information, as part of a referral,
with a clinic application in a local hospital.  The clinic application would receive the
information about the prescriptions for the referred patient and it can understand the
information such that it can then present this information usefully to the clinic staff,
so that they can see and understand the medication(s) ordered, the dosage
instructions for the medication(s) and the time frame of them, even if that time frame
was some years previously.  The system should present the information in such a
way as to be clear that, unless there is additional supporting information (possibly
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from elsewhere), the prescription is an order only, and unaccompanied by any
related dispensing or administration information is not a guarantee that the patient
received the medication, only that it was prescribed.  In addition to presenting the
information usefully to humans, who can make sensible interpretations and often
intuitively fill in information gaps, semantic interoperability would allow the
information about the prescriptions for the referred patient to be safely usefully used
within the clinic system in the hospital, such as for use in decision support (drug
interaction checking etc.).
There have been various initiatives, both national and international, in the last 10-15
years that have aimed to produce a specification for a semantically interoperable
electronic health record; the major such initiatives are described in the section below.
However, in the last 5 years, the focus has shifted away from attempts to specify a
full longitudinal EHR towards specification of an interoperable Patient Summary.
This summary is a synopsis of the most pertinent points of a patient’s health status
and an outline of their current situation, with the focus to inform and support all
healthcare professionals that provide care for that individual. Medication retains a
key position in the summary, in that, as shown below, all summaries include
information about a patient’s medication in some form or other.  Some of these
specifications directly list and/or describe the data elements that they require; others
describe the functionality that they require systems to provide using a summary.
However, in order to provide functionality, there has to be a fundamental
understanding of the data elements that are need to support that functionality.
Therefore, studying these specifications should give a clear set of requirements for
the data elements needed for a Medication Profile, and a set of functionality that a
Medication Profile should support.
Overview of EHR Specifications and their Medication information
The following overview starts locally, with the vision of the English NHS, which was
the first of the national initiatives that produced a specification for an overarching
electronic health record, then moves to take a European view, and finally looks at
what is specified in the United States.  There have also been initiatives other realms,
for example Australia and New Zealand; the Australian initiative in particular looking
to achieve something of a mixture of NHS England’s ICRS18 using the international
EN ISO 13606 EHR structure130 together with some elements of the HL7 Clinical
Document Architecture131.
Information for Health (NHS England)
The NHS in England was one of the first health services to bring the EHR into focus
by the publication, in September 1998, of ‘Information for Health’132.  The purpose of
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the EHR was to ensure that patients received the best possible care, and to support
healthcare professionals in delivering that care, through provision of lifelong
electronic health records for every person in the country and for all NHS clinicians to
have round-the-clock access to those records.
Information for Health resulted in the development of an output-based specification
for the Integrated Care Record Service (ICRS)18, which had two parts: part one for
National Services and part two for Local Services.  The National Services were to
include a clinical ‘spine’ which was to provide core services such as a person
demographics service, terminology services, messaging services (including e-
Booking and the Electronic Transfer of Prescriptions service for primary care) and a
clinical summary.  This latter was to provide summary or status information such as
(a) medication summary (previous and current medication). In addition to the status
information, the spine summary was also to provide event-based information, one of
which was ‘medication events’.   This would result in the provision of full medication
records (being) available, promoting prompt recognition of conflicts and potential
problems, as well as giving insight into patient compliance with drug regimens.
Indeed the Clinical Spine Applications Service actually used the phrase ‘Medication
Profile’ for one of its components.
The Local Services were to be where ‘deep, rich clinical functionality and clinical data
resides to support the end-to-end process of care delivery across a broad range of
settings’ (page 6).  In all three of the exemplar scenarios described in Part Two,
prescribing, dispensing and administration of medicines played a crucial role in the
patient care, highlighting the importance of medication both in general patient care
and in the information technology strategy to support it.  Following a general
introduction which includes some overall requirements, the specification is split into
over twenty sections, each focussing on a set of clinical functionality that a local
system should perform, such as managing clinic referrals and appointments,
reporting of (laboratory) results, maternity care, decision support and prescribing and
pharmacy (medication management).  Within each section, there are overview and
scope sections, followed by the desired benefits and outcomes expected by using
the functionality, both generally and specifically for patients and clinicians.  There is
then a table of detailed requirements statements, for example ‘When the current
prescription course has ended, it shall disappear from the current list although still
be present within the medication history’ (113.5.5). Section 113 of the ICRS
describes all the requirements for ‘Prescribing and pharmacy’ reiterating the
statement that ‘prescribing and administering drugs to patients is a key care process’
and that ‘if inadequately informed, can also cause serious risks to patient safety’.
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Comment
Within Information for Health, although its clinical summary was to include ‘(a)
medication summary (previous and current)’ and the Spine was to gather ‘medication
events’, no definition or description of exactly what either of these really entailed was
provided.  This meant that the specification was open to a wide range of
interpretations as to what would or would not be a sufficient summary, and how that
summary could be generated from the currently available event-based information
sources and those that might possibly be available in the future. Differing
interpretations of a goal mean that it was almost impossible to achieve it, and that
indeed unfortunately was the case for the medication summary as described in the
Information for Health specification.
CEN/ISO EN 13606, Health informatics - Electronic Health Record Communication
In the wider European community, rather than defining a specification on the basis
of its outputs, the focus was on developing a specification for the architecture of an
EHR, the structure it should have to support its goal of being a cradle-to-grave record
of a patient’s health status and clinical care that could be communicated between
systems.  This effort centred on EN ISO 13606: the Electronic Health Record
Communication specification130.
13606 defines a rigorous and stable information architecture from which to
communicate part or all of the EHR of a single subject of care (patient) in order to
support the interoperability of systems that need to communicate (access, transfer,
add or modify) EHR data via electronic messages or as distributed objects.   It
stresses the importance of being faithful to preserve the original clinical meaning of
the data as intended by its author and of reflecting the confidentiality of that data as
intended by both the author and patient. As such, it has a generic reference
information model to represent the information structure (record components, with
items of content), which is then populated to describe the actual instances of clinical
information.   However, it does not provide definition of any individual clinical data
elements that would populate that reference information model; these are the
‘archetypes’: constraints and legal combinations of the classes of the reference
information model (specifying particular record component names, data-types and
prescribed value ranges and values) that then can be used to describe the things of
importance in particular clinical domains, organisations, and operational contexts.
Archetypes, once defined and verified, can be stored in a repository (library) for use
by a healthcare enterprise.  This library would form a metadata repository for that
enterprise, and the meaningful shared clinical semantics of the enterprise are then
metadata and terminology focussed rather than model (pattern) focussed.
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Comment
In terms of information to support a Medication Profile, 13606 does not and would
not explicitly reference medication data elements at all; that would be a task for an
archetype repository for an enterprise.    Because the current incarnation of an
archetype repository is enterprise-based, even though this was not its original
intention, there is a risk that different archetype repositories, even though based on
13606, would design different medication archetypes, depending on the functional
use cases to be supported. Although semantically interoperable communication
within the enterprise should be possible, as soon as communication outside the
enterprise is required, point-to-point information transform (mapping) will be required
with all its attendant risks of loss of information or unintended addition of meaning.
There are a number of initiatives currently looking at the development of archetypes,
or their close relation, detailed clinical models.  The openEHR Foundation133
provides ‘a set of archetypes for clinical use in an international setting’ though its
archetype repository134 (Clinical Knowledge Manager - CKM).  Searching in the CKM
for ‘medication’ offers 36 archetypes (as of January 2015) that include 24 that
reference medication information (e.g. an archetype for recording an adverse
reaction) and 12 whose focus is directly on medication information (e.g. an archetype
to describe an amount of medication).    None of the medication-focused archetypes
is standard in that their status is either ‘draft’ or ‘team review’, although one
composition archetype, which could be used to describe a medication list (in
conjunction with other more specific medication archetypes) has the status of
‘published’. Unfortunately, there is currently no formal quality process that could
move these archetypes to what could be considered a standard status.  The data
elements present in these archetypes have therefore not been considered for
inclusion in the analysis below because they cannot be considered a published and
authoritative.  The same would be true for the detailed clinical models produced by
openCIMI (Clinical Information Modeling Initiative)135.
HL7 EHR-S FM
In the USA and to a lesser extent in Canada, the focus has been on a functional
specification for the EHR, the operations that clinicians and others would undertake
that should be supported by the information in the EHR.  This focus centred on the
HL7 Electronic Health Record System Functional Model (EHR-S FM)136.  The HL7
EHR-S FM specifies sets of functions, divided into seven functional areas, which an
EHR system should support.  It also gives a standardised description of each
function so that there can be a common understanding of what the function actually
entails.  Finally, it creates domain Functional Profiles that go across the functional
areas and create subsets that constrain individual functions as required or desired
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in a way that is deemed appropriate for use in various contexts of care (primary,
secondary).  The specification is clear that implementation of it ‘is not sufficient to
provide a longitudinal health record’.  It does however aim that ‘information exchange
enabled by (it will) support the population of clinical documents, event summaries
and in the future will enable a longitudinal health record’.
The HL7 EHR-S Functional Model also provides a Glossary, so that concepts
referenced in the requirements statements can be understood. Also in the Glossary,
there is a definition of that most elusive concept, a patient’s ‘Current Medication’: ‘A
medication that a patient is using, either on a regular basis or on an ad hoc basis
(e.g., “two pills as needed for pain”).  A medication that has been dispensed to a
patient and whose administration has not yet been completed or finished according
to the medication’s intended duration, dose, frequency, and quantity.’
Section CP.6 in the EHR-SFM describes Medication focused functionality, ‘the
functionality required to support the safe administration of medications or
immunizations to a patient based on medical requirement and orders within the
system. This includes presenting providers with the list of medications or
immunizations that are to be administered to a patient, necessary administration
information, and capture all required and relevant administration details’.  The
specification then gives a long set of formal requirements statements that a system
could claim conformance to, for example: ‘The system SHALL provide the ability to
render the list of medications that are to be administered’ and ‘The system SHALL
provide the ability to render the list of medications that are to be administered
including all administration directions/instructions (SIG)’.
Comment
Although the HL7 EHR-S Functional Model is primarily about functionality, it does by
implication provide some data element requirements, as the functions mentioned list
(although do not define) particular items of information, for example to describe
dosage instructions.  The Glossary goes some way to address the definition
necessary for implementation of such a functionality-based specification, much more
so than the NHS ICRS.  However, it can be argued that in health informatics, the
relationship between concepts is as important to their definition as a textual
description, and therefore although the Glossary in the HL7 EHR-SFM is useful, it is
not sufficient to support its implementation in such a way that conformant systems
would be semantically interoperable.
Within the HL7 EHR-SFM, in the initial overview section (section 4) the example
used following the section descriptions is ‘Manage Medication List’.  This highlights
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how often a medication management activity is a poster child in healthcare
informatics generally and in this specification in particular.  In the Glossary, there is
a specific clarification section (section 7.6.4 Clarification of Terms) that deals with
distinction of ‘nuanced’ or ‘troublesome’ terms and it has just one entry: to discuss
the difference between a ‘medication order’ and a ‘prescription order’ – again
showing just how complex the whole medication domain is deemed to be. The
outcome of this clarification was that, for the EHR-S Functional Model ‘prescription’
was to be used only to refer to the document from an authorised practitioner that is
required for ordering of medications because of jurisdictional legislation, before the
medication can be supplied. ‘Medication order’ is a wider term, covering the use of
all medicines, and is the preferred term in the HL7 EHR-S Functional Model.
Overview of Patient Summary Specifications and their medication
information
None of the EHR initiatives has solved the problem of how to share health
information, and specifically information about medication, although they have
obviously contributed to the field.  In more recent years, the focus of standardisation
has shifted away from trying to specify the EHR or parts of it in terms of functionality
or in terms of record architecture, towards patient summary interoperability
specifications, of which European Patient Summary Guidelines137 and the Continuity
of Care Record19 have been two of the most prominent.  The aim of both of these
interoperability specifications is to describe a core set of information that systems
should be able to share between them to support basic patient care, then, over time
gradually enrich these specifications to (hopefully) lead towards a shareable cradle
to grave record.
The Continuity of Care Record (CCR) (USA)
The Continuity of Care Record (CCR) describes a core set of the most relevant
administrative, demographic, and clinical information about a patient’s healthcare,
which may be derived from one or more healthcare encounters. Its purpose is to
provide a mechanism for one healthcare practitioner and/or system to aggregate all
of the pertinent data about a patient and forward it to another practitioner and/or
system to support the continuity of care for that patient. The colloquial phrase often
used is to share ‘a snapshot in time’ from one system and therefore one practitioner
to another for a specific patient. The intent of the CCR is to enhance patient safety
by reducing errors and to reduce the cost of care by enhancing efficiency of health
information exchange.  It aims to do this by assuring at least a minimum standard of
health information transportability when a patient is referred, transferred, or is
otherwise seen by, another healthcare provider.
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After its introduction describing its scope and purpose, and a large glossary section,
the CCR specification expresses its intended significance and benefits to patients
and clinicians from its use.  It is in this section (4.2) that the CCR summarises the
information that it considers is essential for the delivery of good patient care, which,
when provided can ‘serve as a necessary bridge to a different environment, often
with new practitioners who know little about the patient’. It is here that medication
information is listed, along with allergies, current and recent past diagnoses, most
recent healthcare assessments and services, advance directives, and the
recommendations of practitioners who last treated the patient. The main focus of
the specification then follows, describing the CCR itself, and the sections of the body
of the record.  Section 5.1.2.9 Medications should contain ‘a patient’s current
medications and pertinent medication history’ and that ‘At a minimum, the currently
active medications should be listed, with an entire medication history as an option,
particularly when the CCR is used for comprehensive data export’. There then
follows, as an Annex, a description of the xml schema elements (tags) that make up
the CCR, with their definition and description, examples and optionality, and in a
second Annex, some implementation guidance with exemplar completed xml
snippets for various sections.
Comment
Despite having listed medication information as essential to support good patient
care, the CCR specification somewhat contradicts itself in its focus on the criticality
of medication information, as in the detail of the specification in the xml data objects,
the Medication data object is stated as ‘optional’ in any one CCR for any one patient
in any one context.  But it then says, in the same line, ‘At a minimum, the currently
active medications should be listed, with an entire Medication History as an option,
particularly when the CCR is used for comprehensive data export’. This paradox of
such specifications, trying to be flexible enough and generic enough to please
everyone and therefore not risking mandating everything, does risk the value of the
specification and makes useful and conformant implementation difficult.
Just as with the HL7 EHR-SFM, medication information plays a poster child role in
the CCR; for example, when describing the requirement to validate critical
information from the CCR before further action, ‘current medications’ are given as
the example (section 1.6); and in the examples of data objects in the CCR, given in
the Appendix (A2.3.1.4) the first example is of amoxicillin as a medication object.   In
describing medication information, the CCR relies heavily on an existing US-based
Community Pharmacy standards organisation, the National Council for Prescription
Drug Programs (NCPDP)138 and on two US-based identification systems for
medicinal products: the National Drug Code139, managed by the Food and Drugs
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Administration and RxNorm, a metathesaurus managed by the National Library of
Medicine112.  However, the CCR does provide a significant amount of detail on the
data elements that it specifies are part of the Medication section, and these have
been analysed in detail in the Results section below.
The European Patient Summary Guidelines
The European Patient Summary Guidelines have their primary focus to support the
objective of continuity of care and patient safety across borders, as stated in Article
14 (2) (b) (i) of the Directive on patients’ rights in cross-border healthcare140. The
Guidelines focus on defining the data elements needed to safely provide emergency
or unplanned care in a cross-border context.  They also have a secondary purpose
of being available as reference material for member states; the Guidelines
acknowledge that ‘advanced and elaborate Patient Summaries exist in some
member states’ (page 3) but for other states, the Guidelines serve as a baseline for
development.  This means that they describe not only what data is to be included in
the Patient Summary but also that they provide the ability to assess the implications
of adopting a patient summary in practice, especially in terms of organisational,
technical and semantic requirements. The aim of the Guidelines is that member
states should commit to implementing the dataset in whatever systems are or will be
developed in their jurisdictions.  Semantic interoperability is highly desirable for the
Patient Summary, and towards that aim, the Guidelines offer a ‘a non-exhaustive list
of data that are to be included in patients’ summaries and that can be shared
between health professionals to enable continuity of care and patient safety across
borders’ (page 5).  The Patient Summary should be useful in any clinical encounter,
but it is likely to be most useful when the health professional and patient do not share
the same language and where, as an unplanned encounter, no information is readily
available. Following on from its introduction, giving its scope and purpose and
describing its context in the European e-health landscape, the Guidelines provide a
set of exemplar use cases, showing when the Patient Summary would be used, not
just textual descriptions of the event, but also how the systems providing information
to each other would interact.
The Guidelines then move to the Dataset itself, which consists of ‘essential and
understandable health information’ that is made available ‘at the point of care to
deliver safe patient care during unscheduled care [and planned care]’ but which
should have its ‘maximal impact in unscheduled care’ (page 9).  This then constitutes
the minimum essential dataset needed to provide safe ongoing care for the patient,
especially for unscheduled care. The Guidelines list in detail the sets of variables
(data elements) that should be present in the Summary and giving definition of and
comments about them, and qualifying them as ‘basic’ or ‘extended’. Each field in
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the dataset was defined while ‘keeping in mind the medical perspective and the
clinical purpose’ (page 17). Implementation of the Guidelines is the responsibility of
the member states, although some guidance is given in the sections following the
dataset description, including how shared communication of the dataset might be
implemented technically, by the use of 13606 or the HL7 Continuity of Care
Document (the HL7 implementation of the CCR) or by the use of an IHE Profile for
Patient Care Coordination141.  Within the dataset there is a section called Medication
Summary which should contain a ‘list of current medicines’ and which define the
individual variables that would fulfil that summary (page 12).  These data elements
have been analysed in detail in the Results section below.
Comment
The Medication Summary is listed as ‘basic’ and therefore is considered by the
Guidelines to be core information within the Patient Summary.  The Guidelines
themselves identify areas where further work is required, and pick out in particular
the need for shared controlled terminology to be used to support the value sets for
each data element in the dataset.  This was the only specification to do this, and
reflects the very broad and multi-lingual nature of the healthcare enterprise being
addressed.
Methodology
As described in the Introduction, there is no one single gold standard specification
for a description how a patient’s medication information should be described in a
Medication Profile to support patient care, whether that Profile be in a longitudinal
health record or in a patient summary.   The aim of the investigation was therefore
analyse a set of the recognised national and international electronic health record
and health record summary specifications to document the data elements about
medicines that these require.  A data element that is present in all of the
specifications could be considered essential, a first class requirement on the
Medication Profile, whereas a data element present in only one of the specifications
may be considered a less important optional requirement in terms of the use case of
supporting patient care. There was not scope in this research to undertake an
exhaustive international survey of all available specifications, but this is not
considered an important limitation given their similarity. The specifications were
current and publically available during the period of this study, which was January to
April 2015.
Each specification was examined in turn and the medication sections identified.
From within these sections, the data elements requested were noted. The starting
point for the medication data elements was usually a description of the medication
itself (e.g., a section entitled ‘medicinal product’). The semantics (meaning) of each
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medication data element in each specification was determined, by examination of its
name, its description and critically, any examples of the instantiated data element
that were provided.  For instance, the data element named in CCR as <Dose> and
described as ‘This is the dose to be administered, not the dispensed dose’ can only
be identified as the thing that it really is (Dose Quantity) by looking at the example
given: ‘A simple dose example would be “250mg”’.  Each data element was then
given its own name and definition, independent of any one of the examined
specifications.  These definitions were based on or adapted from the relevant ISO
definitional standards142 for the data element; if no ISO standard is available, a data
element name and description has been made up, as semantically robustly as
possible.
The extraction of data elements was crosschecked by the author by undertaking a
separate second pass through each specification. The research supervisor
independently checked the extraction for a sample of various parts of the
specifications. Due to the heterogeneity of the format of the specifications and the
variation in granularity of the data elements themselves, an iterative approach was
used to develop a meaningful description of the Results in tabular form.
Results
Four specifications were examined to ascertain the data elements that each required
in their medication records; the details of the specifications shown below in Table 7
following.
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Table 7: Description of the EHR and patient summary specifications examined
Specification
Short Name
Specification Full Name Owner
CCR Standard Specification for
Continuity of Care Record
ASTM International
HL7 EHR SFM HL7 Electronic Health Record
System Functional Model
Health Level 7
International
EuPS Guidelines on minimum/non-
exhaustive patient summary
dataset for electronic exchange in
accordance with the cross-border
directive 2011/24/EU; Release 1
European
Commission
NHS ICRS Integrated Care Records Service
Output Based Specification Parts
1 and 2
NHS National
Programme for
Information
Technology (NHS
England)
High Level Data Elements
Table 8 below describes and compares the high level data medication information
required by each of the specifications.  The Data Element Definition provides a
standardised meaning for the data element, then for each specification, its stated
requirements for that data element are provided.
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Table 8: Definition of and comparison of the high level data elements of medication information from the EHR and patient summary specifications
Data
Element
Name
Data Element Definition CCR HL7 EHR SFM EuPS NHS ICRS
Medication
(Medicinal
Product)
Description of the medicinal product
itself (independent of the activity it is
used it – be that prescribing,
dispensing, (self) administration,
statement about)
‘list and describe the
patient’s current
medications and pertinent
medication history’
‘The system SHALL provide
the ability to render the list of
medications that are to be
administered’
‘The system SHALL provide
the ability to render the
medication administration
history including administering
provider, date, and time.’
‘List of current medicines’ ‘Medications must be able
to be added to the patient
profile by a patient or a
patient’s practitioner, or
electronically through
uploads from pharmacy
fulfilment files.’
Medication
‘Activity’
Description of the role in the Medication
Process that the medicinal product
played (e.g. being prescribed,
administered, or statemented)
‘list and describe the
patient’s current
medications and pertinent
medication history’
‘The system SHALL provide
the ability to render the list of
medications that are to be
administered’
‘All prescribed medicines whose
period of time indicated for the
treatment has not yet expired,
whether it has been dispensed or not’
Not required
90
Table 8 (cont.): Definition of and comparison of the high level data elements of medication information from the EHR and patient summary specifications
Data
Element
Name
Data Element Definition CCR HL7 EHR SFM EuPS NHS ICRS
Information
Date/Time
Description of the time when the
information about the medication was
made or recorded
Not required ‘Appropriate time stamps for all
medication related activity are
generated.’
Not required Not required
Status Indication of the state (standing, nature)
of the item of medication information
with reference to the role in Medication
Process – and whether it could be
considered current or historic, and
whether it has been reviewed
‘Deﬁnes the <Status> of
the <Product>.
[Active, On Hold, Prior
History No Longer Active]’
‘The system SHOULD provide the
ability to tag the medications that
are to be administered by the
patient (i.e. self-administered).’
‘The system SHOULD provide the
ability to capture an
acknowledgement from a user that
a medication order has been
reviewed including capturing the
date, time and user credentials.’
‘All prescribed medicines whose
period of time indicated for the
treatment has not yet expired
whether it has been dispensed or
not’
Not required
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Table 8 (cont.): Definition of and comparison of the high level data elements of medication information from the EHR and patient summary specifications
Data
Element
Name
Data Element Definition CCR HL7 EHR SFM EuPS NHS ICRS
Dosage
instructions
Description of the full set of
information that supports the
correct administration of a
medication to a patient in order
for it to have its therapeutic
effect143
‘<Directions> is the instructions
(SIG) component describing the
intended patient use of the
<Product>. <Directions>
contains an XML string deﬁned
as follows below:
Can be used to map a single
SIG or a complex recurring SIG
like a tapered dose or sliding
scale. Recurring SIG segments
are represented by repeating
the <Directions> tag and its
children.’
‘The system SHALL provide the ability
to capture, maintain and render
medication administration details as
discrete data, including:(1) the
medication name, strength and dose;(2)
date and time of administration;(3)
route and site;(4) administering provider
(5) observations, reactions and
complications (6) reason medication not
given, and/or medication related activity
not performed; according to scope of
practice, organizational policy, and/or
jurisdictional law. ‘
Some individual items of
dosage instructions
information described in the
dosage instructions table
below
‘Dose’ and ‘Route’
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Table 8 (cont.): Definition of and comparison of the high level data elements of medication information from the EHR and patient summary specifications
Data
Element
Name
Data Element Definition CCR HL7 EHR SFM EuPS NHS ICRS
Course of
Therapy
Timing
Description of the dates and/or
timing information when the
medication was  used by the patient
as a whole (synonymous with a
‘regimen timing’)
Often considered part of the full
dosage instructions set
‘Used to deﬁne dates and times relevant to the patient and the
Product.’
This can be an exact DateTime, an age, an approximate DateTime,
or a DateTime range.’
Not required Not required Not required
Dispensing /
Repeat
(Refill)
Information
Description of information needed
for correct dispensing of a
medicinal product to a patient/carer,
including labelling and repeat
information
‘<FulﬁllmentInstructions> for the <Product>, which in the case of
medications are the instructions to the dispensing pharmacist or
nurse. Label In Spanish, Dispense As Written. <Refill> Deﬁnes the
number of <Reﬁlls> and any constraints on <Reﬁlls>. Includes
<Number>, <Quantity>, <DateTime>, to deﬁne ’Last Reﬁll,, and
<Comment> for any speciﬁc <Reﬁll> alerts or comments.
‘The system SHOULD
provide the ability to
render medications as
dispensed (including dose
and quantity of dispensed
units of medication).’
Not required Not required
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Table 8 (cont.): Definition of and comparison of the high level data elements of medication information from the EHR and patient summary specifications
Data
Element
Name
Data Element Definition CCR HL7 EHR SFM EuPS NHS ICRS
Regimen Description of any order or pattern
between items of medication
information that is important – e.g.
for a treatment regimen
‘<SeriesNumber>
Deﬁnes the <SeriesNumber> of the <Product>, for use when there is
a series of medication administrations. Enoxaparin, chemotherapy,
etc.’
Not required Not required Not required
Note that all bar one of the specifications describe the role that the Medication is playing in the overall Medication Process.  This is done by indicating whether the
Medication is/was prescribed (ordered) (i.e. from a prescription), or was dispensed or administered (i.e. is an administration record) or whether a statement about
Medication administration is being made (i.e. ‘medication was taken from this time to this time’).  The exception is the NHS ICRS, which implicitly assumes that all
information will be in the form of Medication statements, and therefore describes who should add statement information rather than what statements should be made.
Only the CCR and HL7 SFM mention data elements that are specifically to support dispense information – such as refill numbers and repeat dispensing time
information.
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The CCR supported some methodology to relate together different medications as part of a regimen or programme of therapy (as with cancer chemotherapy).  However,
the mechanism to implement this is not clear from the single numeric data element. The CCR also included ‘Course of Therapy Timing’ as a high-level data element;
this would normally be considered part of the more granular dosage instructions.
Low Level Data Elements
Medication
The first high-level data element required in all specifications was identification of the medication itself.  In Table 9 below, the detail of the granular data elements
required by each specification to fully describe a medication is provided.  As in the previous table, the Data Element Definition provides a standardised meaning for
the granular data element, then for each specification, its stated requirements for that data element are given. If a standard definition for the data element is available,
that is used and reference.
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Table 9: Definition of and comparison of the data elements for description of medications from the EHR and patient summary specifications
Data
Element
Name
Data Element
Definition
CCR HL7 EHR SFM EuPS NHS ICRS
Medication
(medicinal
product) code
(often referred to
as ‘ID’)
A machine-readable identifier
- a ‘code’ from a coding
system to identify the
medicinal product. e.g. an
NHS dm+d code or an
RxNorm code
Instance of IDType, which includes child elements <Type>, <ID>,
and <IssuedBy>.
‘The system SHALL provide the
ability to capture and maintain
the medication identification
number of the drug administered
to the patient (e.g., NDC number,
lot numbers, expiration date).’
Not required ‘The medications must be able
to be either entered as coded
drugs…..’
Product Name The human readable
designation for the
medication – either as the
‘preferred name’ from the
coding system used or a free
text product appellation –
brand or generic
‘<ProductName> Deﬁnes the generic name for prescriptions and
over-the-counter medications and non-proprietary name for non-
medication products. An NDC Code or RxNorm Code (preferred)
should be used when <Product> is used to describe a medication.
<BrandName> For the medications that are branded, It deﬁnes
the <BrandName> of the <Product>. One should also provide the
generic name of the medication as <ProductName> above.
<Manufacturer> Deﬁnes the <Manufacturer> of the <Product>.’
‘The system SHALL provide the
ability to capture, maintain and
render medication administration
details as discrete data,
including: (1) the medication
name, strength ‘
Not required ‘The medications must be able
to be either entered as coded
drugs, using the drug search, or
as free text if the item is not in
the formulary (e.g., herbs,
vitamins, etc.).
Medication name; generic name
(if applicable);’
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Table 9 (cont.): Definition of and comparison of the data elements for description of medications from the EHR and patient summary specifications
Data Element
Name
Data Element
Definition
CCR HL7 EHR SFM EuPS NHS ICRS
Active Ingredient
Substance (plus
code)
The
chemical/biologic/mineral
matter of defined
composition present in the
medicinal product that
produces or contributes to
the therapeutic effect of
the medicinal product144
Not required Not required ‘Substance that alone or in combination with
one or more other ingredients produces the
intended activity of a medicinal product.
Example: ‘paracetamol’. Brand name if a
biological medicinal product or when
justified by the health professional (ref.
Commission Directive 2012/52/EU). Code
that identifies the active ingredient’
Not required
Strength
Note: CCR has
‘size’ included in
Strength; this is not
appropriate except
for device products
The amount of active
ingredient substance(s)
present in single
administration unit of the
medicinal product144
‘Strength> Deﬁnes the predeﬁned strength of
the <Product>. MeasureType with <Value>,
<Units>, and <Code>. <Units> has children
<Unit> and <Code>. <Form> <Concentration>
MeasureType with <Value>, <Units>, and
<Code>. <Units> has children <Unit> and
<Code>. <Size> (e.g. small, medium, large)’
‘The system SHALL provide the
ability to capture, maintain and
render medication administration
details as discrete data, including:
(1) the medication name, strength’
‘Content of the active ingredient expressed
quantifiably per dosage unit, per unit of
volume or per unit of weight, according to
the pharmaceutical dose form. Example:
500 mg per tablet’
Not required
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Table 9 (cont.): Definition of and comparison of the data elements for description of medications from the EHR and patient summary specifications
Data Element
Name
Data Element Definition CCR HL7 EHR SFM EuPS NHS ICRS
Dose Form The physical manifestation of the medicinal
product that contains the active ingredient(s)
and/or inactive ingredient(s) that are intended to
be delivered to the patient144
‘<Form> - dose form’ ‘Form in which a
pharmaceutical product is
presented in the medicinal
product packaging (e.g. tablet,
syrup)’
Not required ‘Dosage form’
Diluent or
Vehicle
Any substance used with the medicinal product to
support its  administration to the patient, as in a
diluent or carrier substance
‘Used to deﬁne a <Vehicle> used to deliver
the <Product> such as an IV solution. D5W,
normal saline, etc.
Note: is in dosage instructions section in the
CCR specification’
Not required Not required Not required
Quantity The amount of medicinal product being referred to
(for dispensing/supply)
Note: this is not the dose quantity
‘Quantity> MeasureType with <Value>,
<Units>, and <Code>. ‘
Not required Not required Not required
Note that the HL7 SFM is the only specification to include data elements for the lot number (batch number) and expiry information for the medicinal product.
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Dosage instructions
The other information for which the majority of specifications described requirements for significantly more granular data elements detail is that of dosage instructions.
Table 10 below shows this for three of the four specifications; the NHS ICRS had only a minimal requirement for ‘Dose’ (no further explanation) and ‘Route’ data
elements, so it has not been given its own column in this detailed table. As in the previous tables, the Data Element Definition provides a standardised meaning for
the granular data element, then for each specification, its stated requirements for that data element are given.  If a standard definition for the data element is available,
that is used and reference.
Table 10: Definition of and comparison of the data elements for description of dosage instructions from the EHR and patient summary specifications
Data
Element
Name
Data Element
Definition
CCR HL7 EHR SFM EuPS
Dose Quantity Describes the ‘amount’ of the
described medication that is to
be administered to the patient
at a single point in time (i.e. a
single dosage administration
act)143143
‘<Dose>
This is the dose to be administered, not the dispensed dose. Dispensed dose
is found under <Strength>, above. This is the dose portion of the SIG which
can deﬁne a ﬁxed dose or can repeat to deﬁne a variable dose, dose range,
or dose options. This is the numeric or text expression of the dose. A simple
dose example would be ’250mg’ where the value in this ﬁeld would be ’250’. ’
the medication name,
strength and dose
Number of units per intake that the patient is
taking.
Example: 1 tablet
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Table 10 (cont.): Definition of and comparison of the data elements for description of dosage instructions from the EHR and patient summary specifications
Data
Element
Name
Data Element
Definition
CCR HL7 EHR SFM EuPS
Rate of
Administration
Describes information about
the ‘delivery speed’ with which
a specified amount of a
medication should be
administered to a patient per
unit of time143
‘Dose also includes: Also contains <Rate> and for multiple or variable doses.
<DoseSequencePosition> and <MultipleDoseModiﬁer>.’
‘<DoseCalculation>
This segment is used to express a dose as a calculation, such as ’40mg/kg/day divided into 3
doses’. This segment is used in conjunction with <Dose> to allow the expression of a dose as a
calculation. Also used to express doses to be calculated by nurses based on physiological
parameters, such as Dopamine, Nipride, etc. Amoxicillin for a child is dosed at approximately
40mg/kg/day/2 to 3 doses. For a 9kg child, an appropriate dose would be 125mg tid. To express
this, the prescribing physician would put ’125mg’ in the <Dose> (and ’tid’ in <Frequency>)
and ’40mg/kg/day/3 doses’ in <DoseCalculation>. This allows the pharmacist to look at the dose
(125mg tid) and do a secondary patient safety check against the desired dosing
of ’40mg/kg/day/3 doses'‘
Not required Not required
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Table 10 (cont.): Definition of and comparison of the data elements for description of dosage instructions from the EHR and patient summary specifications
Data
Element
Name
Data Element
Definition
CCR HL7 EHR SFM EuPS
Route of
Administration
Describes which way that the
administered medication should
take to get into the body or into
contact with the body143
‘<Route>
Used to deﬁne the <Route> of administration. po, pr, sl, etc. ’
‘route and site;’ Not required
Site of
Administration
Describes the specific area of the
body ‘where’ the medication is to
be administered143
‘<Site>
Used to deﬁne the physical location on the patient for use, implantation, or
administration, where speciﬁed.  Right gluteus, left deltoid, Hickman catheter, etc.’
‘route and site;’ Not required
Method of
administration
Describes ‘how’ the medication
should be administered - the
particular way of carrying out or
accomplishing the substance
administration143
‘DeliveryMethod>
The textual representation of the Dose Delivery Method. This is the method in which the
dose is delivered (describes how the dose is administered/consumed). Deﬁnes the
method: take, apply, swish, swallow, inject, insert, chew, use, give, sprinkle, mix,
dissolve’
Not required Not required
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Table 10 (cont.): Definition of and comparison of the data elements for description of dosage instructions from the EHR and patient summary specifications
Data
Element
Name
Data Element
Definition
CCR HL7 EHR SFM EuPS
Dose Timing Describes fully the ‘when’ for
medication to be (or was)
administered to the patient143
‘<AdministrationTiming>
This is used to deﬁne a speciﬁc administration or use time. Can repeat for more than
one administration time. Can be a text string (Morning, Evening, Before Meals, 1 Hour
After Meals, 3 Hours After Meals, Before Bed) or an exact time.’
‘date and time of
administration’ ‘Date when
patient needs to start taking
the medicine prescribed’
‘Date of onset of
Treatment: Date when
patient needs to start taking
the medicine prescribed’
Frequency Describes when the medication
(expressed as the dose quantity)
is to be (or was) administered to
the patient using a measured
time pattern (twice per 24 hours,
once per 2 weeks, every 6
hours)145
‘<Frequency>
Used to deﬁne a <Product> frequency of use/admini stration qd, bid, tid, qid, qod, etc.’
‘<Interval>
Used to deﬁne a <Product> interval of use/administration. q15m, q2h, q4h, q12h ’
Not required ‘Frequency of
Intakes: Frequency of
intakes per
hour/day/week/month.
Example: every 24 hours’
Duration of
Therapy
Describes how long the course of
therapy of that medication is to be
or was143
‘<Duration>
Used to deﬁne the <Duration> of use or administration of a product. x 10 days’
Not required ‘Duration of Treatment
Example: 14 days’
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Table 10 (cont.): Definition of and comparison of the data elements for description of dosage instructions from the EHR and patient summary specifications
Data
Element
Name
Data Element Definition CCR HL7 EHR SFM EuPS
Dosage Upper
Bound
Describes a limit for the amount of
medication that can be administered
during a particular timing period143
‘<DoseRestriction>
This segment can repeat for more than one dose
restriction. This is the dose restriction segment of the
SIG which deﬁnes a maximum or dose imit. ’Not to
exceed 10 Tablets in 24 Hours’ or ’1000 mg/kg/hr’.’
Not required Not required
Indication Describes the intended (therapeutic) use
and reason for the medication being
administered146
‘<Indication>
Deﬁnes the <Indications> for the use of the
<Product>. This can be a <Description> or a
<Problem> or a link to a <Problem> within the CCR, or
one or more <PhysiologicalParameter>. It also
includes a PRN designator.’
Not required ‘The service shall facilitate the documentation
against patients or individual drugs of: the
reasons / indications for drug therapy initiation
and the reasons for an individual drug choice
and/or the reason for rejection of a particular
drug;’
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Table 10 (cont.): Definition of and comparison of the data elements for description of dosage instructions from the EHR and patient summary specifications
Data
Element
Name
Data Element Definition CCR HL7 EHR SFM EuPS
Non-
administration
Reason
Describes the cause or motivation why
a medication was not administered to
the patient as according to the
described dosage instructions
Not required ‘reason medication not given, and/or
medication related activity not
performed; according to scope of
practice, organizational policy, and/or
jurisdictional law.’
Not required
Discontinuation Describes information about when the
medication administration (is to be)
ceased
<StopIndicator>
Used to express a hard stop, such as the last SIG sequence in a tapering
dose, where the last sequence is ’then D/C’ or where the therapy/drug is
used to treat a condition and that treatment is for a ﬁxed duration with a
hard stop, such as antibiotic treatment, etc.
An instance of CodedDescriptionType. Can have the value Yes or the tags
will not exist and there will be no content (the null instance of a
<StopIndicator>).
Not required Not required
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Table 10 (cont.): Definition of and comparison of the data elements for description of dosage instructions from the EHR and patient summary specifications
Data
Element
Name
Data Element Definition CCR HL7 EHR
SFM
EuPS
Clause
Sequence
Describes the (ordinal) position of a particular clause
(set of dosage instructions) within a full set of
dosage instructions for a single medication; should
be used with the conjunction ‘then’ 145
<DirectionSequencePosition>
Used when the <Direction> repeats (multiple SIGs) such as with an insulin sliding
scale or tapering dose, etc.
Not required Not required
Clause
Conjunction
Describes the relationship between of two dosage
instructions clauses (within a full set of dosage
instructions for a single medication (or, then, and)143
<MultipleDirectionModiﬁer>
Deﬁnes the relationship between multiple directions (SIGs). Used with the values
AND, OR, or THEN to express when there is more than one SIG as to whether all the
SIGs must apply (AND) or if any of the SIGs can apply (OR) or if the SIGs are
sequential (THEN), in the sequence deﬁned by <DirectionSequencePosition>.
Not required Not required
Additional
Instructions
Describes any other additional instructive information
about the administration of the medicine; it is usually
non-quantitative in its nature143
<PatientInstructions>
Deﬁnes the <PatientInstructions> for the <Product> that are not covered under
<Directions> - in other words <PatientInstructions> that are not traditionally part of
the SIG. Take with water.
Not required Not required
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Discussion
High level Data Elements
All specifications have a description of the medication (medicinal product) being
referenced.  Whilst this would seem to be almost an absolute requirement – how
could information about a patient’s medication be described without describing the
medication? – this is not necessarily so.  In the clinical research domain, medication
has been described less directly, by reference to its membership of a therapeutic
group, or by its indications, as will be seen in the following chapter.
Only the EHR SFM explicitly mentions a timestamp for the system capture of
medication information.  To know when something occurred seems such a key
requirement that possibly the other specifications consider such information to be
metadata about the medication information and therefore do not explicitly describe
it in the detail of the specification.  For example, the EN ISO 13606 model requires
the capture of that time stamp for all information, which would include medication
information, if that was part of the archetype being used).
All but the NHS ICRS have some way to indicate whether the described role of the
Medication is current (active) information or historic (no longer active) information.
From the description and examples in the specifications, ‘current’ information is
implicitly taken to be medication that the patient is actively using at the time the
information was recorded (for example, a current prescription implies that the patient
may have received a supply as dispensing information is available and therefore is
assumed to be administering it at that time). ‘Historic’ information concerns
medication information that was used at some time before the time when the
information was recorded. ‘Current’ and ‘historic’ as terms here are given their
meaning in the context of administration of medication, not in the context of
medication information that is relevant to clinical decision-making.   It is concerning
that there is no explicit definition of ‘current’ and/or ‘historic’ given formally, since
these are informatics specifications and implicit definition is always at risk of
misinterpretation.
All the specifications mention dosage instructions in some way, ranging from just the
two elements of ‘Dose’ and ‘Route’ in the NHS ICRS through to very granular and
detailed data elements in the CCR.  The CCR also has a specific Course of Therapy
Timing data element at this high level, which, from its description, indicates that it
allows this timing to be expressed not just as a set of actual dates but as relative
timing, by specifying the age of the patient when the medication statement is/was
relevant.  For example, it would support a statement such as ‘phenytoin was taken
[by this patient] from age 5-9 years’.
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Low level Data Elements
Medication
All but the EuPS have requirements for a machine-readable code to describe the
Medication and a human readable display name as separate data elements.  Note
that most system implementations (and especially all those using the ISO 21090
healthcare datatypes147) this would be implemented in systems as a single data
element with a complex datatype, thereby not splitting the machine-readable and
human readable elements for the same thing.  It is likely that the EuPS does not
have this requirement because there is no applicable pan-European Medicinal
Product code system that is able to satisfy this requirement; the Horizon 2020148
openMedicine initiative149 from the European Commission has specifically set up a
project to address this need.   Because of this lack of a pan-European Medicinal
Product code system, the EuPS specification has an active ingredient data element,
allowing the use of the international non-proprietary name for medicinal substances,
which is applicable throughout Europe.
All but the NHS ICRS have a description of the product strength as a separate data
element, even though this is likely to be in the medication display name obtained
from a code system.  This is also true for information about the product dose form,
and here the EuPS is somewhat illogical in that it does not require this data element,
so the Summary would contain information about active ingredient(s) and strength(s)
but not the dose form that these would be formulated into for use by the patient.
However, some medicinal product code systems do have the additional facility to
describe the product in an abstract way, without dose form and strength information,
so specifications have to allow for that variability.  Unfortunately, without guidance
and examples (which none of the specifications gave), there is a risk that an
inappropriate combination of data elements are populated, or worse, populating the
data elements with contradictory information, making the medication information less
than fully useful.  For example, if the Product was described as ‘amoxicillin 250mg
powder for solution for injection’ but the dose form was given as ‘oral solution’ there
is a clear inconsistency in the information which cannot but cast some level of doubt
on the accuracy of the information overall.
The CCR also has data elements to support information about diluent(s)/vehicle(s)
to be used with the Medication and for quantity; all of these are ‘instructional’
information that would specifically support dispensing activity, which is consistent
with CCR also having repeat and refill information.
Description of a medication is not the subject of this thesis, but the medication
(medicinal product) does have to be described in sufficient detail for the information
in the Medication Profile to make clinical sense, to support the linking together of
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information from the different medication processes and to support the distinction of
the various types of courses of therapy.  With the implementation of the ISO 11615
specification144 to provide a full international code system for all authorised and
investigational medicinal products, a human readable product name and machine-
readable code should suffice; however, dose form, strength and diluent vehicle
information may be needed (together) to describe magisterial products.
Dosage instructions
The lower level data elements in the dosage instructions section describe in
machine-readable detail when and how the medication is being, was or should be
administered to the patient.
The minimal requirements specified in the NHS ICRS for dosage instructions were
for a ‘Dose’ data element, with no further explanation of what this should be, and no
examples provided, and a ‘Route’ data element.  It is here assumed that ‘Dose’
means at a minimum the Dose Quantity, but possibly also some aspects of Dose
Timing.  This is very poorly specified, especially for such an important document for
the English NHS (at its time) and as such meant that the specification was un-
implementable for any system, and particularly a system that was envisaged to be a
central care record.
Dose Quantity
This data element is included by all three of the specifications that provide granular
data elements for dosage instructions.  However, to make that statement, one must
make the assumption, for the HL7 S-FM, that ‘Dose’ is indeed dose quantity. For
continuous administrations, such as intravenous infusions or gases administered
through masks or similar devices, a rate of administration may be given rather than
a dose quantity (specified as a quantity per time period).  Only the CCR specification
had a rate of administration data element.
Route, Site and Method of Administration
The CCR, HL7 S-FM and the NHS ICRS all included a route of administration data
element; the EuPS did not include this.  Occasionally, specifications may assume
that route of administration information can be imputed by knowing the dose form of
the medication itself (for example, tablets are normally for oral administration, eye
drops for ophthalmic administration etc.) however the EuPS does not specify a dose
form data element.
The CCR and the HL7 S-FM both had a data element for site of administration,
whereas only the CCR specified method of administration information.    Both of
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these data elements are necessary only in a proportionally small number of sets of
dosage instructions.  For example site is given when laterality is important (e.g. left
eye for eye drops), in situations where similar products are to be used at different
sites (e.g. different strength topical steroid products on different body sites) and
when the medication itself needs a particular site (e.g. cytotoxic medication that
should be administered through a specific usually central vein).  Similarly, method of
administration is only important when there are choices (infusion or injection) or
when it is unclear (for example that a tablet should be chewed before swallowing).
Timing
All of the specifications had some timing information, particularly information as to
when the medication should/did start, except for the NHS ICRS, unless one assumes
that the ‘Dose’ was meant to include it.   The CCR and the EuPS specify data
elements for both a frequency of (single dose) administration and the duration of the
therapy, and no specification had a data element for dose duration (for continuous
administrations where the quantity is specified by rate) or for the duration of a cycle
of therapy (for example the 28 day cycle of an oral contraceptive medication, in which
medication is only administered for 21 days, or for chemotherapy cycles).
None of the specifications made any mention of implementing the data elements in
such a way as to allow partial timing information to be recorded – for example,
supporting timing of ‘early-2008 until mid-2010’.  This facility can be very useful for
recording generic statements made by patients or carers when gathering or verifying
a medication history.
Other Data Elements
The CCR and the EuPS specified a data element to capture the indication for the
use of the mediation.
The EuPS also specified a data element to describe a reason for a medication not
being administered.  It is not clear whether this is to be used for total non-
administration (this therapy was prescribed but never dispensed or administered for
this reason) or non-administration of a single dose (the 10pm dose was not
administered, as the patient was asleep) or would be suitable for both.   The CCR
specified a ‘stop indicator’ – when the medication should be discontinued (as
opposed to when it was discontinued which would be part of the duration of therapy
information).  Neither of these data elements as described would be suitable to
capture discontinuation reason information (e.g. medication discontinued due to
intolerance or ineffectiveness).
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The CCR had a data element to describe ‘additional instructions’ which are mainly
aimed at dispensing and labelling, and as such are relevant only to that one part of
the medication process and not to summary information.
The CCR was also the only specification to describe dosage instructions clause
information, the sequence in the high-level data elements and the conjunction of
these, and therefore was the only specification that could support the description of
complex dosage instructions.  This indicates the depth of the CCR specification
through its requirement to support complex dosage instructions in a machine-
readable way.  This is in contrast to the other specifications that, it is assumed,
expect complex dosage instructions to be given in human readable text only.  Given
that only machine-readable dosage instructions are candidates for dosage checking
functionality and that in the spectrum of health information, even complex dosage
instructions are highly structured, it would seem reasonable to have the facility to
specify and implement machine readability of dosage instructions at some level of
complexity.
Limitations of this study
All of the specifications that have been described and analysed here have been
authored following a similar process, by the brainstorming a set of either invited or
volunteer experts, and for some of these there is little if any transparency in that
development process.  Only the HL7 EHR-S FM actually provides any reference to
its development process in its content: in the Scenarios section [5.5.1] it states:
‘Dr. Smith and interested colleagues review an Ambulatory Care
registered profile to see how the use setting and scenario illustrate the
EHR functions related to their practice; they look at the Ambulatory
Care prioritization of the individual functions that a group of experts
working with HL7 have identified. They both begin by looking at an
Acute Care balloted profile to see how a group of experts working with
HL7 have identified how an EHR-S could be used within a hospital.’
For both 13606 and the HL7 EHR-S FM there has been a ballot process, in
accordance with the procedures of the relevant standards development organisation,
and indeed the HL7 EHR-S FM states: ‘committee members and interested industry
participants have formally reviewed and balloted [the normative content] following
the HL7 procedures’ [section 1.1, Table 1].  For all the other specifications, the
development and consultation process is far from transparent, and therefore likely to
be based on the professional opinion of those (invited to be) involved.
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Decisions made in healthcare, whether at the highest levels of policy for a nation or
group of nations, or at the lowest (but most personally important) level of the care of
an individual person in a family, should be made with consideration of the best
available evidence as to the validity, safety and efficacy of the course of action
decided upon.  That evidence is therefore foundational and in itself should be
validated, and there is a growing recognition that not all evidence is equally valid.
Initial work on evidence validation assessed the evidence of interventions made to
sustain or improve health, and this have led to the understanding that the
randomised controlled study provides one of the most valid levels of evidence150.
However, in recent years understanding has developed to take a broader view of
evidence, so that rather than looking at single studies, a systematic review of all
studies is undertaken, with each contributing study being evaluated for quality before
its contribution to the overall set of evidence is evaluated151.  However, randomised
controlled studies are not appropriate research methods in all situations, other
methods can be more appropriate; so these need then to be evaluated for the risk
of error and/or bias in their results.  This has led to the description of hierarchies of
evidence to allow different research methodologies to be categorised in terms of the
probable validity of their results as evidence152.
One of the best-known hierarchies of evidence is that produced and most recently
revised 2009 by the Centre for Evidence-Based Medicine153 - the ‘Levels of
Evidence’.   In all areas, and specifically relevant here in the category of ‘Economic
and decision analyses’, expert opinion, and particularly expert opinion without critical
appraisal is specified as the lowest level of evidence (of 5).  The CEBM also wisely
opines: ‘What are we to do when the irresistible force of the need to offer clinical
advice meets with the immovable object of flawed evidence? All we can do is our
best: give the advice, but alert the advisees to the flaws in the evidence on which it
is based’. That same caveat should surely apply to all these specifications; however,
by having undertaken a systematic comparison and analysis of them, it is possible
that the outcome, i.e. the requirements described in this chapter, could then be
considered as closer to a  systematic review, which would move it evidence to level
3a.
Recommendations for further work
Specifications in EHRs and patient summaries, particularly for medication
information, should be authored in open and transparent processes, based on best
available evidence of need, as opposed to continuing to be authored based on
(limited) expert opinion.  Using this work as a basis, further evaluation of the
evidence to support the requirements for data in EHRs and patient summaries
should be undertaken, nationally and internationally.  This should allow development
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of specifications and systems that truly serve the needs of patients and healthcare
professionals using the limited resources available for that development. All
specifications should clearly and fully define the concepts they use, providing full
examples.
Conclusion
Based on the assessment of current specifications for EHRs and patient summaries,
the data elements that essential to be present and populated in a Medication Profile,
in that they are required by the majority of the specifications, should be as follows:
 A description of the medication itself, preferably from a robust medicinal
product terminology, but if that is not available, through description of active
ingredient substance(s) and strength(s) and dose form
 A description of the status of the medication (active/current/ongoing,
concluded/past)
 Basic data elements from the dosage instructions; at a minimum the
o Dose quantity
o Course of therapy timing; the date of starting (and stopping, if
relevant) the medication
o Route of administration
Data elements that should be present in a Medication Profile, based on their
presence in one or more of these widely available EHRs and patient summaries are
as follows:
 Other elements of dosage instructions
o Site and method of administration
o Individual dose frequency
 Indication for the medication
 Discontinuation information, including reason
 Dosage instructions clauses, with their attendant sequence and conjunction
indicators
Information to supporting dispensing and active administration are pertinent to those
processes only and are not necessary as part of a Medication Profile.
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Part 2:  Safe Medication Processes and Medication
Decision Support
Introduction
The administration of a medicine to a patient is by far the most common therapeutic
intervention made by healthcare professionals as they seek to change the course of
events of a healthcare condition for the benefit of the patient concerned1.  It is also,
after staff costs, the most resource intensive; in the year 2014/2014, the NHS in
England spent £14.4 billion on medicines154 that is approximately 15% of the total
budget155.  Using medicines safely and reducing risks has been and is of continuing
concern to individual healthcare professionals, to their employers and related
organisations, to national responsible authorities and internationally.  Increasing
patient safety by improving the safe administration of medicines to patients has
rightly become a focus in both the provision of healthcare itself and the development
of information technology applications to support the provision of that care.  But it is
clear that in current practice, medication errors continue to occur with disturbing
frequency and that information deﬁcits are a major contributor to adverse medication
events156.
In any examination of improving patient safety with regard to medication use, there
are two distinct types of unsafe situations that are to be avoided; these are:
 Adverse drug reactions, which are defined by the World Health
Organisation as ‘any response to a drug which is noxious, unintended
and occurs at doses used for prophylaxis, diagnosis or therapy’ (p 42)157
 Medication errors, whose definition by the National Co-ordinating Council
for Medication Error Reporting and Prevention has been adopted by the
NHS National Patient Safety Agency and is ‘any preventable event that
may cause or lead to inappropriate medication use or patient harm while
the medication is in the control of health professional, patient or
consumer’158, are mistakes which occur in one or more of the processes
of prescribing, dispensing and administration of a medicine which
produces an unintended and (potentially) harmful outcome
The European Medicines Agency now also provides a definition of medication error,
including it within its definition of an adverse drug reaction: ‘unintentional errors in
the prescribing, dispensing, administration or monitoring of a medicine while under
the control of a healthcare professional, patient or consumer’159. It notes that these
are the most common single preventable cause of adverse events in medication
practice.  The EMA is now includes the reporting of adverse events due to medication
error in the national pharmacovigilance databases and onward to the Eudravigilance
113
system, to support analysis of such events to take forward into risk management
planning157.   The understanding of adverse drug reactions per se, the science of
pharmacovigilance, is discussed in relation to the Medication Profile in detail in
Chapter 5(2) of this thesis.  This chapter focusses medication safety in terms of
systems available for the avoidance of adverse drug reactions occurring in the
medication process, and for the avoidance of medication errors.
In the UK, there was an entire NHS report focussed on the safe use of medicines:
‘Building a Safer NHS for Patients: Improving Medication Safety’ published by the
Department of HealthError! Bookmark not defined..  There is a growing body of
research and consequent understanding about when medication safety is
compromised and when medication errors and adverse events may occur.  One of
the key statements made within the report relates to the use of information
technology generally in improving medication safety (page 11): ‘The electronic
national care record is central to this strategy and will ensure that any health
professional treating a patient will have access to essential clinical information,
including the medicines they are taking.  This will provide increased safety in the
prescribing, dispensing and administration of medicines’. This, coupled with the
premise, expanded further on in that section of the document, that because a
significant number of serious medication errors involve a failure to receive,
recognise, interpret or act appropriately on the medication and/or patient data, and
therefore that well designed and implemented information management systems
could have potential to reduce the scope for human mistakes and lapses and
possibly even to eliminate completely some types of error, show the strongly held
belief at the highest levels that having an electronic care record will indeed make a
major contribution to improving medication safety.  However, although the report
discussed the lack of exploitation of opportunities to improve medication safety
provided by information technology only a few actual recommendations were made.
Unfortunately, despite reports such as this, there is little if any evidence in the
literature of the value of information technology applications.  In the key report on
evidence-based safety improvement practices by Shojania et al160 only two
information technology based medication safety applications – computerised
physician order entry (CPOE) with clinical decision support systems (CDSS) and
using medicine bar coding – were discussed, although the former was cited as an
opportunity for research.  In their reflection on this situation, Leape et al comment
that research into the efficacy of system change, particularly change involving such
applications as CPOE, is difficult and expensive to conduct161.  A systematic review
to investigate the effects of CPOE and CDSS on medication safety was undertaken
by Kaushal et al22 and did find evidence that these systems can substantially reduce
medication error rates, but most of the studies looked at home-grown systems, often
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concentrating on specific therapeutic areas (e.g. antibiotic prescribing).  This is in
contrast to the rather broader levels of CDSS functionality described in a recent
report by a JAMIA Clinical Decision Support Workgroup162, which includes drug
allergy checking, drug interaction checking, and other clinical information display
(such as contra-indication information) in its basic functionality level, moving on to
more advanced functionality such as weight-based dose checking for paediatrics,
pro-active disease management alerts, and drug-lab alerts23.  Note that in the UK,
the term CPOE would be more readily understood as ‘electronic prescribing’,
sometimes also written as eRx.  Within the Building a Safer NHS for Patients report,
electronic prescribing systems linked to the patient record are seen as valuable in
reducing the risk of many prescribing errors (page 45)1, and the use of decision
support is implicit (for example, in the recommendation ‘that all drug allergies should
be recorded on the computer in a way that will trigger an alert if an attempt is made
to prescribe these drugs in future’ (page 71)1, behaviour that is an almost universal
standard to medication decision support applications; however no specific
discussion of decision support per se is given.
In order for CDSS to function successfully and provide alerts to clinicians to warn
against possible unsafe activity, they require in addition to their own knowledgebase
and algorithms, inputs from the medication activity being supported, and these
include inputs from the Medication Profile.  The aim of this chapter is to describe the
information requirements that CDSS place on the Medication Profile in order to
support a safe medication process.
In addition to the activities of the medication process having potential for error and
therefore the requirement for the use of decision support, these same activities also,
somewhat paradoxically, are themselves the source of data for the Medication
Profile.  As such, these activities form the foundations of the dynamic model part of
the domain analysis model discussed in detail in Chapter 9.
Methodology
As discussed in the Introduction, there is little literature available that focusses on
the data requirements for provision of clinical decision support to support the
medication process.  In the paper by Kuperman et al162, which is a review of decision
support in order entry systems, various modules of decision support are discussed,
but mostly in terms of evidence for their use rather than in terms of the requirements
for them to function; it does however include a set of recommendations for drug
knowledgebase vendors, acknowledging that they are the core providers of the
functionality needed to improve safety.
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In most healthcare cultures knowledgebase providers are commercial organisations
or specialist (and quasi-commercial) sections of professional bodies (such as Z-
Index163, the medication knowledgebase provider for Dutch healthcare, which is
affiliated to the professional society for pharmacists in the Netherlands, the
Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, KNMP164 and
the British National Formulary45).  These bodies rarely if ever publish their data
structures, not least because to do so could be commercially unwise, despite
requests to do otherwise in the literature165.  However, the author has had
considerable experience in this area, and this section has been written based on
knowledge and experience gathered in roles over the preceding 20 years. This
experience is described in detail in the General Methodology.
Analysis methodology adopted
To elicit the requirements placed on the Medication Profile by the decision support
systems that provide support for the ongoing safe use of medication, each of the
various activities that occur in the medication process were examined.  There are
three separate but interrelated activities that occur in the medication process:
prescribing, dispensing and administration.  These involve various healthcare staff
from different professions, as well as the patient themselves and sometimes a carer
also.  This complexity is a well-known distinctive of medicines use3, which has the
potential both to be beneficial or detrimental to the final result of the activity. Using
the knowledge and experience described above and evidence from the literature (as
cited in the text below), each medication activity was described highlighting where
and how errors and issues may occur and also describing the types or modules of
decision support can be offered to mitigate against those errors occurring. Then, the
data elements from the Medication Profile required by these modules were
described. Note that in all of the decision support modules discussed, the usual
process is to alert the clinician if, and only if, an issue is detected, and in which case
both the reason for the alert and the medication triggering it would be provided.  In
addition to this, all clinicians have the responsibility to review the patient’s Medication
Profile before taking a medication related action.
As well as the inherent complexity of the medicines process itself, the complexity of
care provision arrangements (shared care) are also a source of potential problems.
A summary table of the data elements from the Medication Profile required by the
activities and decision support modules that these use was produced.
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Results
Errors in prescribing - the medication selection activity
To prescribe is defined as to ‘give directions, either orally or in writing, for the
preparation and administration of a remedy to be used in the treatment of any
disease’166.    In order for the prescriber to be able to ‘give directions’, there a decision
process must have occurred in the mind of the prescriber as to selection of the
medicine itself (the therapeutic product) and selection of an appropriate set of
dosage instructions to ensure its correct use.  Then, the directions themselves must
be given either directly to the patient or to another healthcare professional who is
involved in the medication process.  It is a matter of both law and ethics that all
prescriptions for particular types of medicines are written, but some medicines are
prescribed verbally, principally those which may be purchased over-the-counter and
self-administered or administered by a carer; this activity, particularly if undertaken
in a pharmacy, is often referred to as counter prescribing167.   Note that counter
prescribing is sometimes described as a dispensing activity rather than as a
prescribing activity168, the activity being primary viewed as the supply of the
medication rather than the selection and communication of the appropriate
medication and dosage instructions.
Within the single activity of prescribing, there are two distinct sub-activities in which
error may occur, the medication and dosage instructions selection process and the
communication process.  For the purpose of this study, which focuses on the
requirements placed on the Medication Profile to support a safer medication process,
it is the former that is of most importance in the prescribing process.  Management
of the communication process, and systems that support that (verbal, written or
electronic), are outside of the scope of this examination, however some discussion
of them is given in the chapter on patient record and summary specifications, where
the data elements required for prescription information are described in those
specifications.
Errors in the medication and dosage instructions selection process within prescribing
may occur when there is insufficient knowledge of the patient, the medicine or both1,
or when insufficient attention is paid to the knowledge available.  An accurate
medication history is essential for safe prescribing1, making the availability of
medication history information an important requirement on the Medication Profile.
Indeed, lack of this knowledge about the patient or failure to access this knowledge
when it is needed has been identified as one of the major causes of medication
prescribing errors169.
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Repeat prescribing
Due to the chronic nature of many of the conditions for which medicines are
prescribed, the medication and dosage instructions selection process is likely to be
performed once but the prescription itself may be repeated many times, often over
years, and sometimes without review.  Repeat prescribing, the re-issue of a
prescription for supply of a medicine or medicines previously authorised, has been
identified as a significant source of error, not least because if an error occurs, it may
be repeated for a prolonged period170.  Repeat prescribing should be undertaken in
the framework of a regular, protocol-based review and monitoring process171,172 in
which the Medication Profile of the patient plays a prominent part.  Particularly for
those medications with known bioequivalence issues, patients should be stabilised
on a particular product from a single manufacturer and encouraged to continue to
use that product. Having the facility to accommodate that manufactured product
description is therefore a requirement, in addition to any generic description.
Drug interactions
When a patient is using more than one medicine concurrently (or in close proximity
of time) there is a potential for the effects of one medicine to interact, either desirably
or undesirably, with the effects of the second medicine.  If the effect is undesirable,
it is known as a drug interaction. Drug interactions are either pharmacodynamic or
pharmacokinetic in nature and are deemed to occur between a two drugs in a pair;
three-way or four-way interactions are not evaluated.   In all cases of a drug
interaction, it is the concurrent presence of the medicine in the body of the patient
that is the cause of the interaction.  This is because some medicines continue to
have a presence in the body for some significant time after the last administration
(e.g. amiodarone, which has a plasma half-life in the order of 50 days173), use of
medicines in the preceding period must also be considered when interaction
checking.  It is also important to consider route of administration, as medications that
are applied topically and whose action is only topical should not be considered for
drug interaction checking.
There are many drug interaction checking applications available from drug
knowledgebase suppliers which will perform this assessment of a newly prescribed
medication against the patient’s existing medication and alert the prescriber to
possible problems with drug interactions.  All of these can only operate if they are
provided with the necessary information regarding current (now) medication use and
medication use from the recent past so that these can be considered with the newly
prescribed medicine and evaluated for the possibility of interactions occurring.  The
recent past should be at least 180 days, taking amiodarone as a worst case, as the
half-life for this is one of the longest of all174, and 180 days represents at least three
118
half-lives, such that elimination should have reduced to in the order of 10% of
therapeutic steady state levels.
Using combinations of medicines concurrently that are known to interact does not
necessarily result in undesirable clinical manifestation, particularly if the use of the
medicines is managed carefully175.  There may be overriding clinical reasons to use
medicines that are known to interact, therefore the risk is accepted and managed as
much as possible; or the interaction itself may be considered clinically insignificant
in some groups of patients.  For example, the well-known pharmacodynamic
interaction between a thiazide diuretic such as bendroflumethiazide and an ACE
inhibitor such as enalapril which results in increasing hypotensive effect is commonly
exploited in clinical practice in the step-wise treatment of hypertension176.  Therefore,
even if a drug interaction is present, its actual potential for harm to the patient must
be separately evaluated on the basis of the patient’s clinical condition.  This
evaluation may itself draw on information from the Medication Profile.  For example,
a patient taking bendroflumethiazide is prescribed digoxin; this pair of medicines has
a drug interaction that puts the patient at increased risk of cardiac toxicity from the
digoxin due to the hypokalaemic potential of the thiazide diuretic.  However, further
examination of the Medication Profile may reveal that the patient is also taking
amiloride, a potassium sparing diuretic, which will mitigate the hypokalaemic effect
of the bendroflumethiazide and therefore mitigate the potential for harm of the drug
interaction.
Duplicate therapy
Without knowledge of the medication that a patient is already using, a clinician might
unintentionally prescribe the same medication causing the patient to be overdosed,
or a medication from the same therapeutic class, risking toxicity similar to an
overdose situation.  This risk is particularly great when healthcare is being provided
from a variety of different provider situations and access to a complete Medication
Profile is restricted or unavailable.  It is also a risk with the use of over-the-counter
medicines, especially as more medicines move from being available only by
prescription to being available from a pharmacy.  Although all such sales should be
supervised and require investigation of the patient’s Medication Profile, not all
patients will be able to give that information comprehensively.  Example scenarios
might be: a patient with active cardiovascular disease has heard that there is a
medicine to control cholesterol levels that can be acquired over the counter so they
purchase some Zocor Heart-Pro, unaware that they are already receiving statin
therapy from their GP in the form of pravastatin tablets; a patient taking already one
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NSAIDb preparation as an anti-inflammatory and then being advised to take a
medication such as ibuprofen, also an NSAID, as an analgesic, again not realising
there is a duplication occurring because different words are used.
The risk of duplicate therapy occurring should be completely eliminated if a patient’s
Medication Profile were available for consideration for all prescribers, including those
managing over the counter sales of medicines, and a duplicate therapy checking
module was used to alert practitioners if prescription or sale of a medication is a
duplicate therapy risk.
Contra-indication/caution checking – using implied morbidity
Despite the ideal of every prescriber having access to a patient’s medical record, at
least in summary, this is still not the norm.  In particular, much emergency healthcare
is provided ‘blind’, or on the basis of the information that can be obtained from the
patient or relative at the time.  Patients or their carers can usually give some
information about the medicines being taken, even if they are completely unable to
give any information about the indications for those medicines; for example: a
significantly greater proportion of parents of special needs children were able to list
their child’s medications than to describe their child’s medical condition177.
Therefore, this medication information, a verbal summary of a Medication Profile,
can give significant information to a clinician about the patient’s clinical state, which
in turn may be used to promote medication safety178.
Two examples to demonstrate this use case are described:  A patient on holiday
presenting at an Emergency Department with a fractured limb is likely to be
prescribed an NSAID for short term pain relief; if questioning reveals the patient has
recently taken a course of a proton-pump inhibitor medicine such as omeprazole, it
is prudent to assume that the patient has suffered some gastro-intestinal reflux or
ulceration and therefore to avoid the use of an NSAID.  In the self-care domain, a
patient seeks advice and treatment for a verruca in a community pharmacy; the
pharmacist has no access to the patient’s medical record, but asks about general
health, which the patient says ‘is good’.  The pharmacist thinks that a topical salicylic
acid preparation is indicated, and despite this being a topical preparation and
therefore having no drug interactions issues, makes the standard check in all counter
prescribing about ‘Any other medication use?’.  The patient mentions that they take
glipizide, which immediately alerts the pharmacist to the fact that the patient suffers
from type II diabetes mellitus, which the patient did not mention in response to the
question about general health because their view of their health is that it is good, the
b Non-steroidal anti-inflammatory drug
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medication controls the diabetes mellitus, and they are happy.  Use of topical salicylic
acid is contra-indicated in diabetic patients; this contra-indication for this patient is
detected from information about the content of the patient’s Medication Profile, not
from their medical history/current condition.
Symptom management
Almost all medicines have some side effects; these are usually minor and
manageable.  Occasionally, the severity of a side effect outweighs the benefits of
the medicine and treatment must be changed.  Side effects usually manifest
themselves as one or more symptoms, and it may or may not be easy to differentiate
these symptoms as side effects of a medicine rather than as symptoms of a
condition.  Knowing the content of a patient’s Medication Profile is an important piece
of information in this investigative process.  For example, if a patient presents with
dry cough, if they are known to be taking an ACEc inhibitor, the dry cough is possibly
a side effect of this rather than a presenting symptom of another condition.  The
management of the symptom will then probably involve management of the patient’s
current medication, rather than initiating new therapy for the new symptom.
Dose range checking
Dose range checking allows the dosage instructions information given with a
medication to be checked for suitability for the patient (correct daily dose quantity,
frequency and duration of course).  Without indication information, a dose range
check is a somewhat blunt instrument, as some medications have distinctly different
dosage patterns or ranges depending on indication (e.g. methotrexate for
chemotherapy or for rheumatic disease suppression, proton pump inhibitors for
gastro-oesophageal reflux disease or for Zollinger-Ellison syndrome).  Having
indication information available with any prescription or available in the Medication
Profile would significantly increase the sensitivity of dose range checking, making it
a more effective tool for medication safety.  Advanced dose range checking would
also take into account other medications being administered concurrently, for
example, administration of carbamazepine often lowers the plasma concentration of
valproate, such that a larger dose of the latter is required. For truly useful and
sensitive dose range checking, current medication information should be available,
from the Medication Profile.
c Angiotensin converting enzyme (inhibitor)
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Care pathways
Many chronic conditions are now being managed using a care pathway, ‘a
multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to
help a patient with a specific condition or set of symptoms move progressively
through a clinical experience to positive outcomes’179.  A pathway is a structured and
documented evidence-based set of goals, clinical milestones and therapeutic
interventions that are appropriate to provide at those milestones, with the supporting
documentation and communication180.  Many of the interventions provided will
involve one or more medications.
Using care pathways is becoming a key feature of the provision of higher quality and
more standardised and cost effective care, which by its very nature, should be safer
care.  Although the pathways themselves are documented, systems to document an
individual’s progress through a pathway are rare, and yet successful the use of these
clinical pathways or patient trajectories is dependent on up to date and correct
information being available181. That information includes the medication
interventions have been used, their indication for use, and whether that use was
successful or unsuccessful for that patient, so that at any particular pathway
milestone to know where to go next along the path, it is the Medication Profile that
must be referenced.
The nature of the care of chronic conditions using care pathways is such that
including information in the Medication Profile about medications that are planned to
be administered would also be useful.
Laboratory test checking
Medicinal products may interact with laboratory tests such that test results provided
may be misleading.  Decision support alerts can be produced to highlight this when
appropriate.  This form of decision support requires, as each test is ordered or result
is processed, information on the medications being taken by an individual, which can
be provided by the Medication Profile.
Allergy checking
Allergy checking is a major contributor to safety events involving medication.
Recording of allergy information has been deliberately excluded from this analysis
because it is argued that rather than managing allergy information as part of a
Medication Profile, it should be managed as a separate and distinct topic in an
individual’s more general health profile or problem list.  An individual may be allergic
to a range of items other than medicinal products, including foods and cosmetics and
natural substances such as rubber or venom.  The allergy checking process requires
information about the allergy itself (causative agent, severity, etc.) and information
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about actions being taken (e.g. prescriptions being written or medications dispensed)
rather than information from the Medication Profile per se.
Errors in dispensing - the prescription fulfilment activity
To dispense is defined as to ‘to give out medicine and other necessities to the sick;
to fill a medical prescription’166.   The dispenser fills the prescription by providing a
medicinal product that fits the description given by the prescriber to the patient or
their carer(s) and by providing a label for the medicine that describes the prescriber’s
instructions for the dosage instructions of the medicine in a way that the patient/carer
can understand and follow.  There is also a professional responsibility on the part of
the dispensing pharmacist to ensure that the prescription as dispensed is safe for
the patient as well as following the prescriber’s intentions.
In many healthcare environments, dispensing is a process that takes place
separately and remotely from the prescribing process; the healthcare professionals
concerned may well not have access to the medical record nor to the decision-
making processes that have led to the particular prescription.  Despite this,
particularly in healthcare cultures such as the Netherlands or the United States, it is
the community pharmacy that is likely to have the most comprehensive record of a
patient’s Medication Profile, and many of the checks that have been discussed
above in relation to prescribing will operate at the time of dispensing, most
particularly the detection and avoidance of drug interactions and duplicate therapy
issues.
The majority of dispensing errors, 60% in one recent study182, occur due to incorrect
selection of the medicine to be dispensed, against which knowledge of the patient’s
Medication Profile would contribute little, but there are some types of dispensing
errors that could be avoided if the Medication Profile information was available to
support safety checking.
Supporting the labelling process
Incorrect labelling of an otherwise correct medicine for dispensing may lead to
confusion of the patient, such that the medicine is administered incorrectly (over or
under-dosage, with the attendant risks in these cases) or may be omitted completely.
Having access to the patient’s Medication Profile, and allowing this to provide
information into the dispensing label generation process reduces the likelihood of
labelling errors by providing information against which to cross check (for example
for the system to highlight if a repeat dispensing is showing a different strength of a
medication or a different set of dosage instructions).  If label generation were then
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also linked to bar-coded checking of the item to which the label is attached, then
incorrect medicine selection errors can also be significantly reduced.
However, having access to the Medication Profile and allowing information from this
to flow into the dispensing/labelling process must never be seen as a substitute for
reading the prescription against which the dispensing is authorised.  The prescriber
may have altered the presentation and/or the dosage instructions such that the
prescription is intentionally slightly different from the previous one shown in the
Medication Profile, and the new information must be used correctly, not accidentally
overwritten with previously applicable information.  Providing ‘reason for change’
information for any therapy change is particularly helpful to support good dispensing
practice.
Clarifying safety concerns
Having access to the Medication Profile to support the dispensing process is useful
to clarify safety concerns about a prescribed medicine.  In the prescribing safety
section, the management of drug interactions was discussed; this is also an issue in
the dispensing process.  If a dispensing shows an interaction either between two
medicines that are part of it, or between its medicine and those within the Medication
Profile, by examination of the Medication Profile the dispenser may assess the
interaction.  This will focus on whether the interaction is new, whether the interaction
is likely to be significant such that it should be referred back to the prescriber, or
whether it has been present previously and is being managed or is deemed not
clinically significant.
Supporting the compounding process
Despite increasing rarity, there are still occasions when a medicine must be
compounded in an extemporaneously prepared formulation for a specific patient.
This is acknowledged to be a process with a greater degree of risk than dispensing
of licensed formulated medicines, and as such has specific guidance attached to
it183.  Having the formula (ingredient substances and strengths) for an
extemporaneously prepared medicine available as part of a Medication Profile or as
an easily accessible addendum to it provides continuity, ensuring a medicine is
always compounded in a specific way for a specific patient.  This avoids risks of
toxicity or under-dosage due to changes in bioavailability from different compounding
methods (e.g. the use of different suspending agents).  It also avoids constant
recalculation of strengths and volumes at each dispensing, which is a known area of
risk and is particularly the case for medicines dispensed for children184, where it is
known that errors can also be more serious185.
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Errors in administration - the giving activity
Whereas the concepts of prescribing and dispensing can be defined within the
healthcare domain, the final step in the medicines management process, the
administration, is a concept that has much wider linguistic use, and as such does not
have a precise definition within the healthcare domain.  But its use has implicit
understanding of the process of giving the medicine into or onto the patient’s physical
body where it can have its therapeutic effect.
This giving activity should be performed in accordance with the dosage instructions
given by the prescriber, covering the quantity to give, the timing (frequency and
duration) of when to give it, the route of administration (way in/on to the body), the
method (how to do it) and site (where on the body to do it) of administration if
required.  There may be a device to use to assist in the administration, and there
may be some manipulation of the medicine itself to be performed (e.g. dilution).
By far the majority of medicine administration occurs in the patient’s home
environment, unsupervised and unrecorded by any healthcare professional.  There
is an assumption that all the effort and checks that occur in the prescribing and
dispensing processes to ensure that the patient receives the right medicine, with the
right dosage instructions to give the required therapeutic effect have been effective.
Any errors that occur in self-administration – misunderstanding, misinterpreting or
simply forgetting - are rarely detected, unless they give rise to a significant health
issue.
In situations where medicines administration is undertaken by a healthcare
professional, it is known that errors do occur, but the majority of these occur in the
activity of administration (e.g. wrong administration technique, missed doses etc.)
and therefore knowledge of the patient’s Medication Profile would provide little
mitigation of these.
In care homes, where medicines administration is undertaken by the home staff,
medication administration records (MARs) are often used to manage the
administration process.  The management of MARs themselves such that they
provide accurate information to support the administration process has been
identified as a risk for error1.  Having real-time access to the current medication
section of a Medication Profile with which to verify, or possibly even to produce MAR
sheets would reduce the risk of this type of error occurring.
Errors in the communication process – shared care environments
There is now an ever more disparate care environment; whereas in years gone by
patients were cared for by a single general practitioner, used a single community
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pharmacist, and if necessary received care in a single district general hospital, they
now may receive care from a number of sources within and between the traditional
distinctions of primary, secondary, tertiary and social care.  This care may be
delivered contemporaneously or sequentially, but in either case, the interfacing
between the care environments is a source of risk for medication error, as discussed
in many of the papers in the Literature Review. Having an accurate shared view of
a patient’s Medication Profile can make a key contribution to error reduction in this
complex care environment.
As the delivery of healthcare changes, with more and more chronic conditions and
complex care protocols being managed in a shared care environment, the
importance of having a shared Medication Profile increases.  A central source of
truth to which all those involved in the provision of care can refer reduces the
likelihood of the errors that might otherwise occur; as evidenced in the Literature
Review, this is the point at which most medication reconciliation effort is
concentrated; more than half of all medication errors occurring in secondary care
occur at a care interface, with over a quarter attributed to incomplete medication
information obtained on admission115. Building a Safer NHS for Patients noted that
effective communications are critically important when patients move from one care
setting to another and that many medication errors occur at such ‘handover points’1.
Serious errors have occurred because of poor communications between primary and
secondary care.  Accurate information about current therapy is essential when
patients are admitted to hospital to enable an accurate clinical assessment and to
plan future treatment.   And on discharge, the patient’s drug regimen and treatment
plan need to be communicated in a timely and reliable way to ensure safe and
seamless transfer of care back to the primary care team.
Evidence for this requirement for shared access to a patient’s Mediation Profile can
be seen from four therapeutic areas discussed below; the first three are well known,
the fourth is now just emerging.
1. Despite the narrow therapeutic index of oral anticoagulants, the
management of patients requiring oral anticoagulation through pharmacist-
or nurse-led clinics is now widespread.  Oral anticoagulants are well-known
for being involved in a large number of drug interactions, the majority of
which will increase the anticoagulant effects of the medicine, putting the
patient at risk of excessive bleeding. It is vital that all those involved in the
care of these patients have access to the patient’s Medication Profile, so
that the risk of introducing drug interactions is minimised.
2. Methotrexate as used for its immunosuppressant properties as opposed to
cytotoxic properties is unfortunately well known for problems in
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communication for shared care such that it has been the subject of repeated
National Patient Safety Agency alerts186, having a single central Medication
Profile that included indication information would significantly reduce the
errors around methotrexate dosing.
3. Opiate analgesia is another area of concern for communication in shared
care.  Many terminal care patients are cared for by a multi-disciplinary team;
part of this care involves opiate analgesia and considerable effort is
expended to tailor the opiate regimen to the patient’s individual need.  This
regimen may involve using both immediate release and extended release
formulations of opiate products.  Confusion can occur between these
formulations across the team such that the dose of what should have been
the extended release formulation as prescribed and administered as an
immediate release formulation.  If this happens, severe overdose effects can
occur.
4. Amphotericin treatment errors are also increasing187, as patients on this
therapy are moved from hospital to the community and having intravenous
infusions supplied from a home healthcare organisation; confusion as to
whether the patient should receive the standard amphotericin formulation or
a lipid formulation, with their attendant significant difference in dose, has led
to individuals experiencing severe overdose.
A different paradigm in shared care is in terms of out of hours and emergency care
provision.  Changes to how primary care is provided and the development of out-of-
hours service centres and walk-in clinics increase the importance of access to a
Medication Profile for the healthcare practitioners working in these environments for
current medication, with its indication, and recent past medication.  The NHS
Summary Care Record in the UK and the Continuity of Care specification in the US
(discussed in detail in the Chapter 5(1)) both contain medication information
specifically to support such care.
Results summary
Table 11 following provides a summary of the data element requirements that each
of the activities of the medication process and their decision support modules place
on the Medication Profile.
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Table 11: Summary of the Medication Profile data element requirements from the medication process activities and their decision support modules
Medication Profile data elements
All current (‘now’)
medication
Recent past
medication
All past
medication
Indication Dose
instructions
Ingredient substance
and strength
Prescribing
activity
Drug interaction
checking
  x x x x
Duplicate therapy
checking
 x x x x x
Contraindication
and caution
checking; implied
morbidity
 x x x x x
Symptom
management
  x x x x
128
Table 11 (cont.): Summary of the Medication Profile data element requirements from the medication process activities and their decision support modules
All current (‘now’)
medication
Recent past
medication
All past
medication
Indication Dose
instructions
Ingredient substance
and strength
Prescribing
activity
Dose range
checking
 x x   x
Care pathways  x   x x
Laboratory test
checking
 x x x x x
Dispensing
activity
Label checking  x x x  
Compounding x x x x x 
Administration
activity
MAR sheets  x x x  x
Shared care   x   
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Discussion
In each of the three major activities of the medication process and in the
communication process, there are various types of decision support functionality that
can contribute to safer medication use.  All of these place some requirement on
information from the Medication Profile
Access
The first requirement, which might almost be missed as it can be seen as implicit, is
access to the Medication Profile, is a significant issue for some healthcare
professions.   Most prescribers have access to their own records, which will have a
section that records medication information and fulfils a Medication Profile type role.
However, this will contain only the information from their own activities.   A general
practice system will contain records of prescriptions generated in that practice, and
possibly may not even reference administrations occurring in different sections,
which would have to be searched for separately (e.g. vaccinations given by the
practice nurse may be in a separate record)).  Information received from other
healthcare providers, such as secondary care institutions, will remain in document
form (even if electronic) and medication information will probably only ‘transfer’ to
the proxy medication profile if a prescription is required.  Short-term therapy (e.g. a
course of antibiotics given during a hospital stay) is likely to remain as isolated
information.  Most hospitals do not currently have a comprehensive health
information system; prescribing and administration of medicines may be maintained
in a single system (even if on paper) but dispensing will be managed separately (and
electronically).  Again, the system will record only the activities it is responsible for,
and not activities that have occurred elsewhere (e.g. in a theatre or in an investigative
unit such as radiology).  Community pharmacists also maintain their own medication
records based on the prescriptions they have dispensed for patients, and possibly of
over-the-counter sales made to specific patients.  They may also have records of
medication reconciliation activities performed, some of which may be shared records
with the general practice responsible for the patient.  Some linked community
pharmacies may also now share records amongst their membership (with the
permission of the patient concerned).
All of these activity-based records are no substitute for a comprehensive Medication
Profile, which is a central shared repository of information that should be accessible
by all who need to.  Providing access to a comprehensive Medication Profile has
both technological and political considerations; neither are topics for the focus of this
research. Since a comprehensive Medication Profile is designed specifically to meet
the needs of all the healthcare professionals providing care for a patient, and having
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such an artefact designed and made available for implementation, it would seem
sensible to create the necessary infrastructure and political willingness to allow it to
be made available to all those it seeks to serve.
In their special article on the use of information technology in improving patient
safety, Bates and Gawande188 stated that a ‘good information technology
infrastructure is vital, and that an electronic record and computerised physician order
entry are fundamental areas for implementation to improve safety.  To provide high
quality healthcare requires everybody to ‘be on the same page’ – to have the same
information available, and the single biggest reason for medication error was not
having all the necessary information to hand’.  A key phrase in that is ‘all the
necessary information to hand’, implying that access to and availability of this
information must be seamless within the business process; any interruption to the
workflow to obtain the information would be considered a major barrier to its
acceptance and use.  An example of this is a Medication Profile implementation in
Canada that takes so long (several minutes) to download the information that
clinicians find it unacceptable to use189.  These usability issues therefore form non-
functional requirements on implementation of the Medication Profile within systems
and the architecture, both technical and business, of those systems.
Medicinal product description
The second requirement is a good description of the medication being used; each of
the all current (now) medication, the recent past medication and all past medication
needs to be described in a way that all those involved can easily recognise and
understand.  To facilitate this, the medication terms should be drawn from a robust
terminology of medicinal products that conforms to the Cimino desiderata190, the best
practice for healthcare terminology.   Implicit in the concept of terminology is that it
is a code system191 – a managed collection of designations (the human
readable/recognisable descriptions, including synonyms, of the concept) and one or
more codes (the machine-readable identification of the concept).  For decision
support, the code is implicitly important, because this is what can most quickly and
easily be processed by algorithms.
In the development of CPOE and DSS, there is a clear requirement for standards in
terminologies used; the requirement for a ’convenient, usable standard dictionary for
medication ordering’ is identified by Teich et al23, along with standards for
identification of doses, allergies etc..  In ‘Information for Health’132, the report that
commissioned the UK Clinical Products Reference Source, the forerunner of the
NHS dm+d192, there is the oft quoted comment about the ‘lack of standardisation in
the UK in describing medicines, appliances and medical devices, in how such
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descriptions are organised, and in linking knowledge required for decision support to
these descriptions’.
In the report on Improving Medication Safety, Building a Safer NHS for Patients1,
drug name confusion is sited as a cause of medication error in prescribing (3.1.18),
dispensing (3.2.5) and administration.  This is a recurring theme found in medication
error research8,193.  It has been reported that roughly one in every four errors reported
to the Medication Error Reporting Progam (MERP, run by the Institute for Safe
Medication Practices and the United States Pharmacopoeia) involves a pair of
medicines whose names look or sound alike194. The American Society of Health-
System Pharmacists has produced a series of recommendations for preventing
medication errors in cancer chemotherapy, which include having standardisation of
prescribing vocabulary ‘including drug names’195. Similarly, a study assessing the
impact of various patterns of label information on nurses’ and physicians’ ability to
select the correct strength of a liquid parenteral showed that error frequency was
reduced when a standardised format of information was used196.  In addition, the use
of ‘Tall Man’ lettering and/or colour has also been shown to reduce errors in drug
name confusion197, although this has tended to concentrate on medicine labelling, it
is suggested that it could have applicability in computer applications198.  In collecting
medication error information, the European Medicines Agency are now also actively
looking at the potential for medication errors associated with the name of a medicine,
and naming is routinely assessed by the EMA’s Name Review Group, whose
mandate includes the assessment of medicinal product names from a safety and
public health point of view prior to marketing authorisation.
The problem of a having a good description of a medicinal product is one that has
been recently addressed by the Identification of Medicinal Products suite of
standards that have progressed through the international standardisation process
and are manifest in the Identification of Medicinal Products (IDMP) suite of
standards.  These are ISO 11615 (Medicinal Products)144, 11616 (Pharmaceutical
Products)199 and the accompanying standards to describe Substances, Dose Forms,
Routes of Administration, Dose Units and Package Descriptions.  The
implementation of this suite of standards, which is being led by the European
Medicines Agency and the US Food and Drugs Administration, will provide unique
identification for all authorised and developmental medicinal products globally.
Having this foundation, from the key source of such information (i.e. the regulatory
agencies) provides a very solid basis from which to work forward into clinical care.
Indeed, it is on this premise the Horizon 2020 openMedicine149 initiative is working,
specifically for the use of cross-border prescribing and dispensing, and since these
are two of the three main activities in the medication process, if these can be
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supported, the description of the medicinal product should by implication be accurate
and clear such that it would be useful in a Medication Profile. In addition, the ISO
technical specification that is currently in development, for Medicinal Product
Dictionaries200 lists use cases and requirements for such a terminology.
So at this time, for the first time, it would appear that the perfect storm is occurring
for development and implementation for standardised medicinal product terminology
at both national and international level, which will meet the requirement for clear
identification of current and past medicinal products in the Medication Profile.
Dosage instructions description and indication
The third requirement is a full and unambiguous description of the dosage
instructions and indication information so that these can be correctly communicated
to the patient and, in a machine-readable form can be used in dose range checking.
Currently, there is no formal definitional standard for the representation of dosage
instructions, although there is some work in the ISO community, in the form of TS
17251, the Requirements for a Syntax to Exchange Structured Dose Information for
Medicinal Products142.  This work is currently strongly influenced by the work of the
National Council for Prescription Drug Programs (NCPDP)138138 in the USA, which is
being used in the Meaningful Use legislation, although it also has its roots in the work
done in HL7 on a structured dose syntax that was originally produced for the English
NHS.   In other parts of this work, where dosage instructions are referenced, it is the
HL7/NHS Dose Syntax structure and definitions that are used, as these have been
developed to support all aspects of dosage information and particularly for machine
processing with dosage checking.  The full HL7/NHS Dose Syntax is described in an
Appendix to this thesis, as it was developed by the author of this thesis.
For dose range check to function appropriately, the minimum information
requirement is either a single dose quantity and a single dose frequency or a daily
dose quantity, and the route of administration.  The route of administration may be
explicitly stated as part of the dosage instructions, or it may be implied information;
implied either from the product being dose checked, for example a dose check on
the product ‘Methotrexate 2.5mg tablets’ implies oral administration, or the dose
quantity may be stated as ‘two tablets’ with the tablets implying oral administration.
Course duration is helpful for a course length check but this check is less frequently
used than a dose range check.
For dose range checking to be useful in a wide range of circumstances and
particularly not to generate unnecessary alerts, which are well known to be an issue
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to users201, information on the indication for use is required.  This is rarely, if ever
provided, but would be a very valuable data element in a comprehensive Medication
Profile to support safety checking.  Indication information would also be valuable as
part of care pathway medication documentation, and in that context, when a
particular medication is discontinued due to either intolerance or lack of efficacy that
information should be present, in addition to the date of the discontinuation (which is
a standard part of the course of therapy detail).
For several of the decision support modules, if the description of the medication(s)
involved are provided only at a high level, particularly without dose form information
(e.g. ‘amoxicillin’ rather than ‘amoxicillin 250mg capsules’), even if the description
comes from a robust and coded controlled terminology, then the dosage instructions
information becomes important to the decision support algorithms.  Both drug
interaction checking algorithms and duplicate therapy algorithms will process
medications administered systemically differently from those administered topically
to avoid inappropriate alerting; for example: a patient may use two NSAID
medications if one is topical and the other is administered systemically.
Cradle to grave lifespan
The fourth requirement of a comprehensive Medication Profile is that it covers all
medication activity for an individual, from cradle to grave.  So often, as discussed in
the Access section above, records exist for activity occurring only in that system.
This is improving in the UK, with the ability to transfer general practice computer
records from one surgery to another when a patient moves202, but no such system
is available for hospital records, for example, or for community pharmacy records.
Only a single, central shared Medication Profile will be able to provide information
about both current medication use and the historic medication use that is needed for
drug interaction checking; the current, past and planned medication use information
for care pathway intervention selection and, until other medical information is shared
and available (diagnoses and conditions), implied morbidity information for contra-
indication checking.
Limitations of this study
One of the main limitations of this study is the lack of published information on how
medication decision support works within systems that support medication activities,
and therefore the requirements gathered from it are confined to those that are
available or are known personally to the author.  This limitation could be overcome
if more information were publically available, or alternatively if an assessment of
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medication decision support functionality and its requirements such as is presented
here were formally reviewed by other experts in the field.
Recommendations for further work
Further efforts should be undertaken to provide good evidence for the effectiveness
of the various different modules of medication decision support, particularly of the
type provided by the commercial knowledgebase vendors that underpins most of the
systems used by clinicians day to day. Having an understanding of the most
effective functionality and the requirements that these place on the Medication
Profile would support prioritisation of those requirements to systems that particular
data to be gathered, stored and shared.
Conclusion
It is clear that having knowledge of and access to information about an individual’s
comprehensive and shared Medication Profile, containing current, past and planned
medication information can play a significant part in making the overall process of
medicines use safer for patients.  Without this, important safety checks that can be
provided by information technology, such as drug interaction checking, are not
possible.
Based on the assessment of the various decision support functionality that supports
the activities of the medication process, the data elements that essential to be
present and populated in a Medication Profile:
 A description of the medication itself, preferably from a robust and machine
readable (coded) medicinal product terminology
 A description of the status of the medication (current, past, with a sense of
how far in the past a medication was last used – see below for course of
therapy timing)
 Basic data elements from the dosage instructions for dose range checking
and to support other functionality if the medication is not fully described
o Dose quantity and dose frequency – to calculate the total daily dose
o Course of therapy timing; the date of starting (and stopping, if
relevant) the medication
o Route of administration
o Indication for the medication
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Chapter 5: Requirements for the Medication Profile
from Clinical Research
Part 1: Patient Recruitment and Protocol Feasibility
Studies
Introduction
The complexity of the clinical studies required to bring a new therapeutic entity to
market has increased over time, with detailed requirements for information to
demonstrate both safety and efficacy being required by the regulatory agencies203.
In 1970 it was estimated that 1600 subjects were required per trial; in 2000 this figure
had risen to 6345.  Similarly more trials are required per New Drug Application
(NDA); 30 trials in 1970 as opposed to 70 in 2000204.  In the United States in 2004,
the average for a new therapeutic entity was for it to be tested in more than 4000
patients across 37 different clinical trials before receiving FDA Approval205.
Patients are selected as suitable for recruitment into a clinical trial based on eligibility
criteria that are formally documented as part of the protocol for a study. Finding
these patients is known to be difficult206, and success in recruitment appears to be
variable: levels of study participation vary according to condition/disease; it is
estimated that 3% of all cancer patients have participated in a study of some sort,
whereas 80%+ of paediatric cancer patients have participated in studies207.  This is
despite the fact that generally, patients appear to be willing to participate in studies,
although only a small proportion of patients – less than 10% - actually have
participated in a study208. Interestingly, given the above, a fairly small proportion of
time is being invested ‘in the field’ to actually finding potential patients: clinical
research coordinators generally devote only 13% of their day to finding subjects (8%
to ‘subject recruitment activities’ and 5% to ‘searching medical records for potential
study subjects’)209. Up to 25% of sites within a trial enrol less than 5% of the total
number of patients, with 10-15% of sites not enrolling a single patient210. Patient
recruitment is often the rate-limiting step for many clinical studies. Up to a third of
the overall trial process is taken up by patient recruitment, and almost half of all trial
delays are caused by patient recruitment problems211. This not unnaturally has a
significant effect on the cost of clinical trials, estimated at €710-790 billion in 2007
with an annual growth rate of 10.2-13.6 % since 2003212.  Delays to the process to
obtain a market authorisation may cost millions both in sales, estimates range from
between $600,000 for a small or niche product to $8million for a blockbuster drug
per day in lost sales213 and in additional trial costs.  It is estimated that $1.3-8.0
million additional costs are incurred for each day a trial runs over time204.
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Various strategies are being adopted in order to minimise trial delays and ever
increasing costs due to problems with patient recruitment; there are various
developments underway, including the EU Innovative Medicines Initiative (IMI)214
project EHR4CR24 that are investigating the use of electronic health record data in
clinical research, and particularly in protocol feasibility studies and patient
recruitment support.
Protocol feasibility testing
Although no formal definition of protocol feasibility testing exists, it can be described
as a process of comprehensive review and analysis of all aspects of the protocol; it
is undertaken to minimise barriers to successful completion of the study in terms of
science, safety, quality, or operability.  It is frequently performed by the use of
checklists of questions to test, for example, the appropriateness of the eligibility
criteria to select the patient population to be recruited and to determine which of the
criteria may be the most challenging to fulfill.   Eligibility criteria are themselves
defined as ‘the medical or social standards determining whether a person may or
may not be allowed to enter a clinical trial; they are based on such factors as age,
gender, the type and stage of a disease, previous treatment history, and other
medical conditions’215.
Objective testing of the eligibility criteria aspect of protocol feasibility may be
undertaken by decomposing the probable inclusion and exclusion criteria from the
draft protocol and using their content to construct queries that are then run against
a suitably large cohort of patient information containing the types of data items
described in the criteria.  This patient information may be in a registry, constructed
for the purpose as described above or in a clinical data warehouse derived from one
or more EHR systems.   Once a study has been designed, protocol feasibility studies
may also be conducted to ascertain whether a site is likely to be able to fulfil its
recruitment quota of study subjects for that trial based on the eligibility criteria, by
running the eligibility criteria queries against the clinical data warehouse of that
particular site. If the site does not show close to the required number of likely
subjects, then the effort and expense of setting up the trial in that site can be avoided,
as can the delay in the study as a whole that would occur when that site would not
be contributing recruited subjects to the overall total.
Patient recruitment strategies
As described above, fulfilling the recruitment requirements for the increasing number
of trials being conducted is a challenge, especially as the number of investigational
sites has not increased proportionally, thereby increasing pressure on the available
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patient pool for any one site. There has been a trend to conduct more trials from
contracted small clinical research centres in addition to using the large centralised
research hospitals/institutions.  This increases the size of the pool of patients who
have the potential to become trial subjects, but it also increases the risks in variability
of the application of the trial eligibility criteria, which can cause problems in results
reconciliation.
Another approach to improving recruitment is to use referral sites; this involves
contracting with various organisations to find patients that match the eligibility
criteria, then identified patients are referred to central clinical research centres in
institutions for further screening, and if accepted, are managed in the trial from these
centres.  This approach shares the same benefits for recruitment as described
above, a bigger pool to work through, but by using the central sites for conducting
the trial, the risk of variability, both in patient selection and in the actual conduct of
the trial, is reduced.
An alternative strategy that is being used by some pharmaceutical companies and
some of the larger contract research organisations and business intelligence
organisations is to invest, often quite heavily, in the development and maintenance
of patient registries.  These are defined as ‘an organized system that uses
observational study methods to collect uniform data (clinical and other) to evaluate
specific outcomes for a population defined by a particular disease, condition, or
exposure, that serves as a predetermined scientific, clinical or policy purpose’ 216 .
Constructing a registry involves building databases from vast quantities of pre-
existing information, usually by combining information from numbers of smaller
databases or warehouses, for example information on all the patients and
investigators and trial sites that the company has had contact with in previous
studies.  Registry data can then be queried to locate potential patients for new trials.
Some registries are disease-based whereas some are more general.  Whilst these
registries have value in supporting the recruitment process (and for protocol
feasibility testing), they can be expensive to produce due to differences in structure,
description and granularity of data and it is extremely hard to keep them accurate
and up-to-date. The use of registries can mean that patients are used in multiple
trials, which in itself becomes a problem, since many trials now specifically exclude
patients who have been subjects in other trials recently.
Any of this data, in a clinical data warehouse or in a patient registry, can be
interrogated with queries based on the eligibility criteria to identify individual patients
who may be suitable for recruitment.  Because this filtering process is conducted by
algorithmic querying, it has several benefits.  It eliminates the human variability of
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interpretation of the eligibility criteria and it is applied across the complete cohort of
patients, rather than being applied selectively to those the investigator deems
reasonable to consider initially; this primary selection in itself may introduce bias or
result in some eligible subjects being overlooked.
In order that the processes described above can perform well for protocol feasibility
testing and patient recruitment, it is important that the data, be it in a registry or a
clinical data warehouse, has the necessary elements to support the queries. A
cursory review of almost any set of eligibility criteria shows that a proportion of them
include medication information. Analyses of eligibility criteria to date, and specifically
analysis of computability to support clinical research, have primarily focused on the
semantic structuring of the criteria, rather than on their clinical content217; the
analysis that has been done on content appears to have been a by-product of the
structural analysis218.    This structural analysis has investigated for example, the
proportion of criteria that describe temporal data (when something occurred) without
any particular interest as to what sort of thing (for example, procedure, diagnosis or
medication administration) was that was being described temporally. Van Spall et
al219 undertook a systematic review of the description of exclusion criteria (only) in
published randomised controlled trials; 54.1% of the trials examined had medication-
related reasons for exclusion, meaning that over half of all trials studied required at
least some medication-related information for eligibility assessment.  Ross et al218
conducted an analysis to characterise eligibility criteria into three categories, one of
which was a treatment or intervention on the participant, which is presumed to
include medication, and to quantify their patterns and the complexity of these
patterns.  There is little or no analysis of the clinical content itself, and none that
looks particularly at medication information.  This means that there is no
standardised information as to the data items that are necessary to support for
protocol feasibility testing and patient recruitment actually are.
The aim of this study was therefore to analyse a set of study eligibility criteria and to
specifically investigate in detail the medication-related data elements which could be
used as parameters to query a patient’s Medication Profile to assess their suitability
for entry into a trial (patient recruitment) or to query a set of Medication Profiles in a
data warehouse to assess whether the eligibility criteria as described would yield a
reasonable cohort of patients as potential subjects (protocol feasibility).   These
medication-related data elements then become information requirements that a
Medication Profile should ideally meet, in order to be able to support these two uses
in the Clinical Research domain. A subsidiary aim was to have some sense of the
value, in terms of frequency of use, of each of these data elements, such that an
assessment of their importance for the particular use case can be made.  If a
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parameter is used in many eligibility criteria, the value of its presence in the
Medication Profile is high and vice versa.
Methodology
This analysis studied eligibility criteria from 41 clinical trials conducted in Europe by
nine different pharmaceutical companies provided to the EHR4CR project24
specifically for use in protocol feasibility and patient recruitment studies.   There were
1112 individual eligibility criteria from the protocols for these trials, which had been
submitted to the project by the participating pharmaceutical companies specifically
for research into improving protocol feasibility and patient recruitment.
Note: there was considerable variability in what each trial considered a single
eligibility criterion to be.  For some trials, a single criterion might contain a number of
related parameters, for example, the following was considered as a single criterion
in its study:
‘Laboratory values (within 1 week prior to the first dose of Drug
X): - Absolute neutrophil count = 1500/mm3. - Platelets =
100,000/mm3. - Creatinine = 1.5 times upper limit of normal
(ULN) or creatine clearance rate = 60 mL/min. - PT
international normalized ratio (INR) and partial thromboplastin
time (PTT) within normal limits. - Hemoglobin = 10 mg/dL. -
Total bilirubin = 1.5 times the ULN. - Aspartate
aminotransferase and alanine aminotransferase = 2.5 times
above ULN. - Alkaline phosphatase = 2.5 times above ULN’
This is in contrast to another trial where the following five parameters were detailed
as five separate criteria:
‘Hemoglobin ≥ 9.0 g/dL independent of transfusion;
Platelet count ≥100,000/μL; Serum albumin ≥ 3.0 g/dL;
Serum creatinine < 1.5 x ULN or a calculated creatinine
clearance ≥ 60 mL/min;
Serum potassium ≥ 3.5 mmol/L’
Since the investigation was seeking a more of a qualitative understanding of the
requirements that eligibility criteria place on the Medication Profile than a truly
quantitative measure, no attempt was made to normalise the pattern of eligibility
criteria such that each describes one and only one parameter.  The eligibility criteria
have been used and counted exactly as they were supplied in the protocol.
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Each of the eligibility criteria from the protocols was extracted into a spreadsheet
from where it was examined, and those whose parameter(s) involved medication
information were identified for further detailed study. This comprised identifying the
how the medication was described, and any medication data elements and additional
contextual information (for example, medication used for a particular diagnosis or
indication, or medication allergy information) that might be expected to be available
from the Medication Profile.
Eligibility criteria that described adverse events to medication occurring during the
study (i.e. after a subject has been recruited into the trial) were not included for
detailed evaluation, since these would not be relevant for protocol feasibility testing
or patient recruitment. An example of such a criterion is:
‘Any other hemorrhage/bleeding event > CTCAE Grade 3
within 4 weeks of first dose of study drug’
Eligibility criteria that described adverse events to medication that occurred prior to
the study, and therefore which might be expected to be in documented in a patient’s
Medication Profile and which therefore could be used for protocol feasibility testing
and/or patient recruitment applications were identified and studied, and were
categorised as medication related information.
Each item of descriptive data was categorised, with definitions for data elements
being provided based on or adapted from the relevant ISO definitional standards142
for the data element; if no ISO standard is available, a data element name and
description has been made up, as semantically robustly as possible.
The identification of the relevant eligibility criteria, the description of medication the
data elements and the categorisation of additional context was crosschecked by the
author by undertaking a separate second pass through each protocol. The research
supervisor independently checked the extraction for a sample of various protocols.
For the categorisation, an iterative approach was used to develop a meaningful
description for the Results in tabular form.
To provide a comparison to the medication information based data elements,
eligibility criteria whose description and data element(s) involved laboratory test
information were also identified.   Laboratory test information was defined as
biochemistry and haematology tests only; observables such as blood pressure
measurement, pathology and microbiology information were not included.
Laboratory test information was chosen as a comparator for medication information
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as like medication information, it is highly structured with little additional free text and
is similarly stored in patient records.
Results
As shown graphically in Figure 5 below, of the 1112 eligibility criteria, 201 made a
direct reference to medication that a potential subject may be taking or may have
taken.  In addition, 79 eligibility criteria described medication related information
(allergy to medication, adverse events from medication administration) that should
be available from an extended Medication Profile, or that could be queried by
inference. As a comparison to the medication-related eligibility criteria, 99 eligibility
criteria that involved laboratory test information were identified; of these 39 were
inclusion criteria and 60 were exclusion criteria.  Two inclusion criteria contained
both laboratory test information and medication information as they were both criteria
describing a number of parameters (and therefore are counted in both categories in
Figure 5).
Figure 5: Bar chart showing proportions of medication-based and laboratory test
based eligibility criteria
Identifying the medications in eligibility criteria
Only 10 of the 201 eligibility criteria explicitly described a specific medication by
name; all the others used a class description referring to characteristics or use of the
medicines in that class.   These class descriptions were categorised into five groups
as shown in Figure 6 below.
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Figure 6: Bar chart showing the different categories of medication description in
eligibility criteria
Categorical characteristics
Medications were described on the basis of their categorical characteristics, for
example whether they are in the chemical group of ‘bisphosphonates’ or
‘anthracyclines’ or share a common mechanism of action, for example ‘beta-
blockers’ or ‘glucocorticosteroids’.  These grouping features are part of the
categorical information about medicines, information is always and necessarily true
for that medicine.
Example:
‘Chronic treatment with a non-steroidal anti-inflammatory drug’
Therapeutic use
Medications were also described and identified as a group based on their therapeutic
use, for example whether they are used to treat hypertension or in cancer
chemotherapy.  This information is not part of categorical medicinal product
information, it is contextual and it changes over time.  For example: for many years
aspirin (acetylsalicylic acid) was used only as an analgesic and antipyretic, then it
was discovered to have antithrombotic properties and so is now additionally used as
secondary prevention therapy after myocardial infarction, stroke and a variety of
other cardiovascular events, so its therapeutic use has changed over time.
Example:
‘Patients receiving antipsychotics who are not on stable doses of atypical
antipsychotics for four weeks prior to baseline’
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Non-therapeutic (adverse) effects
Just as medications can be described and identified as a group according to their
therapeutic use, they can also be grouped by particularly significant non-therapeutic
effects; these are usually considered unwanted and undesirable and are therefore
often known as adverse effects.  This information is also contextual and changes
over time, especially as experience with the use of the medications grows.
Example:
‘Any concomitant medication known to prolong the QT interval’
Authorisation status
Medications in eligibility criteria were described and identified as a group by their
authorisation status, whether or not they have a formal marketing authorisation.  This
is information about medicinal products at a point in time within their overall
development lifecycle.
Example:
‘Treatment with a non-approved or investigational drug within 30 days before
Day 1 of study treatment’
Medication information and its context of use in eligibility criteria
The 201 eligibility criteria containing information relating directly to the Medication
Profile were examined in more detail to ascertain the information that would be
required from the Medication Profile to query correctly for potential subjects. Figure
7 describes the results of this, focusing particularly on the context of the medication
use, and whether that information was used in an inclusion or exclusion criterion.
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Figure 7: Bar chart showing the contextual medication information present in
eligibility criteria
Current medication use
Current medication use is defined as those eligibility criteria that identify that a
medication (or group of medications which might be defined by therapeutic category
or by shared indication) being taken by a patient/potential subject at the time of
recruitment into a study using words and where identified by phrases such as
‘(current) use of’ or ‘concomitant administration of’ . The large majority of these were
exclusion criteria with just 2 being inclusion criteria.
Example:
‘Currently on any medication to treat high blood pressure’
Included in the current medication use category are those eligibility criteria where
there was some indication of the timing of the medication administration in relation
to the current point in time or to a particular point in the study such as randomisation,
and for which it is likely that the medication would (still) be being used ‘in the present’.
Example:
‘Treatment with oral neuroleptics within 4 weeks prior to the screening visit’
Past medication use
Past medication use is the category of eligibility criteria that describe a medication
(or group of medications) that has been taken in the past and are no longer being
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taken (words and phrases such as ‘prior administration or’ or ‘history of’).   Some
eligibility criteria were not explicit in their reference to past medication use, for
example the criterion:
‘At least one but not more than 2 cytotoxic chemotherapy regimens for
metastatic castration-resistant prostate cancer’
This criterion implies that the chemotherapy must have occurred previously to the
current point in time, and would therefore be recorded as past medication. The past
medication use criteria were split with two thirds being exclusion criteria and one
third being inclusion criteria.
Example:
‘History of prior exposure to carisbamate’
Diagnosis with medication use qualifier
The set of eligibility criteria described in the group of ‘Diagnosis + Medication’ are
those where the primary criterion is that the subject has the condition/symptom
described (a diagnosis) with a supplementary qualification identifying a medication.
The subject must have both the condition/symptom (diagnosis) and be using or have
used the treating medication to fulfil the criterion.
Example:
‘Cardiac arrhythmias requiring anti-arrhythmic therapy’
Prior study medication
Prior study medication is the category of eligibility criteria that describe the use by a
patient of a study agent in a previous study; the overwhelming majority (35) were
exclusion criteria, but there were 3 that were inclusion criteria (such that the patient
would be eligible as a subject for a follow-on trial).
Example:
‘Investigational drug therapy outside of this trial during or within 4 weeks of
study entry’
Treatment failure
There were 10 eligibility criteria that concerned treatment failure which was
recognised by phrases such as ‘inadequate response to’, ‘resistance/resistant to’
and ‘relapse after’; with just one exception these were all inclusion criteria.
Example:
‘History of inadequate response to at least 1 AEDd….’
d AED = anti-epileptic drug
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Medication information and dosage instructions information in
eligibility criteria
Dosage instructions information is information about dose quantity (individual dose
quantity, daily dose quantity or cumulative (‘lifetime’) dose quantity), about timing of
administration (frequency of individual administrations or duration of the course of
therapy or start/stop dates) and about route of administration.  Indication information
is not considered a core component of the dosage instructions information but is
assessed with them as provision of the reason for the medication can be given as
part of the instructions. Figure 8 shows the dosage instructions data elements that
were present in medication based eligibility criteria.
Figure 8: Bar chart showing the dosage instructions data elements for medication
information present in eligibility criteria
Dose quantity
Less than 10% of the medication focussed eligibility criteria made any reference to
dose quantity information and of those half criteria did not specify a dose quantity
per se, but specified ‘stable dosage’ or ‘changing dosage’ as part of their description,
implying that dose quantity would need to be queried.
Example:
‘Low dose warfarin (1 mg po qd) is permitted if the INR (International
normalized ratio) is < 1.5.  Low-dose aspirin is permitted (≤ 100 mg daily).’
Route of administration
A similarly small percentage of the eligibility criteria specifically referenced one or
more routes of administration for medications directly (oral, intravenous) and a
further 7 criteria referenced route of administration by the proxy grouper concept of
‘systemic’, which implies oral or parenteral routes of administration (as opposed to
topical routes).
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Example:
‘Patients that required any use of IV vasodilators’
Indication for use
However more than a quarter of all medication focussed eligibility criteria described
the indication for use of the medication that the patient was administering as part of
their content.
Example:
‘Patients in whom anticoagulant treatment for their index PE or DVT should
be continued’
Timing
Almost half of medication based eligibility criteria described some element of the
timing of the medication administration.   Of these, 73 were ‘within’ and 11 were ‘prior
to’ a certain point, usually a milestone in the study lifecycle, such as screening,
randomisation or first dose of study medication.   The others were ‘for at least…
before’. Some eligibility criteria, particularly those describing use of another
investigational agent, also stated a time period in terms of ‘within x days or 5 half-
lives, whichever is longer’.
Example:
‘History of felbamate treatment within the past 3 months’
Other types of medication related information
The 79 eligibility criteria that referenced medication related information that might
possibly be included in a Medication Profile or related to information within it were
categorised as described and shown in Figure 9.
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Figure 9: Bar chart showing categories of medication related information present in
eligibility criteria
Allergy/hypersensitivity
All the eligibility criteria that described allergy or hypersensitivity to a medication or
an excipient were exclusion criteria.
Example:
‘History of hypersensitivity to docetaxel, or polysorbate 80’
Adverse events
Eligibility criteria describing adverse events to a medication or type of medication
were mostly exclusion criteria.  Note that an allergy could be considered an adverse
event and also included in this category, but in this analysis was classified separately
if specifically described (as above).
Example:
‘Unresolved or unstable serious adverse events from prior adjuvant
chemotherapy or radiotherapy’
Alcohol and substance misuse, smoking status and nicotine use
There were 12 eligibility criteria looking at current or past substance and alcohol
misuse, either directly or by referencing screening and/or current or past smoking
status and nicotine use.  Two criteria were listed as inclusion criteria, but they
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specified a negative result which semantically means that they were effectively
exclusion criteria.
Example:
‘Current alcohol dependence or drug abuse’
Contra-indications to medication use
All the eligibility criteria that described contra-indications to a medication or group of
medications were exclusion criteria.
Example:
‘Contraindications to the use of corticosteroid treatment’
Ability to administer medication formulation
Some eligibility criteria described the subject’s ability or otherwise to administer/have
administered the medication in a particular formulation.
Example:
‘Patients unable to swallow oral medications’
Indications for medication Use
All the eligibility criteria which described the subject being having the required
indication for a treatment with a medication or group of medications were exclusion
criteria; in these criteria the indication for medication use is used as a proxy for a set
of diagnoses.
Example:
‘Indication for anticoagulant therapy for a condition other than atrial fibrillation
(e.g., VTEe)’
Discussion
Importance of Medication Profile information in eligibility criteria
The results of the analysis show that just over 18% of the 1112 examined eligibility
criteria from the 41 clinical trials referred to medication information.  This proportion
is approximately double the proportion of examined eligibility criteria that referred to
laboratory test information, which provides good evidence of the value of using a
patient’s Medication Profile for protocol feasibility studies and in the development of
computer platforms and tools to support patient recruitment.  It also reinforces that
the correct types of information and data elements need to be present in that
Medication Profile.
e VTE = venous thromboembolism
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This 18% is considerably lower than an analysis conducted by Ross et al218, which
found, of 1000 eligibility criteria studied, ‘criteria specifying treatments or
interventions participant has received or will receive’ accounted for 34% of the total;
however no clear definition of the difference between a ‘treatment’ and an
‘intervention’ is provided in that analysis.  The proportion of eligibility criteria
referencing laboratory data was also lower in the Ross analysis; 9% as opposed to
23%; this suggests that the categorisation in this analysis was more granular than
that of Ross et al.
Current medication and past medication
The results show the relatively high level of importance of a subject’s current
medication as compared to the medication history.  Almost twice as many eligibility
criteria referred to medication being administered ‘now’ (and including prior to and
‘now’) compared to those that referred to medication having been administered in
the past and which are no longer being administered.  In the context of eligibility
criteria, the ‘now’ may be any specified point in the trial process – randomisation,
first administration of the investigational product etc.  However, if the number of
eligibility criteria that focus on previous administration of a study agent, which is a
type of past medication, were included, this would give roughly equal value to
knowledge of current and past medication. This is important, because in the
healthcare delivery domain the current medication is deemed the more important,
with the longitudinal record of lesser importance.
Investigational product use
A notable group of eligibility criteria were those that refer to previous administration
of a study agent, or which reference the authorisation status of products that have
been previously administered (which includes use of an authorised medication
outside of its approved indications). This is significant because of the recent growth
in the use of study registries, which accompanied by the concentration of clinical
research in a smaller number of large centres, means that the re-use of potential
subjects is becoming a problem.
To interrogate Medication Profile information correctly for use of study agents or
other non-approved drugs, it should be possible to identify these.  There are two
possibilities.  One is to incorporate the use of a medicines knowledgebase that has
wide coverage of study agents as part of the query application (see below) that could
be used to compare all the medicines in a patient’s Profile with their authorisation
status in the country of use.  Unfortunately, most medicines knowledgebases do not
have full coverage of investigational agents because information about these is not
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widely available and putting such information, even in a limited way, has sometimes
been deemed advertising, which is not permitted for unauthorised medicines.  Even
though there is a move from the regulatory agencies to increase the availability of
information on investigational products and an acceptance that inclusion of basic
information about an unlicensed product in a knowledgebase is not advertising, it is
likely to be some several years before such information is widely available and is
useable in a computable way.  Even if the information were available, the comparison
of each medicine in a Profile against an authorisation status is a considerable task,
especially for protocol feasibility testing when a large volume of potential patients’
information is being queried.  The second possibility is to indicate directly into the
Medication Profile when a patient is taking an investigational agent.  This is not, to
the writer’s understanding, currently done in any formal way by any medication
recording system (PMR or EHR) used in patient care, but on the evidence of this
analysis would appear to be useful.
Identifying medicines – knowledgebase requirement
Only a very small number, less than 3%, of eligibility criteria that focus on the
subject’s use of medicines directly describe the medicines themselves; all the rest
describe medicines in groups either by categorical characteristics or by therapeutic
use, or by non-therapeutic effect. This is significant for any process that wishes to
use Medication Profile information in protocol feasibility studies and/or in tooling to
support patient recruitment in that it introduces a requirement for knowledge about
medicines to be used.  A medicines knowledgebase, such as those that support
medication decision support in patient care should have the categorical information
and the therapeutic use information readily available and in a format that would be
straightforward to process to provide the additional information for querying of these
eligibility criteria.   A knowledgebase of this type will use the Summary of Product
Characteristics (SmPC) as one of its primary sources.  In that document, which is
laid out in standard sections220 the categorical characteristics of a medicine are
described in the ‘Pharmacodynamic properties’ section (5.1) usually by direct
reference to a formal characteristics classification such as the ATC221.  Therapeutic
use is similarly described in the ‘Therapeutic indications’ section (4.1).
Although non-therapeutic effect information of the types seen in the eligibility criteria
is available for medicinal products as part of this authorisation information, it is not
as organised and as accessible as the categorical characteristics or indications
information, nor is it standardised.   For although there is a section in an SmPC
labelled ‘Undesirable effects’ (section 4.8) this merely lists all unwanted effects that
the medication has been found to cause or suspected of causing.  For newer
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medicines, these effects are at least grouped together in categories based on the
MedDRA System Organ Class222 hierarchy and therefore it is possible to identify
those of relevance to an eligibility criterion more easily, say by looking at the cardiac
disorders for QT interval prolongation. This type of adverse effect information may
alternatively be described elsewhere, as in the ‘Special warnings and precautions
for use’ section (4.4).  Information about enzyme modulation caused by a medicinal
product may be even more dispersed in a single SmPC.  It may appear in the
‘Posology and method of administration’ section (4.2), because it is seen as a
requirement for dosage adjustment.  It may appear in the ‘Special warnings and
precautions for use’ section (4.4) as information about co-administration and it will
almost certainly also appear (again) in the ‘Interaction with other medicinal products
and other forms of interaction’ section (4.5).   Therefore, although the raw data is
usually available, even if somewhat scattered in location, it has to be processed into
knowledge for use in practice. This can introduce a concerning lack of consistency.
For example, there is no documented standard set of medicines acknowledged as
those that prolong the QT interval in a clinically relevant manner.  An illustration of
this is that the British National Formulary lists QT interval prolongation as side effect
of macrolide antibiotics223 but does not do so for quinolone antibiotics although such
effects have been documented224 and are noted in SmPC.   The same lack of
consistency exists for information about for cytochrome P450 isoenzyme
modulators, and is more complicated as there are several individual isoenzymes to
consider.    Knowledgebases currently take this raw data on enzyme modulation and
apply it in the maintenance of their drug interaction modules, rather than provide it
directly as information about the medicinal products that are CYP modulators225.
Recognising this issue, some clinical trial protocols will document lists of medications
that in its context are considered to carry these risks, for example:
‘Any concomitant medications that may cause QTc prolongation or induce
Torsades de Pointes (see Appendix D for the lists of medications in Table 1 and
Table 2) or induce CYP3A4 function’ and ‘Concomitant use of CYP3A4 inhibitors or
inducers.  See Section 5.3.2 for list of prohibited medications.’226
The lack of consistency means is information must be managed on a study-by-study
basis, and cannot necessarily be applied to other studies that have not provided such
information.
There were a small number of eligibility criteria that described alcohol and/or
substance misuse and/or nicotine use.  Whilst not directly part of the Medication
Profile, there is information that could contribute to this.  Medications used
specifically in the management of substance misuse, alcohol misuse and nicotine
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replacement therapy are likely to be documented in a Profile and, by using a
knowledgebase to identify these and then querying against that set, some
assessment of a potential subject’s suitability against this type of eligibility criteria
could be made using information in the Medication Profile.
A knowledgebase could be used to provide information to assist in querying for the
small number of eligibility criteria that reference contra-indications to medications,
by listing these contra-indications as conditions and then the patient record querying
for evidence their presence directly.  However, this is a considerable amount of
processing for a relatively small number of eligibility criteria; it would be more
constructive to protocol feasibility studies and patient recruitment support to list the
conditions themselves, rather than use a medication’s contra-indications as a proxy.
Dosage instructions
The proportion of medication eligibility criteria that describe dosage instruction
information showed some clear patterns.  Less than 10% required dose quantity or
route of administration information.  However, nearly half of all eligibility criteria that
describe use of medicines also reference when the course of therapy occurred,
either that it was currently in progress or when in the past it had occurred and ceased,
as already described in the classification of those eligibility criteria that reference
either current medication or past medication.
Given the complexity that can easily develop in describing dosage instructions
information in a machine-readable way, these results indicate that there is little value
to be obtained by attempting complex querying of this information within the
Medication Profile for protocol feasibility studies and patient recruitment tooling.  But
the results show that it is important for protocol feasibility studies and patient
recruitment tooling to be able to ascertain the basic timing of the course of therapy
(i.e. start and stop dates), even if the detail of the dose quantity, frequency of
administration or route of administration within that course is not provided in any
machine-readable/query-able way.
Indication for treatment and discontinuation
A significant proportion (almost a third) of eligibility criteria that include medicinal
product use also require evaluation of the indication for the use of the medication,
but this information is rarely directly recorded in a medication process and therefore
is presently unlikely to be directly available in a clinical data warehouse or EHR
system.  The information may well be present implicitly: the patient was diagnosed
with breast cancer at point X and three weeks later doxorubicin is administered; it is
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almost certain that the doxorubicin would be indicated for the treatment of the breast
cancer. Whilst a clinician reviewing a patient with a complete health record can make
that connection straightforwardly, if they can find the data, an application querying a
clinical data warehouse or EHR system would find that an extremely complex task
to accomplish successfully given the current state of such systems. Even a clinician
may find this type of inference difficult for those medications with a diverse set of
therapeutic uses; being clear of the indication for the use of amitriptyline, whose
primary use has been as an antidepressant but is now as likely to be used as an
analgesic in post herpetic neuralgia or as a prophylactic against migraine, is a much
more tricky task.
Indication information in an eligibility criterion is subtly different from the combination
of a particular diagnosis with a medication qualifier, although each describes a
medication and a condition/symptom being treated.   The latter is somewhat easier
to query for in a clinical data warehouse or EHR system; the diagnosis can be
queried directly, and if found, then the qualifying medication can then be
investigated, again directly.  Since both mechanisms achieve roughly the same
ends, potential subjects with a particular diagnosis also taking a particular
medication that is related to that diagnosis, wording eligibility criteria in the pattern
of ‘diagnosis + medication qualifier’ is likely to be more efficient for querying in
protocol feasibility studies and patient recruitment tooling than using the ‘medication
and indication’ pattern.
A small number of eligibility criteria referred directly to treatment failure; the subject
had therapy with the particular medication, but it was unsuccessful in achieving the
desired therapeutic effect. In addition, in the analysis of those criteria that were
deemed to not be directly related to the Medication Profile but referenced medication
in some way, the majority concerned allergy/hypersensitivity or an adverse event.   If
these are considered together as ‘reason(s) to stop’ a therapy, this amounts to
significant number of the eligibility criteria.  Reason for discontinuation information is
rarely recorded explicitly in any clinical record system, but these results suggest that
it would be of use if it were.
Other
The very small number of eligibility criteria that are concerned a potential subject’s
ability to self-administer particular formulations of a study agent do not currently have
any data that would support identifying such subjects computably. The small
proportion of criteria does not offer significant evidence to support this as a new
requirement for addition to the Medication Profile.
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Ethical and medico-legal implications
This analysis of eligibility criteria requirements for the Medication Profile has
focussed on the medication specific data elements that the Profile would need to
contain to support the systems mediated detection of suitable subjects for protocol
feasibility testing and patient recruitment.  However, for these data to be actually
used in such testing or going forward as part of a clinical trial data set, it would be
necessary to comply with all the appropriate ethical and medico-legal requirements,
including those of Good Clinical Practice (GCP)227. These include the requirement
that the authorship and time stamping of all data is preserved, and that all changes
are made in a version controlled manner permitting full traceability and the potential
for rollback to a prior version of the data, a comprehensive audit trail and a long-term
commitment to data retention. Many of these GCP medico-legal requirements are
identical or very similar to the medico-legal requirements for electronic health record
data, such as published in ISO EN 18308:2011 ‘Requirements for an electronic
health record architecture’228.
Limitations of this study
The main limitation of this study that it used information from phase III trial protocols
provided by the pharmaceutical industry specifically for research. Despite this, the
number of criteria studied was similar to that investigated in the few other studies in
this area. Repeating this investigation using a different set of protocols would be
beneficial, as would a similar type of investigation using other study phases and
study types.  This should include observational (phase IV) studies for medications,
and studies into other types of medical intervention (procedures, device use).
Recommendations for further work
Since a proportion of eligibility criteria refer to groups of medicines with specific non-
therapeutic actions, such as Q-T interval prolongation or CYP modulation, it would
be useful if work were undertaken to establish clearly which medications should be
considered members of these groups, based on evidence of clinical effect rather
than theoretical possibility.  These standard lists could then be used in all studies, in
both design and execution, and would have value in the wider context of clinical
decision support.
Further investigation could be undertaken into whether it is indeed valuable to
encourage study protocol authors to employ a ‘diagnosis with medication qualifier’
structure in the statement of an eligibility criterion as opposed to using a ‘medication
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for this indication’ structure, particularly if one pattern was significantly more effective
in protocol feasibility studies and patient recruitment tooling.  Given the known lack
of recording of indication information, the former pattern appears the more useful,
yet the latter pattern appears to have use that is more extensive in eligibility criteria.
Optimisation of the eligibility criteria given in a study protocol would be expected to
optimise recruitment of subjects to that study, so this would be a useful area for
further work.
Conclusion
Information from a potential subject’s Medication Profile makes a significant
contribution to the overall set of queries based on study eligibility criteria, which are
used in protocol feasibility studies and patient recruitment tooling.  Information on
both current medication use and past medication use where shown to be equally
useful, when use of a past study agent is included as a type of past medication,
which supports the requirement to have longitudinal information in a Medication
Profile as well as current medication information.
In terms of the detail of what is recorded in the Medication Profile in addition to the
identification of the medicinal products themselves, the most useful element is the
timing of the course of therapy – when it commenced and if/when it has ceased.
Other dosage information, including route of administration and dose quantity was
found to have limited use.   In conjunction with the start and stop timing, direct
recording of information about the indication to start a therapy, and reasons for its
cessation were found to be of benefit in this context.  Neither is currently recorded in
routine practice.
The analysis demonstrated the requirement to be able to query a Medication Profile
to ascertain whether any of the medications that a patient has received is an
investigational agent (i.e. a medication that does not possess a marketing
authorisation and therefore is administered as part of formal clinical research).
It was clear that, due to the way eligibility criteria are currently written, a medicines
knowledgebase is required to expand some grouping concepts from the criteria into
individual medication concepts such that the Medication Profile can be queried
directly.
The results of this analysis give several recommendations, beyond the provision of
requirements for the content of a Medication Profile. These recommendations are
primarily aimed at authors of eligibility criteria, but also to authors of medicines
knowledgebases and to the providers of electronic health record systems.
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Medication Profile information in EHR systems should be structured and designed
such that their recording of medication information and in particular the granularity
of the data elements within that support all of the relevant use cases for that
information: high quality direct care delivery and also secondary uses, including
clinical research.
Standardised sets of the medications that are acknowledged to cause important
clinical effects such as prolongation of the QT interval and CYP modulation should
be developed.  These should be agreed for use in both patient care and clinical
research, and should be available for use in knowledgebase systems.  In the interim,
when an eligibility criterion refers to such an effect, it should provide the set of
medications that the author(s) deem to be causative, to avoid different investigators
using different sets.
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Part 2: Pharmacovigilance
Introduction
Adverse drug reactions have an enormous human and economic cost.  This is in
terms of the suffering caused to individuals and their families, in direct costs to the
healthcare system of treating the adverse events, in the loss of revenues if/when a
medicinal product must be prematurely withdrawn from the market and in terms of
any litigation arising from inadequate safety information for the sponsoring
pharmaceutical company.
Clinical trials, despite having a clear responsibility to demonstrate safety229, no
matter how carefully they are undertaken or how much data they collect, will always
have limitations in terms of the safety information they provide230.  This is not least
because the primary purpose of any pre-authorisation trial is to actively and explicitly
demonstrate efficacy, not to assess harm231,232, whereas safety is demonstrated
passively and implicitly.   This is seen in the contrast of the two submission
documents included in an eCTD233 (electronic Common Technical Document)
submission to the FDA based on pooled cross study data:  the Integrated Summary
of Safety (ISS) and the Integrated Summary of Efficacy (ISE).  The first looks to try
to find ‘the needle in the haystack’35 through critical assessment of the safety data
itself and by analysis of additional data that might be a pointer to safety issues such
as trial drop-outs etc. whereas the second looks to actively demonstrate the benefits
of the product and particularly that these benefits outweigh any risks234.
The adverse effects of a medicine can be hard to detect and this may be made
harder still in the context of time-limited clinical trials.  This is because some adverse
events take time to manifest themselves (late reactions) and may even occur after
the medication course has finished (delayed reactions) 235 and the trial has been
completed. In addition, age236,237 and morbidity238,239 can have a considerable effect
on the pharmacokinetics of many medications, which may then have a consequential
effect to their adverse event profile in those sub-populations.  Yet most phase II and
phase III clinical trials are both age limited and co-morbidity limited. One area that
is assessed is the effect on safety of concomitant medications taken by study
subjects240.  Therefore, for any subject in a clinical study who has an adverse event,
having information on the concomitant medications they are taking is a requirement.
This information is gathered in the trial for each study subject and is reported in the
Concomitant Medications domain of the Study Data Tabulation Model31.
Since understanding serious adverse events is a critical component of the overall
medication safety landscape and because of the detection difficulties in clinical trials,
continuing to gather safety information beyond the formal clinical trials phases is
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vital.  This means that the role of the spontaneous adverse event reporting systems
that provide post marketing surveillance of medicines operating throughout the world
is invaluable, indeed essential, in detection of adverse events241. Capturing
information about spontaneous adverse events is a major, possibly the major,
element in shaping the necessary understanding of the overall safety of a medicinal
product.  Spontaneous adverse event reporting must therefore be a global initiative
to gather enough data to have a realistic chance of success.
Spontaneous adverse event reporting is usually managed by what the WHO refers
to in it its Partners in Pharmacovigilance as the collating agencies157, the National
Pharmacovigilance Centres, who, alongside the WHO’s own teams, provide the
main co-ordination for post-marketing surveillance and whose core activity is the
collection of suspected adverse drug reaction information.    These agencies form a
major part of the partnership, which includes the different organisations and
disciplines that must work together in the science of pharmacovigilance to safeguard
the public in their use of medicines.   National medicines regulatory agencies are
also core members of the partnership and need close collaboration with the national
centres242 and indeed in some cases may incorporate the national centre within their
structures243.
The cornerstone of spontaneous adverse event reporting systems and therefore of
post marketing surveillance is the collection and analysis of adverse drug reaction
information from healthcare practitioners and increasingly, from patients themselves.
The raw data collection is undertaken through the adverse event forms that the
reporter completes and submits to the collating agency.  The older systems started
using paper-based forms submitted by mail or fax and most have now moved to also
offer web-based forms submitted directly on line.  The data from the forms is entered
into the collating agency’s database.  These databases grow over time, the FDA’s
AERS database receives approximately a thousand reports per day, and is the
primary resource for adverse event analysis and detection244, although that detection
is an extremely complex and difficult process35.
The adverse event reporting forms are therefore of great significance since it is these
that provide the raw material for the adverse event assessment.   However, there
has been little critical assessment of the requested data elements on spontaneous
adverse event reporting forms, although it is clearly acknowledged that reports with
little clinical data are of limited value because the relationship between a drug and a
suspected adverse event cannot be assessed245.
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Getz et al246 undertook an assessment of the completeness and basic accuracy of
the information present in a set of FDA MedWatch forms.  This assessment noted
that the patient information was generally more complete than the data on the
suspect product, with dosage information (for the suspect product) being complete
in less than a third of reports.  Further analysis showed that information that was
provided was often erroneous; a quarter of the names given for the suspect product
were inaccurate, with spelling, even of common medicines, being a key issue. Getz
et al concluded that the low levels of completeness of suspect product information
were ‘troublesome’, since this information is essential to identifying root causes in
adverse events.  This analysis concentrated only on patient and suspect medication
data elements; no assessment of information on the concomitant medications was
undertaken.
One known issue with spontaneous adverse event reporting forms is the amount of
time taken to complete247; it is estimated that the FDA’s 3500 MedWatch form takes
a healthcare professional an average of 36 minutes to complete manually248.    There
are been some initiatives to obtain the information for the forms directly from an
electronic health record.  Probably the most widely known of these is the proof of
concept undertaken by the ASTER pilot249.  This pilot used the electronic health
record to supply data directly into an adverse event report when requested by the
user, and in addition used information from the electronic health record to trigger a
query to the user that an adverse event may have occurred and therefore to request
that a report be submitted.
The patient’s Medication Profile is a valuable source information for the information
required for pharmacovigilance, so it should be the most robust and reliable source
for the data elements needed.  Therefore, by undertaking an analysis of the
requirements of reporting forms, both for spontaneous adverse events in post
marketing surveillance and for clinical trials, the requirements that the Medication
Profile must meet to be that authoritative information source will be elucidated.
Methodology
The aim of the investigation was to analyse a set of spontaneous adverse event
reporting forms from various national medicines regulatory agencies to document
the data elements about medicines, both suspect and concomitant, that are
requested from reporters in order to assess adverse events.   These data elements
become information requirements for the Medication Profile, so that, ideally, these
items of information can be drawn directly into an adverse event report by a reporter.
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Post marketing surveillance forms are created by national pharmacovigilance
reporting centres who are often part of the national regulatory agencies, so each
country therefore uses its own standard form(s) for data collection. Although they
vary in the scope of products for which they are to be used, these forms collect a
broadly similar set of data even though they are not conforming to any international
standard. In order to ascertain exactly the data items that are most usually collected
on such forms so as to take these forward as data requirements for the Medication
Profile, a purposeful sample was undertaken of forms used within Europe, North
America and Australasia. There was not scope in this research to undertake an
exhaustive international survey of these forms, which is not considered an important
limitation given their similarity. The forms were those in current use during the period
of this study, which was October to December 2014.  The analysis studied 13
spontaneous adverse event reporting forms that are available electronically for use
by reporters from patient care; and one local one available in hard copy; these forms
were from seven countries.
The forms in languages other than English where translated.  The Dutch form was
translated by a Dutch pharmacist working for the royal Dutch pharmacists’
association, Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie,
(KNMP)164.  The French and Spanish forms were translated by a graduate
specialising in these languages with significant familiarity with medication concepts.
Since medication concepts keep their close association to their Latin base (e.g.
‘posologie’ in French to describe dosage instructions, which translates to posology
in English), the accuracy of the translation could be confirmed by the researcher,
with her own understanding of modern languages and medication concepts.
In the pharmaceutical industry in regulated clinical research, there are just two
standard forms in use; these are the international reporting forms known as the
CIOMS250 form and the ICH E2B(R3)251.  In addition, the data elements (variables)
collected to describe study medication(s) (the exposure domain EX) and
concomitant medications (the CM domain) in CDISC’s Study Data Tabulation Model
(SDTM) were included for study.  This is the only available specification for data
elements to be used in the submission of raw clinical trial data, and it provides the
data that would be used to support investigation of an adverse event occurring during
a clinical study.
Each form was examined in turn and the data elements it requested for both the
suspect medication(s) and any concomitant medications were noted. The extraction
of data elements was crosschecked by the author by undertaking a separate second
pass through each form. The research supervisor independently checked the
162
extraction for a sample of the forms. The parent for the medication data elements
was usually a description of the medication itself (e.g. a section entitled ‘product
name’).  Due to the variation in granularity of the data elements themselves (for
example, two forms collected batch number as part of the product name section,
whilst the others collected batch number as a separate data item) an iterative
approach was used to develop a meaningful description of the Results in tabular
form.
Results
Sixteen forms were examined to ascertain the data elements required to describe
the suspect medication(s) and concomitant medications involved in adverse
reactions.  13 forms were spontaneous adverse event reporting forms for use by
reporters from patient care, 2 were forms for use by the pharmaceutical industry and
one is used to report subject information from clinical studies.  The details of the 16
forms is shown below in Table 12.
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Table 12: Description of the ADR report forms examined
Form Short
Name
Form Full Name Country Owner Reference
Medwatch
3500
Medwatch Voluntary 3500 United States
of America
Food and Drugs Administration (FDA) http://www.fda.gov/downloads/AboutFDA/Rep
ortsManualsForms/Forms/UCM163919.pdf
Medwatch
3500A
Medwatch Mandatory 3500A United States
of America
Food and Drugs Administration (FDA) http://www.fda.gov/downloads/AboutFDA/Rep
ortsManualsForms/Forms/UCM048334.pdf
Medwatch
3500B
Medwatch Voluntary for
Consumers 3500B
United States
of America
Food and Drugs Administration (FDA) http://www.fda.gov/Safety/MedWatch/HowToR
eport/DownloadForms/ucm149236.htm
Yellow Card:
paper
Report of Suspected Adverse
Drug Reactions (paper)
United
Kingdom
Medicines and Healthcare Products
Regulatory Agency (MHRA)
https://yellowcard.mhra.gov.uk/
https://www.medicinescomplete.com/mc/bnf/c
urrent/
Yellow Card:
online
Report of Suspected Adverse
Drug  Reactions (online)
United
Kingdom
Medicines and Healthcare Products
Regulatory Agency (MHRA)
https://yellowcard.mhra.gov.uk/
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Table 12 (cont.): Description of the ADR report forms examined
Form Short
Name
Form Full Name Country Owner Reference
Blue Card Report of Suspected Adverse
Reaction to medicines or
vaccines
Australia Therapeutic Goods Administration
(TGA)
https://www.tga.gov.au/sites/default/files/blue-
card-adverse-reaction-reporting-form-
151102.pdf
ANSM Déclaration d’effet indésirable
susceptible d’être dû à un
médicament
France Agence nationale de sécurité du
médicament et des produits de santé
(ANSM)
http://ansm.sante.fr/var/ansm_site/storage/orig
inal/application/dd527d3fd8e9727b05476386c
555fbcd.pdf
IMB ADR Adverse Reaction Report Form Ireland Irish Medicines Board (now Healthcare
Products Regulatory Agency)
(IMB/HPRA)
https://www.hpra.ie/homepage/veterinary/safet
y-information/adverse-reaction-reporting
Lareb ADR Meldformulier Zorgverlener The
Netherlands
Lareb https://www.lareb.nl/Meld-
bijwerking/Meldformulier
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Table 12 (cont.): Description of the ADR report forms examined
Form Short
Name
Form Full Name Country Owner Reference
SEFV-H A SEFV-H (Madrid) [A] Notificar
sospechas de reacciones
adversas a medicamentos
Spain Sistema Español de Faramcovigilancia
de Medicamentos de Uso Humano
(SEFV)
https://www.notificaram.es/FNotificacionPS.as
px
SEFV-H B SEFV-H-Madrid) [B] Notificar
sospechas de reacciones
adversas a medicamentos
Spain Sistema Español de Faramcovigilancia
de Medicamentos de Uso Humano
(SEFV)
https://www.notificaram.es/FNotificacion.aspx
VAERS Vaccine Adverse Event
Reporting System Form
United States
of America
Food and Drugs Administration (FDA)
and Centers for Disease Control and
Prevention (CDC)
https://vaers.hhs.gov/esub/step1
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Table 12 (cont.): Description of the ADR report forms examined
Form Short
Name
Form Full Name Country Owner Reference
AEFI Adverse Events following
Immunisation Form
Australia Therapeutic Goods Administration (TGA) https://www.tga.gov.au/form/national-
adverse-events-following-
immunisation-aefi-reporting-form
CIOMS 1 Suspect Adverse Reaction Report
Form (CIOMS Form 1)
Global Council for International Organizations of
Medical Sciences (CIOMS)
http://cioms.ch/index.php/cioms-form-i
E2B(R3) Data Elements for the Transmission
of Individual Case Safety Reports
Global International Conference on Harmonisation
of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH)
http://estri.ich.org/e2br3/index.htm
SDTM forms Study Data Tabulation Model for
Exposure to Study Drug (EX) and
Concomitant Medication (CM)
Global Clinical Data Interchange Standards
Consortium (CDISC)
https://www.cdisc.org/standards/found
ational/sdtm
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Scope, Event type and Reporter type
The 13 spontaneous adverse event reporting forms for use by reporters from patient care varied considerably in their scope, usage and paradigm of reported event
type, whereas forms for use by the pharmaceutical industry in regulated clinical research showed less variation.  The following two tables show the scope (the types
of products whose adverse events can be reported on the form) and the types of events that should be reported with the types of reporters that may use the form.
Table 13: Description of the scope (type of products) covered by each ADR report form
Form Short Name Prescription
medicines
Biologic
products
Vaccines Over-the-counter
medication
Nutrition
products
Cosmetic
products
Food
products
Medwatch 3500       
Medwatch  3500A     x x x
Medwatch 3500B      x x
Yellow Card: paper      x x
Yellow Card: online     x x x
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Table 13 (cont.): Description of the scope (type of products) covered by each ADR report form
Form Short Name Prescription
medicines
Biologic
products
Vaccines Over-the-counter
medication
Nutrition
products
Cosmetic
products
Food
products
Blue Card      x x
ANSM     x x x
IMB ADR     x x x
Lareb ADR     x x x
SEFV-H A     x x x
SEFV-H B     x x x
VAERS x x  x x x x
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Table 13 (cont.): Description of the scope (type of products) covered by each ADR report form
Form Short Name Prescription
medicines
Biologic
products
Vaccines Over-the-counter
medication
Nutrition
products
Cosmetic
products
Food
products
AEFI x x  x x x x
CIOMS     x x x
E2B(R3)     x x x
SDTM forms     x x x
The biggest difference across the 13 spontaneous adverse event reporting forms is that two forms are for reporting vaccine events only, whereas all the others and
indeed including the industry-focussed forms, cover medicinal products and vaccines (or they do not differentiate between these two types of product (the SEFV-H,
CIOMS and E2B forms).
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Three agencies (FDA, MHRA and TGA) responsible for adverse event forms listed the types of medicinal products that could have events reported and explicitly
included over-the-counter medication (both the MHRA and the TGA gave a definition of these as ‘purchased without a prescription’) and complimentary therapies
(which the Australian TGA helpfully defined as ‘erbal medicines, naturopathic and/or homoeopathic medicines, and nutritional supplements such as vitamins and
minerals’).  The FDA’s MedWatch form also covers events relating to foods and cosmetic products.  All the other forms were limited to events for medicines only, with
both the IMB and Lareb forms specifically including vaccines as medicinal products.
Table 14: Description of the reporter types and event types for each ADR report form
Form Short
Name
Reporter Type Event Type
Healthcare
professionals
Patients &
Consumers
Pharmaceutical
Companies
Other Adverse
Event
Product
Problem
Medication
Error
Product
Switch
Problem
Medwatch
3500
  x x    
Medwatch
3500A
x x  User facilities
Distributors
Importers
  x x
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Table 14 (cont.): Description of the reporter types and event types for each ADR report form
Form Short
Name
Reporter Type Event Type
Healthcare
professionals
Patients &
Consumers
Pharmaceutical
Companies
Other Adverse
Event
Product
Problem
Medication
Error
Product
Switch
Problem
Medwatch
3500B
x  x x    
Yellow Card:
paper
  x x  x x x
Yellow Card:
online
 x x x  x x x
Blue Card  x x x  x x x
ANSM  x x x  x x x
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Table 14 (cont.): Description of the reporter types and event types for each ADR report form
Form Short
Name
Reporter Type Event Type
Healthcare
professionals
Patients &
Consumers
Pharmaceutical
Companies
Other Adverse
Event
Product
Problem
Medication
Error
Product
Switch
Problem
IMB ADR  x x x  x x x
Lareb ADR  x x x  x x x
SEFV-H A x  x x  x  x
SEFV-H B  x x x  x  x
VAERS    Vaccine
administrators
   x
AEFI   x x  x x x
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Table 14 (cont.): Description of the reporter types and event types for each ADR report form
Form Short
Name
Reporter Type Event Type
Healthcare
professionals
Patients &
Consumers
Pharmaceutical
Companies
Other Adverse
Event
Product
Problem
Medication
Error
Product
Switch
Problem
CIOMS 1 x x  Investigators  x x x
E2B(R3) x x  Investigators  x  x
SDTM x x x Investigators  x x x
Some agencies provide a set of spontaneous adverse event reporting forms, aimed at their different reporter communities.  The FDA provides three separate forms;
the MedWatch 3500 may be used by healthcare professionals and consumers/patients, the MedWatch 3500A is to be used by all industry reporters
(manufacturers/distributers etc.) and the MedWatch 3500B is aimed solely at consumers. The MHRA’s Yellow Card paper version may be used by healthcare
professionals and members of the public, whereas the on-line version should be used by healthcare professionals only. SEFV-H provides two forms – one for
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healthcare professionals only and one for patients only. Both the specifically
vaccines-focussed adverse event forms accept reports from both healthcare
professionals and members of the public.  All the other agencies provide only one
form, which is for the use of healthcare professionals.  The TGA advises members
of the public to seek advice from a healthcare professional if they feel they have
experienced an adverse event, but very recently a consumer focussed form has
been placed on-line252.  The CIOMS and E2B forms are industry only, which includes
any healthcare professionals in their role as investigators conducting clinical trials
on behalf of the clinical research industry.
Whilst all of the report forms cover product adverse events, the FDA forms have the
broadest event coverage, including product problems (defects etc.), medication
errors and product switching problem (adverse event because of being given an
alternative manufactured product for the same medication).  Two of forms (MHRA
Yellow Card: paper and TGA Blue Card) specifically stated that product problems
should be reported using a separate system.   The SEFV-H and E2B forms explicitly
included medication errors in their event types.
Medication Data Elements
Each of the 16 ADR report forms were examined in detail and the medication data
elements required by each form, both for the suspect medication (Table 15) and for
the concomitant medications (Table 16) were recorded.
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Table 15: Presence of the detailed medication data elements for each report form: Suspect medication
Form Product description Dosage information Therapy dates Indication Batch or
Lot
number
Other
Name Code Dose
quantity
Dose
frequency
Route Start
date
Stop
date
Duration
Medwatch
3500
Trade/brand name
OR
Generic name +
manufacturer
Strength
         Expiry date
Medwatch
3500A
Trade/Brand Name
OR
Generic name +
manufacturer OR
Foreign trade
name +
manufacturer
         Expiry date
Medwatch
3500B
Name(s) of the
product
Name of company
that makes product
      x   NA
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Table 15 (cont.): Presence of the detailed medication data elements for each report form: Suspect medication
Form Product description Dosage information Therapy dates Indication Batch or
Lot
number
Other
Name Code Dose
quantity
Dose
frequency
Route Start
date
Stop
date
Duration
Yellow
Card:
paper
Name of
Drug/Vaccine (Brand
if known)
x 
free text (daily dose)
   x   NA
Yellow
Card:
online
Name of
Drug/Vaccine (from
drop down)
x 
free text (daily dose)
   x   NA
Blue Card Medicine/vaccine
(please use trade
names)
 
Dosage (dose number
for vaccines e.g. 1st
DTP)
x   x   NA
ANSM Medicine name x 
free text (daily dose)
   x   NA
IMB ADR Name of
Drug/Vaccine (brand
name where
possible)
x 
free text (daily dose)
      NA
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Table 15 (cont.): Presence of the detailed medication data elements for each report form: Suspect medication
Product description Dosage information Therapy dates Indication Batch or
Lot
number
Other
Name Code Dose
quantity
Dose
frequency
Route Start
date
Stop
date
Duration
Lareb
ADR
Name of product
(from drop down)
x      x  x NA
SEFV-H A Name of product
(from drop down)
      x   Expiry
SEFV-H B Name of product
(from drop down)
x      x   Expiry
VAERS Vaccine (type) +
Manufacturer
x Number of previous
doses
 Date of vaccination x  Site of
administration
AEFI Name (brand) x Dose number  Date of vaccination x  Site of
administration
CIOMS
Form 1
Drug name (include
generic name);
Manufacturer
x 
free text (daily dose)
   x   NA
E2B(R3) Medicine (generic &
proprietary)
x         Active
ingredient
SDTM EX Name +
Dose form
x       x  Site of
administration
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In the FDA forms where medication errors are specifically included as reportable events, there is a note that in the case of overdose, the overdose amount should be
reported rather than the prescribed dose quantity for the suspect medication.
Table 16: Presence of the detailed medication data elements for each report form; Concomitant medication
Form Product description Dosage information Therapy dates Indication Batch or
Lot
number
Other
Name Code Dose
quantity
Dose
frequency
Route Start
date
Stop
date
Duration
Medwatch
3500
Free text name x x x x   x x x NA
Medwatch
3500A
Free text name x x x x   x x x NA
Medwatch
3500B
Free text name x x x x x x x x x NA
Yellow
Card:
paper
Name of
Drug/Vaccine
(Brand if
known)
x 
free text (daily dose)
  x   NA
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Table 16 (cont.): Presence of the detailed medication data elements for each report form; Concomitant medication
Form Product description Dosage information Therapy dates Indication Batch or
Lot
number
Other
Name Code Dose
quantity
Dose
frequency
Route Start
date
Stop
date
Duration
Yellow
Card:
online
Name only
(from drop
down)
x x x x x x x x x Source:
Blue Card Name x Dosage x   x  x NA
ANSM Product name x 
free text (daily dose)
   x  x NA
IMB ADR Drug name x 
free text (daily
     x NA
Lareb
ADR
Name:
can include
strength and
form
x      x   Expiry
SEFV-H A Name x      x   Expiry
180
Table 16 (cont.): Presence of the detailed medication data elements for each report form; Concomitant medication
Form Product description Dosage information Therapy dates Indication Batch or
Lot
number
Other
Name Code Dose
quantity
Dose
frequency
Route Start
date
Stop
date
Duration
SEFV-H B No requirement for information
VAERS Vaccine (type)
Manufacturer
Other
medications
(free text)
x Number of previous
doses
 Date of vaccination x  Site of
administration
AEFI Allergies and previous vaccination reaction information only
CIOMS
Form 1
Name x x x x   x x x NA
E2B(R3) Name         x NA
SDTM CM Verbatim
name and
standardised
name
X       x  Site of
administration
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Product Description – Suspect and Concomitant
All forms required some identification of the medicinal products (and/vaccines)
involved in the event.   In several forms, there was a difference in the level of detail
required for the description of the suspect product from that of any concomitant
products.   The brand/trade name for the suspect product was specifically requested
in the FDA forms, Yellow Card, Blue Card and IMB ADR forms whereas concomitant
medications just requested a name.  In both the industry forms, brand and generic
names are equally requested.
Almost all forms collect information about concomitant medication, but it should be
noted that one of the forms (SEFV-H B) did not collect concomitant medication
information at all, and the FDA MedWatch for Consumers form collects it only in free
text in the ‘patient/person information’ section rather than in a medication information
section.
The FDA forms, the SEFV-H A form and the TGA form request the user to provide a
code for the medication as does the SDTM CM domain form, which expect a code
and product name from the WHO Drug Dictionary Extended (WHO DDE)253.   The
ANSM form requests a tracing number if the suspect product is a blood product
(only).  The on-line forms from the MHRA, Lareb and SEFV-H allow the user to select
the suspect product from a drop down list, which implies that there may be coding
scheme underlying that; only the MHRA form also allows concomitant medication
selection using a drop down, although the Lareb form, once a name has been
entered in free text for the concomitant medication supports description of the form
and strength using drop down value sets.
Only the Lareb form does not request batch number information for the suspect
product; batch number information is not requested for concomitant medications on
all forms except the MHRA paper Yellow Card.
The Lareb form is unique in that it supports the uploading of a patient’s medication
list; this is possible because in the Dutch healthcare culture there is a centralised
process to manage patients’ medication information, provided under the auspices of
their national healthcare organisation NICTIZ15.
Dosage Information
Dose quantity (the amount of medication taken in a single administration event),
dose frequency (the number of times in a given – usually 24 hour – period that an
administration event takes place) and the route of administration form the dosage
information collected on adverse event forms and for clinical trial submissions, with
this latter also collecting total daily dose information even though that can be
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calculated from the dose quantity and dose frequency. Although each of these data
elements has a definition (given above and used throughout this work), no definition
is provided on the forms themselves.   Indeed several of the forms (from the MHRA,
TGA, ANSM and IMB ADR) do not request dose quantity and dose frequency as
separate data elements but ask for ‘dosage’ as free text, with the route of
administration as a separate data element.  The vaccine event forms request dose
number or previous dose information rather than dose quantity and dose frequency,
and also ask for site of administration as well as the route. The FDA forms did not
specifically request dosage information for concomitant medications but the other
forms used the same pattern of information for both suspect and concomitant
medications.
Start/Stop Dates
All of the forms request start and stop dates for all medication, both suspect and
concomitant, except the SEFV-H form that has no concomitant medication
information at all and the FDA Consumer MedWatch form that collected concomitant
medication information as text with the person/patient information. In contrast, only
the IMB ADR form requested duration of therapy and this was in addition to the start
and stop dates.  The FDA forms allow the reporter to give duration of therapy (or an
estimate of such) if start and stop dates are not available.
Indication
All of the forms request indication (or reason for use) for the suspect medication, with
the exception of the vaccine specific forms, where of course the indication is implicit:
prophylaxis of the disease caused by the antigen(s) administered. Similarly in the
SDTM Concomitant Medication domain form, no indication would be required as this
would be stated in the protocol for the study itself.  Also in the SDTM Concomitant
Medication domain form, the verbatim name is the name of the medicine as it is
provided by the reporter, exactly, including any spelling errors, whereas the
standardised name is the name of the medication as it is held in a medicinal product
terminology used in clinical research, such as the WHO DDE253. Several of the forms
also requested indication for concomitant medications.
Concomitant medication description
The description of concomitant information that each form employed is given where
that was provided on the form itself or in the completion instructions accompanying
the form in Table 17.
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Table 17: Definition of concomitant medication from the report forms
Form Concomitant medication description
Medwatch
3500
Medicines used at the time of the event
Medwatch
3500A
Medicines used at the time of the event
Medwatch
3500B
All current prescription medications,
All OTC medications any vitamins, minerals, supplements herbal remedies, and medical devices being used
Yellow Card:
paper
Other drugs
(including self-medication and complementary remedies) over last 3 months including medicines obtained from the
internet
Yellow Card:
online
Additional medicines in the last three months (inc. prescription, OTC or herbal)
Blue Card Other medicine(s)/vaccine(s) taken at the time of (over the period of) the reaction
ANSM None given
IMB ADR Any other drugs used over this period? (None/Unknown)
Lareb ADR None given
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Table 17 (cont.): Definition of concomitant medication from the report forms
Form Concomitant medication description
SEFV-H A Other medicines in last 3 months
SEFV-H B No requirement for information
VAERS Any other vaccinations within 4 weeks prior to the date
List any prescription or non-prescription medications the patient was taking when the vaccine(s) was given.
AEFI Allergies and previous vaccination reaction information only
CIOMS 1 None given
IMB ADR Any other drugs used over this period? (None/Unknown)
No formal definition of what is required as concomitant medication is available.  The FDA provides guidance of other products ‘used at the time of the event’; the MHRA
and one of the SEFV-H forms requests ‘additional medicines in the last three months (inc. prescription, OTC or herbal)’; the TGA asks for other medicines ‘taken at
the time of (over the period of) the reaction’and the IMB asks for the names of medicines taken ‘over this period’ which is presumably the period of the adverse event.
For the VAERS form, concomitant medication has two components: ‘any other vaccinations within 4 weeks prior to the date (presumably of the event)’ and ‘any
prescription or non-prescription medications the patient was taking when the vaccine(s) was given’.
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Discussion
The Forms
The set of 16 forms examined were somewhat heterogeneous in terms of their scope
(the products they covered), the reporters who should use the form and the
medication event types that they covered.  Indeed others have found a similar
heterogeneity when seeking to do analysis of other paradigms in pharmacovigilance
and have found it a hindrance to true comparative analysis254.  Each of these
paradigms is discussed below.
Product Scope
Vaccines only
Two of the 16 forms have a very limited scope, collecting information about vaccine
adverse events only.  There are several reasons why information about adverse
events to vaccines may be collected and therefore evaluated separately.  In some
healthcare cultures, most notably the United States, vaccines are licensed by a
separate part of the national regulatory agency, the Center for Biologics Evaluation
and Research (CBER)255, and placed into a separate adverse event reporting
system: VAERS, the Vaccine Adverse Event Reporting System256.  This is managed
jointly by CBER and the CDC, the Centers for Disease Control and Prevention257.
VAERS therefore has its own VAERS form, which was used in this analysis.  In
Australia, the Therapeutic Goods Administration licenses vaccines in the same way
as other medicines but collects adverse events separately for their adverse event
database258 using the AEFI form.
Vaccines are generally given to healthy people and have public health as well as
individual health considerations.   The understanding and risk/benefit analysis that
should accompany all adverse event investigations must consider not just the
individual but also the wider community.  This can be seen both in the actual change
in vaccination schedule for MMR (measles, mumps and rubella vaccination) to
include boys as well as girls259 and in the change of attitude of the public to this, as
the public’s perception of the risks to individuals and the benefits to the general
population shifts260. Although many vaccines are administered by healthcare
professionals, the setting for the administration may range from a healthcare
establishment through to a school, a military establishment and indeed, to temporary
clinics in public buildings set up to deal with a specific public health event.
Vaccines are often given in combination, either several antigens administered in a
single product (for example the diphtheria, tetanus, pertussis, poliomyelitis and
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Haemophilus type b vaccine given at 2, 3 and 6 months to all babies in the United
Kingdom) or at a single administration session (for example the BCG and hepatitis
B vaccine products given to at risk neonates at birth).  Alternatively, a single
administration session having both combination vaccines and single vaccines (for
example at 2 and 3 months babies in the UK receive meningococcal group C
conjugate vaccine and rotavirus vaccine in addition to the diphtheria, tetanus,
pertussis, poliomyelitis and Haemophilus type b vaccine) may be used.
Consequently, it can be extremely hard to see the effect of an individual antigen or
formulation of an antigen and assign responsibility for an adverse event.
Other products
All the other forms had a wider scope, focusing on medicinal products and including
vaccines and over the counter medicines.  Each agency will have good reasons to
have separate forms for adverse events for different product types, often related to
the regulations under which they operate.  From the perspective of the data elements
required, the main consideration is to have consistency in the data element use and
definition, even if that definition is worded differently for a patient/consumer focussed
audience.  Otherwise, it becomes extremely difficult to collate data together for
analysis261, which defeats the reason for the data collection. However, to achieve
that consistency of use and definition across a wide product range is difficult; for
example vaccines have a single point administration time, not a start/stop date, they
have a dosing schedule rather than a dose quantity/frequency, and food and
cosmetic products do not have dosage information at all.
A sensible compromise might be to have separate forms for vaccines and medicinal
products for those healthcare cultures that find that explicit division useful and to
have a standard mapping between the defined medication data elements from each
form type, but also to have a completely standard pattern for collection of the data
elements for concomitant medications in both cases.
Rather than attempting to cover such a diverse scope, collecting adverse events for
non-medicinal product types (foods and cosmetics) should use a separate form,
because they do not have the same information available (e.g. dose quantity), so it
is unfair to ask any reporter to provide information that is not available, the data
quality will be poor.
Reporter Usage
In the early years of pharmacovigilance following such triggers as the thalidomide
tragedy, spontaneous adverse event reports were accepted by the national collating
centres from only from medical practitioners.  But recent years as the science of
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pharmacovigilance has matured, there has been a growing understanding of the
issue of underreporting of adverse events.  To combat this, the range of types of
individuals who may report adverse events has expanded, initially to include other
healthcare professionals (primarily pharmacists and nurses) and then also to include
patients themselves.   In several countries, notably France, Italy and Spain,
pharmacist reporting of adverse events to medications is mandatory.
Reporting by healthcare professionals other than medical practitioners in part
reflects the growing role of non-medical prescribers (be they supplementary or
independent) and the responsibility that a prescriber has in reporting adverse events
to medications they have personally prescribed.  As reporting by other healthcare
professionals has expanded, so has the appreciation of those reports262, which is in
itself encouragement for further reporting when appropriate.  By including patients
as reporters of adverse reactions, as well as increasing the number of reports
obtained and generally adding value to the pharmacovigilance process263,264, a
unique view of post marketing surveillance of over-the-counter medicinal products
can gained254.
Some national collating centres supply a single form for all reporters – all types of
healthcare professionals and consumers, whereas others, most notably the FDA,
have different forms, with the wording of the consumer focussed form using language
that is much more inclusive (‘how much of the medicine was taken each day’ as
opposed to ‘daily dosage’).
From the perspective of the medication data element requirements, the
heterogeneity of reporter type is little direct import.  However, in order to have
consistency in reporter use of the medication data elements, these should be clearly
defined and provided in a style that the reporter can unambiguously understand.
Having separately worded forms for consumers to use is therefore likely to be
beneficial, but they should keep the same pattern of data elements.
Event Type
Just as the types of reporter of adverse events as grown in recent years, so have
the types of events that can be reported.
The concept of pharmacovigilance and the management of medication adverse
events has recently been broadened to include adverse events that are not related
to the pharmacology or pharmaceutics of the medicinal product but which are caused
by external factors related to the medicinal product, for example issues with the
packaging or labelling of the product.  An example of this is the case where an
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adverse event occurs due to incorrect dose quantity being administered; on analysis
it might be found that the description of the strength of the medicine on the packaging
lacks the necessary clarity265.
In terms of the medication data elements required, if the analysis database to be
used is for all safety events for medications, then having a single form with well-
defined medication data elements is acceptable.  The advantage of this is that the
reporter does not necessarily have to make any decision as to what type of event
they are reporting and may provide the raw data directly.  The disadvantage is that
some of the wording of the data element description is more appropriate to the
standard adverse event than a medication error, most particularly the division
between suspect and concomitant medication (see more below).
Medication Data Elements
The medication data elements have been assembled into two sections for
discussion; the definition and description of the suspect or concomitant medications,
followed by the dosage instructions information for those medications.
None of the forms gives any guidance as to what to provide if a particular item of
data is not available (whether to add a ‘not applicable’ or a ‘not known’ comment).
The use of such flavours of null147 can be very helpful in analysis, which is the prime
use case for collecting adverse event information.  It does add a little to the time for
completion and therefore this additional reporter burden must be balanced against
the value of the increased data quality.
Product description
One of the major issues in the big analysis databases is lack of standardisation of
product names261 and it is this has been recognised as such a concern that it has
led to the development of the ISO Identification of Medicinal Products (IDMP) suite
of standards and particularly ISO 11615 – the identifiers for Medicinal Products144.
Although the core standards are now available, their implementation is still in
progress, but the E2B R3 form does already specifically reference this system for
product identification (the MPID, PCID and Substance identifier).   However, even
with that in place, the forms themselves demonstrate a lack of standardisation in the
terms they use to request the medication, being as unspecific as asking for the name
of the medicine, with the exception of one of the FDA forms and the SDTM form, all
the others were without any mention of whether that name should include the dose
form and strength if available or not.
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Encouraging the use of electronic data capture and providing lists of medicines with
appropriate levels of granularity of description and encouraging all reporters to use
the most granular to provide all the information they have available should help to
improve this element of the data, including reducing spelling issues in free text entry.
Supporting coded information directly, which only 5 forms did for the suspect
medication, would also improve this.  Only the E2B form supported coded
information for concomitant medications (as it moves towards IDMP implementation)
and it did not support coded information for the suspect medication as in blinded
studies, this information would not be known.
The Lareb form was unique in supporting the acquisition of the correct description of
the suspect and concomitant medication directly from the patient’s Medication
Profile, although the dosage information required separate data entry.  This
demonstrates the initial stages of one of the aims of this work, to be able to acquire
all the relevant medication information for an adverse event report direct from a
patient’s Medication Profile.
Dosage Information
Dosage information, if it is provided, is useful in event analysis to check that the
product was being administered within its authorised schedule and also to compute
disproportionality signal scores against different dose ranges for a medication261261.
Information to populate these three data elements could be sourced directly from the
patient’s Medication Profile for both the suspect and concomitant products and as
such is a requirement for the overall content of that Profile; although, based on this
investigation and the use that the information is put to in analysis, the presence of
these data elements is not as critical as some of the others.
Start/Stop Dates
Start and stop dates are used in basic initial event analysis; if the dates of exposure
for the suspect medication are not contemporaneous with the date of the event, then
a causative relationship between the suspect product and the event is unlikely266.
That start and stop dates are requested on almost all forms indicate that they are
very important, second only to the description of the products themselves and as
such are key requirements that the Medication Profile should be able to support.
Since duration of therapy can always be calculated from start and stop dates, it
should not in and of itself be a data element requirement for the Medication Profile
to fulfil in addition to the start and stop dates, not least because duplication of
information is an error risk.
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Indication
Knowing the therapeutic use for the product in each event allows analysts to
ascertain whether it was being administered according to its licensed indications,
which is important in evaluation of the significance of the event, especially for the
suspect medication.   It is also important when looking beyond traditional
pharmacovigilance toward risk management planning and minimisation strategies
as it gives a measure of compliance with the license and whether there are gaps in
post-authorisation usage230.
One of the major criticisms of the ASTER pilot made by Brajovic et al245 was that,
despite using the patient record as a source for adverse event report information,
none of the submitted reports provided indication information, highlighting how
important indication information is deemed to be in pharmacovigilance.
The indication for a medication, and particularly for the suspect medication is clearly
an important and desirable data element for adverse event reporting and is therefore
a key information requirement for the Medication Profile to supply.
Suspect and Concomitant Medication Definition
Because spontaneous adverse event reports come from situations where a patient
or healthcare professional suspect that a particular unwanted and usually unpleasant
event that a patient experiences is related to the administration of a certain medicinal
product, that product is always known as the suspect product.  Information about
other medicinal products that the patient is taking may also be provided, but these
are not the suspect product and are therefore described as the concomitant
products, those taken in parallel with the suspect product.
Concomitant medication information is particularly important to support the complex
disproportionality and regression analysis required to detect new drug-drug
interactions261 so having an agreed global definition with guidance for reporters is
something that should be developed. Having an agreed global definition for
concomitant medication would then facilitate being able to extract this data directly
and accurately from the patient’s Medication Profile.
Limitations of this study
Responsibility for pharmacovigilance may be national or it may be regional with no
pattern associated; federally managed countries such as the United States of
America and Australia have national pharmacovigilance schemes, whereas Spain
has a regional scheme.  This makes any estimate of the total number of adverse
event forms that exist globally very difficult and no figure was found.  This study
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examined only a small number of adverse event report forms (13) from 7 different
countries and the agencies responsible for their pharmacovigilance, plus the two
globally used forms for regulatory reporting, and the standard forms used for
medication information in clinical studies.  In order to further validate these results,
a larger set of forms could be examined.  However, the value of examination of a
wider set of forms to this work would only be if additional data elements were
introduced that would then need support from the Medication Profile, or if the priority
of others were altered (for example if new forms were found to require site of
administration information for all medicine events, not just for vaccine adverse
events).
Recommendations for further work
Development of a clear specification as to the medication information required in all
adverse event report forms should be undertaken, focussing on gaining agreement
on the most useful data elements such as treatment start/stop dates and indication,
so that the forms could explicitly encourage reporters to provide these wherever
possible.  Supporting information such as dose quantity and dose frequency should
be requested as separate data elements since total daily dosage can be calculated
from this.  If only total daily dose is available, provision should be made to gather
that explicitly.  Redundant information (such as duration of treatment) should be
removed from forms so as not to cause reporting burden or confusion.
Implementation guidance for such a global specification should explicitly state how
‘no information’ should be managed for any particular data element.  Having this
clear global specification would facilitate the sharing and amalgamation of adverse
event reporting, which is so important in order to find the signals of adverse reactions
that occur at very low levels in the population.
The development of a global definition for concomitant medications should be
undertaken to be used in spontaneous adverse event reporting.  This should
describe the scope of what a concomitant medication covers (for example:
prescribed medications, over the counter medicines being taken, and whether or not
herbal and nutritional supplements should be included).  It should also describe the
period during which the medication is considered to be concomitant to the adverse
event (for example: all medications taken in the (4 week) month prior to the adverse
event occurring).   For reporting adverse events in clinical research studies, the
protocol will provide some guidance to the investigator, but work should be
undertaken to standardise this as much as possible so that data from a range of
clinical studies can be properly aggregated for safety analysis.
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Conclusion
Despite an acknowledged desire to have a single canonical adverse event reporting
database supported by standardised forms completed in near-real time261, this
remains an aspiration rather than a reality.   There continues to be a lack of
standardisation in the data collection instruments (different scopes, different
reporters, different product types, different data element formats) such that the
scalability of automatic extraction of information for adverse event reporting and
pharmacovigilance continues to be challenging.
However, by having this understanding of the data elements that are required, and
a sense of the priority of them, it is possible to place these as requirements against
the Medication Profile itself.   The Medication Profile can then be a robust and reliable
– and indeed automatic – source of the necessary data when and if such reporting
is required.   It could also directly provide the necessary instantiation of the data
elements required for concomitant medication information in clinical trials, reducing
the reporting burden, increasing accuracy and thereby increasing the intelligence
available to contribute to the medication safety landscape.
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Chapter 6: Consolidated Results Summary
This chapter presents both the summary and the superset of the requirements for a
Medication Profile gathered in the preceding chapters from the four high level use
cases of recording of information to support patient care and safe use of medication
facilitated by medication decision support, and supporting feasibility checking and
patient recruitment in clinical research and pharmacovigilance.
The Results Summary is presented in tabular form, in the three sections of types of
requirement: the medication use (current or past), the description of the medication
(naming, categorical and clinical information) and the description of dosage
instructions for use of the medication.
Each of tables 18-30 in the Summary has a column for each of the 4 high level use
cases and a row for the requirement; the following abbreviations are used for the
use cases:
 Patient recruitment and protocol feasibility checking: PR & PFC
 Pharmacovigilance: PV
 Patient care: Pt Care
 Medication decision support: MDS
The intersecting cell indicates whether that use case has a requirement for that
information, and uses an informative colour coding:
 red is used where the results indicated all or almost all of the situations
examined in the requirements gathering required the information,
 green is used where at least half of the situations required the information
and
 blue is used where at least one but less than half of the situations required
the information
Current and past medication information
Current medication information is medication that the patient is using or has had
administered to them now (which for pharmacovigilance is ‘the time of the event’) or
has used ‘recently’).  Past medication is medication that the patient has used or has
had administered to them at any point in the past and that is not ‘current’. Table 18
summarises the requirements for this information from the four use cases.
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Table 18: Summary of information requirements for current and past medication
information for the Medication Profile from the four use cases
PR & PFC PV Pt care MDS
Current
medication
YES YES YES YES
Past
medication
YES YES YES
Medication identification
There are various ways to identify a medication, directly and indirectly using
additional factual information (e.g. authorisation status) or additional clinical
information (e.g. therapeutic use).  These latter two types of information are more
descriptional and obtained from knowledge beyond an identification terminology,
whilst the requirements have been documented in the use cases, they do not go
forward as requirements to be met by the Medication Profile itself.  Table 19 therefore
summarises only the requirements for terminological medication identification for a
Medication Profile information from the four use cases.
Table 19: Summary of medication identification requirements for the Medication
Profile from the four use cases
PR & PFC PV Pt care MDS
Medication name YES YES YES YES
Generic name YES YES YES
Brand name YES YES
Manufacturer YES
Medication code YES YES YES
Medication batch number YES
Medication expiry date YES
Dosage instructions information
Table 20 summaries the requirements for the detail of dosage instructions (how the
medication is being or was administered to the patient) for a Medication Profile
information from the four use cases.  The requirements for the dosage instructions
data elements were the most diverse.  To further draw out the relative importance of
each data element, a notional weighting was assigned, based on a ‘YES’ being worth
‘3’, a ‘YES’ being worth ‘2’, and a ‘YES’ being worth ‘1’.
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Table 20: Summary of dosage instructions information requirements for the
Medication Profile from the four use cases
PR &
PFC
PV Pt care MDS Weighting
Dose instructions clause YES 1
Dose quantity YES YES YES YES 5
Total daily dose YES YES 2
Route of administration YES YES YES YES 9
Site of administration YES YES 3
Method of
administration
YES 1
Timing information YES YES YES YES 9
Dose frequency YES YES YES 5
Course of therapy
Start/Stop (dates)
YES YES YES 7
Discontinuation or
future stop (dates)
YES 1
Course of therapy
duration
YES YES YES 4
Indication YES YES YES YES 11
Rate of administration YES YES 2
Dosage upper bound YES 1
Non-administration
reason
YES 1
Additional instructions YES 1
Quantity
prescribed or dispensed
YES 1
Summary discussion
These tables provide a summary and superset of all the information that could be
present in a Medication Profile to support the four high level use cases described in
detail in the preceding chapters.  In those chapters, the information requirements
were gathered from a detailed investigation of a sample of relevant specifications,
chosen based on experience in the field to be representative, or in the case of
medication decision support, described many years of experience in specification
development.  However, this sample is in no sense a robust and randomised sample,
therefore the results from them cannot be considered to be quantitative.  But the
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tables do present a qualitative assessment of the importance of individual data items
in the overall information model for a Medication Profile, and therefore they give a
useful signal as to how much effort should be made to define, capture and maintain
a particular data item within the Profile.
For all use cases, information about current medication is paramount; information
about past medication (history) is important for three out of four use cases – more
than enough to indicate that a full Medication Profile should contain it.
For three out of four use cases, the medication name is essential; the exception
being the feasibility checking and patient recruitment use case where description of
medication can be by ‘proxy’, particularly by therapeutic class rather than individual
product.  A generic description is preferable to a brand description, although for
pharmacovigilance a branded description is desirable, as is manufacturer
information.    A machine-readable (coded) description is of particular value to
decision support, but is also useful for pharmacovigilance and patient care.  The
feasibility checking and patient recruitment use case does not require this, not least
because medications are more often referred to by their classification than described
as individual products and also because within clinical research at present there is
no good terminology to provide such coded information, so not unnaturally, the
requirement cannot be instantiated.  Only the pharmacovigilance use case had
requirements for batch number and expiry information.  No examination was made
of any fraud prevention or counterfeit detection use cases since these relate to
supply chain management at levels above individual patient medication
consumption; had these been within scope, no doubt information about the batch
number of medicinal products would have been seen as important.
The requirements for the dosage instructions data elements were the most diverse.
The weighting highlights that indication information is the most valuable data element
to the four use cases, followed by route of administration information and timing
information – principally the start (and stop if appropriate) dates.  This latter overlaps
with the ‘current’ and ‘past’ medication definition in the first table and provides the
link between the static nature of the data element requirements and the dynamic
nature of a Medication Profile that persists over time and must be populated and
accurately maintained with these data items.  This dynamic paradigm and the rules
that govern it are further described in the dynamic models of the Medication Profile
Model chapter.  However, as previously noted, other than this, there is a notable
absence of requirements for true dynamic (behaviour of objects) model
requirements.
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Chapter 7: Identifying the Scope of the Medication
Profile
Introduction
It might be a natural to assume that ‘medicines’ would form the core of a Medication
Profile, but on the premise that assumption can be misleading, the examination of
exactly what is meant by the ‘medications’ that are recorded in a Medication Profile
is an important part of the development of the requirements for an ideal Medication
Profile.  As was clearly seen in the Literature Review, there is no universal
agreement as to the types of products that should be properly included in the scope.
A further issue that adds to the confusion is that the term ‘prescribing’ is frequently
used to describe the process of a healthcare professional making an order for supply
and use of a product for a patient, where the product could be a ‘medicine, a medical
device, a dressing, or another type of remedy’267.
The phrase ‘medicines are not ordinary items of commerce’ is often used268 to
highlight that medicines form a special class of objects; indeed in the UK there is an
entire statute that makes provisions with respect to medicinal products and related
matters, the Medicines Act 1968, which describes the arrangements for the
licensing, sale and supply of medicines to the population.  This is enacted in
conjunction with the various articles and directives in European law, and it is here
that the current formal definition of a medicine may be found: ‘Any substance or
combination of substances being presented as having properties for treating or
preventing disease in human beings; Any substance or combination of substances
which may be used in or administered to human beings either with a view to
restoring, correcting or modifying physiological functions by exerting a
pharmacological, immunological or metabolic action, or to making a medical
diagnosis.’269
This definition has been further developed as part of the international initiative for
the Identification of Medicinal Products (IDMP) in ISO 11615144, where a Medicinal
Product is defined as ‘Any substance or combination of substances that may be
administered to human beings (or animals) for treating or preventing disease, with
the view to making a medical diagnosis or to restore, correct or modify physiological
functions’.
The Notes in ISO 11615 state that its provisions apply to proprietary (registered)
medicinal products for human use intended to be placed on the market, and to
industrially manufactured medicinal products, the marketing of which has been
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authorised by a Medicines Regulatory Agency.   The Notes then describe other types
of medicinal products: a) those prepared according to prescription, i.e. prepared in a
pharmacy from a prescription intended for a specific patient; b) medicinal products
prepared in accordance with an official formula, i.e. prepared in a pharmacy in
accordance with the instructions in a pharmacopoeia and intended to be given direct
to the patient by the pharmacy; c) medicinal products intended for research and
development trials; and d) intermediate products intended for subsequent
processing by an authorised manufacturer.
The legislation, and the standards that support it, can provide a framework within
which various types of things that could be considered ‘medicines’ can be evaluated
for their inclusion in a Medication Profile.  This chapter therefore to examines each
of these various types of things in terms of what they are exactly and how that
intrinsic nature relates to whether they should (or should not) be included in a
Medication Profile.  Information about products that are not intrinsically medicines
may well still be relevant for various use cases in supporting patient care and clinical
research but that information should reside elsewhere in the patient record structure,
not in the Medication Profile.  This explicit scope statement then avoids ambiguity
and the issues around completeness of information that are frequently seen reported
in the literature102,117 -119.
Methodology
Unfortunately, there is no formal standard to provide a full set of the categories of
things that could be considered ‘medicines’. However, the author has had
considerable experience in this area, and this section has been written based on
knowledge and experience gathered in roles over the preceding 20 years, especially
in international medicines terminology, as described in detail in the General
Methodology. The categories that have been used in this examination are therefore
well known and well used within the domain270.
To fulfil the objective of the provision of a clear scope statement for ‘medication’ that
should be included in the Medication Profile, each of these categories was examined
in turn.  A definition for the content of each category is given, based where possible
on the legislative framework, followed by a description of their use, and particularly
the documentation of that use, in clinical care.    This then forms the evidence from
which to make the assessment for their inclusion or otherwise in the Medication
Profile.
Note that all of the following is written on the premise of the culture and practice of
Western, so-called allopathic medicine; alternative cultures and practices of
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medicine, such as Chinese medicine or anthroposophical medicine have not been
considered here.
Results
Licensed Medicines
Definition: Licensed (or authorised) medicines are medicines that have a marketing
authorisation from the regulatory authority appropriate for the realm or jurisdiction
(nation state) in which the medicines are marketed.  Licensed medicines are
evaluated by a regulatory authority to ensure that they provide benefit and are
acceptably safe and that their manufacture is in accordance with quality
standards271.
Clinicians are encouraged to prescribe licensed medicines for patients whenever
possible, and to ensure that the use is within the terms of the license267. Similarly
pharmacists should dispense a licenced medication whenever possible272.
Biologic product medicines (including immunologic products)
Definition: Biologic product medicines are medicines that are made by or derived
from a biological source, usually using biotechnology processes, such as
recombinant DNA technology.   Biosimilar medicines are a sub type of biologic
products.
In most realms or jurisdictions, the regulatory authority responsible for granting
marketing authorisations deals with all types of medicinal products, be they of
chemical or biological substance composition, and regardless of their use (diagnosis,
treatment, prevention of disease).  However, some jurisdictions, and most notably
the United States of America, have separate authorities depending on product type:
the Food and Drug Administration has various quite separate divisions273 (Centers),
most particularly:  the Center for Drug Evaluation and Research(CDER)274, the
Center for Biologics Evaluation and Research (CBER)255, the Center for Devices and
Radiological Health (CDRH)275.  This division, and the fact that the Centers for
Disease Control and Prevention257 manage most of the information about
vaccination and vaccination programmes, mean that there can be, particularly in
North America, a sense that ‘a medication’ does not include products based on
biologically sourced substances as active ingredients, unless otherwise explicitly
specified. This divided medication world view is reflected in the top level partition of
the international medical terminology, SNOMED® CT276, which currently has a
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‘pharmaceutical and biologic product hierarchy’ [SCTID = 373873005] rather than
simply a ‘medicinal product hierarchy’.
Immunisation products are often not prescribed and dispensed following normal
patterns, for example they are often administered in a clinic environment with only
an administration record produced.  This means that there can be separate recording
entries for that administration information (for example, a separate section in the
Continuity of Care Document for Immunisations, see Patient Care sub-chapter 4(1)).
In some healthcare cultures, recording of vaccine administration may only occur in
a specific vaccination registry system.
Human derived therapeutic products
Products from pooled resources
Definition: Human derived products from pooled resources are medicinal products
manufactured from donations of human blood collected together and processed.
These products include the haemostatic products such as clotting factors and other
substances involved in the clotting cascade, and immunoglobulins and albumin
solutions.
These products are evaluated by a regulatory authority for quality, safety and efficacy
and as such are licensed medicines.  They are prescribed, dispensed and
administered using the standard patterns of the medication process and recording
in systems reflects this.
Individual donated items
Definition: Individually donated items are items of human origin that can be directly
associated to a single donation event, be that autologous or unrelated.  Examples
include whole blood and its components derived from a single whole blood donation
such as platelets or red blood cells.
There is no authorisation process for these items in any regulatory sense. Both the
collection process and the administration process for these items is undertaken and
documented in an EHR as a type of clinical procedure.  This means that the product
collected/administered is described as an integral part of that procedure, not
separate to it.  The requirements277 to describe the collection, management and
administration of these items and therefore that systems used to manage this are
completely different from those used for medicinal products and there is a separate
international terminology to support it (ISBT128)278.
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Other tissue products
Definition: Other human tissue products are products derived from individual human
donations, used therapeutically, either autologously or to an unrelated individual.
They in include dura (mater) grafts, skin fibroblasts and bone tissue.
The use of all human derived products is undertaken and documented in an EHR as
a procedure, with the product collected/administered described as part of that
procedure using ISBT128, the global standard for the terminology, identification,
coding and labelling of products of human origin (including cell, tissue, human milk,
and organ products, including for transplantation).
Orphan designation medicines
Definition: Orphan designation medicines are medicines intended for the treatment,
prevention or diagnosis of a disease that is life-threatening or chronically debilitating,
but that is a rare condition (the prevalence of the condition in the EU must not be
more than 5 in 10,000)279.
The authorisation process for these products is a little different, and includes such
benefits to sponsors as protection from competition once on the market. However,
they are licensed medicinal products and they are subject to the normal activities of
the medication process and are recorded as such.
Previously licensed medicines
Definition: Previously licensed medicines are whose authorisation for sale or supply
has ended, either by voluntary discontinuation (lapsing) or withdrawal, or by
compulsory withdrawal of the license.
These products were once authorised, and as such could be included within the
overall ‘licenced medicines’ category, but in the lifecycle of a licensed medicine they
have moved, either voluntarily or compulsorily to no longer having a license.
Over the Counter medicines
Definition: Over the counter (OTC) medicines are a particular subset of licensed
medicines, characterised by their sale or supply being aimed directly at the
purchaser/consumer of the medicine, rather than being used under the direct
supervision of a healthcare professional.
OTC medicines may be prescribed and dispensed following the standard patterns of
the medication process; they may also be sold and as such recording of their
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administration to individuals is less accurate, often only occurring when the results
of a medication reconciliation activity are recorded.
Unlicensed and investigational medicines
Definition: Unlicensed medicines are those that do not have an active authorisation
for their sale or supply that is valid within the jurisdiction of their use.
In most healthcare jurisdictions, if an unlicensed medicine is used to treat a patient,
the normal professional indemnities are revoked; and the responsibility that falls on
healthcare professionals when prescribing an unlicensed medicine may be greater
than when prescribing a licensed medicine within the terms of its license280.
Extemporaneous (magistral) medicinal products
Definition: Extemporaneous medicinal products are medicines that are prepared by
a pharmacist without a product licence, in the UK under section 10 of the Medicines
Act 1968281, in Europe as described in the European Parliament Directive
2001/83/EC269.
This definition includes parenteral preparations that made by diluting a medicinal
product into a larger volume prior to administration (for example in a CIVAS, a
Central Intravenous Additive Service), even when this is in accordance with the
Summary of Product Characteristics (SPC) (this does not include the act of
reconstitution itself) and also includes fulfilling an order to supply where the
administration of the product requires that it is crushed or opened and mixed with a
specified agent other than water, e.g. a suspending agent282.  For the purposes of
this categorisation, pharmacopoeial standard preparations, also known as ‘officinal
formula’ (such as British Pharmacopoeia (BP)283 formulations) would be included.
The use of extemporaneously prepared medicines follows the standard patterns of
the medication process, although there may be extra information recorded (e.g.
batch numbers of ingredients used in the preparation).
Investigational medicinal products
Definition: An investigational medicinal product is defined as ‘a pharmaceutical form
of an active substance or placebo being tested or used as a reference in a clinical
trial, including products already with a marketing authorization but used or
assembled (formulated or packaged) in a way different from the authorized form,
used for an unauthorized indication, or used to gain further information about the
authorized form’144.
203
This definition, focussing as it does on the product being studied against a
hypothesis in a clinical trial, includes medicinal products where the study relates to
clinical uses outside of a current authorisation.  It also includes products used in
observational studies relating to risk management, to delineate additional
information about the medicinal product’s risks, benefits, and optimal use (phase IV
and phase V studies284).
The use of investigational medicinal products is usually recorded in a specialist
clinical study data capture system by the investigator and is likely to include active
adherence checking.  This information may or may not also be recorded through
standard care systems.
Homoeopathic and herbal medicines
Definition: Homoeopathic medicinal products are ‘any medicinal product prepared
from substances called homoeopathic stocks in accordance with a homoeopathic
manufacturing procedure described by the European Pharmacopoeia or, in the
absence thereof, by the pharmacopoeias currently used officially in the Member
States.  A homoeopathic medicinal product may contain a number of principles’269.
Some homoeopathic products regulated under either the simplified registration
scheme or the national rules scheme; both schemes require data on product quality
and some information about safety285.  Others may be made available in a similar
manner to an extemporaneous preparation.
Definition: Herbal (drug) products are defined by the European Pharmacopoeia as
preparations that ‘are obtained by subjecting herbal drugs to treatments such as
extraction, distillation, expression, fractionation, purification, concentration or
fermentation. These include comminuted or powdered herbal drugs, tinctures
extracts, essential oils, expressed juices and processed exudates.’286
Herbal products typically contain a mix of compounds and it is often difficult to identify
those that are therapeutically relevant.
Homoeopathic and herbal medicines are sometimes subject to the standard patterns
of the medication process, but are more commonly used outside of that.  Information
on their use may be recorded as a result of medication reconciliation.
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Other Types of Products
Nanotechnology Products
Definition: Nanotechnology products are those in which the design,
characterization, production and application of structures, devices and systems are
achieved by controlling shape and size at nanometre scale.
Nanomedicine itself is defined as the application of nanotechnology in view of
making a medical diagnosis or treating or preventing diseases. It exploits the
improved and often novel physical, chemical and biological properties of materials
at nanometre scale287.  The majority of current commercial applications of
nanotechnology in medicinal products are geared towards drug delivery to enable
new modes of action, as well as better targeting and bioavailability of existing
medicinal substances, such as nanostructures that allow transport across biological
barriers and multifunctional chemical structures for drug delivery and targeting of
disease.
Currently, there are no regulations specific to medicines (or medical devices) using
nanotechnology, but it is a developing area and new products are possible in the
coming years.
Nutritional products: Foods and food supplements
Definition: The definition of a food or foodstuff is ‘any substance or product, whether
processed, partially processed or unprocessed, intended to be, or reasonably
expected to be ingested by humans…Food shall not include…medicinal products
within the meaning of Council Directive 65/65/EEC [now Directive 2001/83/EC.]’269.
This definition states that foods are not medicinal products, and can be distinguished
from medicinal products on the grounds of being identified as products which a
person would regard as something to be eaten, drunk or chewed as part of his/her
diet.
Definition: A food supplement or nutritional supplement is defined as ‘[a] foodstuff
or foodstuffs, the purpose of which is to supplement the normal diet and which are
concentrated sources of nutrients or other substances with a nutritional or
physiological effect, alone or in combination, marketed in dose form’269.
Food supplements are concentrated sources of nutrients or other substances with a
nutritional or physiological effect, there whose purpose is to supplement the normal
diet. Although they are usually supplied and marketed in a ‘dose form’ i.e. as tablets,
capsules, liquids in measured doses etc. which can make them appear to be like
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medicinal products, they are clearly not medicinal products as per the definition of a
food above.
There are also a set of dietary foods for special medical purposes; these are ‘foods
used in patients with specific intolerance conditions (e.g. lactose free foods) or foods
for patients with gluten sensitive enteropathies, such as coeliac disease (‘gluten-free
foods’), and low protein foods for patients suffering from inherited metabolic
disorders, renal or liver failure requiring a low-protein diet’288.
Nutritional products that make and can support medicinal claims or can show that
they modify physiological functions by acting pharmacologically, immunologically or
metabolically, and/or are marketed and used with a view to having such an effect,
for example for athletes and persons engaged in significant exercise or for extreme
weight loss, will fall within the definition of a medicinal product and require formal
authorisation for sale or supply.
Food products may be ordered and/or supplied for a patient’s use by a healthcare
professional in the course of their provision of care; this may need to be recorded in
some way within electronic health records, both for general reference and to facilitate
re-supply if required.  It may also be recorded by specialist dietetics systems.
Medical devices
Definition: A medical device is defined as ‘any instrument, apparatus, appliance,
material or other article, whether used alone or in combination, including the software
necessary for its proper application intended by the manufacturer to be used for
human beings for the purpose of: 1) diagnosis, prevention, monitoring, treatment or
alleviation of disease; 2) diagnosis, monitoring, treatment, alleviation of or
compensation for an injury or handicap; 3) investigation, replacement or modification
of the anatomy or of a physiological process; 4) control of conception; and which
does not achieve its principal intended action in or on the human body by
pharmacological, immunological or metabolic means, but which may be assisted in
its function by such means.  In the case of a medical device, the principal intended
action is typically fulfilled by physical means (including mechanical action, physical
barrier, replacement of, or support to, organs or body functions).’289
As well as medical device products whose principal therapeutic action is typically
fulfilled by physical means as defined above, there are products that incorporate a
medicinal substance to the patient as part of their therapeutic process or that
administer a medicinal product.  A product of this type may be regulated as either a
medical device or as a medicinal product, depending on the principal intended
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function of the product and the method by which this action is achieved.  There are
three main types of medical device which incorporate or are used to administer a
medicinal product:
1. Devices which are used to administer medicinal products: for example, a
syringe marketed empty, medicine spoons, droppers etc. This category also
includes devices which can be refilled with further doses of medication
contained within the same pack as the medicine. All of these products are
covered by the Medical Devices Regulations.
2. Devices for administering medicinal products where the device and the
medicinal product form a single integral product designed to be used
exclusively in the given combination and which are not re-usable or re-fillable:
for example: a syringe marketed pre-filled, or a metered dosage inhaler.
These products are covered by medicines legislation, although in addition to
this, the relevant essential requirements in Annex 1 of the Medical Devices
Directive 93/42/EEC apply with respect to safety and performance related
features of the device (e.g. a syringe forming part of such a product).
3. Devices incorporating, as an integral part (i.e. a single component product
(e.g. such as coated or incorporated within) rather than a pack containing the
two components (i.e. a drug and a device)) a substance, which, if used
separately, may be considered to be a medicinal product and which is such
that the substance is liable to act upon the body with action ancillary to that
of the device: for example: a heparin coated catheter, or a thrombolytic
eluting stent, an antibiotic-containing bone cement. These products are
subject to the Medical Devices Regulations. In addition, the safety, quality
and usefulness of the medicinal substance must be verified by analogy with
the methods required in Directive 2001/83/EC concerning the testing of
proprietary medicinal products.
In a comparable manner to food products, medical devices may be ordered and/or
supplied for a patient’s use by a healthcare professional in the course of their
provision of care.  Similarly, their order and supply may need to be recorded in some
way within electronic health records, both for general reference and to facilitate re-
supply if required. Some device products will be recorded in an EHR as part of a
record of a procedure, particularly an implantation procedure.
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Leeches and Maggots
Leeches (Hirudo medicinalis) and maggots (Lucilia sericata or Protophormia
terraenovae) if supplied commercially are sometimes thought of as being ‘products’
when intended for medicinal use; that is, in skin graft salvage and in biodebridement
respectively.  However at present they not subject to licensing as medicinal products
or as medical devices. When they are used in patient care, leeches and maggots
are likely to be described and recorded as part of the procedure that uses them.
Cosmetics and Toiletries
Cosmetics (products applied to the body, especially the face to improve its
appearance290) and toiletries (articles used in washing and taking care of one’s body,
such as soap, shampoo and toothpaste290) are not defined as medicinal products,
even when their use is recommended to a patient by a healthcare professional (e.g.
a sunscreen for a patient with a sun sensitivity due to medication such as
amiodarone).
Just as with food products, some cosmetic and toiletry products may be ordered
and/or supplied for a patient’s use by a healthcare professional in the course of their
provision of care and their order and supply may need to be recorded in some way
within electronic health records, both for general reference and to facilitate re-supply
if required.
Discussion
Licensed Medicines
Most of the medicines in use in clinical practice should be licensed medicines, so it
is self-evident that all licensed medicines that have been or are being used in the
treatment of a patient should be described in a Medication Profile.  However,
because there are several situations that militate against that statement as being
self-evident; it was therefore important to identify each of those situations so that all
the relevant categories of products can be explicitly described for inclusion in the
Medication Profile.
Biologic product medicines (including immunologic products)
Although all biologic products are considered medicinal products, the sometimes
separated view of their regulation by distinct sub-agencies and, for vaccines, the
different pattern of their use and recording within the medication process, mean that
their presence within the scope of a Medication Profile needs to be described
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explicitly to ensure that they are included.  The process of use of vaccine products
is such that a separate section within the Medication Profile could be considered.
Human derived therapeutic products
Individually donated items, both blood and its components and tissue products are
not considered to be medicinal products in a regulatory sense although there is a
substantial level of control placed on such products, due in a large part to various
unfortunate incidents causing patient harm291.  There is significant difference in both
description of and use and recording of individually donated items in systems.  It is
therefore unwise to attempt to duplicate any of this information in a patient’s
Medication Profile.  Furthermore, there is no sense in any of the literature that would
support these items being included with any sort of recording of medication
information.
Products from pooled resources, although related, are different in that they are
licensed medicines, used within the normal medication process; they are included in
the scope for the Medication Profile.   But since they can be confused with
individually donated items, it is useful to state their inclusion explicitly.
Orphan designation medicines
Orphan products are licensed medicines used within the normal medication process
and should be explicitly included in a Medication Profile.
Previously licensed medicines
The supply of medicines is becoming increasingly globalised and consequently
definitive information on licensing and availability of medicines, although managed
on a jurisdictional basis, is becoming less absolute in a global sense.  A medicine
that is discontinued in one jurisdiction may well still be licensed and available in
another, and as such still have limited availability in the original jurisdiction (as a
‘special’ or unlicensed medicine). Since a Medication Profile is a longitudinal record
of a patient’s medication use, it should contain information about medications that
were licensed at a previous point in time, because either they provide historic
information (the product was licensed when it was being actively used by the patient)
or because they are being used currently in a ‘specials’ capacity.
Over the Counter medicines
There is a general worldwide trend in promoting self-medication, described by the
World Health Organisation as ‘the use of medicinal products by the consumer to treat
self-recognised disorders or symptoms, or the intermittent or continued use of a
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medication prescribed by a physician for chronic or recurring diseases or
symptoms’292, to improve the access to treatment while minimising health care costs.
This trend is evidenced in the increasing deregulation of medicines (the so called
‘POM to P switches’) whereby medicinal products initially licensed as for supply by
prescription only, once more safety data becomes available, have also become
available with an OTC license, often in a lower strength or smaller pack size (for
example H2 antagonists such as ranitidine, proton pump inhibitors such as
omeprazole).   This trend emphasises that the boundary between prescription
medicines and OTC medicines is blurred, which in itself supports the premise that
use of all OTC medicines should be explicitly included in a Medication Profile
whenever possible.   Further evidence is available from studies that have focussed
on the safety or otherwise OTC medication use293,294 medications and particularly
their potential for causing adverse effects due to interactions, and that in some
patient groups, almost as many OTC medications are used as prescribed
medications295.
Licenced medicinal products used in other systems: Anaesthetics
and diagnostic agents, dental products
In the above discussion, the pattern of use of the product has been important in
determining its inclusion or otherwise in a Medication Profile. Anaesthetic products,
especially gaseous/volatile products administered by inhalation but also those
administered parenterally are all licensed medicines, but they have the potential to
be omitted from the scope of a Medication Profile because they are almost
exclusively administered and recorded in a specialist setting using specialist systems
(even if those systems are paper-based, such as a specific anaesthetic record
sheet).   The same is true for contrast media for all forms of imaging, and nuclear
medicine products, whose use is usually in diagnosis rather than treatment (although
some nuclear medicine products are now also being used in treatment, especially of
solid tumours).  It is important therefore that such products are explicitly included in
the scope of a Medication Profile, and information on their use documented in
specialist systems is shared with a Medication Profile system.
Similarly, dental practitioners use a range of medicinal products, many of which are
developed specifically for dental use. These include: medicated mouth ulcer
preparations, antibacterial mouthwashes and gels, periodontal antibacterial gels,
ointments and fibres and fluoride tablets. As medicinal products, information on the
use of these products by an individual should be explicitly included in a Medication
Profile for that patient, including their dosage instructions.  Medical devices used in
dental procedures such as sealants for fissures and root canal pits, pulp capping
material and materials for dry socket preparation and root canal dressings (even
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though these usually contain antibiotics and/or antiseptics) should not be recorded
in the Medication Profile; they will be recorded as items used within a procedure.
Unlicensed and investigational medicines
Just as within the broad category of licensed medicines there are various subtypes,
so within unlicensed medicines there are a set of subtypes to be discussed, so as to
be explicit as to their inclusion or otherwise within a Medication Profile.  Medicines
that have been previously licensed in a jurisdiction but whose license has been
discontinued or withdrawn become ‘unlicensed medicines’ if and when they are then
used in patient care in that jurisdiction.  The inclusion of such medicines in the
Medication Profile is discussed above.
Extemporaneous (magistral) medicinal products
Although there may be some challenges in describing and communicating
information for extemporaneous preparations since they fall outside normal
medicinal product terminologies, they are medicinal products and their use should
be explicitly included in a Medication Profile.
Investigational medicinal products
Medicinal products in Phase I (‘first in human’) through to Phase III (large scale
efficacy and benefit/risk) studies must be administered strictly in accordance with the
protocol that governs the study, which must be approved by the regulatory
authority(ies) for all the countries in which the study will be conducted.   Although
many such studies are designed using the double blind design, in which neither the
subject nor the investigator knows whether the subject is receiving the investigational
product or a placebo/comparator product, this information is available in the
randomisation and trial supply management system used to support such a study,
and will be made available after formal database lock for the study.
Although there may be some challenges in accessing and describing the use of
investigational products, these are medicinal products and their use should be
explicitly included in a Medication Profile. During a study, a placeholder description
could be placed in the Medication Profile, which is replaced with explicit information
after the final data lock point.
Homoeopathic and herbal medicines
Although this scoping is written on the premise of the culture and practice of Western
medicine, homoeopathic and herbal medicines sit on the boundary of that culture
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and practice and therefore must be discussed in order for that boundary to be
delineated.
Due to the potential potency of some homoeopathic and herbal medicines, shown
for example by the interaction between Hypericum perforatum and the coumarins,
or milk thistle and simeprevir, if information is available on a patient’s use of
homoeopathic and herbal medicines it should be included in a patient’s Medication
Profile; such information should not be actively excluded.
Other Types of Products
Nanotechnology products
It is likely that as products in this area are developed, they will be formally studied
following an approved protocol, which makes them very similar to standard
investigational medicinal products.  And as such, the use of these products should
be explicitly included in the patient’s Medication Profile.
Nutritional products: Foods and food supplements
These products can be clearly differentiated from medicinal products by their (lack
of) regulatory authorisation and by the recording or otherwise of their use.  Their lack
of therapeutic significance suggests that their use should be explicitly considered
beyond the scope for inclusion in a patient’s Medication Profile.
Medical devices
Medical devices are a diverse category of products that are important to the care of
patients that would at first sight appear to be similar to medicinal products but which
are in fact quite separate.  This is despite there being are some products that were
originally authorised and made available as medicinal products that have been re-
classified and re-authorised as medical devices; for example: carmellose eye drop
solutions.
Since medical devices are not medicinal products, even though some may
incorporate medicinal substances within them, they are explicitly considered beyond
the scope of what should be included in a patient’s Medication Profile.
Leeches and maggots
Neither leeches nor maggots are considered as medicinal products, and the record
of their use is within a procedure.  There is therefore no requirement for their use to
be included in the patient’s Medication Profile.
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Cosmetics and toiletries
Even though these products may be prescribed and dispensed in some healthcare
cultures, they are not medicinal products, and therefore they can be explicitly
considered beyond the scope of the products what should be included in a patient’s
Medication Profile.
Limitations of this study
The main limitation of this analysis is also the reason for it: the lack of published
and/or formally agreed information on the categories of things that should be
considered within scope for a Medication Profile.  The assessment made by this
analysis should therefore be thoroughly examined and tested in the domain, both for
the validity of the categories themselves and for the inclusion and exclusion
decisions.
This analysis explicitly excluded products used in alternative cultures and practices
of medicine; products from these traditions could be examined in using similar
principles.
Recommendations for further work
For those products whose use should be included within a Medication Profile but
whose recording is normally undertaken in discrete specialist systems (e.g. dental
medicines, anaesthetics, investigational medicinal products), the business
process(es) for sharing that information with the Medication Profile should be
investigated.
Currently, based on this analysis, devices that have a medication substance integral
to them are excluded from being recorded in a Medication Profile, based on their
authorisation.  The validity or otherwise of this should be formally investigated
against the use cases for the Medication Profile.
The practice of healthcare, and particularly the development of therapeutic products,
is by no means static, and therefore as and when new types of products emerge, the
inclusion or otherwise of these within the scope of the Medication Profile will need
reviewing.
Conclusion
In order to support the use cases of provision of high quality care to individual
patients and also for secondary use of that information in clinical research to promote
better and safer medication development, a Medication Profile should contain
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information about a patient’s use of all licensed medicinal products of any type,
including those not prescribed (i.e. purchased over the counter for self-medication),
and all unlicensed medicinal products.  Whenever possible, information about use
of homoeopathic and herbal medicines should also be included in the Profile.
But although the premise used in this research is that all licensed medicinal product
types, includes biological products and therefore particularly those biological
products used in vaccination, the management and presentation of some of this
information – particularly for vaccination – will be explored further in the Evaluation
of the model for the Medication Profile.
Information about use of medical devices, nutritional products and cosmetics and
toiletries used in a healthcare context is excluded from the Medication Profile per se.
It is recognised that recording information about these products for reference and for
possible re-supply is of considerable value to both the patient and the healthcare
practitioner, but the Medication Profile is deemed not to be the place to manage that.
Information about the use of whole blood or its major components, although vital for
patient care and clinical research, is recorded separately in EHR systems and should
explicitly not be included in a Medication Profile.
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Chapter 8: The Medication Profile Model
Context of the Model
In the context of the Medication Profile, it is clear from the literature search and from
the requirements gathering that although there has been considerable discussion of
the concept of a Medication Profile and its use, there has been no full and formal
description of the domain in a formal modelling notation covering both the static and
dynamic elements.  Therefore it has proved impossible to date to create a system to
manage a Medication Profile such that it that can provide the necessary information
to meet the requirements of healthcare and clinical research. It is clear that without
this formal domain information model of with the static and the dynamic views, there
is no consistency in the way in which systems provide and populate a Medication
Profile, so none of the use cases can be met dependably.
The following sections of this chapter therefore seek to address this by providing a
complete domain information model of the Medication Profile that can be used to
support a Medication Profile system, on its own or as part of a larger electronic health
record, in order to provide a Medication Profile that contains high quality, consistent,
trustworthy information that can be presented to the use cases efficiently and clearly.
It is not possible to provide exact traceability from the various features in the model
and its sub-models to the Requirements gathered in the previous chapters,
particularly since there was so little available for the dynamic models.  There has
been some consolidation, but generally the requirements for the attributes in the
static model are referenced, and the derived attributes that have been added to the
model to support the functional use cases have been explicitly justified.  The
principles used for the construction of the dynamic models are discussed in detail in
the relevant sections.
UML, Model Paradigms and the Medication Profile
UML is the Universal Modelling Language initially developed by Booch, Rumbaugh
and Jacobson in the 1990s, and now managed by the Object Management Group296
(an international technology standards body).  It is an international standard through
ISO (ISO/IEC 19505-1:2012 Information technology -- Object Management Group
Unified Modelling Language (OMG UML))297. The purpose of UML is to visualise,
specify and document the artefacts in a system, usually a software system (also
called ‘the domain’).298. Because of the limits of the human ability to understand
complexity, it is important to divide and conquer, to reduce the complexity into its
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different parts.  This is achieved by working in two paradigms, the paradigm of the
types of models and the paradigm of the granularity of the models themselves.
The first paradigm expresses itself in the various diagrammatic styles – model types
– that are a grammar and syntax that can be understood by both humans and
machines, to describe the static and dynamic components of the system. This
paradigm embodies the first and last of the four principles of UML: ‘the choice of
which models to create has a profound influence on how a problem is described and
how a solution is shaped; and ‘no single model is sufficient’298.
The static model components are the entities that exist in the system, described
using classes, attributes and relationships, and sometimes also the operations that
can be performed on these components.  The static models are often called the
‘structural views’. The dynamic model components describe the behaviour of the
system, and the entities in the system as they transition through states or interact or
collaborate together. In addition, in recent years, business process modelling has
been added to UML, allowing description of the behaviour of users with a system
The second paradigm is that of using layers within one or more of the types of
diagrams, where detail (or granularity) increases or decreases as the viewer moves
down or up through the layers.  This is the manifestation of the second principle of
UML, that ‘every model may be expressed at different levels of precision’298. By
keeping the layers closely related to each other (using a ‘drill down’ approach) the
overall pattern of the information in the model type is maintained.
But even with clear principles and good tooling support, authoring the models is an
art as much as it is a science, and it is important to remember that ‘the model in its
entirety’ consists of a set of diagrams (sub-models) of various different types and
appropriate levels of granularity, whose aim is to provide a comprehensive and a
cohesive description of the domain of interest.
Static (Structural) Models
The static UML models show the class of (the thing that represents) a Medication
Profile and a representation of the things (data elements) that are required to be in
the Medication Profile in order to meet the business use cases.  These are therefore
the data elements that have been gathered and defined in the preceding chapters
as being those that are relevant for the four core use cases for Medication Profile
information and summarised in the immediately preceding chapter.
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The static model is presented as two layers.  The first is a high level conceptual
model.  This describes the data elements at their most abstract, so the more granular
sub-elements of the Medication Profile are not identified individually, but are shown
only as classes representing groups of similar elements.
The second layer, which is in effect truly an intermediate layer between the abstract
model and implementable models (see the Discussion section), is a more logical
model, where the overall pattern of classes is the same, but the supporting classes
have attributes to represent individual data elements and is where the definition of
these attributes should be provided.
The domain model presented here is focused entirely and specifically on the
Medication part of the Medication Profile; there is no attempt made to further
describe the Patient/Subject to whom the Profile applies and in the logical level
model, the Patient/Subject is no longer shown.
High level conceptual model
Figure 10: High level conceptual model of the classes and relationships of the
Medication Profile
At a conceptual level, this model, drawn in Figure 10, shows the Medication Profile
belonging to a Patient/Subject being totally composed of Medication Records, which
themselves can be composed of Medication Records, through the recursive
relationship.  A Medication Record is the documentation of a course of therapy for a
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single medication (therapeutic moiety).  This focus reflects the scope of this work.
But it does not explicitly exclude other classes of record information, such as allergy
information, being added to a Medication Profile should others consider that
essential.
A Medication Profile is composed of zero to many Medication Records; a Medication
Profile should exist for a patient even if no medication has ever been given to that
patient; the requirement was for a cradle to grave longitudinal record, and information
that no medication has ever been given is valuable information.
A Medication Record has information about the identification of a medication – the
medicinal product that the record relates to, and the additional information from
Dosage instructions and the Status (Current or Past) of the use of the medication
described in the record.
A Medication Record also has metadata, information that accompanies the core data
and describes additional non-core context; for example the provenance: the ‘who’
and ‘where’ of any item of data.  Requirements for the definition and use of general
provenance metadata for records in healthcare is well advanced and documented228
and therefore is not further discussed in here, although, like Patient/Subject, it is
shown on the high level conceptual model.  But specifically, this must include the
information source(s), the medication activities and processes, specifically
prescription, dispense, administration and statement as sources.
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Logical level model
Figure 11: Logical model of the classes, attributes and relationships of the Medication Profile
Medication Identification
+ "Code" [0..*]
+ Brand name [0..1]
+ Generic name [0..1]
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The following sections describe each of the classes and attributes in the logical
model shown in Figure 11 in detail.
Parent Medication Record
Figure 12: Parent medication record class (detail)
The Parent Medication Record class represents the overarching record
(documentation of a course of therapy for a single medication moiety) that is
populated when a continuous course of therapy (see below) has changes during its
lifecycle.  This class is a class generated explicitly for management of the Medication
Profile to meet its use cases, and such all its attributes are derived, as opposed to
being populated from information obtained directly from medication processes.
The Parent Medication Record exists to meet the use case of providing an overall
‘course of therapy duration’ for a particular medication.  This is one of the key
differentiators of a properly managed Medication Profile as compared to a list of
medications used sorted uniquely and presented in an approximate chronological
order.
In the logical model, the Parent Medication Record and the Medication Record are
the result of a single ‘unrolling’ of the recursion shown on the Medication Record
class in the conceptual model.
Medication moiety
This attribute is the description of the medication of the continuous course of therapy,
described at its abstract level (i.e. without presentation – dose form or strength –
information).  This is analogous to a ‘virtual therapeutic moiety’192 or similar classes
in medicinal product dictionaries.  It is information that should be derived from the
medication identification information using a structured medication terminology.
Course of therapy start/stop dates
This describes the timing information for the overall continuous course of therapy, if
and when it has had changes applied to it.  The course of therapy start/stop dates
Parent Medication Record
+ /Medication moiety
+ /Course of Therapy (Start/Stop Dates)
+ /Status
+ /Status date
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are calculated from the course of therapy start/stop dates of the individual medication
record.
Status and status date
This describes whether the overall continuous course of therapy is currently
occurring or occurred in the past and has concluded.
Figure 13: State diagram for a Medication Record status
There are two standard states – ‘current’ and ‘past’ – as gathered from the
Requirements.  The triggers for moving from one to the other are discussed below
in the ‘Processing information into the Medication Profile’ section.  Medication
records may at some point found to be in error and therefore an error state must be
permitted; this should be used following the same principles as for other records
erroneously placed in an EHR system.
Status date: any status can only be truly understood in the context of the point of
time that it relates to, so a status must have a status date to make it relevant at any
single point in time.
Currrent Medication Past Medication
New
Medication
Record
Error
Record
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Medication Record
Figure 14: Medication Record class (detail)
The medication record is the documentation of a course of therapy for a single
presentation of medication in a single course of therapy.
When a continuous course of therapy has a clinically significant change (e.g. change
in dose quantity/frequency or change in strength of the medicinal product), then a
new medication record is created that replaces the previous one, and both are
related to a Parent Medication Record.
Course of therapy type
The course of therapy type describes the overall pattern of the medication
administration to the patient,– as either a single short term course or as a continuous
process.
Indication
The indication is the reason why the medication is administered to the patient to
effect a cure or management of or prophylaxis of a disease or symptom or condition.
Indication has been grouped with the dosage instructions in the Requirements, but
in a logical model would relate directly to the medication itself, and therefore is shown
as such.  In an ideal world, each medication would have an indication (which may
have multiple parts, for example ‘to relieve nausea and vomiting’).
Medication Type
The medication type supports categorisation of the medication by means of
classification, and can be used to identify particular kinds of medication at the
Medication Record level rather than at the Medication Identification level.
In the Requirements, there was a need to be able to identify immunological products
(vaccines) explicitly, for pharmacovigilance and for patient care purposes, and this
could be done by use of the medication type.
Medication Record
+ Course of therapy type
+ Indication [0..1]
+ Medication type [0..1]
+ /Status
+ /Status date
Replaces
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This would also allow a subset of the Medication Profile to focus particularly on
vaccinations.  This is not a use case found explicitly in the literature but one that is
expressed implicitly, for example by the fact that in the specifications examined in
Chapter 4(1), immunisation information is called forth separately from other
medication information.  In addition, the requirement for separate vaccine
information in the Medication Profile has been expressed to the author in discussion
by national health organisations such as Canada Health Infoway.
This attribute could also be used to identify a medication administered as a study
drug in a clinical study; identifying such medications was particularly important in the
protocol feasibility and patient recruitment use cases.
Status and status date
This describes whether the medication that is the subject of the Medication Record
is currently being used by the patient ‘now’ (as in – this point of time) or whether its
use occurred in the past and has concluded.
As described in the state model above, there are only two status envisaged from the
Requirements: ‘current’ and ‘past.  There is no transition back from ‘past’ to ‘current’;
re-use of the same medication after a record has moved to ‘past’ status will require
a new record to be created, as a new course of therapy has been initiated, possibly
with a new set of dosage instructions and new indication, depending on the clinical
context.
Non-administration
Figure 15: Non-administration class (detail)
Non-administration reason provides information to explain why a medication that has
been prescribed has not actually administered or used by the patient; the Patient
Care use case had a requirement for this information, however how it would be
communicated by currently available business processes is not clear.  The attribute
has therefore been added to the static information model, but there is no information
in the dynamic model section as to how this attribute should be populated.
Non-
Administration
+ Reason
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Medication Identification
Figure 16: Medication identification class (detail)
Each medication that is the subject of a Medication Record in the Medication Profile
must be identified, using some or all of the following attributes; the rules for which
combination of each would be managed at implementation to ensure a full
description was available.
Code
The machine-readable identification of a particular medicinal product obtained from
one or more code systems or medicinal product terminologies.  There are a variety
of code systems or medicinal product terminologies available and different
healthcare cultures may specify which terminologies are appropriate for use in that
enterprise.  Some cultures use a single standard system (such as the NHS in the UK
use the NHS dm+d192 or the Dutch healthcare culture that use the G-Standaard299);
some cultures use a range of terminological systems and so identifying the
medication using more than one of those may be appropriate (e.g. the USA uses a
several proprietary terminologies from commercial providers and have the
metathesaurus of RxNorm112 bringing them together).
Brand name
The proprietary name for a medicinal product assigned to it by its manufacturer.
Brand name information is particularly important for the pharmacovigilance use case,
the exact identification of the medication by use of the brand name is desirable, and
brand naming is appropriate for certain types of medicinal products (e.g. those with
a narrow therapeutic index or bioavailability issues or those whose administration is
associated with particular supporting devices, such as insulin injections).
Generic name
This is the non-proprietary name for the medicinal product and usually consists of
the international non-proprietary name with the appropriate dose form and strength
information.  Identification of a medicinal product by its generic name is preferable
for many use cases; however this is not always desirable (see above).
Medication Identification
+ "Code" [0..*]
+ Brand name [0..1]
+ Generic name [0..1]
+ Manufacturer [0..1]
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Manufacturer
The organisation that is responsible for making the medicinal available for use.  This
information is desirable information for the pharmacovigilance use case.  A
medication as administered to a patient can have only one manufacturer.
Dosage instructions
Figure 17: Dosage instructions class (detail)
The dosage instructions describe the how, how much, where and how often the
medicinal product should be or was administered.
Additional Text
This attribute holds any additional text that is relevant to the administration of the
medicinal product and that does not fit in any of the dosage instructions detailed
classes and attributes.
Supply Quantity
Figure 18: Supply quantity class (detail)
Each medication may have an amount that is to be or has been supplied to a patient
for administration.  This information was mentioned in only one of the situations
examined in the requirements gathering exercise (the CCR) and was just an amount
on its own; however, logically in a Medication Profile, both the date of that supply
information and some metadata whether it is a requested supply (from a prescription)
or a performed supply (from a dispensing) is also necessary to truly put the Supply
Quantity information into its correct context.
Dosage Instructions
+ Additional Text [0..1]
Supply Quantity
+ Amount
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Amount
This is the amount of medicinal product that is to be or was supplied to a patient in
a medication process (prescribe or dispense).  The amount should be present as a
quantity (countable or measurable) and a unit.
Dosage instructions clause
Figure 19: Dosage instructions clause class (detail)
A dose instructions clause is a single statement that stands on its own to describe a
single set of dosage instruction information; it will contain a number of component
parts (the quantity, route site and method and timing information).  A single dose
instructions clause may form the complete dose instruction, or two or more dose
instruction clauses may be concatenated together to give the complete dose
instruction, using sequence number to ensure that the clauses are brought together
in the correct order.
A dose instructions clause was mentioned in only one of the situations examined in
the requirements gathering exercise (the CCR, which had both a sequence number
and an indication of conjunction) but logically it would exist in a model of dosage
instructions.
Conjunction
A dose instructions clause that has a relationship to another Dose instructions clause
may have a Conjunction (‘or’, ‘then’ or ‘and’) and, if it is part of a sequence (‘then’) it
will have an indication of where in that sequence it occurs.
Sequence Number
This is an integer that is used to indicate the order of clauses when more than one
Dose instructions clause are used together.
The components that can go into a Dose instructions clause are:
Dosage Instructions Clause
+ Sequence Number [0..1]
+ Conjunction [0..1]
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Dosage Quantity
Figure 20: Dosage quantity class (detail)
Each of the four attributes here relate to the amount of the medication administered
to a patient.  Their definitions are as given in the requirements gathering, but are
repeated here for convenience:
Dose quantity
This describes the amount of the described medication that is to be (or was)
administered to the patient at a single point in time (i.e. a single dosage
administration act).
Total Daily Dose
This describes the amount of the described medication that is to be (or was)
administered to the patient in a 24 hour period of time.
Dose Quantity Upper Bound
This describes a limit for the amount of medication that can be administered during
a particular timing period.
Rate of Administration
This describes information about the ‘delivery speed’ with which a specified amount
of a medication should be administered to a patient per unit of time.
Route Site Method
Figure 21: Route Site Method class (detail)
Dosage Quantity
+ Dose Quantity [0..1]
+ Total Daily Dose [0..1]
+ Dose Quantity Upper Bound [0..1]
+ Rate of Administration [0..1]
Route Site Method
+ Route of Administration [0..1]
+ Site of Administration [0..1]
+ Method of Administration [0..1]
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This class and its three attributes describe the ‘where’ and the ‘how’ the prescribed
medication was or is to be administered to the patient.  As above, their definitions
are as given in the requirements gathering, but are repeated here for convenience:
Route of Administration
This describes which way that the administered medication should take to get into
the body or into contact with the body.
Site of Administration
This describes the specific area of the body where the medication is to be
administered.
Method of Administration
This describes how the medication should be administered - the particular way of
carrying out or accomplishing the substance administration.
Dosage Timing
Figure 22: Dosage timing class (detail)
This class and its attributes describe the ‘when’ the medication was or is to be
administered to the patient, and therefore also forms the foundation for the derived
information about the status of the medication.
Course of therapy (Start/Stop Dates)
This describes the timing information for when the medication was or is being used
by the patient as a treatment whole, and hence is based on dates, rather than the
individual dose by dose frequency timing which is described in the attribute below.
The course of therapy information is synonymous with a regimen timing concept
sometimes described in specifications.  Note that this attribute is specific to the
Medication Record; a similar attribute exists on the Parent Medication Record, but is
derived.
Dosage Timing
+ Course of Therapy (Start/Stop Dates)
+ Course of Therapy Duration
+ Dose Frequency
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Course of therapy duration
This describes how long the course of therapy of that medication is to be or was, in
terms of amount of time (days, months, years) rather than actual point in time dates.
Dose frequency
This describes when the medication (expressed as the dose quantity) is to be (or
was) administered to the patient using a measured time pattern (twice per 24 hours,
once per 2 weeks, every 6 hours).
Dynamic (Behavioural) Models
The static model describes what the Medication Profile should contain in terms of
information at a point in time.  It does not give any indication of where that information
could or should be sourced from and if any transformation of source information is
required, or how that transformation should be undertaken.  Nor does it give any
indication of how that information should be managed over time.  It indicates if the
content of an attribute can be derived from other information (which may be
elsewhere) rather than being populated by instance data.
A Medication Profile is not an ordered list of records of medication activities, it is a
cohesive whole that provides the information to meet the use case requirements in
a reliable and timely manner. For example, no clinician has the time to wait for 90
seconds (or more) while a Medication Profile downloads from a central point only to
find it contains a hundred identical records of daily methadone dispensing from the
past 3 months listed in date order. And no decision support system or protocol
feasibility testing system wishes to wade through this set of a hundred identical
records of daily methadone dispensing, with the attendant risk of generating an equal
number of impractical duplicate therapy alerts.  As the Requirements of the previous
chapters have shown, the users, both human and system, wish to know that the
patient is currently taking methadone and the dosage details of that.
In order to provide a sensibly populated Medication Profile with high quality,
consistent, trustworthy information that can be presented to fulfil the use cases
efficiently and clearly, all of these things must be taken into consideration.   To be
truly successful in meeting its use cases, the population of the Medication Profile
must be managed with a high quality process that supports consistent curation over
time; the Medication Profile is a longitudinal record of care.  There should be
completeness of information visible to all care givers and all use cases;
discontinuation of medication should be clear; non-dispense or non-administration
information should be clear.
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And taking into account that the majority of information from the provision of
healthcare to patient has to be managed in a federated environment, the challenge
to provide a single integrated view of information from a variety of sources with the
possibility of duplication of information and even conflicting items of information,
urgently needs to be addressed.
Yet these aspects have surprisingly not been taken into account within any of the
specifications examined and consequently nothing approaching an ideal Medication
Profile exists in any system or culture; systems continue to develop in an ad hoc
manner with little or no interoperability between them, compromising patient safety
and reducing dramatically the ease with which information can be used for secondary
purposes such as clinical research.
The objective of the dynamic models is therefore to address this using a threefold
approach:
 to describe the business processes that are the source of and provide flows
of information in the real world and to regularise these so that their
information can be reflected into the Medication Profile as accurately as
possible
 to describe how information from these flows can be related together, and
how the information that they provide can be processed and used in the
Medication Profile to meet the use cases
 to describe the status (lifecycle) of the core classes of information in the
Medication Profile (the Medication Record), and how the basic state
transitions through that lifecycle should be managed transparently
Activities in the Medication process: sources and flows of
information for a Medication Profile
As discussed in the Scope chapter, the concept that ‘medicines are not ordinary
items of commerce’268 is often used to highlight that medicines form a special class
of objects, and as such their use is managed through a the medication process, with
its specialist set of activities as defined and discussed in the Patient Care chapter:
prescribing, dispensing and medication administration.  In addition to information
from these directly medication related activities, as in most of healthcare, there is
process of making and recording a statement about a medication process, usually
communicated in the form of a summary administration-type process.
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These activities and the systems that support them are the sources of the information
that will flow into the Medication Profile.  Any system wishing to provide a Medication
Profile must accept information from the three medication activities and from
medication statements, and transform it into a cohesive whole, to populate the
Profile.  Unless this transformation is performed consistently, against a documented
set of rules, different results will be generated by different systems and the
Medication Profile will cease to be a consistent whole, able to reliably support its
various use cases.  This transformation also has implications for how different care
sectors and in particular primary and secondary care, can blend their medication
information together.
All the specifications for medication information which were studied in detail in the
Patient Care chapter detailed what information should be stored and what
information should be shared; none of them made any comment about how to
undertake the transforms to blend different sets of information together to give an
overall harmonious cradle to grave view of a patient’s medication.
Medication process activities
All the activities described below occur in patient care, whereas the scope of the
requirements for the Medication Profile cover both patient care and clinical research.
Clinical research uses the Medication Profile, but it does not have any unique
activities that would contribute information to the Medication Profile.  For example,
even within a clinical study, administration of the investigational product should be
documented as part of the normal patient care process, then that information re-used
(basically, copied) into the appropriate case report form(s) (dealing with the exposure
to the investigational product) and reported in the Exposure domain of Study Data
Tabulation Model specification or similar. Each of the activities is described in turn
below.
Prescription
The prescription activity initiates the overall Medication process.  As discussed in the
Patient Care sub-chapter, it is the prescribing activity where the selection of the
medication itself and its dosage instructions is made. A prescription has two roles:
it signals the prescriber’s intent that the patient should have the prescribed
medication administered and (in most healthcare cultures) it provides the legal
authorisation for the supply of that medication to allow that administration to take
place.
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Dispensing
The dispense activity supplies the medication such that it can be administered.
If the medication has been counter prescribed, the selection of the medication and
its supply has occurred in one activity, and in the patterns below should be
considered as a dispense event because it concludes with that supply activity.
Administration
The administration activity gets the medication into or onto the patient in order for it
to exert its therapeutic effect(s).  The administration activity is recorded in only a
small proportion of all medication use, in care environments such as secondary and
tertiary care facilities or nursing care homes, or on specific occasions in primary care
(vaccination, administration of a steroid injection etc.).  The vast majority of
administration occurs unrecorded and is managed by the patient themselves or their
carer(s).
In medication administration systems, each administration event is usually recorded
as a single entity (e.g. an antibiotic administered with a frequency of ‘every 8 hours’
will have three administration event records in any one 24 hour period) in both
secondary (hospital) and primary (nursing home) care. But the information (the data
elements) that is required by the Medication Profile is ‘the dose timing’; there is no
requirement in the use cases for ‘dose by dose information’. This places a
requirement on the type of administration information to be shared with the
Medication Profile and when it is shared: administration information shared with the
Medication Profile should be a summary of a set of administration events, described
as the dose frequency and course of therapy start and end dates.   The requirements
for the generation and sharing of that administration summary will differ depending
on whether the medication activity is a single event (as in a vaccination), whether it
is a simple course of therapy or whether it is a continuous course of therapy.
Medication Statement
A medication statement describes the activity whereby an individual or a system
provides an account or a report of a medication activity made by someone at a
specific point in time: for example ‘I used salbutamol to treat my asthma when I was
a child’ or ‘this patient was on azathioprine for several months to control a rheumatoid
flare’. Information generated from a formal medication reconciliation process would
also be communicated to the Medication Profile using a medication statement or
series of statements. Note that a medication statement may be made in the context
of another type of communication or report, for example in a referral letter or a
discharge form.  This is a sub-type of a more generalised ‘clinical statement’ for
which there continues to be much debate but no formal definition300. When included
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as part of another communication, the receiving system needs to have the capability
to separate out the medication statement information and forward it to the Medication
Profile system for processing.
Negative Information
Only rarely is negative information captured in health records, and even more rarely
is it shared between systems.
Information that a medication is ‘not prescribed’ would be very rare; a possible
scenario might be if a medication was recommended for use by one clinician, but
another clinician decides not to use it, for example after a specialist consultation a
patient is offered a particular treatment but declines it and therefore no prescription
is necessary.  Information about a prescription being ‘not dispensed’ is also rarely
captured, even though this scenario does occur for many reasons: from clinical
reasons of the prescription being clinically inappropriate due to interaction, incorrect
dosage, etc. through to patient-centred reasons such as being unable to afford the
cost of the medication or simply the patient not wishing to receive the medication.  In
systems that record administration of medicines, a medication ‘not administered’ is
likely to be recorded (indeed, ethically such non-administration information is usually
required); however that may or not be made available for sharing with other systems.
Relating information from the Medication Process together
Simple, fully complete Medication Process
Figure 23: Simple, fully complete Medication Process
This is the simplest and most complete sub-pattern where all activities occur in a
linear pattern.  A medication is prescribed, dispensed and administered and each
activity is recorded and shared.   This complete pattern is only likely to occur in a
small number of situations – for example in a care environment – because
medication administration recording systems tend to be limited to such contexts.  An
example would be of a patient in a hospice, prescribed an antibiotic for an infection
by a primary care physician, which is then dispensed by a community pharmacy but
is administered by nursing staff in the hospice and recorded as such.   However, with
the increasing development and use of mobile applications for use in healthcare,
including a significant number aimed at supporting medication adherence301, it is
Prescribe Dispense Administer
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possible that in the future much more administration information will be available,
including from primary care.
The prescription process is usually recorded on the general practice system in
primary care or in the prescribing module of an electronic system in secondary care
and could be shared from there, especially in a healthcare culture that utilises
electronic sharing of prescription information. The dispensing process is recorded in
the pharmacy system and could be shared from that, especially in a healthcare
culture that utilises electronic sharing of dispensing information for payment
purposes. The administration is recorded (for example as part of the hospice patient
care system) and could be shared from that.  Because administration systems are
required to provide summary information, to support the above, the system needs
the functionality to 1) be clear as to if and when a final administration event occurs,
2) to summarise the individual administrations into a single cohesive whole either at
its end or at a convenient point and then 3) to communicate this to the Medication
Profile.
Prescription and dispense activities
Figure 24: Simple prescribe and dispense only process
This is a less complete but much more common pattern.  A medication is prescribed
and dispensed and these two activities are recorded.  No system information is
available about the administration of the medication; it is assumed that the patient or
carer administers the medication correctly as directed by the dosage instructions.  It
is the most common pattern seen in primary care.
Prescription and administer
Figure 25: Simple prescribe and administer process
This is another less complete but relatively common pattern.  Records exist and are
shared for the prescription and administration of a single medication.  This pattern is
common in secondary care, in cultures where electronic systems are widely used on
Start
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the wards and medication is supplied for use in patients generally (as ‘ward stock’
for example) rather than dispensed (and charged to) individual patients, for a range
of clinical scenarios, including those already described above (for example,
treatment of an infection).
Dispense and administer
Figure 26: Simple dispense and administer process
This pattern is likely to be very rare, as it would be exception for a medication to be
dispensed and have the administration recorded and not to have the prescription
recorded.   A possible example might be a medication purchased through over the
counter sales, although currently this business process is rarely recorded and
shared, for a patient in a formal care facility where all medication administration was
recorded.  It may also occur with protocol based medication dispensing used in
emergency/unplanned care scenarios.
Using the patterns
Although the above patterns describe the logical order for the provision and receipt
of medication information (prescribe, then dispense, then administration) to the
Medication Profile system, there is no guarantee that a) a system will receive
information in that order or b) that information for all three of those processes will be
presented.  This latter is particularly true for administration information, which is
available only in limited circumstances.  Therefore any system wishing to manage a
Medication Profile and make it available for use must be capable of accepting any
medication information from any process and reconcile it to pre-existing information
or allow it to initiate a new item of information.
The following sections describe the logical processing and the rules for that
processing that a system must undertake to allow it to deal with each and any type
of medication information input and to successfully use that in the population of the
Medication Profile to provide a cohesive single view of the patient’s medication
activity in a consistent manner, not merely to regurgitate a list of activities that have
occurred.
This means that the Medication Profile system must compute how the received
information needs to be processed into the Profile using one of the classic
Dispense Administer
StopStart
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‘Create/Update/Delete’ operations – or the Medication Profile specialist equivalents
of these – which have ‘Archive’ rather than ‘Delete’ as information should never be
deleted from a Medication Profile.  Any ‘corrections’ should be made through an
‘update’ and no longer current information is archived with a status of being past
medication. Note that in all of these processes, it is assumed the matching of the
information to a single patient has occurred successfully, using processes
specifically designed for that task.
Populating the Medication Profile
The following activities can be used to take information from the medication
processes populate the data elements within the Medication Profile.
Figure 27: Activity diagram for processing information into the Medication Profilef
The first thing for any Medication Profile system to identify is which of the four
medication activities the information it is receiving relates to; only once this has been
identified is it possible to understand how to further process the information into the
Medication Profile.
The specifications for communicating medication information were examined in the
Patient Care sub-chapter for their contribution to the requirements for the data
elements needed in the Medication Profile.  All bar one of the specifications were
explicit in having the requirement to identify which activity/process was being
communicated.  Communications flow between systems using HL7 V2 or V3
messages, or CDA document communications, or in some realms and cultures,
specific proprietary messaging formats such as those provided by NCPDP138138 in
the US.  In each of those communications it is critical to identify whether a medication
message relates to a prescription, a dispensing, and an administration/series of
administrations or to a statement about administration.  For example: a pharmacy
system must correctly understand that the communication it is receiving is a
f The “infinity symbol” [∞] denotes that there are sub-activities present within a main
activity – part of model drill granularity and drill down
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prescription, since it is this that provides the authority for the dispensing of the
medication for the patient; a reimbursement system must correctly understand that
the communication it is receiving is a notification of a dispensing, in order to be able
to make the correct payment for that supply.
This type of medication activity information is therefore a requirement from the
Medication Profile itself to the systems that provide information into it.   The
Medication Profile system is a communication subscribing system, i.e. it subscribes
to all medication related communications flowing in a federated enterprise (a
‘notification receiver’ in HL7 V3 terms or a ‘subscriber’ in a basic publication-
subscription service) and should receive this business information routinely as a by-
product of the general communication flow.
Identify the course of therapy type
Having identified which type of medication activity the communication is describing,
the second step is to ascertain where the information from that activity fits in an
overall pattern of information present in the Medication Profile.  This fit will be
different for each of the types of medication activity and will be determined by the
information already present in the Profile.   It therefore involves making reference to
an understanding of how medications are used in ‘courses of therapy’. It is this that
differentiates an ordered list of medication activities from a proper Medication Profile,
which sets activity information in its correct place to provide cohesive information
about current medication and medication history (past medication).
It is in the data elements that form part of the dosage instructions that the concept
of a course of therapy can be determined both for the Parent Medication Record and
the Medication Record itself: when did the patient start taking the medication, and if
appropriate and when did they stop (or discontinue) taking it.  The start date and end
date data elements provide that information and therefore it is these data elements
that are critical in supporting the calculation of whether, at any one point in time, a
medication is ‘current’ or ‘past’ - although, as discussed elsewhere, there is little if
any definition of what that actually means in terms of measurable elapsed time.  And
unfortunately, as discussed above, for any one individual medication activity, its
place in an overall course of therapy is not usually explicitly described in any
healthcare culture; it has to be evaluated using logical rules, which are described
below.  For example: the date of any one individual prescription may or may not be
the start date for a course of therapy.  There are possibly some exceptions to this
statement, for example a chemotherapy protocol where each part of the overall
protocol is explicitly documented; but even then, relating the medication events from
those disparate parts together in a Medication Profile system would require those
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relationships to be explicitly documented (e.g. this is administration 2 of 5 against
prescription ABC, which is part of protocol XYZ) and that is almost never done within
the actual prescribing and administration recording systems.
There is currently no accepted standard for nor any documentation on describing the
types of course of therapy for medication so the following is offered, initially as a
discussion of the principles, followed by definition of the types with examples. In the
practice of healthcare, conditions and symptoms are often differentiated using the
terms ‘acute’ and ‘chronic’.  An acute condition or symptom is one that may be of
rapid onset, brief not prolonged, and sometimes loosely used to mean severe302
whereas a chronic condition or symptom is one that is lasting a long time, and
sometimes meaning also low intensity302.  Concentrating on the time period part of
definition of these two terms, rather than the intensity part, they give a divide based
on a qualitative assessment of duration: acute means not prolonged whereas chronic
does mean prolonged. This differentiation, although not the terms themselves (so
as to remove any link to the concept of intensity which would be unwarranted in this
context) can be taken forward and used in conjunction with other differentiators to
describe the different types of course of medication therapy that a Medication Profile
will encounter.
As stated above, prolonged – or in some senses continuous and not prolonged (i.e.
short) are qualitative assessments, and unfortunately, computer systems cannot
make qualitative judgements; systems need to use quantitative assessments.   To
assign a quantitative value to ‘not prolonged’, so that everything of greater duration
would be considered ‘prolonged’ would involve a significant effort in selecting a set
of indicative conditions and their therapy and researching the literature to ascertain
the length of time that each is considered to have an acute presentation and
treatment period, then from that set of information to make an assessment of an
actual time period that can be considered to represent not prolonged or short.  That
is beyond the scope of this work at present, and therefore, to demonstrate the
principle, an arbitrary but hopefully clinically sensible qualitative period of 30 days
has been selected, roughly corresponding to the lunar cycle, and is therefore a time
period common to all cultures.  This is further discussed in the section below on
‘Managing medication activity information to identify courses of therapy type‘.
Unfortunately, that neat divide into prolonged or continuous and not prolonged or
single is complicated by the fact that medications may also be given in an episodic
fashion, where several separate short courses are repeated to give a series that has
a duration considerably longer than the duration that would have occurred if the
medication had been administered continuously.
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Single course of therapy
This pattern describes when a medication is used for a short period of time (a month
or less) as a single instance and independent of any other pattern.  Examples of this
include an antimicrobial preparations used to eradicate an infection, or an analgesic
or anti-inflammatory medication for symptomatic and short term management of an
injury.  This contrasts with and is differentiated from a chronic course of medication
which is one that is prolonged, where the duration of continuous use of the
medication is greater than one month (greater than or equal to 30 days).
Continuous course of therapy
This pattern describes when a medication is used chronically, for a prolonged period
(several months and maybe many years) and usually uninterruptedly, and as such
consists of the pattern that covers the majority of medication use for the management
of chronic conditions such as hypertension, angina pectoris, diabetes mellitus etc.
The continuous course of therapy usually involves some element of a repeating
activity, either by having a formal repeat prescribing or repeat dispensing process,
or by the constant repetition of a basic single prescribe-dispense process.  Note that
the method of managing the latter as a repeated course of therapy will also apply to
the linkage between the conclusion of one time-limited repeat prescribing or repeat
dispensing process into the next one (see further below).
Repeat Prescribing
The repeat prescribing process is one where a number of individual and identical
prescription orders are authorised at a single point in time (a ‘set’) and each can be
used sequentially until they have all been fulfilled or the time limit for the overall set
of prescriptions has expired.  Each dispensing is made as a fulfilment of a single
sibling prescriptiong as shown in Figure 28 below.
g In the English NHS, this process is somewhat oddly described as a repeat
dispensing process, when it is actually a repeat prescription process, including terms
such as repeatable prescription and batch [of prescriptions] held by a pharmacy
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Figure 28: Diagram describing the relationship between a Parent Repeat
Prescription and its Dispenses
Use of identifiers such as UUIDh should support traceability between the Parent
Repeat Prescription and all its sibling Repeat Prescription instances, and for the
Dispense for each Repeat Prescription.   These identifiers can also be used to
support the requirement that some healthcare cultures have, to put limits on the time
interval that must exist between each dispensing.
Repeat Dispensing
The repeat dispensing process is one that is supported by a single prescription that,
when  issued, also instructs how many times it can be used to support a dispensing
of the medication for example ‘Repeat 3x’ would support four dispensing events: the
initial  one and three repeats, as shown in Figure 29.  An example of this would be a
standard private prescription in the United Kingdom.  Use of identifiers such as
UUIDs maintain traceability between the Repeat Prescription and the Dispenses that
it supports.
h UUID – universally unique identifier
class Repeat Prescribing
Repeat
Prescription 1
Repeat
Prescription 2
Repeat
Prescription 3
Repeat
Prescription 4
Dispense 1
Dispense 2
Dispense 3
Dispense 4
Parent Repeat
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Figure 29: Diagram describing the relationship between a single Repeatable
Prescription and its Dispenses
Changed course of therapy
Because the data element requirements elicited from the use cases in the previous
chapters include the data elements that make up the dosage instructions for a
medication, a single continuous course of therapy should be defined as one where
both the medication and the dosage instructions remain the same.  Therefore if there
is a change to a data element present in the dosage instructions, this must be
managed as a change in the course of therapy.  For example, if a patient changed
from taking ‘furosemide 40mg orally once per day’ to taking ‘furosemide 40mg orally
twice per day’, this would constitute a change in the course of therapy, a new
Medication Record in the Medication Profile part of the overall Parent Medication
Record.
This same principle could be applied to a change in the presentation of the
medication itself, since those data elements (medication name, dose form and
strength) are also data elements that form key parts of the requirements for the static
data.  A change in presentation can indicate a significantly different and possibly
unrelated therapy (for example therapy using prednisolone eye drops will occur in a
clinically very different scenario from that using prednisolone suppositories) so this
would not be represented as a change to a continuous course of therapy, it would
be a new course of therapy.  But there are some scenarios where a change in
presentation could also be the implementation of a straightforward dosage change
class Repeat Dispensing
Repeat Prescription
- Repeat value = "3 Repeats"
Dispense 1
Dispense 2
Dispense 3
Dispense 4
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(for example ‘enalapril 5mg tablets, to be taken once a day’ to ‘‘enalapril 10mg
tablets, to be taken once a day’) and this could and probably should be managed as
a change to a continuous course of therapy.
To manage this accurately, there a complex set of rules would need to be developed,
primarily based around route of administration (or route of administration imputed
from the dose form) and which may even need to be medication specific.  At this
point any change in the presentation of the medication will be taken as a changed
course of therapy rather than a new course of therapy, since this most closely fulfils
the eligibility criteria based use cases, with the requirement to know, for example,
‘has the patient being taking medication X for more than 6 months and less than 2
years?’.
Cyclic (episodic) course of therapy
This pattern describes when a medication is used in phases, in a set of successive
short courses (cycles) given at stated intervals which together form a complete
course of therapy.  The most common example of this is cytotoxic medications used
in oncology, but the pattern can also be used to describe vaccination schedules.
This pattern could also be used to describe medication to treat seasonal conditions
(such as seasonal rhinitis (hay fever)), with the complete course being a continuous
course with an annual cycle flowing through that.
The pattern is complex because the course of therapy information recurses.  The
inner part of the recursion describes each of the shorter courses: the single cycles
which may consist of a single administration, or may be as long as a month or more
of repeated administrations.  The outer part describes the complete course of
therapy: its overall duration and the frequency of the repeats within that overall
duration.
Although it should be possible to identify cyclic courses of therapy and manage these
in the Medication Profile, with the information currently available in healthcare
enterprises it would be very difficult to do so accurately, and therefore the logic to do
this has not been described here.  As a pragmatic but admittedly imperfect solution
in current conditions, it is suggested that each cycle is managed as a course of
therapy in its own right.
Managing medication process information to identify course of
therapy type
The following sections examine in turn how to manage information from each of the
four different medication activities into cohesive course of therapy information.
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In all of the sections, a time period has been used to differentiate between a
communication regarding the continuation of an existing (and therefore continuous)
course of therapy and an instance of a new course of therapy.   As can be seen from
the Requirements chapters, there is very little guidance as to what can be considered
a sensible amount of time to actually differentiate this. For pharmacovigilance, only
the VAERS form gave any explicit guidance (which was 4 weeks); all the other forms
used phrases such as ‘concomitant’, ‘at the same time as [the reaction]’ and ‘current’.
In the eligibility criteria, there were only 4 criteria that had explicit time periods for
prior medication, and each of these were different (28 days, 30 days, 12 weeks, 3
months). In the Patient Care chapters, apart from the arbitrary 90 day requirement
for drug interaction checking, none of the specifications or care modules had any
explicit guidance for timing of current or past courses of therapy, or the differentiation
between these. Therefore, in the absence of any consistent guidance, a time period
of 30 days has been selected.  This closely reflects the lower end of the few explicit
figures given and as such can be considered most conservative.
Alternatively, this time period could be determined by the guidance within a particular
healthcare culture (for example, if prescriptions are only valid for fulfilment within 28
days of their issue, as is the case for prescriptions for opiates and similar medications
in the United Kingdom303) and could vary between the different processes.  For
example, a time period of 90 days could be used in the logic for processing dispense
communications on the grounds that this is long enough to cover situations that are
known to occur with seasonally applicable medication; for example a prescription
issued for hay fever treatment in this spring that is not presented for dispensing until
the pollen count for the particular allergens for that patient has reached a level to
induce symptoms, which might be high summer for patients mostly affected by grass
pollens.  A dispense event notified to the Medication Profile more than 90 days after
its instantiating prescription event would therefore be managed in the Profile as
representing a different course of therapy from its instantiating prescription event.
This might not always be a completely accurate reflection of the real situation, but
any clinician viewing the Profile would make their judgement as to the actual situation
and act appropriately.  Any system using the information in the Profile would process
both the prescription and the dispense event separately and therefore would have a
double positive in terms of alerts for decision support or matches for recruitment,
which is a safer alternative than a negative.
For practical purposes, a continuous course of therapy represents treatment for a
chronic condition, and a patient would be expected, indeed encouraged, to obtain
further supplies of medication before existing supplies had run out; this is part of
good treatment compliance and medicines management.
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There are two possible ways to ascertain course of therapy (as indicated by the drill-
down shown in Figure 27) these are shown below in Figure 30: one using identifiers
(e.g. UUIDs) to relate processes together to give course of therapy type information,
the other using the medication name.
Figure 30: Alternative sub-activity for ascertaining course of therapy type
Processing prescription information
For a prescription, the dynamic model describes that this is the start of ‘a medication
process’ in some way; it will authorise
 The start of a new single course of therapy
 The start of a new continuous course of therapy
 The start of the next portion of a continuation of a continuous course of
therapy
 The start of a cyclic course of therapy
 The start of the next cycle of a continuation of a course within a cycle of
therapy
When processing single prescriptions without any explicit course of therapy
information, it is impossible to distinguish between the start of a new continuous
course of therapy and the start of a new single course of therapy; in the flows that
follow these will both be termed a new course of therapy.  Later on in the process it
is possible to differentiate these using rules and logic.  Note also that the latter two
options are not explored in detail in this section, for the reasons already described
above in the cyclic course of therapy section.
CHOICE
Ascertain course of
therapy type using UUID
or similar
Ascertain course of
therapy type using
Medication Name
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In order to correctly process any prescription information that it receives, a
Medication Profile system must use rules to elicit – to the extent to which that is
possible – which of these the prescription represents.  Within the current practice of
healthcare and particularly medication information and its communication, there has
been to date no expression of a requirement for a prescription to describe the course
of therapy type that it supports, other than in the context of repeat prescribing or
repeat dispensing.  But even in those contexts, there is no indication of whether a
set of repeats is initiating a new therapy or continuing an existing course.  This limits
what can be done by and for the Medication Profile purely by logic when examining
a prescription in isolation.
In the absence of any such specific course of therapy information, the Medication
Profile has two other areas in which to apply logic; the first is a reasonably accurate
area in that it uses and matches artefacts designed for machine processing (UUIDs),
whereas the second relies on matching the information that is available, the
medication and the accompanying dosage instructions.
In all the figures below that describe the logical flow and rules for processing
information, the convention shown in Table 21 is used.
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Table 21: Symbols used in the flow diagrams describing the logic used to process
information into the Medication Profile
Question/Decision
Indicates a question or decision that
the information must be processed
through
Data Transform
Indicates a data transformation should
occur
New Course of
Therapy process
Indicates the next process that should
occur is a new course of therapy
process
Changed Course of
Therapy process
Indicates the next process that should
occur is a changed course of therapy
process
Change with a
Continuous Course
of Therapy
Indicates the next process that should
occur is change to information in an
existing continuous course of therapy
process
Update to an existing
record in the MP
Indicates the next process that should
occur is an update to an existing
Medication Record in the Medication
Profile
Confirms existing
record within the MP
Indicates the next process that should
occur is confirmation of the information
in an existing Medication Record in the
Medication Profile
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Using UUIDs
As described above, in a Repeat Prescribing scenario, UUIDs can be used to match
‘child’ repeat prescription communication with their parent and also allows
identification of the parent itself; this allows identification of either a continuous
course of therapy (a new parent repeat prescription) or a continuation of a continuous
course of therapy).
The flow diagram in Figure 31 shows the logic that the Medication Profile must apply
when receiving a prescription containing a UUID.
Does the Prescription
have a UUID? NO
Is there any previous
reference to the UUID? NO
Confirm by
YES
Confirm unchanged
Continuation of Course
using Name and Dose
Instructions
YES
Prescription with
Changed Course of
Therapy
information
Prescription within a
Continuous Course of
Therapy
YES
No
Use Name and Dose
Instructions for further
processing
Likely to be either
prescription for New
Course of Therapy or
Continuation of Existing
Course (new set of
repeats)
Figure 31: Flow diagram of logic used to ascertain course of therapy for a
prescription using UUID
Using the medication name and dosage instructions
In a healthcare culture that does not support the use of UUIDs to relate prescriptions
and their dispenses together, to meet its use cases in that environment, a Medication
Profile must employ logic based on the information that is available, the description
of medication itself and the accompanying dosage instructions, to ascertain what an
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individual prescription represents in terms of the course of therapy.   This matching
process is complicated by the fact that medications are named in various ways and
at various different levels of abstraction.  The flow chart shown in Figure 32 seeks to
address this; there is a transformation process between a brand name and a generic
name; some healthcare cultures allow generic substitution or interchangeability of
branded products based local rules and guidance.  By having this transformation in
the process, a prescription with its medication written as a brand but dispensed as a
generic, or dispensed using a different brand name can be related together correctly
and accurately.  It would also be possible, if the information is available, to use the
medication code as an alternative to or in conjunction with the medication name
although this is not shown in the flow due to special constraints.  Either or both of
name and code should be used in conjunction with a knowledgebase that contains
equivalence relationships between branded and generically named products.
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Is there a medication in
the Medication Profile
that has exactly the
same Brand Name?
Is there a medication in the
Medication Profile that has
exactly the same Generic
Name? (even if the brand
names do not match if Brand
prescribed)
Is the medication
prescribed using Brand
Name?
YES
Transform
Brand Name
to Generic
Name
Prescription for
New Course of
Therapy
NO
NO
Are the Dosage
Instructions
equivalent?
YES
YES NO
Is there a medication in
the Medication Profile
shares the same Brand
Name, but with difference
of dose form or strength?
NO
YES
Is there a medication in
the Medication Profile
shares the same Generic
Name, but with difference
of dose form or strength?
NO
Prescription with
Changed Course of
Therapy information
YES
NO
Is the timeframe within 30
days of the (scheduled)
end of the last
documented process
YES
Prescription with
Changed Course of
Therapy
information
New Prescription
within a Continuous
Course of Therapy
YES
NO
Figure 32: Flow diagram of logic used to ascertain course of therapy for a
prescription using medication name and dosage instructions
Processing dispensing information
Dispensing events provide information on the supply of the medication against a
prescription; information from that prescription may or may not be already present in
the Medication Profile and this is the first thing that the Profile must determine.  Once
that has been elucidated, for a dispense that provides information that is not
supported by a prescription, then the type of course of therapy that the dispense
supports must be ascertained.
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Dispensing: supporting an existing prescription or providing new medication
information
The Medication Profile has to apply logic to differentiate these two different scenarios
and again there are two options: using UUIDs or matching the information that is
available using the medication name; each is shown below in Figure 33 and Figure
34 respectively.
Using UUIDs
Does the Dispense have
a UUID? NO
Is there a Prescription
with a related UUID?
NOYES
YES
Dispense fulfils an
existing Prescription
within the MP
Use Name and Dose
Instructions for further
processing
Are the Dosage
Instructions
equivalent?
YES
NO
Dispense describes an
update to an existing
Prescription within
the MP
Figure 33: Flow diagram of logic to ascertain whether a Dispense supports an
existing Prescription using UUID
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Using the medication name
Is there a prescription
in the Medication
Profile that has exactly
the same Brand Name?
Is there a Prescription in the
Medication Profile that has
exactly the same Generic
Name? (even if the brand
names do not match if Brand
prescribed)
Is the medication
dispensed using Brand
Name?
YES Transform
Brand Name
to Generic
Name
NO
YES
YES
NO
Is the timeframe within 30
days of the (scheduled)
end of the last
documented process
YES NO
NO
Dispense fulfils a
existing Prescription
within the MP
Are the Dosage
Instructions
equivalent?
YES
NO
Dispense describes an
update to an existing
Prescription within
the MP
Dispense provides
de novo
information on a
New Course of
Therapy
Figure 34: Flow diagram of logic used to ascertain whether a Dispense supports an
existing Prescription using medication name
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Dispensing (no prescription): de novo course of therapy
If there is no supporting prescription already present in the Medication Profile, then
the type of course of therapy that the dispense supports should be clarified using the
logic shown in Figure 35 below.
Is there a medication in
the Medication Profile
that has exactly the
same Brand Name?
Is there a medication in the
Medication Profile that has
exactly the same Generic
Name? (even if the brand
names do not match if Brand
prescribed)
Does the Dispensed
medication use a Brand
Name?
YES
Transform
Brand Name
to Generic
Name
Dispense supports
a New Course of
Therapy
NO
Are the Dosage
Instructions
equivalent?
YES
YES NO
Is there a medication in
the Medication Profile
shares the same Brand
Name, but with difference
of dose form or strength?
NO
YES
Is there a medication in
the Medication Profile
shares the same Generic
Name, but with difference
of dose form or strength?
NO
Dispense supports a
Changed Course of
Therapy
YES
NO
Is the timeframe within 30
days of the (scheduled)
end of the last
documented process
YES
Dispense supports
a Changed Course
of Therapy
Dispense supports a
Continuous Course of
Therapy
YES
NO
NO
Figure 35: Flow diagram of logic used to ascertain the course of therapy for Dispense
only information
Processing administration information
Administration events provide information on the final activity in the medication
process.  There may be one or both of the supporting prescription and dispensing
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information already available in the Medication Profile, such that the administration
information is the final piece; or there may be only administration information, in
which case the type of course of therapy that the administration supports must be
ascertained.
Administration: supporting existing Prescription and/or Dispense or providing new
medication information
As with dispense information, the Medication Profile has to apply logic to differentiate
these different scenarios and again there are two options; using UUIDs or matching
the information that is available, the medication name.  The logic is somewhat
similar, but it is described in detail below in Figures 36 and 37 to be explicit for
implications for further processing.
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Using UUIDs
Does the
Administration have a
UUID?
NO
Is there a Prescription
andor a Dispense with a
related UUID?
NOYES
YES – “Prescription only”
Administration fulfils
an existing
Prescription within
the MP
Use Name and Dose
Instructions for further
processing
Are the Dosage
Instructions
equivalent?
YES NO
Administration
describes an update
to an existing
Prescription within
the MP
Are the Dosage
Instructions
equivalent?
YES – “Dispense” & “Prescription + Dispense”
Administration fulfils
an existing Dispense
within the MP
Administration
describes an update
to an existing
Dispense within the
MP
YES NO
Figure 36: Flow diagram of logic used to ascertain whether Administration
information supports an existing Prescription and/or Dispense using UUID
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Using the medication name
Is there a prescription
or dispense in the
Medication Profile that
has exactly the same
Brand Name?
Is there a Prescription/
Dispense in the Medication
Profile that has exactly the
same Generic Name? (even if
the brand names do not
match if Brand prescribed)
Is the administered
medication described
using Brand Name?
YES Transform
Brand Name
to Generic
Name
NO
YES
YES – “Prescription only”
NO
Is the timeframe within 30
days of the (scheduled)
end of the last
documented process
YES NO
NO
Administration fulfils
an existing
Prescription within
the MP
Are the Dosage
Instructions
equivalent?
YES NO
Administration
describes an update
to an existing
Prescription within
the MP
YES – “Dispense” & “Rx + Dispense”
Administration fulfils
an existing Dispense
within the MP
Are the Dosage
Instructions
equivalent?
YES NO
Administration
describes an update
to an existing
Dispense within the
MP
Administration
provides de novo
information on a
New Course of
Therapy
Figure 37: Flow diagram of logic used to ascertain whether Administration
information supports an existing Prescription or Dispense using medication name
Administration (no prescription or dispense): de novo course of therapy
If there is no supporting prescription or dispense information already present in the
Medication Profile, then the type of course of therapy that the administration
information supports should be clarified using the logic shown in Figure 38.
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Is there a medication in
the Medication Profile
that has exactly the
same Brand Name?
Is there a medication in the
Medication Profile that has
exactly the same Generic
Name? (even if the brand
names do not match if Brand
prescribed)
Is the Administered
medication described
with a Brand Name?
YES
Transform
Brand Name
to Generic
Name
Administration
supports a New
Course of Therapy
NO
Are the Dosage
Instructions
equivalent?
YES
YES
NO
Is there a medication in
the Medication Profile
shares the same Brand
Name, but with difference
of dose form or strength?
NO
YES
Is there a medication in
the Medication Profile
shares the same Generic
Name, but with difference
of dose form or strength?
NO
Administration
supports a Changed
Course of Therapy
YES
NO
Is the timeframe within 30
days of the (scheduled)
end of the last
documented process
YES
Administration
supports a
Changed Course of
Therapy
Administration
supports a
Continuous Course of
Therapy
YES
NO
NO
Figure 38: Flow diagram of logic used to ascertain the course of therapy for
Administration only information
Processing statement information
Medication statements, in system terms, are a sub-type of medication administration
communications since they describe an administration process, but not in the usual
context of the prescribe-dispense-administration activity model.
As such, information from medication statements may be processed into the
Medication Profile using the flow for ‘administration only’ information shown in
Figure 38 (above), since they may provide information about a new course of therapy
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medication (i.e. one that is not already present in the Profile) or they may provide
new information about a medication already present in the Profile, or they may
confirm information already present in the Profile. However, based on any course
of therapy start and stop dates, it may be that a new record that is created goes
straight to the ‘past’ status and into the archive part of the Medication Profile, and
also, based on those start and stop dates, if the course of therapy was longer than
30 days, with the type as ‘continuous’ rather than as ‘simple’.
A medication statement needs to provide its content to the Medication Profile using
the attributes described in the static model, and this in turn places requirements on
how medication statements are recorded in systems.  Medication statements also
need to have their metadata: who made the statement, when it was made and in
what context it was made, available for reference, so that a user of the Medication
Profile can see the clinical context of the statement, in the same way that they could
see the context of prescription, dispense or administration information.  This may
mean that the Medication Profile has to have links to other parts of an EHR, and this
in turn may mean that the Profile ceases to be self-contained.
Medication statements can be made in the negative, for example, ‘the patient asserts
that they have never taken nifedipine’.  Handling negated information continues to
prove difficult in all electronic health record contexts, and the Medication Profile is
no exception in that.  For this reason, negated medication statements have not been
explicitly addressed at this point, and further work should be undertaken in this area,
as soon as the more general issue of handling negated data in health records is
resolved.
Processing the information to populate the Medication
Profile
In each of the process flow diagrams above, the conclusion positions are that the
activity information supports one of
 a new course of therapy
 a continuing course of therapy
 a changed course of therapy
Having ascertained this, the final activity is to process the information into the
Medication Profile, either creating a new record or making an update to an existing
record.  As shown above in Figure 27, this activity has sub-activities, which are
shown in detail below in Figure 39.
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Figure 39: Alternative sub-activities for processing the types of course of therapy
information into the Medication Profile
The actions that the Medication Profile should perform for each of these are
discussed below.  In all these, it is assumed that the Medication Profile system can
semantically process the dosage instructions information.   If dosage instructions are
provided only as unstructured text and with no parsing facility, the only option is to
process based on medication name.
New single course of therapy (a ‘create’ record)
Process supports a
New Course of
Therapy
Figure 40: New course of therapy
On receipt of information about a new course of therapy, the Medication Profile
creates a record (an entry in the Profile) for this Medication, with all the available
attributes (indication, dose quantity, route, site and method, and the dose frequency
and duration attributes of dosage timing) being filled with information from the
process.   At this point, it is impossible for the Medication Profile system to ascertain
the type of course of therapy, so it must be typed as a single course of therapy type.
For the course of therapy timing (Start/Stop date), the following rules would be
applied as shown in Table 22 below.  Administration information may be provided in
summary at the end of the administration process (the most likely scenario) or in
near to real time; for the latter, no change would be made to the Medication Profile
in formation based on provision of intermediate information.
CHOICE
New Single Course of
Therapy
Continuing Course of
Therapy
Changed Course of
Therapy
New Single Course of
Therapy
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Table 22: Rules for processing course of therapy timing information into the
Medication Profile for a new course of therapy
Prescription Dispense
(only)
Administration
Summary
(only)
Administration
(near to real
time)
Course of
therapy
start date
Date of
prescription
Date of
dispense
Date of first
administration
Date of first
administration
Course of
therapy
duration
Calculated
from supply
quantity or
supply period
Calculated
from supply
quantity or
supply
period
Not stated Not stated
Course of
therapy
end date
Not stated Not stated Date of last
administration
Not stated, until
last
administration
The timing of the receipt of the information about new course of therapy, coupled
with the dosage timing information, will also necessarily affect how the Medication
Profile will calculate the derived value for Status (and StatusDate).  Receipt of
information from any process at or very near to the date at which that process
occurred and within the duration of the applicability of the process will mean that the
status will be set to ‘current’.   Receipt of information from any process greater than
30 days after the projected end of the process will mean that the status will be set to
‘past’.  For example, a prescription dated 1 November 2012 for a 7 day course of the
antibiotic amoxicillin, received by the Medication Profile system on 2 November 2012
would be processed with the status of ‘current’ since the receipt of the information is
within the 7 days’ duration of the process activity.  An administration summary dated
26 February 2014 for a 3 day administration of dobutamine given in hospital after
major surgery and communicated to the Medication Profile system 31 March 2014
would be processed with the status of ‘past’ since the receipt of the information is
outside the duration of the process activity and more than 30 days have elapsed
since the end of the reported medication process.
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The metadata that must be recorded and made accessible to a user (human or
system) of the Medication Profile content is the type of process that provided this
information (prescribe, dispense, administration or statement).
Archival Process
After a period of time, initially suggested to be 30 days after the projected end of the
duration of a new course of therapy, where no further process information has been
received, the record/entry in the Medication Profile needs to be managed such that
its status changes from ‘Current’ to an inactive ‘Past’ status.  There is no business
process to effect this change of status; it must be managed by the Medication Profile
itself.
Continuing course of therapy (an ‘update’ record)
Process supports a
Continuous Course of
Therapy
Figure 41: Continuing course of therapy
On receipt of information that supports a continuous course of therapy, the
Medication Profile updates a record (an entry in the Profile) for this Medication.  This
update depends on the initial information itself.
If the record/entry in the Medication Profile already has the course of therapy type of
‘continuous’, then no further action/processing on this component is required.
If the record/entry in the Medication Profile is noted as a single course of therapy
type, which must be the initial default for any new entry, on receipt of a
communication that moves the Medication to a continuous course, there must be an
update made in the Profile to change the course type to ‘continuous’.
For a continuous course, there should be no change to any of the descriptive
information (indication, dose quantity, route, site and method, and the dose
frequency part of dosage timing).  The course of therapy start date is unaffected but
the information may affect the calculation of end date/duration, which may itself affect
the archival process (whereby a Medication status changes to ‘past’).  If the process
is communicating an extension to a continuous course (e.g. is a new prescription or
is a new dispense with no prior prescription), then the course of therapy duration
Continuing Course of
Therapy
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should be extended by the amount of time calculated from supply quantity or supply
period.
The supporting metadata for the Medication Profile should be updated to indicate
that the record has further process information supporting it.  Over time, for a
continuing course of therapy, this list of metadata has the potential to be of significant
size (for example, for the prescription and dispense data for monthly supply of
medication to treat a chronic condition over a number of years this will give
approximately 24 entries per year per medication). Managing this is an
implementation issue that is out of scope for this modelling of the clinical content of
the Medication Profile, but it is important because managing and if necessary
displaying this metadata sensibly can support the veracity and reliability of the
information the Medication Profile provides.
Archival Process
After a period of time, initially suggested to be 30 days after the projected end of the
duration of a continuous course of therapy, where no further process information has
been received, the record/entry in the Medication Profile needs to be managed such
that its status changes from ‘current’ to an inactive ‘past’ status.  There is no business
process to effect this change of status; it must be managed by the Medication Profile
itself.   The course of therapy end date should also be entered, either by using an
explicitly provided end date (e.g. from an administration record) or by using a date
that is calculated as the projected end of the course, based on the duration.  If the
end date is calculated, this should be indicated as such to the user.
Note: if the archived continuous course of therapy is the final child record of a parent
containing record, the status of the parent containing record should also be moved
from changes from ‘current’ to an inactive ‘past’ status and an end date added using
the same logic as described above.
Fulfilment of a pre-existing process
Process fulfi ls a pre-
existing Process
within the MP
Figure 42: Fulfilment of a pre-existing process
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This activity is supplementary to the processing of a new course of therapy type or
a continuous course of therapy type, where the information received from a
medication activity communication provides confirmation of the fulfilment of a pre-
existing activity (the dispense information confirms the fulfilment of a prescription, or
the administration confirms the fulfilment of a prescription and/or a dispensing), and
there is no update in any of the supporting information.  There is therefore no
information to be changed/updated for that Medication Record in the Medication
Profile, with the exception of if the process is an administration, in which case the
course of therapy stop date may require updating using the logic described above in
the new course of therapy section, or possibly if there is further detail as to the actual
brand/manufacturer of the actual medicinal product dispensed.   Display of
brand/manufacturer information obtained from a dispense communication should be
optional and an implementation decision, although the information should be stored
for use if required particularly for pharmacovigilance use cases.
The course of therapy type will remain as described by the logic from the initial
process information (prescription or dispense) as the fulfilment of a pre-existing
activity may relate to medication being given in either a new single course or in a
continuous course.   The supporting metadata for the Medication Profile should be
updated to indicate that the record has further activity information supporting it.
Changed course of therapy and update to a pre-existing process (an ‘update’) record
Process supports a
Changed Course of
Therapy
Process describes an
update to a pre-
existing process
within the MP
Figure 43: Changed or updated course of therapy
This is a complex situation requiring further logic and processing from the Medication
Profile to be correctly managed and thereby to provide the data to support the use
cases.
Changed Course of
Therapy
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Additional information
If the information received provides additional new information or a greater level of
detail for the indication or dosage instructions (for example the dispense information
contains detailed dosage instructions whereas the prescription had no instructions
or only ‘use as directed’), then then the new information should be added and used
if required in further processing (e.g. to calculate archival and change to ’past’ status
in due course).  The Medication Profile system should indicate to users, particularly
human users, by the use of some sort of graphical interface indicator (such as
highlighting) that the information presented has been updated, and should allow the
user to see the previous information (e.g. by a double-click drill down).  The rationale
to support the update is that both the dispensing and the administration process
move closer to the actual clinical use of the medication by the patient and should
therefore be the most accurate reflection of what actually happened/is happening.
For example: a prescription for ‘amoxicillin 500mg capsules’ was actually
administered as for ‘amoxicillin 250mg/5ml oral solution’ with the dose quantity
adjusted appropriately because the elderly patient could not swallow the large
capsules.  This situation is rare in UK primary care, where the dispensing (and
administration) normally follow exactly the item as ordered, but is more common in
other healthcare cultures.
This logic applies to both course of therapy types although the changes expected to
continuous courses are likely to be small.  However, there may be a practical
situation in the repeat prescribing and dispensing pattern where this simple single
update may prove difficult, if the prescription always states the dosage instructions
as ‘use as directed’ and the dispense always has the detail of ‘inhale two puffs
morning and evening’.  There are various alternatives for resolving this, using both
systems and process, but this degree of practical implementation complexity is out
of scope for the basic modelling of the clinical content of the Medication Profile; it
would be a significant topic for further practical investigation.
Changed medication presentation
A change in the presentation of the medication itself (different dose form or strength)
has the potential to significantly alter the clinical effect of the medication in the
patient.  This is because such a change will either increase or decrease the total
amount of medication present in the patient’s body or by change the pattern of
distribution of the medication in the body.  The Medication Profile must process these
changes differently depending on the course of therapy type.
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For a single course of therapy, the information should be updated with the new
information, with the previous information available for view.  For a continuous
course of therapy, several actions are necessary.
1. The new information should be used in full to create a new child Medication
Record in the Medication Profile. The course of therapy start date for the new
related record follows the pattern given in the new single course of therapy
section
2. The now replaced record should have its course of therapy end date entered,
using the same date as for the course of therapy start date in 1) above
3. A containing Parent Medication Record should be created or updated, that
may or may not be initially visible to the human user.  The course of therapy
start date should be the course of therapy start date from the first child record
in the container
Managing negative information
If the Medication Profile system receives non-administration information it should be
processed in a similar way to normal information, i.e. ascertain if a Medication
Record already exists for that medication.  If it does, the non-administration
information should be appended to that, and the reason for the non-administration
added to the record as an attribute.
If the non-administration information is such that the course of therapy has ended,
then the system should process this, adding the stop date, and marking the
Medication Record to be archived into a ‘past’ state after the appropriate time period
(30 days).
Model examples
This section gives examples of the application of the dynamic model process, the
activities and rules described above, used to populate the data elements of the static
model in exemplar scenarios.  There is an example for each of the main areas of
processing, using data from activities as would be encountered in day to day
healthcare without specifying a particular context of culture and practice.
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Example 1: Simple Course of Therapy, Prescription and Dispense,
with UUIDs
Prescription [ABC123GH456] for Stephen Smith, dated 02 October 2015, received
by the Medication Profile System 03 October 2015 for ‘21 Amoxicillin 250mg
capsules [323509004], one to be taken every 8 hours’
Identify the process: ‘Prescription’
Identify the course of therapy:
Is there a UUID? Yes
Does the UUID match anything already present in the Medication Profile? No;
confirm using brand and generic name check; still no match.
Therefore: start of a new course of therapy
Action: Process into the Medication Profile as a new single course of therapy,
with status ‘current’ (as is current dates)
Table 23: Initial population of Medication Record attributes for Example 1
Data Element Example Comments
Course of therapy: Single
Indication: no information
Medication type: no information
Status: ‘Current’ (based on date of prescription = 02 Oct 2015,
received into system 03 Oct 2015)
Status date: 03Oct15
Non-administration reason: Not applicable
Table 24: Initial population of Medication Identification attributes for Example 1
Data Element Example Comments
Medication code(s): 323509004
Brand name: no information
Medication type: no information
Generic name: ‘Amoxicillin 250mg capsules’
Manufacturer: no information
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Table 25: Initial population of Dosage Instructions attributes for Example 1
Data Element Example Comments
Additional text: no information
Supply quantity: 21
Dosage instructions clause: ‘single’ conjunction and sequence number not
applicable
Dose quantity: ‘1’ (250mg capsule)
Dose quantity upper bound: no information
Rate of administration: no information
Total daily dose: no information
Method of administration: no information
Route of administration: no information could be implied to be ‘oral’
Site of administration: no information
Course of therapy start date: 02 October 2015 date of prescription
Course of therapy stop date: 09 October 2015 Implied from supply quantity and dose
frequencyCourse of therapy duration: 7 days
Dose frequency: ‘every 8 hours’
Dispense [123XYZ987MN] in response to prescription [ABC123GH456] for Stephen
Smith, dated 02 October 2015, received by the Medication Profile System 03
October 2015 supplied as ‘21 Amoxicillin 250mg capsules (Fred’s Pharmaceuticals)
[644811000001234], one to be taken every 8 hours’
Identify the process: ‘Dispense’
Identify the course of therapy:
Is there a UUID? Yes.
Does the UUID match anything already present in the Medication Profile? Yes;
is in fulfilment of a prescription already processed into the Medication Profile
Do the Dosage Instructions match? Yes; therefore this Dispense is fulfils an
existing prescription
Action: Update to the metadata for this record in the Medication Profile plus
update to Medication identification information; this may or may not be displayed
in any implementation of the Medication Profile.
267
Table 26: Updated population of Medication Identification attributes for Example 1
Data Element Example Comments
Medication code(s): 323509004 644811000001234
Brand name: no information
Medication type: no information
Generic name: ‘Amoxicillin 250mg capsules’
Manufacturer: no information Fred’s Pharmaceuticals
Archive: To ‘past’ medication
The prescription is for 7 days’ supply, which calculates a stop date of 09 Oct 2015
(both the prescription and the dispense were dated for 2 Oct 2015), so 30 days from
this course of therapy stop date (8 Nov 2015), if no further information is obtained
(e.g. another prescription for amoxicillin, which would be clinically very unlikely) the
record status should be changed to ‘past’.
Example 2: Continuous Course of Therapy, Prescription, no UUIDs
Prescription for Jane Jones, dated 10 September 2015, received by the Medication
Profile System 12 September 2015 for ‘56 Metformin 500mg tablets [325278007],
one to be taken three times a day’
Identify the process: ‘Prescription’
Identify the course of therapy:
Is there a UUID? No
Does the medicinal product match anything already present in the Medication
Profile (based on brand or generic name and/or code match)?
Figure 44: Initial display of Medication Profile for Example 2
Yes; there is a match; therefore there is a continuation of an existing course
of therapy.
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Most recent events in the ‘Further details’ were a prescription and dispense both
dated 14th July for 56 Metformin 500mg tablets [325278007]
Are the presentation and dosage instructions the same? Yes ‘Metformin
500mg tablets’ and ‘One to be taken three times a day’
Action: Process into the Medication Profile as a continuation of a Continuous
course of therapy; no update required to dosage instructions, status stays as
‘current’; the information for the prescription is stored to be used as part of the
‘Further details’ if required.
Example 3: Changed Course of Therapy
Prescription for Toby Chang, dated 6 July 2015, received by the Medication Profile
System 8 July 2015 for ‘Beclomethasone 250microgram/dose inhaler, two puffs to
be inhaled twice a day’
Identify the process: ‘Prescription’
Identify the course of therapy:
Is there a UUID? No
Does the medicinal product match anything already present in the Medication
Profile (based on brand or generic name and/or code match)?
Figure 45: Initial display of Medication Profile for Example 3
No; there is no direct match.  However, using knowledge accessed in a medicinal
product terminology, the Medication Profile can deduce that the prescribed
medication is a different presentation of an existing medication present in the
‘Current Medication’ part of the Medication Profile.  This is therefore a changed
course of therapy.
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Action: Process into the Medication Profile as a new record in the Medication
Profile, with a type of continuous course and a status of ‘current’ and ‘replacing’
(by updating) the existing record.
In addition, the Medication Profile will:
1) Create a new parent record for beclomethasone:
Table 27: Initial population of Parent Medication Record attributes for Example 3
Data Element Example Comments
Medication moiety: Beclomethasone
Course of therapy:
Start date
Stop date
3 February 2014
Status Current
Status date Today’s date
2) Move the existing record to an archive, with a replaced relationship to the new
record, and with the addition of the course of therapy stop date based on the
projected supply duration for the last process applicable to the record, which in this
case was the last dispensing of a Beclomethasone 100microgram/dose inhaler, on
2 May 2015.  [200 dose inhaler, 4 doses per day – 50 day’s supply; projected to last
until 21 June 2015.  The record would be moved to archive (as ‘past medication’) on
21 July 2015.
Example 4: Medication Statement
Medication Statement, made as part of a referral letter, that Nadia Goldberg (aged
43) took chlorphenamine to control severe hay fever for several years in her teens
and early twenties – 1978 to 1993.
Identify the process: ‘Statement’
Identify the course of therapy:
Is there a UUID? No
Does the medicinal product match anything already present in the Medication
Profile (based on brand or generic name and/or code match)? No; so a new
record in the Medication Profile
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Action: Process into the Medication Profile as a new record, with type continuous
course of therapy, and status of ‘past’ (due to the start and stop dates being many
years ago).  Ensure that the metadata of the statement (where it was made (in
this case in a referral letter), who authored the statement (in this case the same
person as authored the letter), and when the statement was made and to whom)
is recorded in the Medication Profile metadata section.
Medication Record: (direct into archive)
Table 28: Initial population of Medication Record attributes for Example 4
Data Element Example Comments
Medication (moiety): Chlorphenamine
Course of therapy:
Start date
Stop date
1986
1991
Status Past (Archive)
Status date Today’s date
Discussion
Static (Structural) Models
Levels of model
Only two levels of static information models have been defined in this chapter.
Several further levels could be defined, through the platform independent and
platform specific models of the Model Driven Architecture304 (MDA) moving towards
a model that could be physically implemented in a particular database technology (a
platform specific physical model).
The addition of a datatype for each attribute, using those defined in Health
informatics - Harmonized data types for information interchange (ISO
21090:2011)147 would move the static model further through the MDA levels, to the
level most usually seen in health informatics in the domains of reference, such as
the HL7 Reference Information Model305 and HL7/NCI/FDA/CDISC BRIDG model306.
This level starts to go beyond the conceptual towards implementation but without
necessarily being platform specific.   For example, in the Medication Identification
class, the code and the name of a medication/medicinal product are given as
separate attributes, and the two most common types of medication name (brand
name, generic name) are shown explicitly as these are explicit requirements for
some of the use cases.  However, if this information was to be managed using the
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Concept Descriptor datatype of ISO 21090, the code and displayName would be
included in a single attribute. Similarly, in the model as currently defined, the
manufacturer of a medicinal product has been modelled as a specific separate
attribute, again reflecting its place as a separate data element requirement.  But in
many medicinal product terminologies this would be included as part of the brand
name concept and would be available through reference from the code representing
the branded product.
There are other attributes defined within the static model that could be further refined
and elaborated to greater depth and detail; for example indication for a medication
could be described with more granularity by the symptom or disease being
addressed and the aim or prospective effect of the treatment (prophylaxis, cure,
alleviation etc.) being given as separate attributes.   This level of static model
representation is available in other models and standards, but was beyond the
requirements for this model.
The static model for the Medication Profile has been limited to the two conceptual
levels, to reflect a close tie to the use cases and requirements described in the
preceding chapters.  As such is at a similar level of abstraction to some more recent
standards in the domain, such as Health informatics — Identification of medicinal
products — Data elements and structures for the unique identification and exchange
of regulated medicinal product information (EN ISO 11615:2012)144.
Recursion and Unrolling
Moving from the conceptual level of model to the logical level, the recursion on the
Medication Record is unrolled to give a Parent Medication Record and a child
Medication Record class, which itself can have a recursive replaces relationship.
This is required to describe an overall course of therapy for moiety, a requirement
which is present in both clinical research and patient care.  When this logical model
is implemented in real systems, this would need further detailed investigation and
modelling to support the presentation of the information for the various use cases.
This would be particularly pertinent to the view model (or presentation model or GUI
model), where a system presents the Medication Profile to a human user.  In this,
the view is likely to be primarily on the set of current Medication Records, but for any
record that has a Parent, a reference to that, and most particularly the start date of
that, may need to be made.
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Medication Type
Medication type is present as an attribute in the Medication Record class supporting
classification of the medication, particularly to fulfil the use case of being able to
identify vaccines as a specific sub type of medicinal product or to identify
investigational medications.  The knowledge that a particular medicinal product is a
vaccine or investigational product could be obtained from a medicines
knowledgebase, but this requires the Medication Profile to have access to such a
knowledgebase, whereas having this information directly present allows the Profile
to be self-contained to fulfil this use case.  Many healthcare cultures have explicit
messages for vaccine administration and these would be processed directly these
into a vaccination view of the Medication Profile.
Medication process metadata
A description of the type of medication activities that are contributing information to
the Medication Records in the Medication Profile are not explicitly identified in the
static model currently.  This type of activity information is deemed to be metadata
rather than primary data, which reflects the requirements gathered in the use cases.
Negative information
There is no negation indicator present in the static information model.   No specific
requirements for negative medication information were found that would justify its
inclusion.  The semantics of negated information in electronic health information are
well known to be problematic and no widely accepted approach to the issues
currently existi.  The only actual requirement for information with negative
connotation was the facility to record a non-administration reason if an ordered
medication was not administered according to the prescribed schedule, which is
present as an explicit class in the static model.
This lack of negative requirements is probably due to a closed world assumption that
is implicit in this area.  Most EHR systems are developed from databases and
database technology generally works on the closed world assumption; specifications
for EHRs and EHR communications will therefore adopt this prevailing philosophy.
And for the world of medications, which are highly regulated both in their
development and their use, this closed world assumption is a reasonable assumption
to hold because there is good availability and considerable control of the information.
i The author has participated in many discussions of this topic in a variety of fora,
including in meetings of international standards development organisations, over
many years.
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The closed world assumption supports the related concept of negation as failure
whereby every predicate that cannot be proved to be true is deemed to be believed
to be false. So, if there is no record that ‘Patient X took ibuprofen’ then ‘Patient X
has not taken ibuprofen’.
Dynamic (Behavioural) Models
Machine-readable Dosage Instructions
In all of the logic described in the dynamic models to determine course of therapy
type and timing for status information (current/past), there is an absolute requirement
for the Medication Profile system to read and understand the dosage instructions
information.   Dosage instruction information is generally easy to provide as machine-
readable information; the traditional Latin script and abbreviations of dosage
instructions take the clinician most of the way towards structured and coded
information as part of routine practice, so implementing this in all medication process
systems should be routine.  There are also a small number of intelligent parsing
systems for dosage instructions available307, so even if information is presented to
the Medication Profile only as human readable text, the Profile system could interpret
this and use it to provide the information needed for the rules to determine course of
therapy type and timing for status information.
Using UUIDs
In the dynamic model, there are two sets of rules for processing; those that involve
the use of UUIDs and those that do not.  The logic required for processing medication
information that has UUIDs is considerably less complex.  If all medication
communications were to have UUIDs and these were used in conjunction with a
descriptor for the course of therapy as described above, it would be possible for a
system to clearly ascertain the role that an individual prescription communication is
playing within the overall set of patterns for Course of Therapy, even complex
courses such as a cyclic course.  For example, to identify a continuation of a cyclic
course of therapy, if there was a prescription communication of the cyclic course of
therapy (e.g. ‘Doxorubicin 60mg/m2 given IV as a single dose once every 21 days
for 6 cycles’) and each of the single prescriptions – the third cycle described here
‘Doxorubicin 100mg IV on 20150803’ - could be easily identified and managed within
the Medication Profile.
Some secondary care systems do have the facility to record and share this type of
information, at least for cyclic courses of therapy, but almost all systems and
healthcare cultures do not.   Making this small addition to the standard patterns of
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communication information for prescriptions would significantly improve the
accuracy of the information that a Medication Profile could provide in order to meet
its use cases.
Counter prescribing
Currently very few if any systems either record or share information about counter
prescribed medication.  With the growth of patient managed medical information
systems on smart phones etc. this area of medication information should be
developed and patients should be encouraged to participate in this.   As modelled
currently, the Medication Profile would treat a counter prescribed medication in the
same way as for a dispensed medication.
Communicating medication administration to the Medication Profile
The requirements for the Medication Profile are for the dose timing information; there
is no requirement found in the analysis of the use cases for dose by dose
administration information.  This in itself provides an implicit requirement from the
Medication Profile to the information that is shared with it; for this information to be
provided in a format that gives a summary of a set of administration events,
described as the dose frequency and course of therapy start and end dates.  Within
the requirements from the use cases, and therefore within the dynamic model, there
is no recommendation as to when that summary information should be provided:
options include daily, weekly, monthly, at the end of the course of therapy or at the
end of a care event such as a stay in hospital.
There are two paradigms to consider in finding the optimal time for sharing
administration summary information: the course of therapy being described and the
set of activities occurring.  Taking the latter first, it is unusual in the medication
process that an administration record would be the only record available for the use
of a medication by a patient, and therefore administration information is usually
supporting and confirming information that has already been processed into the
Medication Profile.  The need to have administration summary information quickly
(e.g. a summary of each day’s administrations, starting from day one and continuing)
in order to have a current medication recorded in the Profile is not great, and
processing administration information on a daily basis could quickly and
unnecessarily fill the metadata of the Medication Profile (although not the core data,
which would continue to have one consolidated record).   There is one major
exception to this: vaccination.  Due to the protocol and schedule driven nature of the
vaccination, and that the majority are administered under the auspices of schemes
such as the Patient Group Directions308 or similar provisions in other jurisdictions, no
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prescription or dispensing process takes place in advance of the administration, and
the administration is the only process that is recorded and available for
communication to the Medication Profile.
It is at this point that the other of the two paradigms should be discussed: the course
of therapy being described.  Most vaccinations are single events and as such
correspond to single simple courses of therapy.  Therefore, communicating the
single administration is the same as communicating the administration summary for
a single short course.
For other types of medication administration, communicating the administration
summary for a single short course is also considered an appropriate point.  For
continuous courses of therapy where prescription and possibly also dispense
information is available, the communication could be at monthly intervals,
corresponding to the pattern used for the course of therapy definition itself.
Medication statements
Medication statements, whether they are made as part of a medication focussed
activity such as medication reconciliation or whether they are part of a more general
care communication such as a discharge summary or referral letter, should
contribute content to the Medication Profile.  This in turn places requirements on how
medication statements are recorded in systems.  Firstly, they should be clearly
identifiable so that they are available for processing, and secondly they should use
a similar pattern of descriptive attributes as the medication processes: medication
identification and dosage instructions, even if only partial information can be
provided.
Recommendations for further work
Static model
Further exploration of the various options for the view model could be undertaken,
with the use of wireframes etc. to present options for evaluation.  As discussed
elsewhere, currently there are no documented requirements for such a model, even
in projects that have looked specifically at GUI design for healthcare systems such
as the NHS Common User Interface project309.  Such exploration may also provide
additional requirements into both the static and dynamic models for the Medication
Profile.
Once accurate and informative Medication Profile information becomes routinely
available to clinicians in healthcare, the boundary between primary data and
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metadata could be further explored to see if it would increase the usefulness of the
Medication Profile.
Testing of the validity of the closed world assumption for the Medication Profile
should be undertaken, particularly in conjunction with those use cases that
interrogate the Medication Profile for such negative information (e.g. patient
recruitment – an inclusion criterion of ‘patient has never taken oral steroids’).
Similarly, further work to gather requirements for negated medication information, for
example ‘medication X was not prescribed’ and/or negative statements such as ‘the
patient asserts that they have never taken nifedipine’ – should be undertaken.  This
will be particularly relevant for negated statements arising from medication
reconciliation, where the clinician undertaking the reconciliation may wish to negate
a set of information already present in the Medication Profile.
A related topic for further investigation is the availability of information regarding
reasons for non-administration of a medication; this appears as a requirement in the
use cases, but sources for such data are not currently evident.
Dynamic model
The dynamic models have proposed a course of therapy type, which can be
determined from the dosage instructions for the medication.  The proposal detailed
here should be further evaluated and validated, as should the drawing of the
boundary between the simple course of therapy and the continuing course of
therapy, and when medication is deemed to be ‘current’, or ‘past’ and archived.  If
these are confirmed to be useful concepts, in order to support the creation of useful
and accurate Medication Profile information, it is suggested that course of therapy
type information including continuation information, should become a routine
addition to prescription information.
In a situation where course of therapy type remains unstated and therefore requires
calculation, there should be further evaluation of the rules to determine whether a
change in presentation for a medication is truly a changed course of therapy, using
medication moiety and route of administration, or possibly dose form as a proxy for
route of administration.   It may even be that some systems would wish to develop
course of therapy rules based for on the medication itself.  These would be based
on the premise that certain medications are always used in a course of therapy (e.g.
hormone replacement such as insulin) and certain medications are almost never
used in a course of therapy (e.g. some antibiotics).  It is suggested that this would
be a very useful area for exploration in further research and testing.
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Management of repeating differences in granularity of information provided from a
prescription and its associated dispensing activity within the continuous course of
therapy, would be a valuable area for further research and development.
The dynamic models presented above have adopted a simplistic approach to
identifying and managing cyclic courses of therapy in the Medication Profile.  This is
another area that would be valuable to investigate further, to ascertain whether it is
possible to obtain enough information from the medication activities to correctly and
usefully describe cycles of medication therapy in the Medication Profile.
If and when counter prescribed medication information is collected and shared, the
current assumption that the Medication Profile should treat a counter prescribed
medication in the same way as for a dispensed medication should be further tested
to confirm that it is correct.
The suggestions are when to communicate summary administration information are
currently untested and further research and evaluation in this area, to confirm that
this guidance does provide sufficient timely information into the Medication Profile to
meet the use cases should be undertaken.
Some healthcare cultures have specified discontinue medication messages: in
particular the Netherlands310 and Canada311; these are not currently widespread, but
if their use increases, further research into how best to process these into the
Medication Profile should be undertaken.
In the dynamic models, medication statements are processed using the same
pattern as for administrations, reflecting the practice of healthcare in that medication
statements are made using administration patterns and reflecting that their
information is usually confirmatory rather than novel.  However, further investigating
the processing of medication statements from various sources and contexts into a
Medication Profile to confirm this pattern would be a useful area of further research.
This further work could also investigate the value or otherwise of linking medication
statement information in the Medication Profile to source documentation, especially
if this resides elsewhere within an EHR system.
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Chapter 9: An Evaluation of the Domain Information
Model for a Medication Profile
Introduction
Development of a domain information model and indeed of all information technology
artefacts, is iterative, with review and evaluation being part of that iterative process.
It is important that the review relates back to the use cases, although those use
cases may be extended and/or supplemented as new requirements emerge from
new processes to be supported, or new ways of managing data evolve.
Various approaches can be used for the evaluation of a domain information model.
One of these is direct review of the model itself, which requires expert knowledge
both of the domain and of the principles of domain modelling, and is therefore
somewhat theoretical, as a model in itself is a reference artefact only.   Another more
powerful approach is to generate implementation artefacts from the model; this
method makes the content of the model accessible for user evaluation (both to the
expert, and to the ordinary user) in the service of the real world scenarios (use cases)
that the model aims to support.  This approach can be performed in a variety of ways:
 The development of a new full stand-alone Medication Profile system,
constructed and implemented within an enterprise, using the structures
(static part) and populated according to the processes and rules (dynamic
part) of the model
 The development of a Medication Profile system within an existing
medication management system within an enterprise, adapting its existing
functionality to implement the structures of the domain model and populating
those structures according to the processes and rules of the model, either
as additional functionality or in parallel to current process
Both of these approaches are expensive in both time and resource, and require an
enterprise able to undertake the initiative.  The second approach carries the
additional risk of disruption to the existing work of the enterprise. Neither would
therefore be considered until after a successful proof of concept had been
performed.  Therefore, the most appropriate approach for this research, in terms of
resource efficiency yet still facilitating review by a range of users, was the
development of a paper-based evaluation.  This provided mock-ups of the
functionality that would be available to users as if the Medication Profile system had
been developed and implemented using the structures and processes of the
Medication Profile domain model, and as such fulfils the criteria for an early proof of
concept.
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Methodology
Preparation of the evaluation material
The paper-based evaluation examined five exemplar scenarios where medication
information is used to support performance of a clinical or clinical research activity.
Following standard good software development practice, where the use cases for
the requirements logically flow into the forming the formal test cases312 the testing
scenarios were developed from each of the areas from which requirements for the
Medication Profile had been elicited.  Three scenarios focus on patient care; two of
these, the emergency medication supply scenario, which uses the Medication Profile
as a proxy medical history and the decision support scenario, support a prescribing
activity, which as discussed in Chapter 4, is the foundational activity in the overall
medication process; the third focuses on medication history supporting an
administration activity, specifically relating to Immunisation information.   Two
scenarios focus on the areas in clinical research that provided requirements; a
patient recruitment scenario to assess a patient’s suitability to be included in as a
subject in a clinical study and a pharmacovigilance scenario, reporting a suspected
adverse reaction.
Each scenario was presented with its own clinical story, described in text. Stories, or
storyboards as they are often called, are part of the standard methodology for
undertaking testing and are written to set the context for the data under
examination313. Having set the context, sets of medication information were
presented in diagrammatic form, simulating the presentation to a user in a basic
graphical user interface of a clinical application. This used basic presentation
(slides) technology, as is normally undertaken in initial user centred system design.
The medication information was presented as it would be, having been transformed
into the structures and using the processes and rules described in the Medication
Profile model.  A small set of questions about the medication information were posed
following each scenario, to guide the evaluators’ consideration of the accuracy,
relevance and comprehensiveness or otherwise of the medication information as it
supported the scenario, following standard practice in user acceptance testing of a
system314. Any additional comments were also explicitly sought.
Emergency medication supply scenario
In this scenario, the main research question to be explored was whether the
Medication Profile, if correctly structured and populated, could provide enough
information about an individual’s use of medicinal products to enable a clinician who
does not know the individual to make a decision on a course of action which itself
results in the supply and use of medication to that individual. This reflects the use
case that, whilst the Medication Profile should exist as a core part of a full electronic
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health record within an enterprise, it is well recognised that until that full health record
situation is reached, any available medication information is pragmatically used as a
proxy for a health record in an unplanned care situation, as described in the chapter
on patient pare requirements. This scenario also contained a question about the
display of ‘current medication’ information in the context of an example Medication
Profile, to elicit the evaluators’ thoughts on this somewhat vexed concept.
Patient recruitment scenario
One of the aims of this research is to model the structures of the Medication Profile
and populate them by defined processes not only to support the care of the individual
patient but also to meet secondary uses of medication data, particularly those from
clinical research.  The research question underpinning this scenario therefore looks
to investigate to what extent Medication Profile information is helpful in identifying
potential subjects for recruitment into a clinical study.
Immunisation record scenario
This scenario explores the scope of the Medication Profile in relation to a group of
medicinal products, vaccines, whose use is not usually through the normal
medication process of prescribing, dispensing and administration, as they are
frequently administered through specific clinics, as this scenario identifies.  It was
also seeking to explore how much information should be provided for these
medicines, especially in terms of representation of dosage information, and how
information that is essentially ‘repeated’ could or should be presented.
Pharmacovigilance scenario
This scenario evaluates the extent to which the Medication Profile, when structured
and populated according to the Model described in this research, is able to fulfil the
secondary clinical research use case of the provision of information for
pharmacovigilance, and specifically for reporting of medication information a
suspected adverse event report.  An explicit secondary research question was to
explore the provision of information about the indication(s) for the medication(s)
involved in a suspected adverse event.  This scenario was also specifically set in a
secondary/acute care context to explore the similarities or differences of Medication
Profile information this care environment.
Decision support scenario
One of the requirements placed on the Medication Profile is that it can provide
information to decision support systems as inputs for their algorithms, to guide
clinicians in delivering safer medication care.   The research question in this scenario
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looked to explore this, in that the medication activity described in the scenario was
interrupted by a decision support alert (notification of a drug interaction).   There was
a secondary question to explicitly investigate how ‘as required’ medications should
be managed and displayed by the Medication Profile, although several evaluators
had already raised this as a theme independently in a previous scenario.  The setting
for this scenario was in a healthcare culture where different clinicians have
responsibility for different types of care provision and there is no single clinician
responsible for care co-ordination.
Pilot of the evaluation material
An initial quality assurance process and piloting of the evaluation material was
undertaken with two volunteers. Both were known to the author but neither had had
any previous connection with this research. One was an extremely experienced
informatics pharmacist who as guided the digital development of his nation’s premier
medicines information product and the second an internationally recognised
healthcare system architect and analyst who specialises in medication information.
Both volunteers piloted completion of the questionnaires, also examining the
scenarios, the diagrammatic information and the questions for ease of
comprehension, to minimise the possibility of ambiguity in the text or questions and
to check for any errors such as a medication misspelling. No significant changes
were required after this testing and therefore the responses to the questions from
the two volunteers was included in the main set of results.
Conduct of the evaluation
A package (provided in Appendix 2) with the five scenarios, their diagrams and their
questions, and accompanied by a personalised covering letter and a synopsis of the
thesis as a whole was sent to a set of evaluators. Evaluators were given a timescale
in which to complete the evaluation (3 weeks from receipt) and also requested, if at
all possible, to give notice if they either would be able to complete the evaluation but
needed a longer timescale or were sure that they would be unable to complete it
(and therefore would not be included in any further correspondence on it). For those
evaluators who had either not indicated ‘no further participation’ or who had not
returned a completed evaluation, further contact was made after approximately 3
weeks from the initial contact.  Evaluators were also given the facility to contact the
investigator with any queries although no respondents exercised that option.
Since this was a qualitative evaluation, using purposive sampling to obtain a set of
evaluators is acceptable315, not least because this is an area where there is a limited
number of people who have expertise in the area being researched. The set of
evaluators was not aiming to be representative, but was aiming to have as much
283
diversity as possible.  Evaluators were drawn from the researcher’s contacts, both
professional and personal, who it was felt would be able and willing answer the
questions and therefore give an evaluation of the effectiveness of the Medication
Profile Model in providing the information to meet the use cases. The candidate list
of invitees was reviewed and supplemented by both thesis supervisors, in order to
ensure that all relevant stakeholder categories were included with experts having
suitable career backgrounds. The set of people sent the evaluations encompassed
a range of professional disciplines: healthcare professionals (physicians,
pharmacists, nurses) at different stages of maturity of their careers, and covered
those working in primary care and in secondary care, those working in academia,
and also a small number of software engineers experienced in working in health
informatics and the design and development of systems to support medication
focused processes.  From the healthcare professionals, the scope of experience
covered those working in health informatics, in clinical research (from both sides: the
conduct of research and the regulation of research) and those continuing to work in
direct care provision.  Several of the evaluators either currently or in the past have
worked for vendors of medication decision support systems, either as knowledge
engineers or as software engineers and several are or have been active in
international standards development organisations. The evaluators came from a
range of healthcare cultures: the United Kingdom, with its National Health Service
and unified health information environment; and a variety of countries in Europe,
North America and Australasia and therefore covered cultures with no unified health
information environment at all and a spectrum of positions in between.  Not all
evaluators were or are working in English speaking environments.
Because this evaluation was qualitative in nature, there was no requirement to
quantify or therefore to reach statistically significant numbers of different types of
evaluators, nor a requirement to achieve a minimum number of responses, in total
or from the different types. However, a minimum target of 20 responses from the
original set of 43 evaluators was targeted, with the intention that if that objective were
not achieved, an extended pool of potential evaluators would be sought. This sample
sizing was selected in order to explore and appraise the evaluators’ perceptions of
and preferences for the data presented from the Medication Profile in each of the
clinical scenarios in some depth, as in a phenomenological study, where small
sample sizes are appropriate316.
Before the evaluation was undertaken, the Principal Supervisor (DK) who was also
the Head of Department checked the UCL Research Ethics Committee’s criteria for
exemption from the requirement for approval, published at
http://ethics.grad.ucl.ac.uk/exemptions.php:
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‘In accordance with the following criteria, Department Heads have final
judgement as to whether a particular activity should be exempt from the
requirement for approval by the UCL Ethics Committee.’
In his assessment, the following exemption was deemed to apply.
‘Research involving the use of non-sensitive, completely anonymous
educational tests, survey and interview procedures when the participants are not
defined as "vulnerable" and participation will not induce undue psychological
stress or anxiety.’
Evaluation assessment
The responses were analysed using a thematic analysis technique317, whereby the
dataset is assessed for the patterns (themes) present, in the context of the research
question(s) itself.  The 6 steps of thematic analysis were undertaken.  The initial step
of data familiarisation normally occurs through a process such as transcription. All
the responses from the individual evaluation documents were collated together into
a single dataset, allowing each to be read and be familiarised with.    The next step,
which is termed ‘coding’, was to systematically review each scenario, highlighting
relevant features in the data.  Steps 3-5 are essentially a recursive process of taking
the highlighted features and examining the patterns of those features into one or
more themes.  In thematic analysis, the prevalence and therefore the weight given
to the presence of a theme within the data is not measured in any way; the ‘keyness’
of a theme is assessed in the light of the overall research question, not in terms of
any proportionality of how much attention the theme received within the dataset.
Finally, in step 6, the analysis is reported by describing the compelling themes from
the dataset in relation to the research question.
To support the analysis process, a commercial qualitative analysis package was not
used, since the researcher was able to use an SQL database directly, whereby each
evaluator’s verbatim response to each question was identified, stored and codified.
Although there was no facility to quality assure each coding event, the researcher is
a certified terminologist and coding professional and one supervisor (DK) examined
samples of the responses and their coding to confirm the theme extraction. An
example of an evaluation response and its coding is given in Appendix 3.
Although thematic analysis is clear that the themes should not and must not
correspond to questions asked317, each evaluation scenario was analysed as a data
item within the overall dataset (the full set of evaluators’ responses and comments);
this allows the analysis to be properly rooted in the research question asked.
Evaluators occasionally commented on the clinical content itself, e.g. whether the
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best choices of medication had been made in these fictitious patients. These
comments were not highlighted because they were not relevant to the evaluation
being undertaken.
A concept map visualising the different themes and their interrelationships is
provided in addition to the narrative description of the themes for each scenario. The
core themes are shown in bold directly connected to the Profile. Sub themes are
shown in a smaller font, connected to the relevant core theme. Themes that
represent a caution, a risk or an element of information that requires some sense of
negation are represented in red.
The recursive nature of thematic analysis317 was also followed in that, as well as
presenting the themes for each scenario, an overall set of themes from the dataset
was given to tell the overarching story that the evaluators gave as they provided a
qualitative assessment of the validity of the information that could be provided from
a Medication Profile, if it was constructed using the structures and populated
according to the processes and rules described in the Medication Profile Model.  This
overall set of themes was also visualised using a concept map.
Results
Including the two initial volunteer scrutineers, 43 people were contacted to undertake
the evaluation, and of these responses were received from 28 (a 65% response
rate), as shown in Table 29.  Two respondents returned paper copies of their
evaluation; everyone else responded electronically, although one in text in an e-mail
rather than using the facility within the package itself.
Table 29: Describing evaluators’ professional expertise
Profession Initial request
sent
Number of
respondents
Number of respondents
with Health Informatics
expertise
Pharmacist 19 14 10
Nurse 3 2 1
Physician 11 7 6
Clinical Research 6 2 1
Software engineer 4 3 3
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Table 30: Describing evaluators’ geographical location
Geographical Location Number of respondents
United Kingdom 10
Europe (excluding UK) 6
Australasia 3
North America 9
Themes of results
In the following discussion of the results, quotes from evaluators can be pseudo-
identified using the following information.
Table 31: Evaluators’ identification information
Identifier Profession Geographical Location
A Physician UK
B Software engineer UK
C Pharmacist UK
D Pharmacist Europe
E Pharmacist UK
F Physician Australasia
G Software engineer North America
H Pharmacist North America
I Pharmacist Australasia
J Physician Europe
K Physician Europe
L Physician Europe
M Pharmacist UK
N Physician North America
O Pharmacist UK
P Physician North America
Q Pharmacist North America
R Physician Australasia
S Pharmacist North America
T Pharmacist UK
U Pharmacist Europe
V Software engineer UK
W Nurse North America
X Clinical research North America
Y Pharmacist UK
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Emergency medication supply scenario
The main research question explored in this scenario is whether the Medication
Profile can provide enough information about medication use to enable a clinician
who does not know the individual to make a decision on a course of action which
itself results in the supply and use of medication to that individual.   There was also
a question about the display of ‘current medication’ information in the context of an
example Medication Profile.
The main response from the evaluators was that the Medication Profile information
was useful and helpful, as in the comment:
‘Yes this has been helpful for her to know what he has required previously and
helps build a picture of his previous exacerbations.’ A
But certainly not all evaluators felt there was ‘sufficient’ information in the scenario
as presented.  However, the overall sense was that the full Medication Profile
implemented in a system would be able to provide sufficient information to support
the emergency supply:
‘There is not enough information in the medication history alone. Additional
information from other parts of the [medication] record is also required. Why did the
medications change? What were the triggers for the change?’ B
In terms of additional information within the Medication Profile, the scenario did
present evaluators with course of therapy details for one of the medications and
several evaluators stated they would have wanted to see this for other medications
listed on the main screen before being able to provide emergency supply medication,
which in a working system would naturally be available to them:
‘However, I would have wanted to review the salmeterol “further details” before
proceeding’. C
Several evaluators wanted to see explicit indication information, particularly since
the medication in focus in this scenario could be used for different indication,
although in this particular case that would be unlikely:
‘For conditions like asthma and diabetes the medication is defining but inferring the
underlying condition from the medication profile is not something to be
recommended. Each medication should be associated with an indication’ C
A small number of evaluators also explicitly requested information about reason for
therapy change and particularly the reason if a medication is stopped.
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A secondary theme arising from the evaluation of this scenario was a sense of how
to use Medication Profile information to assess a patient’s compliance with their
medication, although that had not been explicit in any of the evaluation questions.
One of clinical conditions in focus in the scenario was asthma, where compliance
with prescribed medication is important to maintain good control and the reason for
the emergency consultation was that the patient was not in good asthmatic control.
In the requirements gathering chapters of this research, medication compliance
assessment had not been explicitly studied, so any unique requirements for the
Medication Profile have not been explicitly documented.  But for this use case in this
scenario, a significant number of evaluators expressed a requirement to drill down
through the Medication Profile, to see the raw prescription and dispensing activity
information that produced the Medication Profile information, to use this to assess
compliance.  Only then did they feel they would be able to make the emergency
supply:
‘Frequency of repeat prescription and fulfilment dates would help build the picture.
We don’t actually know how much medication was used as we don’t have the
dispense history available.’ B
One evaluator was confident that such information would be available to them in a
real situation:
‘It would be nice to see something indicating how frequently the salbutamol was
being prescribed as the dose is not specific and this would give an indication of
severity of asthma. Presumably this information would have been available via the
“more detail” tab.’ E
Others were more specific that they would like the Medication Profile to actively
support compliance, pointing out that, of itself, the prescribing and dispensing
information does not indicate actual use of the medicinal product:
‘Prescription and/or dispense does not indicate administration!  The long gaps
between scripts would suggest this patient has not been using sufficient medication
to be an asthma preventative and depending on the meaning of the dates may not
have had some of the scripts dispensed’ F
‘Given that this is a system that does have dispensing information…..explicitly tell
the viewer that this prescription had never been dispensed against’. G
Two respondents specifically requested presentation of the ‘Medication Possession
Ratio’ explicitly as part of the Medication Profile:
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‘Computing a compliance score such as a Medication Possession Ratio (MPR)
may be useful as a “dashboard” next to each medication prescription to allow rapid
identification of potential compliance issues’ H
And one of these two requested display of compliance information by graphical
means:
‘It would probably be more helpful to display Dispense medication histories in a
more cognitively useful manner such as using a simple timeline to show breaks in
medication compliance’ H
For the Medication Profile to support this would require supply quantity (pack size)
information to be captured and processed, and the display of this data item was
explicitly mentioned by a small number of evaluators.
In their responses to the current medications question, evaluators also raised the
theme of the scope of the Medication Profile and in particular the availability of and
rules for inclusion of information about over the counter medication use.  Several
respondents felt that a Medication Profile cannot be complete without the inclusion
of this information:
‘No [the display is not correct]. There may be herbal or OTC medications or
medications that have not been recorded.’ B
There was also a suggestion that patients should be actively asked about OTC and
herbal medication use for then that information to be explicitly and directly recorded
in the Medication Profile.
The final theme from this scenario was the need to make any calculation of
information presented in the Medication Profile clear to the user, although very few
comments on how to do that were made, other than this one:
‘I think the best solution for that is at least to show on the profile which profile it is:
the intention of the doctor, just the dispense data, or the profile with the real usage
by the patient. That makes clear how to weigh (?? Right wording??) these data and
what you do not know when you see the data.’ D
In the comments relating directly to the display or otherwise of ‘current medication’,
it was clear that there was no collective understanding of that concept, although there
was a wide sense of agreement that medications whose use is to be ‘as required’
should be included in a current medications section.  One evaluator wrote:
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‘An absolute answer [to the question about display of Current Medications]
depends on the formal definition of Current Medications and on the presumption of
how ubiquitous the clinical professions’ understanding of that definition is’ I
A small number of evaluators suggested that, whatever the definition of current
medication, when a particular patient had did not have any of these that should be
explicitly stated:
‘It would be better for it to state “No current Medications” as otherwise a failure of
data retrieval may not be recognised.’ F
The concept map for the emergency medication scenario is shown in Figure 46
below.  For the completeness theme, the related subthemes were: the requirement
for having explicit indication information and having information about reasons for
changed regimens; for the scope of the Medication Profile to include all medication,
including medicines not prescribed (purchased over the counter); and to be able to
drill down into the detail of the medication information to see individual prescribing
and dispensing activities.  Supporting the main theme of clarity, the subthemes were
to be able to access the rules and calculations that provided the summary Profile
information (particularly in relation to compliance scores, hence the cross-link to the
relevant completeness subtheme) and the definition of the concepts used in the
Profile, particularly for current medication.  The need for explicit negation information
affects both major themes and therefore links to both.
Medication Profile
CompletenessClarity
Indication
Scope
OTC
Medication
Rules &
Calculation
Further detail
drill down
Compliance
information
Reason(s) for
change
Elicit
explicitly
Definition
Current
Medication
Explicit
negation
Figure 46: Concept map of themes in the evaluation of the emergency medication
scenario
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Patient recruitment scenario
The overall sense from the evaluators was that there was sufficient information given
in the Medication Profile for the query as presented to have correctly identified the
patient as a potential subject.  Although as one evaluator pointed out, to confirm this:
‘It still needs elaborate mental processes (and time and
focused attention) for the physician to figure out the story
behind these numbers/data’ J
This ‘elaborate process’ and the risk that it is unlikely to either be undertaken at all
or undertaken consistently is one of the main reasons why using a query/algorithm
directly onto Medication Profile data should be much more effective than the most
common currently used method, in which research staff look directly at patient
records either on paper or on screen, and make those judgements and deductions
based on raw activity data.  For this scenario, the predominant theme of the
comments was the need for a clear presentation of all the relevant information, in
particular covering the whole of the relevant time period – which was longer than that
covered by the information provided in the scenario.  This opens a possibility that
the content of a Medication Profile might need to be presented in different formats
to support different use cases, particularly for clinical research when confirming long
term use of medication is often important.  However, suggestions for more useful
presentation styles from the evaluators could also be appropriate for other use
cases:
‘the separation in 2 separate screens for history and current
profile is not user friendly and does not give an easy picture of
the situation and may lead to errors. It would be much better to
have a time line showing – per therapeutic area – when a drug
was started, when potentially dosage was changes and when
the drug was stopped. This allows seeing the complete
medication profile in a much easier way’K
‘I think providing a timeline rather than tabular data would be a
better way to present the information’ B
Some sort of timeline type of display per medication might also address a theme
from several evaluators, which concerned whether it would possible to easily see if
there were any significant gaps in what might otherwise be considered a continuous
course of therapy.
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One suggestion given in this scenario but nowhere else, and particularly to improve
the clarity of information presentation focussing on longitudinal medication use, was
to explicitly provide a ‘last information date’ for the set of information provided for
each medication (available from the metadata). Other suggestions that also appear
as comments to other scenarios include the reason for stopping for any course of
therapy, and to have provision for inclusion of over the counter medicines.  And one
evaluator noted in this scenario, as others did in other scenarios, that:
‘regular dispensing is not definitive proof of compliance’ M
The concept map for the patient recruitment scenario is shown in Figure 47.  In this
scenario, the core theme of clarity was the most commented upon, particularly in
respect to the course of therapy subtheme, and using different presentation methods
to highlight those medications that are part of a continuous course from those used
acutely.  This presentation subtheme itself was related to the possibility of
longitudinal display of information (with drill down facility, linking it across to the
completeness theme) and which could include a last information date.  The need for
access to rules and calculations, especially when using algorithms to select patients
for recruitment was also highlighted.  The core theme of completeness in this
scenario had only one supporting subtheme; the requirement to be able to drill down
for further information, particularly compliance information.
Figure 47: Concept map of themes in the evaluation of the patient recruitment
scenario
Immunisation record scenario
The overarching theme from the evaluators’ responses was that immunisation
information is important in health records for individual patients and that it should be
covered within the overall concept of a Medication Profile.  However, some
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evaluators – and particularly those from North America – commented that for
example:
‘The most typical practice in the US would be to have a
separate immunization (US spelling) section that would not be
part of the medication record (profile)’ N
Several of the non-North American evaluators were positive that for immunisation
information, there is a good justification for a separate section within the Medication
Profile.  Reasons to support this view were quite consistent across the evaluators
and can be described in three subthemes.  Firstly, the use of medicinal products to
provide immunisation (i.e. vaccines) does not follow the usual ‘prescribe, dispense,
administer’ medication process.  Often only administration is recorded and this may
well be in a completely separate and possibly atypical system external to the normal
healthcare enterprise, such as a national immunisation repository or a travel clinical
system.  One comment summarises this well:
‘Yes it is essential to have accurate immunisation history, and
one that will be reliably updated if the vaccines are received in
different places (changed GP surgeries, travel clinics) and very
useful to have these clearly laid out in their own section for
easy reference’A
Administration occurs infrequently and at particular points in a lifetime and personal
remembrance of that information can be particularly difficult:
‘many people forget or are 'hazy' about recall’ O
Secondly, the information about immunisation is usually relevant for a protracted
period, possibly even an entire lifetime, not for a limited period close to the time of
the medicinal product administration; as pointed out thus:
‘Vaccines are effective for years and so if included in main med history would be
less easy to identify amongst other short and longer term meds that may be in
patient medication history’ E
Another evaluator highlighted the risk that such information might get effectively lost
over time unless it is managed specially:
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‘Even though Immunizations are medications, having a
separate section for them pulls out relevant data that is not
easily done by the user if immunizations were lumped in with
other medications.  As well, there might be archiving strategies
in place for historical medications that would lead to
immunizations not being readily available, i.e. maintaining 24-
36 months of medication history readily and requiring a service
call to a data warehousing facility to access older information
would lead to immunization information not being on many
patients’ profiles’ G
And finally, and particularly persuasively, having a special immunisation section in
the Medication Profile would enable this section to have data structured to describe
immunisation status rather than be required to follow the structure of the main
Medication Profile which exists to support the standard medication process of
prescription, dispense and administration of a medicinal product. Several evaluators
felt that having a separate section would provide the opportunity and freedom to
present information in a different and possibly more useful way, based on describing
the conditions or organisms for which there is immunity and the status of that
immunity, and on completion of courses and correct administration of booster doses,
rather than being constrained by the data structures required for non-immunisation
medicinal products.  Several comments were particularly pertinent to this, one of
which is:
‘To this point, it may also be useful to see the age at
vaccination and elapsed time since the vaccine was given to
alleviate having to do the math. If vaccines have boosters or
need re-administration then missed boosters and repeat
vaccines should be highlighted, as should missed doses in a
course. In fact a grid based around “condition immunised for”
and status would probably be a more helpful way of providing
the information…... The important thing is to track the
immunisation status of the patient without the Doctor having to
‘work it out’ in his head from the presented information’ B
However, it was clear that the rules for processing information into such a structure
would need to be defined and widely accepted, and that these rules would need to
be clear about now to deal with missing or incomplete data:
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‘So I think there must be good consensus among the hcp’s
what’s primary and what’s booster before you can use these
terms’ D
But one evaluator, although supportive of a separate section for vaccination
information, pointed out that there is a risk in this:
‘Where is the end? Then there is the risk that the
dermatologists want to have a separate section for the
cutaneous preparations, the physicians for the medicines used
in the clinic (because he do not want to see that), and in the
end all the information is scattered. What’s the criterium to
create separate sections? That should be clear beforehand. - In
case you create different sections, there is a risk that a doctor
overlooks a section and do not see all the information that is
important to see’ D
That comment leads into the last major theme in this section, that however
information is presented for immunisation, it needs to be clear and complete, with
nothing important hidden away, and minimising the risk of being misleading.  As
such, most evaluators felt that the full ‘medication process information’ such as what
(actual product and batch number), when and how (full dosage information) must be
available somewhere within the Medication Profile, for completeness and to support
adverse event reporting; for example:
‘Knowing the dosage given means knowing, rather than
assuming’ P
Two points of interest that were made in this dataset by individual evaluators
concerned use cases that have not been found in the requirements gathering
exercise and that are relevant to immunisation information.  One described
functionality to support recording and sharing of future administration information
(administrations that will be required at some distant point in the future to provide full
protection or that will be required to maintain full protection (booster doses)); no
requirement for future administration information, other than normal prescribing
process which expects fulfilment of the order usually within hours or days of its
issuing, has previously been documented.  The other described the need for
complete vaccine product administration information to support supplies forecasting,
although this latter could be considered a pharmacoepidemiology use case or a
pharmacoeconomics use case, both of which are out of scope of this research.
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The concept map for the immunisation scenario is shown below in Figure 48.  In this
scenario, the core theme of clarity is supported by the subthemes of the requirement
for different presentation formats, including the separation of the immunisation
record, with its own subthemes of immunisation status information (as opposed to
medication use information) and planned administration information.  The
completeness theme is supported by the scope subtheme, which includes a link to
planned administration, since this would be an extension of the scope of a
Medication Profile.  The separation of immunisation information introduces the risk
of fragmentation of information, which clearly affects completeness and as such is
shown as a risk both to clarity and completeness.
Figure 48: Concept map of themes in the evaluation of the immunisation record
scenario
Pharmacovigilance scenario
The most striking theme visible from the responses to this scenario was the
evaluators’ own understanding of the information requirements of the suspected
adverse event report form, as it was displayed in the scenario.  The mock-up form
used the same data elements, terms and layout as the United Kingdom’s Yellow
Card form, issued by the MHRA and as found as tear-off cards in the back of the
British National Formulary, and as studied in detail in Chapter 5(2).  It had been
assumed that all of the evaluators from the United Kingdom would be very familiar
with its data requirements and that non-UK evaluators should find the form self-
explanatory.   However, when asked to evaluate whether completion of the specific
medication related sections of the form presented in the scenario accurately
reflected the information in the patient’s medication history, approximately a third of
the evaluators, including some from the UK, noted that the medication given to treat
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the adverse reaction had not been included.  Treatment of an adverse reaction,
including any medication which is necessarily given during and sometimes after the
adverse event has occurred, should be described the Treatment section, a different
part of the form, not least because it cannot be included in any causative analysis
for the event.  The fact that a proportion of evaluators thought that this treatment
information should have been included in the ‘Other drugs in the last three months’
section emphasises that offering an initial rules-based population of information from
the Medication Profile directly into safety reporting forms has value in providing
consistency in the interpretation of the form itself, on top of any additional value in
reducing transcription errors or missing information.
The second major theme centred on the presentation of information about a
cancelled or withheld medication.  Since this scenario was set in acute care, the
Medication Profile information presented was close to real time and there was much
comment from the evaluators as to what should therefore appear as current
medication in these circumstances.  Most evaluators felt that the medication given
as single doses, and single immediate (‘stat’) doses such as those for emergency
treatment of the hypersensitivity reaction, should not be presented in the current
medication section, even though they had been administered very recently and the
course was shown as complete.
‘The history [Medication Profile] contains everything has been
administrated on chronic basis as well as on emergency basis,
from a start date to an end date or at one moment in history’
and ‘“perhaps stat doses should be in a different colour to
demonstrate the difference between short courses and one
only doses.’ L
Others commented that the prophylactic antibiotic medication should not have been
listed in the ‘current medication’ section, even though it had been prescribed,
because that prescription had been cancelled as the surgery did not take place.  The
display showed the cancelled prescription in red, but evaluators did not feel this was
enough and there could be a risk that it would be administered incorrectly.
‘I think the pre-op antibiotic order would be cancelled and
should not appear on the course of therapy details. This was
not a case of failure to administer’ R
Following a theme found in another scenario, one evaluator commented on the need
for the Medication Profile to manage information about the medication that has been
and is being used by a patient, as compared to a separate and distinct piece of
298
information about medication that it is planned for the patient to use at some point in
the future:
‘The profile contains all medicinal products that has to be taken
/ administered on ongoing basis from start to end date, the end
date being a date in the future at the moment of registration’ L
This was re-enforced by the following comment:
‘I have problems with this Cefuroxime registration. It has no
added value. It only “spoils the screen". Exception might be in
case a "planning" was recorded that needs to be "cancelled"’ L
This comment also circles back to the subtheme of how to safely manage and display
information about cancellation of an order.   Another evaluator commented:
‘It is not because something is prescribed that it should be in
the medication profile if not actually administered (even with red
colour. this is confusing – useless information as it does not say
why it was not administered)’ K
A small number of evaluators commented on the need to distinguish between
‘cancelled’ and ‘not administered’:
‘There is a difference between “not administered” and
“cancelled”. Cancelled seems more appropriate here’ L
This is particularly pertinent in a near real time secondary care environment, and
several evaluators commented on the need to show the status of a medication more
clearly
‘I think that having a status on the medication and also a link to
allergy/adverse reaction would provide better information’ S
Some evaluators noted, as has also occurred in other scenarios, that there should
be provision to record over the counter medications, and one evaluator pointed out
that for assessing a suspected adverse reaction, it would be helpful to look a lot
further back into the patient’s past medication history to see if medications similar to
the suspect medication had been administered in the past.
Since this scenario focused on a hypersensitivity reaction, several evaluators
commented that they expected to specifically see allergy/hypersensitivity information
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recorded directly in the Medication Profile, to hope to avoid any risk of the allergen
being administered to the patient again.
For the subsidiary research question in this scenario, regarding the provision of
indication information, the responses were split.  More evaluators were in favour than
against, some very definitely:
‘Absolutely! And in general indication should be provided with
any drug in the medication profile to help the physician to
assess overall clinical picture’ K
The evaluator described benefits they felt existed beyond those anticipated in the
scenario itself:
‘Inclusion of an indication or reason for prescribing would
support the process of complete documentation of all patient
conditions e.g. post-operatively a script for a cephalosporin
could be related to post-operative UTI which would not
otherwise be documented other than in the progress notes and
not in a secondary diagnosis data field’ R
One evaluator gave their thoughts as to how obtaining indication information could
be facilitated, either specifically for an adverse event form or more generally:
‘That may be possible if the “prescribed for” field is filled from a
coded list and the codes are from (or can be mapped to) an
agreed (preferably international) terminology’ F
Others were less enthusiastic but still positive:
‘Yes, but don’t feel that this benefit is likely to be the major
benefit from this practice or sufficient justification on its own for
making this a standard for medication ordering’ R
But a small number of evaluators, including two pharmacists, were definitively
negative, and thereby expressing somewhat contradictory views to comments from
other evaluators in other scenarios, on the value of indication information:
‘No.  Indication or "diagnosis" may not always be confirmed at
the point medication may be initially started.  For many
300
treatments that can be used for multiple indications there may
be misclassification which could have other consequences’ O
But one evaluator felt that this one topic was significant enough to warrant further
investigation in its own right:
‘Many clinicians would argue that the cognitive and workflow
load created by requiring an indication (and the subsequent
effort to add conditions to the problem list etc.) is not justified or
possible within existing work practices and software design -
this is probably needs to be the subject of further investigation
as to effort and benefit’ R
The concept map for the pharmacovigilance scenario is shown below in Figure 49.
The core theme of completeness was again supported by the subthemes of needing
indication information, OTC medication information (as a subtheme of scope) and
reason for change information.  In addition in this scenario, the inclusion of allergy
information as part of the Medication Profile was raised.  Linking across from the
completeness theme to the core clarity theme, there is again the subtheme of
availability of drill down information, drilling through any calculated longitudinal
display.  Within the core clarity theme, this scenario introduced the subtheme of the
status of each medication, which itself is related to the previous mentioned planned
medication, current medication, and particularly highlighted in this scenario,
cancelled medication.
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Figure 49: Concept map of themes in the evaluation of the pharmacovigilance
scenario
Decision support scenario
Evaluators’ opinions were evenly split between the negative and positive in their view
as to whether the Medication Profile was providing enough information to support a
prescribing decision, particularly after a decision support alert has been raised:
‘I don’t think that there is any information in the Medication
Profile to support Dr. Hoffman’s decision.  We do not know the
diagnosis or the antibiotic susceptibility’ Q
‘Yes I do.  Luisa has been told to reduce the dose of
zolmitriptan should she get a migraine attack while on the
ciprofloxacin.’ U
One evaluator was detailed in their comment, although ambivalent as to their view
of whether the Medication Profile did enough to in terms of decision support for safe
care:
‘There’s no medication history available and the decision
support system appears to be the typical context-insensitive
alerting system. So it will tend to over-alert. In this case,
because of the lack of dispense data, the alert is useful in that it
should trigger further investigation by the physician’ H
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A theme recurring in this scenario was to have allergy information provided as part
of the Medication Profile, and alongside this request for allergy information, one
evaluator returned to the theme of the Medication Profile not being the only source
of information needed in the clinical situation of the scenario:
‘she cannot get sufficient information from the medication
profile alone to make the prescribing of a new medication safe.
She would require information about the patient’s allergies and
intolerances, as well as information about any co-morbidities’ C
Although there was a specific question about ‘as required’ medications, it was clear
that several evaluators were concerned about this as part of the main assessment
of the scenario itself, and wanting more information about the amount of actual use
of the ‘as required’ medication.  There were several reasons given for the desire for
more detailed information: firstly as a way of assessing clinical condition, for
example:
‘Also it would be good to know how often she has taken the
Zolmitriptan as a measure of the severity of her migraines’ F
Secondly as a measure of how relevant the decision support alert was in this
individual situation:
‘knowing when the prn was likely to have last been used would
help assess the suitability of the ciprofloxacin’ V
And thirdly, in this distributed care setting to try to get an overview of the patient’s
condition:
‘Usage patterns for “take as required” medications would be
very helpful especially in a situation where a patient is getting
somewhat fragmented care’ H
When asked specifically about how to manage ‘as required’ medication information
in the Medication Profile, evaluators were divided, almost equally, in whether their
preference was to see them as a separately with their different pattern of use made
explicit, or whether to see them as no different from any other medication in the
Medication Profile:
‘Clearly a separate section’ J
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‘A new section would be more obvious at a quick glance. The
more specific the better’ W
and in contrast:
‘We believe it is best to list them all in one place.  Having to
look in two different places to get the full story on a patient
would not be desirable’ X
That comment leads back to one of the main themes: although evaluators were split
about the best method of displaying all the information, many expressed wanting to
avoid any danger of available information being hidden:
‘Anecdote on using “flags” or separation – currently in the Drug
Information System I am working on, we separate out
continuous, short term and “Other” (aka OTCs, etc).  We are
finding that users are only looking at continuous and short term
without recognizing that there may be meds categorized in the
other section.  I would put in the same section, but flag
differently’ S
A sub-theme expressed by a small number of evaluators on how to best achieve
presentation of information about ‘as required’ medications was to consider using
different models of presentation in different care environments.  The most detailed
comment to that effect was:
‘Different profile for primary and for secondary care, I think. In
primary care systems seen,  p.r.n medication included as part
of ‘current’ and ‘repeat’ templates, which is useful (when
checking patient’s medication history) In secondary care, in
systems worked with, p.r.n medications are separated from
‘regular’ and ‘stat’ medications, which again is useful in this
particular clinical environment’ Y
A theme re-emerged has been expressed elsewhere but here
was expressed with particular respect to ‘as required’
medications is the need for clear and shared definition of the
concepts themselves:
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‘Creating a separate section that defines “prn-ness” within its
data definition provides no greater certainty of the record being
correct if the clinical professions do not manage the standard of
population of that’ I
And finally, and specifically in response to the explicit research question concerned
with ‘as required’ medication, was the recurrence of the request for wider, supporting
information to be available to enable estimation of the degree of requirement for use
of the ‘as required’ medication:
‘but there should be an ability to show how often and how
recently they have been taken. A prn medication that has been
taken daily for the last 2 weeks  needs to be flagged as
different from a prn medication that is taken once a year and
last time more than 6 months ago’ F
This sense of data to support estimation of the degree of requirement for use of the
‘as required’ medication was made more simply the request here:
‘Adding the date of last use or of last dispensing could be
helpful’ L
The concept map for the decision support scenario is shown in Figure 50.  In this
scenario, the core clarity theme was underpinned by the status subtheme that arose
in the previous scenario, but in this case particularly in the context of medication
given as required, and the subtheme of different presentation formats by the differing
requirements in various care contexts (primary and secondary care).  The
completeness theme was supported by the scope subtheme, and particularly again
OTC medication, and by the drill down for compliance information (linking back to
the as required medication subtheme).  Inclusion of allergy information was also a
repeated subtheme.
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Figure 50: Concept map of themes in the evaluation of the decision support scenario
General comments
This section returned explicitly to two research questions that were explored in the
scenarios: that of the definition of current in ‘current medication’ should be 30 days;
and of the value or otherwise of differentiating between a continuous course of
therapy and an acute course of therapy in the Medication Profile.  It also provided
opportunity for evaluators to provide any additional thoughts, observations and
comments on the Medication Profile as demonstrated in the scenarios that they had
not made elsewhere in the Evaluation.
Current medication
On the first of those questions, evaluators were generally positive, with this comment
being typical:
‘That is a reasonable approach.  The 30 day window is certainly
arbitrary, but is likely close to optimum.  A shorter window might
pose some risk of missing potential issues and interactions (for
example, with fluoxetine).  A longer window would have to
potential to clutter the profile with clinically irrelevant data’ N
However, there were two comments, with one given here, both from non-clinicians,
connecting ‘currency’ with a sense of the pharmacokinetic half-life of medication:
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‘Yes.  In my experience, using past 30 days is reasonable.  If
one had a source of drug half-life information (the length of time
that a drug is considered to possibly be active in a patient for
purposes of interactions), then you could perhaps change the
definition of “Recently Active” to be the half-life of the drug” G
Comments from other evaluators went beyond the simple ‘is this time period
reasonable’ to an orthogonal approach to for current medication:
‘I think (for display purposes) it would be more intuitive for
“current medication” to include only those currently prescribed
(or obtained OTC) and then all completed treatments can be
grouped together within “medication history”. Provided the latter
are ordered in reverse-chronological order (with the most
recently completed course at the top of the list) it should still be
reasonably easy to identify completed treatment courses that
may still be having a physiological impact’ C
However, one evaluator did address the root issue of how to draw what might be
considered an arbitrary line based on a time period, and how different medications
would affect that, and therefore proposed that the time period should actually not
exist at all, but be clearly marked as cessation of therapy:
‘I would not recommend to define a certain period after
stopping the medicine during which you still say it is “current”.
Firstly because 30 days is arbitrary, and does everybody know
the assumption that the medication is still considered to be
current during 30 days? And secondly, this period differs per
drug. It is not needed to have a period of 30 days after an
antibiotic treatment of 5 days. Who decides when such a period
is needed or not? I prefer clear definitions: just put it “current”
only when the end date is not in the past’ D
The recurring theme of clear definition and ubiquitous understanding was also
underlined in this context:
‘No approach will be perfect I think that the important thing is
that the clinicians using your medication profile understand the
definition that you are using and the limitations of such a
definition’ Q
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The theme of clear definition and minimising the risk of presenting information that
is in any way misleadingly was highlighted with reference to the need to be very clear
about those medications that have been used recently but whose course has
concluded, either normally or exceptionally:
‘Probably but need a very explicit differentiation of completed
courses from currently prescribed meds, as completed courses
aren't technically ‘current’ and completed/stopped courses may
otherwise be in danger of being restarted erroneously’ T
The theme of using status to indicate active and stopped medication in some way
was also present in this context:
‘All medications which are currently active should be
mentioned. That may mean that also recently stopped
medications should be mentioned.’ J
Two other themes recurred in responses to the current medication question; firstly
that of the need to be able to see more from the Medication Profile when necessary:
‘The last year of therapy should be readily available e.g. by
scrolling’ F
Secondly, the issue of how to manage ‘as required’ medications, which revisited and
re-enforced the opinions expressed in the specific question from those that wished
to see ‘as required’ medications in a ‘current medication’ section.
In particular, two comments described how, for ‘as required’ medications, a 30 day
timeframe may not be appropriate, and therefore highlight this dosage instructions
pattern as being one that really does merit special consideration:
‘Yes. It’s never going to be simple to define a time period
appropriate for currently relevant therapy but for most meds 30
days is sufficient although when required meds are more
difficult as the interval between prescription and usage may be
much greater. Maybe 30 days for current regular but longer for
prn meds? ’E
The concept map for the exploration of how to handle current medication is shown
in Figure 51.  This shows clearly how the evaluators’ main concern was with clarity
of information – its definition, status and how it was calculated for display, particularly
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for as required medication and cancelled medication.  The completeness theme was
less prominent, with the requirement for drill down beyond a longitudinal display or
similar being the only subtheme.
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Figure 51: Concept map of themes for current medication in the general comments
Acute and continuous courses of therapy
Most of the evaluators expressed a view that this differentiation between acute and
continuous use of medication was valuable for the information in the Medication
Profile:
‘Yes I'd say it's essential otherwise short courses could be
mistakenly continued’ T
The theme of clear definition of these concepts was emphasised, along with a
question as to whether this differentiation is something that can be implemented by
algorithm or whether it is something that should be explicitly indicated by a clinician:
‘I do think that it is useful, but again, you need a clear definition
that clinicians understand and a determination of whether a
system can determine if a medication is acute (based on your
definition) or whether a clinician needs to enter that data’ Q
One commentator listed clearly the three differentiations they perceive should exist
within the Medication Profile:
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‘Chronic therapy (with or without a planned stop date) acute
therapy (with foreseen duration), and “if needed”, should be
differentiated’ J
Another evaluator commented on how the differentiation could be implemented, and
remarked on the need to keep a patient’s ‘medication story’ (a concept that no one
else had brought out in any other context) within the Profile:
‘Yes. Though I prefer the approach you have adopted here of
using a visual key to deliver than meaning rather than a
structural key resulting in the separation of current and
historical medications into sub-sections that will break the flow
of the ‘medication story’ that can be derived from the profile’ I
Just one or two evaluators were not keen on having this type of differentiation, as
expressed by this comment:
‘It doesn’t seem that differentiation needs to be explicitly
represented, other than in the start and end dates of the
medications.  That is a clear enough means of differentiating
between the two cases’ N
The concept map for the exploration of how to handle course of therapy is shown in
Figure 52.  Similar to the previous question, this also shows clearly how the
evaluators’ main concern was with clarity of the information, its definition and
calculation, and the status of the medication.  The completeness theme was again
particularly focused on the requirement to be able to drill down to see detail beyond
the initial presentation of Profile information.
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Other comments
Only a few evaluators took the opportunity to make additional comments.  The
substance of the comments reflected an expansion of themes expressed already
through the scenarios:
 the need for clear definition and clear presentation of information and the
requirement for functionality to drill down for more detailed information:
‘Main one is that I really think it is important to give treating
staff, information in a simple/graphical way rather than a lot of
text and tables.  What is also important is to understand what is
truly needed/helpful and what is noise (e.g. detailed on the
doses of the same vaccine). The detailed information should be
available on request not by default’ K
 the possible need for information to be displayed in different care scenarios
‘Which elements need to be displayed up front (without further
user clicks/scrolls etc) may be care setting dependent e.g.
primary care vs hospital’ F
 that allergy information should also be available
‘Allergies need to be displayed wherever possible as part of the
medication profile as this helps inform as to why certain
medications may or may not be in the profile’ F
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 and the same evaluator felt that indication information is useful but may be hard
to obtain
‘Reason for prescription is very valuable but difficult to capture
without interrupting workflow’ F
One new theme also appeared; that the different healthcare disciplines possibly
approach medication information differently, and what if any affect this has on
requirements for a Medication Profile:
‘A complete healthcare record including present and past
prescriptions helps paint a profile of any acute or chronic
conditions the patient might have.  In past experiences, the
pharmacist is much more apt to look at concomitant
medications and see possible adverse drug interactions than
are physicians.  Physicians must take the time to read the
record before prescribing new medications.  Again, past
experience is that the physician may move too quickly while the
pharmacist is more attuned to the patient’s medication history.
Just a personal observation based on my own situation and
those of aging relatives’ X
And finally, two comments that focus on the overall requirement for the concept of a
defined, modelled and dynamic (process based) Medication Profile that truly
supports clinicians providing care for patients on a daily basis:
‘I believe that we focus too much on providing a medication
profile as a dump of data, which is difficult for clinicians for
clinicians to review and fully understand.  I think that we need
to focus more effort on simplified views of the profile with the
ability to “drill down” and get more details.  I would characterize
it as providing information instead of data’ Q
‘That systems recognise that a medication history is a clinical
process and that the prescribe [+] dispense data can be used
to assist with the population of this’ R
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Discussion
Themes from the Evaluation
The analysis of the results yielded a set of themes, most of which were recurring
throughout all the scenarios.  The only themes that were specific to a single scenario
were those concerned with immunisation information and were specific to the
immunisation scenario.
The concept map below (Figure 53) shows all the themes and sub-themes from all
the scenarios and general questions and comment section, related together around
the two core themes for evaluation of a Medication Profile: clarity and completeness.
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Completeness
One of the two key themes expressed by the evaluators was the requirement for the
Medication Profile to be ‘complete'.  This theme relates most closely to the structural
part of the model for the Medication Profile, evaluating whether all the necessary
data elements are present.   The concept of completeness is somewhat difficult to
fully evaluate, as completeness can only be defined and tested in the context of a
set of use cases314, and as such one of the core research questions of the evaluation
was asking evaluators to assess whether sufficient information was presented.  The
scenarios were presented with various sets of information, some of which were
representations of likely initial views and some of which were representations of the
sort of further information that a Medication Profile application could provide and
which could be presented to the user (human or system) on request – the so-called
drill down functionality. There was a general positive sense that the Medication
Profile as presented would provide sufficient information to support its use cases.
Several aspects of completeness were picked out as sub-themes; one of these
concerned the scope of product coverage for the Medication Profile, and in particular
the availability of information about the use of over the counter and herbal medicines.
These are within the scope of the Medication Profile (see Chapter 7) and information
on their use would be available in the Medication Profile; however there were no
examples of this in the scenarios, so this was a valid concern from the evaluators.
One evaluator suggested an additional data requirement that is not covered in the
current model, and which was not found in any of the specifications or use cases is
that of functionality (implemented for examples as a flag or statement) that explicitly
states, when appropriate, that the patient is not taking any other (over the counter)
medication.  This additional data item could be added to the model as an attribute of
the Medication Record class, whilst acknowledging the complexity of stating
negative information, particularly in the closed world view.  But a practical challenge,
at least currently, would be population of the attribute: this information is not captured
in any currently known system other than ad hoc in text or in a paper record.  But, if
it was captured, it would be straightforward to incorporate into the Medication Profile
by processing as a specific type of medication statement and applying the
Medication Profile rules for those.
An additional functional requirement suggested by an evaluator was the inclusion of
a ‘last information date’ relating to information as presented.  This requirement could
be satisfied in an application, using ‘metadata already present in the content of the
Medication Profile, and as such is would not require a change to the model, it is a
requirement on the display of the content of the Profile to the user.
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Another sub-theme under the overall theme of completeness of the Medication
Profile included the inclusion of allergy information.  This is a specific exclusion of
the Medication Profile as defined by this research, but is obviously a critical
component of evaluators’ thinking in regard to medication information.  It is clear
therefore that any system wanting to support the medication process must also have
allergy information available to it and must present it in tandem with Medication
Profile information.
The inclusion of indication information in the Medication Profile was a specific
research question posed by the evaluation, since it is a data item that is included in
the patient care specifications and was found to be one of the most useful items of
data for the clinical research use cases.  It is included in the model, but it is not
currently captured by most medication systems so could not be easily populated and
is not accounted for in the rules-based processing.  Evaluators were generally but
not unanimously in favour of the Medication Profile containing indication information,
not least because it is hard to obtain, but their reasons for its inclusion were to
provide clarity when assessing medications used for a variety of indications and for
completeness in understanding the patient’s care as a whole.  Some were so positive
as to provide suggestions as to how collection of this information could be facilitated
in systems, especially for adverse event reporting (where it is important to ascertain
whether a suspect product was being used within the scope of its authorisation).
This topic is obviously one that challenges, since one evaluator directly suggested
further formal investigation of the benefit/cost of indication information, which would
no doubt be useful for those evaluators who, whilst positive, expressed doubt on that
particular benefit/cost ratio, or for those few evaluators who did not feel there was
any benefit from indication information.
Linked to indication information in that it provides rationale for medication related
actions other than commencing a therapy, is the data on ‘reason(s) for change in
therapy’ (where change includes cessation).  The structural model for the Medication
Profile does have a ‘non-administration reason’ attribute which was included based
on a small number of requirements and which was therefore not explicitly tested in
the evaluation scenarios.   This evaluation suggests that the definition of this attribute
could be broadened to a more general ‘reason for change in therapy’ usage.
Although this would likely be desirable information to inform clinical decision making,
there are no well accepted documentation standards in clinical applications and/or
EHR systems for how this information should captured today (there was nothing in
the specifications studied in Chapter 4) and the rationale for prescribing changes is
not always well documented.   It is therefore likely to be even more challenging to
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populate this data than indication data in practice, if it were included in the Medication
Profile specification.
In discussion of the themes around completeness, it is important to review the
evaluation comments on the specific research question of the inclusion of
immunisation information in the Medication Profile.   The regional difference in
evaluators’ thoughts was marked; those from the North American healthcare culture,
where immunisation products are licensed separately from other medicinal products
and adverse events tracked using separate forms etc. were more of the view that
whilst immunisation information should be present in an overarching electronic
health record, it would not necessarily be seen as part of the Medication Profile.  This
view is further reflected in the separate Immunisation section of documents such as
the Community of Care Record specification reviewed extensively in Chapter 4(1) of
this research.  This separation of opinion highlights very clearly the need to define
‘completeness’ in the light of its use cases; for many evaluators from other healthcare
cultures, immunisation was very positively part of the Medication Profile, although,
for the many reasons given in the Results above, a special case within.  This was
not least because by being a special case, some data element requirements could
be specifically tailored for this use case: both to exclude those structures supporting
dosage instructions which are not relevant and to include other data elements
specific to vaccination courses only (for example, the ‘immunisation status’ of the
patient, based on the antigen(s) received and the completeness of the course,
including booster administrations, rather than on the medicinal products
administered) and the calculation rules to support these.
The final completeness subtheme focussed on the provision of information about the
patient’s adherence to their therapy.  Whilst quantitative measurement of adherence
can be calculated from the data and metadata that underpins the Medication Profile,
a couple of evaluators suggested the explicit inclusion of the Medication Possession
Ratio318 as a data element.  No requirement for this data element had been found in
the use cases as developed in this research, probably because Medication
Possession Ratios of various types are all calculations (as evidenced by their ‘ratio’
nature).    The fact that this information is calculated from raw data leads to the
second major theme of the evaluation: that information from the Medication Profile
must be presented to users with clarity.
Clarity
The other key theme expressed by the evaluators was the requirement for the
Medication Profile to have clarity in the information that it presents.   This theme
relates most closely to the processes and the rules that are applied to the data that
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these processes can supply into the Medication Profile and as such evaluate the
dynamic part of the Medication Profile model.   One of the subthemes from the
evaluators was that these rules and calculations need to be properly validated in a
wide community, so that their acceptance by the wider clinical community – the
whole clinical community - can be assured.  It is not sufficient, and could be
construed to be dangerous, to leave the development and application of such rules
to individual suppliers of medication process systems, where there can be no
guarantee of consistency.  Clinicians using a variety of systems could make incorrect
assumptions on information presented in similar ways but generated by different
calculations, leading to incorrect care of patients.    Similarly, the definitions of the
data elements themselves should be validated such that they have acceptance
across the whole clinical community.  And given the international nature of the
market for clinical systems supporting medication processes, this validation must be
at an international level, beyond the limitations of the partial specifications existing
at present and discussed in Chapter 4(1).
The area that appeared to concern evaluators the most, and which strikes at the
heart of the motivation for this thesis, is clarity in – and ubiquitous clinical
professional acceptance of - the definition, calculation and implementation of the
‘status’ of a medication in a patient’s Medication Profile.   The Medication Profile as
designed in this research presents information about the nature of the use of a
medication on two different axes, only one of which was termed ‘status’.  The first
axis is not one that is currently recognised or used in systems or specifications and
is concerned with the nature of the medication as a therapy and its pattern of use:
whether it is/was a continuous/long term course of therapy of a condition or
symptom, or whether it is/was an acute course of therapy for management of a short
term condition or symptom.    Evaluators were asked specifically about this and most
of them were comfortable with this distinction and felt it added value to the
presentation of medication information.   However, there may need to be further
investigation as to how to recognise any significant gaps in what might otherwise be
considered a continuous course of therapy, and what to do in that situation.
The second axis is the more widely recognised distinction between ‘current
medication’ and ‘past medication’ (i.e. that which has been used historically) and
additionally as some evaluators suggested, particularly in regard to immunisation
information but also more generally, the concept of ‘planned medication’.   A couple
of evaluators felt that ‘the Medication Profile’ should only include current or active
medication information and that all information about past medication use should be
in a history section ‘somewhere else’ in the electronic health record.  Unfortunately,
that view would defeat the request for completeness for the use cases, which do
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require information about past medication use.   Most evaluators felt that an arbitrary
limit on currency was acceptable, as long as it was explicitly stated what that limit
was.  Only non-clinician evaluators expressed concern about how that arbitrary limit
would relate to pharmacokinetic considerations, presumably with a consideration of
how to query for information for drug interaction checking in their thoughts.   A couple
of evaluators felt that status and therefore this distinction per se was not a useful
concept, and that alternatives, such as a timeline display or therapy cessation dates
(which are present in the Medication Profile) and display ordered by date, could
remove the need for this concept.  Whilst there is merit in this suggestion in that it
avoids the need for an agreed definition of the concepts across the clinical
professions, it neglects the practical issue that in a distributed enterprise, the query
to a Medication Profile applications would still need an initial time limit for information
return because to return the total set of information for a patient is likely to rapidly
become unsustainable due to system response times.  Bearing in mind the
requirement for completeness, it would appear that, based on this evaluation, the
best proposition is to have a clearly defined, agreed, accepted and stated time limit
for ‘current medication’ (even if it is arbitrary - such as 30 days) and the ability to drill
down for further information quickly and easily to see beyond this limit; whether or
how the necessary clinical professional agreement for this can be achieved is
another matter.
There were two further sub themes related to clarity of information, and particularly
that information presented as ‘current medication’: that of ‘as required’ medication
and medication administered as a single immediate (urgent) administration (often
termed a ‘stat’ administration, based on the Latin abbreviation of ‘statim’ meaning
‘immediate’ used in dosage instructions).  Evaluators commented that although stat
administrations need to be available in the Medication Profile, it is important that they
are not accidentally repeated and therefore should be presented differently, possibly
not in the ‘current medication’ section even if they had been administered in the last
30 days, and the same comment was also made about completed courses (usually
acute courses of therapy).   Although these comments relate more to the
presentation of information from the Medication Profile than to the actual information
itself (either in terms of data elements or population of them), they possibly also
indicate a system requirement for restricting the functionality of any medication
process application using that information.  For example, an application could display
stat administrations and completed acute courses in the current medication display,
but (if a prescribing application) not allow further use (prescribing) of those
medications without an explicitly entered reason.
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One issue that relates to clarity is the difference between the display of medication
activity information and the display of Medication Profile information.  The Medication
Profile dynamic model recommends that information from medication activities that
occur during an episode in secondary care be processed into the Medication Profile
from their distinct applications either at specific points during that episode of care
and/or at the end of the episode.  There was a sense that some evaluators were
looking at the display of Medication Profile information as if it was synonymous with
a medication chart or prescription chart at the patient’s bedside, because of their
comments about the need to avoid accidentally administering cancelled medications
or re-administering the one-off stat medications (for example).  This is
understandable since the Medication Profile information presented in the scenario
was simple and tabular and therefore looks similar to a basic secondary care
medication chart that some evaluators would be familiar with on a daily basis. This
leads into another of the sub-themes from the evaluators in relation to clarity: that of
different presentation formats for Medication Profile information.  In a sense the
comments could be considered out of scope of the evaluation of the Medication
Profile model itself, but as humans we not unnaturally comment on the presentation
and not just the content of information, particularly when that presentation can have
an effect on the interpretation of the information itself.  They are therefore akin to
user requirements for clinical applications that would utilise the Medication Profile as
their data source.   The scenarios used a very basic presentation of information since
it was the model that was the focus of the evaluation, and it is expected that real
applications would use much more sophisticated user interface techniques, including
timelines etc. and good application development should use a range of methods to
engage users in interface design.  However, the evaluation theme on presentation
did offer some useful insights, including having different displays for different usage
contexts – particularly primary and secondary care – and particularly having different
presentation for immunisation information.  This latter would further support the
suggestion of having some different data elements for an immunisation section in
the Medication Profile, as discussed above.   No evaluator suggested different
presentations for different types of healthcare professional, but that might be
because each focussed on their own area only and did not think more widely; there
was only one comment in the entire evaluation that actively put comments regarding
professional groups and their relationship to the Medication Profile in conjunction
with each other.
The last set of sub-themes concerned with clarity of information are those that
concern specific negation of information: the first of these was to clearly indicate
cancelled medications, those whose course is terminated prior to their initially
intended end, which would also overlap with the suggested ‘reason for change’ data
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element.   The second of these was to express specifically when no information was
available; for example to specifically state ‘no current medications’ when the
processes and rules have been applied to the available information at a particular
point, and a query for current medications has returned nothing appropriate.
Finally, there were two sub-themes from the evaluators that were cautions, rather
than comments.  One caution was expressed in regard to having different
presentation formats, especially for different types of medication information and the
necessity to avoid the risk of fragmentation of information and therefore to lose both
its clarity and its completeness.  So whilst there seem to be sound reasons for having
a specific subsection within the Medication Profile to handle immunisation
information, this should not encourage the sense that any other type of medication
information should be handled separately.  For example, in the patient recruitment
use case, many oncology studies will wish to query about past history of use of
cytotoxic medications; this should not be taken as a requirement to have a separate
section within the Medication Profile for cytotoxic medications, since there are no
other characteristics about these medications other than their therapeutic class that
sets them apart (they have dosage instructions, and courses of therapy just like all
other medications even though these may be complex).   The second caution, which
is also linked to both clarity and completeness, is to avoid hiding any information
through presentation issues or through the application of rules etc. that are not well
defined and well accepted.  This again hits at the heart of this research: to have a
Medication Profile that is structured and populated against robustly defined rules and
processes to properly support the use cases placed upon it.
Limitations of this study
Most evaluators were comfortable with the paradigm of representation of initial views
of data from the Medication Profile and then representation of some of the further
information that a Medication Profile application could provide and which could be
presented to the user (human or system) on request – the so-called drill down
functionality.   But the static representation of what would be a dynamic situation in
a real system is an obvious limitation of the evaluation, particularly since evaluators
were unable to explore dynamically how additional information populated from the
Medication Profile would meet their assessment of completeness.    Despite these
limitations, there was a general positive sense that the Medication Profile as
presented would provide sufficient information to support its use cases.
The display of medication information in this evaluation was tabular.  Other more
graphical methods using timelines could have been used, although these are more
complex to produce by hand.  Different display methods may have elicited more or
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different comments from the evaluators, but since the evaluation was aimed at
examining the validity of the information that could be provided from a Medication
Profile, not the display of that information, the limitation of the tabular display was
not felt to be significant.
The ideal evaluation
The ideal evaluation for both the static and dynamic parts of the model for a
Medication Profile would be somewhat complex, time consuming and expensive.  It
would involve the construction of a Medication Profile application developed using
the structures, processes and logic rules defined in the Medication Profile model
(Chapter 8) of this thesis, set in the context of a wider healthcare enterprise.  This
Medication Profile application would then be used over a number of years (minimum
of 5 years) and its content would be populated from a range of different clinical
systems (minimum of 3) that deal with medication information in the enterprise, in
both primary and secondary care, and covering all the activities that occur in the
medication process: prescribing, dispensing, administration and making statements.
These systems would also query and receive information from the Medication Profile
application to support their processes.  The system would need to ensure that it
included a whole range of patients, covering a variety of ages and a wide range of
states of health and healthcare needs, and therefore a different set of frequency of
interaction with healthcare.   Other care provision systems that require medication
information could also query the Medication Profile application to receive information
required to support the care processes that they facilitate (e.g. in unscheduled care).
During this time of use various evaluations would take place, including assessment
of the ease of construction of a software application (and particularly whether there
was information being received that could not be properly processed) and accuracy,
validity, acceptability and timeliness of the information provided in response to the
queries received for various use cases.  No doubt during that time, refinements of
the structures, processes and rules would be required to produce a working system
that really did meet the use cases, which is of course why system development now
uses not just the Rational Unified Process, with significant initial investment in
analysis and design, but also Agile319 methodologies that allow requirements and
solutions evolve through collaboration between end users, designers and system
engineers.
Unfortunately, no enterprise level implementation of electronic health records or
shared patient summaries has, to date contemplated, never mind actually embarked
upon such a coordinated approach to development and evaluation for any
specification for an interoperable healthcare information resource such as a
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longitudinal individual patient Medication Profile.  Therefore all such specifications,
such as those evaluated in detail in Chapter 4(1), and the model from this thesis,
remain largely un-validated by any robust methodology.
However, the responses received from the evaluators, as exhibited in the depth of
thought and interest in their comments, shared through the quotes in the Results
above, demonstrates that the community – clinicians, informaticians and software
engineers – do see the Medication Profile as a critical area in healthcare, and that
there is a problem, and it is worth trying to solve it.  The evaluation also gave a
positive endorsement of one of the core tenets of this thesis, that the Medication
Profile can and should support requirements for both patient care and clinical
research, as translational research becomes a reality.  Although not asked directly,
no evaluator gave any sense that they felt that any of the scenarios were
inappropriate or unworkable with or for medication information.
Recommendations for further work
One clear recommendation for further work must be to investigate how to achieve
ubiquitous acceptance of the robust definitions for the medication data elements and
particularly the definition of current medication provided by this research in the wider
community.
Further investigation of the suggested specific data elements for presentation of
immunisation information as a separate section within the Medication Profile and the
dynamic model for their population would seem a constructive area for further work.
Indication for use is clearly a vital data element within the Medication Profile, no
source of such information is available from any of the medication processes in any
healthcare culture currently.  The benefits and costs of providing indication
information, should be urgently investigated.
Validation of the concept of ‘course of therapy’ and its use within a Medication Profile
should be undertaken, initially focusing on the two types proposed here (acute and
continuous), and then moving on into the complexity of seasonal and episodic
courses.
Although the presentation of Medication Profile information to users could be
considered out of scope of the evaluation of the Medication Profile model itself, it is
clearly an area that is of great importance in maintaining the clarity and
completeness of the information provided, and this, although implementation
focussed, should be further explored using the development techniques specifically
available for this such as user centred design320.
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Conclusion
The general consensus from the evaluations received against the research
questions asked was that the Medication Profile, as structured and populated based
on the Medication Profile model, does support its use cases.  The model for the
Medication Profile can therefore be described as complete, although there were a
small number of minor modifications that could be made, such as the change to
support a wider ‘reason for change’ information attribute.  The inclusion of indication
information is perceived as very important, despite there currently being no source
to provide that information. In terms of clarity, the overall sense was positive, but to
truly claim to be fit for purpose, the definitions and calculation rules would need
confirmation of acceptance in the wider clinical and research communities.
The specific research question about inclusion of immunisation information, the
general consensus was that it is a very valuable part of the Medication Profile but
that it does also merit a special section for itself.
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Chapter 10: Overall Discussion and
Recommendations
Original hypothesis, aims and objectives
The original hypothesis for this thesis was that, despite there being a pervasive
understanding that high quality comprehensive and cohesive medication information
is a vital component of electronic health records, for use in the safe provision of care
to individuals and for secondary use clinical research to promote better and safer
medication development for the future, no evidence based formal definition of what
that medication information should be exists. Nor is there any sense of how that set
of information, the Medication Profile, could be maintained over time using available
information from medication activities.  The aim of the thesis was therefore to
formally document the requirements for a Medication Profile from a set of use cases
from patient care and clinical research, and having blended these together, to
produce a formal domain information model of the Medication Profile to meet both
sets of requirements in an integrated manner.  The model would have its scope
defined, its data elements identified (static model) and a process for populating those
data elements consistently and meaningfully over time, based on the business
process that occurs (the dynamic models), such that a comprehensive and cohesive
cradle to grave longitudinal record of medication use by an individual can be
maintained. The information provided by the Medication Profile delivers the solid
foundation from which to conduct the safe and high quality performance of the
processes of patient care and clinical research, mediated by the application of filters
and queries to supply the data relevant for each of the different use cases of patient
care and clinical research.  Having produced that model, the intention was to subject
it to evaluation by a range of reviewers from both patient care and clinical research.
A secondary objective was, by dint of producing a formal modelled specification for
the Medication Profile, to achieve the melding together of the academic discipline of
a thesis, with the practical and formal discipline of the informatics/systems
development process.  This process uses modelling with various diagramming styles
as well as text to define data elements and formally describe processes and also
uses requirements as the basis for testing and user evaluation. The aim of this
melding was to produce something that is truly evidence-based but directly and
practically implementable in the development of the healthcare systems of tomorrow.
It has been possible to gather a set of requirements for the Medication Profile from
both patient care and clinical research and to blend these together into a cohesive
whole.  There have been no conspicuously conflicting requirements, only slight
differences in emphasis between the various requirements scenarios.  Requirements
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for data elements have been the clearest, excepting the glaring lack of shared
understanding as to what ‘current medication’ actually means; and therefore
construction of a static model for the Medication Profile to support the superset of
those data element requirements was possible and has been completed.
Requirements for the scope of the Medication Profile was a little more challenging
as there was less clarity and some cultural and practice differences, particularly in
pharmacovigilance, which considering this use case needs global data to be most
effective is perhaps all the more perplexing.  As with all boundaries, clearly defining
exclusion is as important as defining inclusion, and therefore the scope definition in
this thesis is considered to be of significant value overall. True requirements for the
dynamic model, to manage the population of the data elements over time, were
almost non-existent in the formal sense.  Therefore, in the presentation of a dynamic
model, this thesis has developed new knowledge, and as such this area should be
subjected to considerable further evaluation and refinement over time.  However, by
formally presenting dynamic models and rules, there is a firm foundation from which
to further evaluate and refine, which has never been present before.  This explicit
definition and understanding the limits of that definition was one that was picked out
specifically by the evaluation as valuable.
The melding together of the academic discipline of a thesis with the formal discipline
of the informatics/systems development process to produce a domain information
model for a patient’s Medication Profile to meet the requirements of patient care and
clinical research has been successfully achieved and has been well received in
evaluation.  It provides a foundational set of artefacts from which to develop the real
systems that healthcare acknowledges it needs to achieve safe medication practice
and continuing safe and effective development of new medications.
Discussion of research studies
Each chapter of this work has a detailed discussion section for that particular topic;
this section provides a summary and reflection of the research as a whole, focussing
on the key themes from the various components of the research.
The Literature review
The Literature Review showed that healthcare generally clearly acknowledges the
need for consolidated and reconciled medication information derived from multiple
sources to exist for each patient, in order to underpin their ongoing safe and high
quality care.  This information is sometimes even referred to as the ‘gold standard’
medication record or medication profile.  However, the review also confirmed the
premise that despite this acknowledgement and all the studies that document when
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and who should provide such information, the scope, the detailed content and the
detailed maintenance processes for that content are very rarely defined and are
almost never justified.  The urgent requirement for this work, to examine the use
cases, gather the requirements and then formally to define a Medication Profile by
defining the scope, the content and a methodology for the population of that content
was therefore confirmed.
The Requirements for the Medication Profile
From patient care
By examining a number of national and supranational health record specifications,
this thesis was able to conduct what was in effect a systematic review of the content
of the specifications, and therefore to promote the evidence base of their
requirements from a lower level corresponding to their authorship being by volunteer
expert opinion, to a more robust level commensurate with that systematic review.
In the health record specifications examined, and indeed in all the literature, for
patient care it is vital to have information about the actual medicinal products that
the patient is using; at a minimum this is the medicinal product name (either brand
name or generic name, or sometimes by both, especially if bioequivalence issues
exist) and including the dose form and strength of the product.   If coded identification
of the medicinal product is available, use of this is encouraged.  The clear
identification of each medication is also vital for any of the various types of decision
support safety checking that can be provided electronically to operate, and for
interpretation and action of any alerts provided.  It is also essential for any ongoing
management of the patient, especially at points of transfer of care for ongoing course
of therapy management and in shared care.   In addition, and principally for
adherence management, information about the package of medicinal product, in
terms of the amount of medication supplied and any accompanying compliance aids,
is useful.    Part of the fulfilment of these requirements relies on the availability of a
high quality medicinal product terminology and the other part on the use of that within
the Medication Profile.
For any one set of medication information, its place within the medication process
was important (prescribed, dispensed or administered) and in all the health record
specifications examined this was the only area in which any sense of a dynamic
model for medication information was described.  No specification gave any
description of how medication information should be maintained longitudinally over
time, using information from various sources, to give the comprehensive cradle to
grave record.  All that is ever described is some sort of list of ‘current’ and ‘past’
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medications, with these terms remaining undefined, although with an implicit sense
that the former relates to the medications that a patient can reasonably be assumed
to be using at the point of time that is ‘now’.   This is a glaring absence, since to
provide high quality healthcare to a patient requires all the healthcare professionals
to be on the same page, to have the same comprehensive set of information
available and to understand it in the same way.
The requirements for the different detailed data elements that make up the dosage
instructions for a medication were varied across the health record specifications
examined, with dose quantity and route of administration being important in all
specifications, although this latter can be implicit from some dose forms (e.g. the oral
dose forms).   Timing information, particularly dose frequency but also start and stop
date information were described, but there was no explicit requirement for partial
date information, even though it is well known that this frequently is all that is
available.   Indication information was explicitly required.  For medication safety and
particularly for decision support, route of administration is important for dose
checking and drug interaction checking
From clinical research
Almost all of the literature that studies the concept of a patient’s Medication Profile
does so from the perspective of the care of that individual patient; no literature, other
than that written as a result of this thesis, has examined the requirements from the
perspective of clinical research.  Yet clinical research uses the same medication
concepts and this is very significant information.   When describing inclusion and
exclusion criteria for studies, just under a fifth of all the eligibility criteria examined
for this thesis referred to medication use.   In pharmacovigilance, as well as
identifying the suspect medical product itself, all reports require information about all
other concomitant medication use.
When describing inclusion and exclusion criteria for studies, the actual medication
was of little importance, in contrast to all the other use cases.  Inclusion and
exclusion criteria most often describe medication using grouping concepts; chemical
grouping, therapeutic use grouping, or even adverse effect grouping, rather than
naming specific mediations.    Whereas for pharmacovigilance, each individual
medicinal product (and for some jurisdictions, use of products that are not considered
medications and which are considered out of scope of a Medication Profile, such as
foods or cosmetics, if they are suspected of causing an adverse reaction) should be
explicitly described in full.  This should be either by brand name or generic name, or
both, or including the dose form and strength of the product and any machine-
readable code if known.
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Just as in patient care, the terms ‘current medication’ and ‘past medication’ are
widely used but never formally defined in clinical research, meaning that their
application by individual investigators or by querying systems is unlikely to be
consistent, which for eligibility criteria risks compromise to the study and its final
results and conclusions right at its outset, and underlining yet further the need for
formal definition.  For pharmacovigilance, this lack of consistency could cause
important concomitant medications not being reported, so that effects such as
emerging new drug interactions may be missed.  An explicit formal time-bounded
specification for ‘current medication’ is therefore clearly required; no compelling
evidence of what this should be was found, but the candidates were of the order of
4 weeks or 3 months prior to the now point in time (be that the time of a suspected
adverse event or the application of the eligibility criteria).
The detailed data element requirements from clinical research were less than those
from patient care, with dosage instructions information being of less significance,
although timing information, as in the start and stop dates for a course of therapy
was important, as it is these that will differentiate between what is ‘current
medication’ and what is ‘past medication’ at any one point in time.  Indication
information (reason for use) was a clear requirement for both eligibility criteria and
pharmacovigilance.  In eligibility criteria, it could be expressed using two different
patterns: the diagnosis + medication qualifier pattern or the medication + indication
pattern.  Although diagnosis is usually recorded in a healthcare record, it is not a
data element for the Medication Profile, so to query against that pattern is more
complex: it requires querying of two different record types and relating these through
timing (whether in a system or in paper records).  The use of the medication +
indication pattern in eligibility criteria should therefore be encouraged alongside
encouragement for population of the indication data element in a Medication Profile.
The scope of the Medication Profile
It was clear that there is currently no universal agreement as to the types of products
that should be properly included in the scope of a Medication Profile, and that this is
an issue for patient care, and to a lesser extent to clinical research.   By examination
of the various types of products that are possible candidates for inclusion against the
use cases for the Medication Profile it has been possible to define a scope, thereby
removing the ambiguity that the lack of universal agreement on scope would
otherwise maintain.   The examination was such that it aimed to transcend the
influence of any particular healthcare culture, especially regulatory culture, because
patients themselves are less and less likely to receive care within a single culture
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and because systems too are now so large and resource intensive to build and
maintain that they must be suitable for use in a variety of cultures and practices.
The scope of the Medication Profile as defined in this thesis is such that it should
contain information about a patient’s use of all licensed medicinal products of any
type, including those not prescribed (i.e. purchased over the counter for self-
medication), and all unlicensed medicinal products.  Whenever it is available,
information about use of homoeopathic and herbal medicines should also be
included in the Profile.   Information about the administration of blood products and
the use of medical devices, nutritional products, dental products and cosmetics and
toiletries used in a healthcare context is excluded from the Medication Profile per se
and should be held elsewhere in healthcare information systems not in the
Medication Profile.  The scope for the Medication Profile will however need reviewing
as new products emerge and/or new healthcare practices develop.
Note that here scope is specifically constrained to the types of products to be
included rather than the data elements themselves; some might argue (for example)
that other areas, such as recording allergy information, should be in scope; that is
not the type of scope discussed here.
The Medication Profile model and its evaluation
A domain information model for the Medication Profile was constructed.  The static
model (data elements) was defined based on the consolidated requirements
gathered from the use cases, but due to a general lack of detailed requirements for
the dynamic modelling, this latter was developed by documenting the usual business
process and deriving a set of logic rules to process data from various activities in the
process to meet the objective of populating a comprehensive and cohesive
longitudinal record of medication use.  The static models were constructed in formal
UML using layering, whereas the dynamic models, reflecting the premise that
modelling is both an art and a science, use both standard business process models
and more freeform non-standard diagrams to describe decision trees.
The models were deliberately kept at a conceptual level to such an extent that
attributes were not assigned formal healthcare datatypes; this is because as soon
as those sorts of assignments are made, a degree of implementation configuration
is imposed which the requirements themselves do not justify.   Similarly, due to no
clear requirements for it, the overall model did not include any facility to manage the
acknowledged problematic areas of negated information and is developed explicitly
on the closed world paradigm.  As well as presenting the model, some exemplar
population of different parts of the model using the processes and showing the
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application of the model dynamic processes and logic was provided, in order to bring
some reality to an otherwise theoretical modelling process.
Because a full systems and technology based evaluation of the model for a
Medication Profile was not a viable option, by building on the exemplar population of
the model using various clinical scenarios reflecting the requirements, a paper-based
qualitative evaluation was undertaken to evaluate the validity of the information that
could be provided from the Medication Profile, constructed from the conceptual
model.  The two key themes arising from the evaluation were the desire for clarity
and completeness in the information content of the Model.  These reflect strongly
and positively on the validity of the original aims for the thesis itself and the model at
the heart of it: to provide ‘high quality comprehensive and cohesive medication
information’.  It also reflects on the continuing lack of these core values in the
medication information, and the requirements for that information, currently present
in specifications and working systems used in practice.
In terms of completeness, the Medication Profile model is explicit as to its scope,
which, although there were no examples of these products in the test scenarios
would include over the counter medications and herbal products, as mentioned in
evaluation. Some may wish to argue for a wider scope (e.g. inclusion of allergy
information, or inclusion of food supplement products) but having a clear statement
of what complete means for this Medication Profile is in itself part of its clarity.   It
was evident that despite medication for immunisation being seen as a different type
of medication, evaluators were clear that information on immunisation was in scope
of the Medication Profile, although the presentation of that information could be
implemented separately, still supported by the overall model.
There was no sense in the evaluation that the model for the Medication Profile was
incomplete, and it was deemed to provide sufficient information for its use cases.
Indication information, as a specific data item present in the gathered requirements
for all use cases but rarely captured in existing systems, was specifically
investigated.  Evaluators were generally supportive that this information should be
included to make the Medication Profile sufficiently complete.    The one data item
that the static model does not currently have but which would be a modest alteration
to make would be to support ‘reason for change’ information.  This should be held
against the Medication Record class, and as such would be most simply effected by
broadening the definition of the Non-Administration Reason class to the a Reason
for Change class.
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It is difficult to divorce the concept of the clarity information in itself from its
presentation in an implementation, and a paper-based evaluation is very limited in
what can be offered in terms of presentation.  However, by having a formal defined
model underpinning any implementation, there should be clarity as to what any item
of information actually represents and how it has been derived, if it has.  In a real
system a user could access those definitions using drill downs, tool-tips or other user
interface technologies which support both clarity and completeness.   Even if a user
does not particularly like a formal definition (e.g. current medications are those that
the patient is or has been taking within the last 30 days) at least it is clearly and
explicitly articulated and the dynamic model and logic used to calculate those
medications that fall into that definition is also explicitly available.  Evaluators were
generally supportive of the clarity that comes from the explicit definition of a formal
model, as well as commenting that it forms a basis from which to move forward to
get wider professional agreement.
Strengths and limitations
A core strength of this work has been the formal requirements gathering from two
distinct subdomains within healthcare that traditionally are somewhat divorced from
each other; patient care and clinical research.  Medication information is a topic for
which there is a pervasive sense of it being fully defined, yet this research has shown
that this is clearly not the case, for either of the two subdomains.  By gathering
requirements from a range of perspectives and specifications, it is suggested that
the evidence level for the requirements moves from the individual item level towards
systematic review, which has value for the wider domain as well as supporting the
modelling activity.  However, by gathering requirements from specific areas, this by
definition excludes others.  In patient care, patient adherence (compliance) was a
specific area that was not explicitly studied for requirements but it was a use case
that some evaluators raised.  Two areas that are secondary users of medication
information and from which requirements should be further investigated in the future
are pharmacoepidemiology and pharmacoeconomics.  Similarly, other areas within
clinical research itself may require further investigation in the future for requirements
onto the Medication Profile.
This research has taken the gathered requirements and used them to underpin a
fully defined domain information model for the medication information in a Medication
Profile to meet the use cases.  It has provided formal and explicit definition for those
things that previously have been either undefined or had implicit and therefore
possibly ambiguous definition.   By undertaking this definition using formal
conceptual modelling techniques, the definitions themselves provide value to the
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domain by increasing the precision and understanding of these important concepts,
whether or not they are actually implemented in systems.
Because of the notable lack of requirements for the dynamic model, other than a
sense that the Medication Profile must be able to harmonise data from many and
various sources and support ‘current’ and ‘past’ medication information, the dynamic
side of the Medication Profile model has been developed de novo, and introduces
the concept of a ‘course of therapy’ to as a structure to support the presentation of
information from the various sources and medication process in a cohesive manner.
It also presents a methodology for the population of the course of therapy information
based on explicitly elaborated rules reflecting the possible sources of information
from the overall medication process.  This therefore provides, for the first time, a
formal and firm foundation from which to build onward to meet the objective of a high
quality comprehensive and cohesive medication information that is maintainable and
useful both for patient care and clinical research.
There is an area that could be considered a strategic weakness of this work in that
the model as presented has had only an initial validation, and in order to be
considered in any sense authoritative the Medication Profile model would need
considerably more robust testing, particularly for the dynamic model logic.  The initial
validation showed that the foundations are solid to support the use cases, but some
modification to peripheral parts of the static part of the model such as reason for
change should be undertaken prior to more robust evaluation within larger systems.
The dynamic model should also be tested with a much larger set of information,
using a wide range of medicinal products, including over the counter medications,
managed over a significant period of time, with varying amounts of supporting data
provided (e.g. from the dose instructions) as is found in the real world.  In addition,
the fundamental assumption of the closed world paradigm and the lack of any
evidence of requirements to manage negative or negated information should also be
more widely validated against all the use cases in both subdomains, particularly
since this was not tested at all in the evaluation. There was also no attempt in this
thesis to explore if situations might arise where conflicting information was presented
to the Medication Profile for processing, and therefore no investigation as to how this
might be resolved.
There are therefore considerable opportunities to take the firm foundations
established in this work forward to deliver a Medication Profile that will truly provide
the high quality comprehensive and cohesive medication information for use in the
provision of care to individuals and also to support secondary use of medication
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information in clinical research to promote better and safer medication development
for the future.
Further research
In patient care, medication adherence (compliance) was not specifically studied for
its requirements; these should be investigated and if not already supported by the
model for the Medication Profile, the necessary data elements, metadata or
process/logic should be added.
Two areas of secondary uses of medication information that were explicitly not
studied in this thesis, pharmacoepidemiology and pharmacoeconomics, should be
formally investigated for their requirements and if that investigation reveals additional
data element or process requirements, these too should be added into the
Medication Profile model.  It is unlikely that there would be conflicting requirements
found, because intrinsically these disciplines are secondary users of information and
are therefore reliant on the main medication processes for that information.
The Medication Profile domain information model should be significantly more
robustly tested.   The static model development should include the additional data
elements to support reason for change information.  The concept of the course of
therapy as defined in the Medication Profile domain model should be more widely
validated, and particularly in terms of the level(s) of recursion to be supported, the
rules that implement that recursion and the display of this to users through the use
of the Parent Medication Record and Medication Record.  The practical
implementation of such recursion is closely tied to the dynamic model rules and the
reason for change information; the further investigation of these could initially be
undertaken by development of more detailed scenarios to illustrate this prior to a
larger systems level evaluation.  The metadata from the activities that the logic uses
should also be more thoroughly evaluated, as should how episodic course of therapy
could best be incorporated.
The fundamental assumption of this work of using a closed world paradigm, based
on there being few if any requirements for negative information, should be further
explored.  This fundamental assumption may need to be challenged, especially if
after a deeper investigation of the medication reconciliation requirements a need for
negated information is established for the Medication Profile.  There should also be
further investigation of patterns of situations where conflicting information could be
presented to the Medication Profile, and the options for resolving that, both
programmatically and by human intervention, should be explored.
335
The Medication Profile model evaluation included one scenario that specifically
focussed on how a particular subtype of medicinal product information could be
managed within it, that of vaccination information.  Various reasons for treating
vaccination information as a special case were expounded, and the evaluators had
a number of suggestions about how vaccination information should be managed,
including the possibility of having an antigen based record rather than a medication
based record.  This subdomain merits its own detailed investigation, in terms of both
the static data elements (antigen rather than product, immunity status rather than
dosage instructions) and the dynamic model (course completion status rather than
course of therapy) and also the possibility of display of prospective future
administration information.
Future work
Testing of the dynamic model in processing information from the variety of
medication processes performed in all contexts of care (primary, secondary and
tertiary) should be undertaken, and particularly to confirm that medication statement
information and especially that arising from a medication reconciliation process, can
be seamlessly and effectively integrated into the Medication Profile model.   The use
of UUIDs to further facilitate reconciliation of information from various sources and
various stages in the medication process should also be investigated, as should
explicit description of course of therapy in the medication process.  The availability
and use of machine-readable dosage instructions to support management of course
of therapy information should also be investigated more deeply, looking at both
simple and complex scenarios.
As stated in the Modelling chapter, the static information model was presented at
only a conceptual and intermediate logical level.  Further development of lower levels
of model, towards a more implementable solution using the ISO 21090 healthcare
datatypes and the various national and international medicinal product terminologies
should be explored, and particularly whether there these introduce any detrimental
effects on the ability of the model to support the various use cases (for example,
whether the use of pre-co-ordinated medicinal product and manufacturer information
is an issue in any way).
As part of a larger and more robust testing process, two areas of information that
according to the requirements and use cases are clearly needed within the
Medication Profile but which are known to currently be rarely available, should be
further investigated.  These are: the inclusion of over the counter medication use,
where the examination should focus on the dynamic model to support the
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identification of the sources of this information and the processing of that information
into the Medication Profile; and the inclusion of indication information, which is rarely
captured in systems.  For this latter, it would be important to investigate any options
for facilitating the gathering of this data element with as little disruption to current
practice or process as possible.
Finally, although this work has provided a very robust and formally defined domain
information model for a high quality comprehensive and cohesive Medication Profile,
it is clear from all of the research that, because of the current state of ambiguity for
many of these things that persists in clinical practice, there needs to be widespread
and inter-professional agreement and acceptance of definitions (particularly for
‘current medication’ and ‘past medication (history)’ and the place of ‘as required’
medication within them) and business rules of the information concepts and for the
information processing.  Due to the global nature of healthcare and particularly to
the global nature of clinical research, it would be valuable if that inter-professional
agreement could be reached at a global level, through international standardisation
processes and implemented in systems across the globe.  If further work could be
undertaken towards gaining that global inter-professional agreement, and this was
then implemented uniformly in medication systems which were able to provide a
Medication Profile for individual patients based on that, the goal of providing safe,
high quality healthcare to individual patients whilst also providing information to
support clinical research to promote better and safer medication development for the
future could become a reality.
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Appendix 1: Report of the initial literature search
The following is the literature search that was initially undertaken as a proof of
concept for the thesis.  This focussed on an investigation of the use and
understanding of the term “medication profile”.  This initial single keyword search
found that the term was used extensively, very often in very clinically focussed
studies of a disease area, to generically describe “information about a patient’s
medication”50-53 – but almost never was any formal definition of what the term actually
meant is given either explicitly or implicitly.  Some gave a little information; in a study
by van Bruggen et al321 on clinical inertia in diabetes care, one of the measurements
was “treatment intensification” which was assessed using a “complete medication
profile of all participating patients” by gathering the electronic records from all the
pharmacies in the study area and using these to obtain “accurate medication
histories” of all patients using those medications in the focus of the study (based on
ATC code), which were then matched with the research data. The criteria used in
the matching were not given.  Interestingly in a study by the same authors, this time
focussing on patient non-adherence to diabetic medication322, used the same
process to obtain “the complete medication profile” of its subjects and used this to
calculate adherence indices.
“Medication profile” as a synonym for “current medication”
It was clear that some authors use the term “medication profile” to implicitly refer to
a patient’s “current medication”– the medications actually being taken by the patient
at the time.  This definition can reasonably be implied to the study by Guill et al323
because the inclusion criteria for the study was for the subject to have “8 or more
active medications”; in the study by Sobieraj324 the results used an endpoint of a new
prescription being made “on the medication profile” and in the study by Naso325 the
pharmacists involved were expected to “conduct a prospective review of the
individual patient's medication profile” to determine if a prescription for a particular
class of therapeutic agent already existed as a safety measure against inappropriate
therapeutic duplication. In the large-scale (10,000 patient) genetic database created
for cardiovascular studies reported by Agah et al326 “medication profile” is one of the
main additional sets of data sorted in the database; however all that is described is
that the profile is “a complete list of medications (exact formulation)” for every patient
enrolled (no other data such as dosage instructions appears to be collected), and,
by implication since the data collection tool includes a list of “100 common vitamins
and herbals”, the scope is not be limited to prescription medications.   Since the
Medications Module in the appendix notes that the list contains the medications
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patients were on at the time of enrolment, by implication one must assume that
“medication profile” here means “current medications”.
In many situations, although no formal definition or description of what is meant by
the concept of a “medication profile” is provided, some information about its form and
content (and exclusions) can be gleaned implicitly from details given.  In a study on
using fax as a method for sharing medication information327, it is clear that allergy
information was excluded from the profile as it is mentioned as a separate
characteristic; there is a sense that a medication profile would be longitudinal, as
“current medication” is also given as a separate concept that would be used to
“update the medication profile”. Becket et al328 studied “medication profile
appropriateness” as an endpoint to compare pharmacist medication reconciliation
against the institution’s normal practice.  For a medication profile to be deemed as
‘‘appropriate,’’ it required all discrepancies from the medication reconciliation to have
been resolved and all medication use to be appropriate as documented by the
reviewing pharmacist.  Therefore the interpretation of “medication profile” in this
context would be the patient’s current medication, an interpretation both challenged
and supported by other work in this area, discussed in detail below in the section on
Medication Information at the Point of Transfer of Care, which looks at medication
information and the medication reconciliation process in detail.
Undefined use of “Medication profile”
In a survey of psychiatrists' expectations of clinical pharmacists329 “maintenance of
a medication profile” was one of the survey criteria.  However, it gave very little
indication as to what was meant by this; the most that can be gleaned is from one of
the participant’s quotes “I expect clinical pharmacists to maintain a complete
medication profile on my patients (i.e. medication history, allergy history)". Similarly
a study investigating the role of community pharmacists in improving asthma care330
used the “medication profile” to mean a patient’s dispensed medication history, but
it described “the daily dose of medications” to be a separate clinical entity from that
profile; by implication therefore the concept of medication profile in this study was
just the list of a patient’s medications with no other supporting information about
dosage, duration or authorisation of use. McAuley331, investigating epilepsy patients’
view of the role of their community pharmacist noted that 61% of patients wished
that their community pharmacist could maintain a “complete and current medication
profile”.  This was in the context of the statement that epilepsy patients are expected
to be administering medication for most of their lives, and as such must imply that a
“medication profile” in this context must be a longitudinal record. Stuijt et al332 used
a “medication profile” as a basis from which to measure appropriateness of
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prescribing for elderly patients in a residential home.  This medication profile
combined the patient's medical records with his or her complete prescription record
(current and previous [last 3 years] medication history) and pharmaceutical record
(electronic journal entries (“dispensings”) for the patient over the same period) and
took approximately 45 minutes of pharmacist time per patient to prepare.   As such,
the concept of medication profile here is broader than just medication, in that it was
looking to see how clinical problems can be revealed as (probable) drug related
problems and make alterations in prescribing as a consequence.
Even in studies where medication management was the focus – as in the study by
Jing et al333 looking at medication adherence the description of the “medication
profile” was not explicitly given, however some sense as to what the authors meant
can be gathered from the information sent to the primary care physician of non-
adherent patients, which included the “medication names, dosage, dispensing
date(s), quantity dispensed, days’ supply and name of prescriber”.
Other authors334,335 clearly saw the “medication profile” purely as a source of
information for study rather than something for clinical use – for example to when
investigating polypharmacy in elderly patients suffering from falls.  In the second of
these two papers by Kojima et al, at least give some indication as to what was meant
by “medication profile” was given in the specific mention of “therapeutic drugs” and
information on “prescribed drugs obtained from the chart”).
Medication profile and safety events
Other papers emphasised the importance of the “medication profile”, particularly
those focussing on drug interactions – but again without any definition as to exactly
what it might contain.  For example, in describing the potential for and implications
of lidocaine drug interactions, a paper by Bill et al336 highlighted that “medications
that a patient may consider innocuous have the potential to greatly increase surgical
risk” and noted importance of  obtaining a complete preoperative history that includes
all medications.  However, it made no reference as to the source of that information,
other than to advise that a “complete preoperative history that includes all
medications” should be obtained.
A study of drug interactions for warfarin and the newer anticoagulants337, uses the
concept of “medication profile” but again gives no definition, whereas an analysis of
drug interactions in cardiac and cardiothoracic intensive case uses the same
concept, but by implication this is deemed to mean all current medications that the
patient receives whilst on the unit338.
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The “medication profile” was a term used in studies and reports concerning adverse
events – as in a “non-confounding medication profile”339 and to describe “the set of
things being currently administered” when the adverse event occurred340 and to
identify those medications that had or had not been modified and therefore would be
(un)likely to be responsible for the adverse event341.
Definitions for “Medication profile”
However, there were just a few articles where the medication profile took centre
stage and a significant amount of detail was provided. A study by Vawdrey et al
into the impact of adopting medication reconciliation referenced an “Outpatient
Medication Profile” (OMP) which was maintained in their EHR system as a “coded,
longitudinal medication list”86.  This was made available to clinicians through the
facility’s commercial EHR system and in community-based clinics.  Active
prescriptions could also be entered into this Profile.  There is little detail as to the
structure or content of the Profile other than that it contained “coded data elements”
and optionally, “form, dose, route, frequency and start and end times”.  Being a
longitudinal record, it was available for use when a patient subsequently revisited
the facility, at which point it was updated as part of the reconciliation process and
this updated Profile was then used to support admission prescribing.   Although the
focus of this study was improving compliance with the medication reconciliation
process to meet Joint Commission requirements, it made several observations that
are pertinent to this thesis.  It showed that that tools such as the OMP as
implemented are dependent on human intervention for their accuracy and therefore
for their value; at the start of the study the average number of medications in the
OMP for a patient was less than 2, whereas after one year of active effort to improve
compliance with the reconciliation process, the average number was 4.7.  The study
also noted the benefit of a longitudinal medication record, in that over a two year
period, the average number of modifications made to the record on admission
decreased from more than three to approximately one; the record as refined and
maintained over time more accurately reflected what the patient was actually taking.
Two other points can be drawn: the study notes that clinicians complained about the
amount of time taken to perform the reconciliation; an accurate medication profile
that did not require significant human intervention and effort to maintain would
alleviate this.  Indeed the study recommended that “synchronising data with external
pharmacies and personal health records to enhance the accuracy and completeness
of home medication lists” would be beneficial and it admitted that “no ‘gold standard’
home medication list” exists and that there is often uncertainty about the medications
a patient is taking”.  The specification for an integrated Medication Profile for a patient
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would aim to address these recommendations directly and provide the framework
for that “gold standard” to exist.
Hornick et al342 developed a Visual Medication Profile (VMP) to aid communication
between patient and physician and to improve patient compliance with their
treatment regimen, for optimisation of medication regimen for elderly patients.  This
was a web-based tool that visualised each of a patient’s medications in pictorial
tabular form and interpreted the dose schedule into columns for when to take the
medication.  It was designed by an interdisciplinary team that included patients and
used data from a pharmacy database, a patient database and pill photograph
database.   It was found to be helpful in several areas, in particular for the healthcare
professionals who expressed issues with an ongoing mismatch between a patient’s
self-report of their current medications and their medication record.
A second larger study of the medication reconciliation process by Varkey et al343
looked at both admission and discharge medication and documented the medication
name, dosage, route, and frequency of administration for all medications.  On
admission, the information source was patients, family members and the
medications brought in; no reference to external sources other than these was
sought.  The discharge medication list in the hospital summary document was
compared against the original patient’s home medications list, inpatient medication
proﬁle, and prescriptions detailed in the hospital EHR to investigate any medication
discrepancies. The discharge medication list included medications to be continued
after discharge, new medications added to the patient’s regimen, and any
medications that were to be discontinued. Changes to preadmission medications,
new medications ordered upon hospital discharge, and discontinued medications
were to be speciﬁcally noted on the discharge sheet.  The study noted a reduction
in discrepancies as it progressed, including a gradual decrease in the severity of the
discrepancies.  The effort involved in undertaking the reconciliation was significant,
although it also reduced as the study progressed.  This study distinguished between
an “inpatient medication proﬁle” which was defined as ”active medication orders on
the day of hospital discharge” and “the patient’s regimen” which appears to be a
more comprehensive term for the overall picture of a patient’s medication.  It also
highlighted that it viewed information about changes to that regimen, and in particular
separately documenting discontinued medications, as important components of the
overall profile.
Finally, one study whose focus was to investigate the use of potassium and
phosphorus repletion, rather than in any sense having a medication profile focus,
actually did provide a full description of its concept of a “medication profile”344, which
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was: “a description of the product ordered, including drug formulation, dose, route,
frequency and rate of administration, the day and time of the initial order, and the
stop date for administration, if applicable”.
Initial Conclusion
From this initial brief review of the literature, it was indeed clear that, despite being
a widely used term in the clinical community generally and in medication process
focused study in particular, no formal definition of a “medication profile” exists in the
literature.   This initial review and its sense of there being a lot of generic and implicit
information but not very much explicit information, helped to inform the fully
structured and broader examination of the literature, whose intent was to explore the
broader sense of “medication information”, so as to evaluate what information does
exist and what could or should be used in support of a formal definition of a “Gold
Standard Medication Profile” for this thesis.  It would also hopefully confirm the value
of such a fully defined concept to the provision of high quality healthcare.  This initial
review also gathered further evidence for the position that the present published
specifications are inadequate for the task in hand: which is how to construct a high
quality longitudinal Medication Profile to serve the use cases for it from patient care
and clinical research.
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Appendix 2: Evaluation package
Julie M James
Centre for Health Informatics and Multi-professional Education (CHIME), University
College London
Supervisors: Professor Dipak Kalra; Professor Jane Portlock
Evaluation Storyboards
In the following pages, you will find five separate storyboards, describing five
different patients in different care or research scenarios; each one focuses on a
different use case for information from the patient’s Medication Profile.
In each case, there are one or more representations of information in the patient’s
Medication Profile that have been generated according to the models and patterns
developed through my research.   The display shows only a name and date of birth;
it is assumed that “patient matching” has been performed to EHR best practice.
Please read through the storyboard and the Medication Profile and provide your
answers to the questions and give comments for each one.
Please note that the representation is exemplar only, but that there is some meaning
in the colour of the typescript:
 black text indicates continuous course of therapy
 purple text indicates a short course of therapy (<30 days’ continuous
treatment)
 red text indicates therapy prescribed but known not to have been
administered
There are also some general questions at the end of the scenarios.
I estimate completing this evaluation will take about 60-90 minutes hour of your time.
Thank you so much for your assistance and support.
Julie
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Please return the completed document to me, preferably electronically, at
Julie_james@bluewaveinformatics.co.uk or alternatively by post to 20 West Garth
Road, Exeter, EX4 5AH, UK.
There is a short abstract describing my thesis appended to the back of this document
for your interest.
Clinical Care – Emergency Medication Supply Use Case
Winston Gordon is a 13-year-old boy on an activity holiday with his local youth group
in the early summer of 2015.  During that time he picks up a viral infection, but he
carries on with the activities despite a mild fever, sore throat and slightly runny nose.
As a child, Winston has suffered from asthma, but like many teenagers, he’s not
keen to acknowledge this too much; he didn’t put it on his form for the activity holiday
and he hasn’t brought any medication (inhalers etc.) with him.  In fact, he hasn’t used
his inhalers regularly since he started senior school and really no longer thinks of
himself as “asthmatic”.  He has one old “reliever” inhaler at home that he occasionally
uses if he thinks he’s wheezy.
Probably due to a combination of the virus and all the activity, Winston’s asthma
reappears and after a day or so of trying to hide it and ignore it he really needs help.
After phoning his parents to get their permission, one of the activity holiday leaders
who has been mentoring Winston takes Winston to the local Walk-in Centre.
Dr Sarah McMasters sees Winston, talks to him and the accompanying adult about
his recent symptoms and past history and listens to his breathing and his chest and
takes a peak flow reading.  Sarah then searches on-line to get an overview of
Winston’s Medication Profile.  She is presented with the following:
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In the system that Dr McMasters is using, the symbol with the yellow
colour denotes that the course of therapy has changed during the dates displayed in
the Medication Profile History section.  So, by requesting these further details for the
Beclomethasone course of therapy, Sarah is then presented with the following
information:
The red date in Sarah’s system indicates that the Medication Profile has derived this
date; the last prescription for this medication was issued to Winston on 28 February
2013 but no dispensing information was ever received for processing by the Profile.
346
This confirms Winston’s admission that he hasn’t regularly used any asthma
medication since he started secondary school.
Based on the history, examination and information from the Medication Profile,
Sarah McMasters is sure this is Winston’s asthma getting the better of him, and she
is able to prescribe medications that he is familiar with (salbutamol and
beclomethasone in a dry powder inhaler formulation) to get the situation under
control again.
For Reviewers
Do you think there is enough information in the Medication Profile to support Dr
McMaster’s conclusions about Winston’s asthma in the past?
Is it correct to display no current medications for Winston in the Medication
Profile?
Is there any other information about the medication that you think should have
been present?
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Clinical Research - Patient Recruitment Use Case
Harry Peters is a 72-year-old gentleman who has suffered from reasonably well-
controlled primary hypertension for some years.  He was initially treated with
bendroflumethiazide, but in 2010 this was augmented with ramipril.
In 2011, at a routine check-up, Harry was found to have a raised blood-glucose level.
Harry is not overweight and exercises regularly (and has done since he was
diagnosed with hypertension); carbohydrate restriction did not give enough of a
reduction in the glucose level, so Harry was started on Metformin, which has kept
his blood glucose at a satisfactory level since then
In 2013, in a review of his treatment and to bring this in line with recent guidelines,
the thiazide diuretic was stopped and long-acting nifedipine introduced.
Harry’s GP, Dr Anthony Chung, is participating in a retrospective observational
clinical study being managed by Good Health University Hospital (GHUH).  The
study is investigating the effects of ACE inhibitors on reducing cardiovascular
outcomes (e.g. myocardial infarctions, cerebrovascular accidents) in patients
receiving this class of medication for treatment of primary hypertension.
There is a secondary study investigation, looking for incidence of type 2 diabetes
mellitus arising in this population10.
In order to identify subjects who would be eligible for recruitment to this study, GHUH
has sent participating centres a structured query to execute against their patient
database.  This query searches for all patients who have received an ACE inhibitor
medication (ATC C09A or C09B) for more than 2 years of continuous therapy in the
last 10 years.  The query lists all the medications in the relevant classes explicitly; it
does not expect the patient database to determine this itself.
A second query is then performed against the cohort of patients found by the first
query, to identify patients who commenced taking one or more medications from
ATC class A10BA (Biguanides) or A10BB (Sulfonylureas), and for whom the start of
that therapy was concurrent with the ACE inhibitor therapy.
Dr Chung has run the queries sent by GHUH and is reviewing the results against the
Medication Profiles of the various patients that have been selected by the query as
potential subjects for the study.  Harry Peters is one of seven patients (out of the
2760 that Dr Chung has in the practice) that are possible subjects for both the
10 For a similar study, see NCT 01152567
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primary and secondary parts of the study, so Dr Chung looks at the detail of Harry
Peters’ Medication Profile and confirms that Harry is indeed a potential subject.
He puts Harry’s name on the list of patients to receive an invitation to find out more
about participating in the study.
All of the information in Harry’s Medication Profile has come from prescription and
dispensing medication processes in primary care and Harry has been consistent in
having prescriptions dispensed (fulfilled) within a couple of days of their issue, so
that it has been easy to tie together prescription and dispensing information.
When Dr Chung requested “Further details” for the Ramipril course of therapy, he
was presented with:
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Similar screens were available for the Metformin and Adalat LA courses of therapy,
confirming to Dr Chung that Harry Peters conscientiously has his prescriptions
dispensed and is therefore likely to be conscientious about taking his medicines, and
may indeed be a good subject for the study.
The queries from GHUH identified Harry Peters as a potential subject for the study
because:
A current course of therapy for ramipril (an ACE inhibitor in the ATC class C09A)
was identifiable and the start of the course of therapy was identifiable (24
February 2010) allowing the duration to be calculated (5 years 7 months)
This fulfils the criterion “patients who have received an ACE inhibitor
medication (ATC C09A or C09B) for more than 2 years of continuous therapy
in the last 10 years”
A current course of therapy for metformin (a biguanide in the ATC class A10BA)
was identifiable and the start of the course of therapy was identifiable (2 May
2011) and could be compared with the dates for the course of therapy for the
ramipril (24 February 2010 to present)
For Reviewers
Do you agree that, based on the medication process information in the story
above, the display of the Medication Profile information is accurate?
Please give reasons for your answer
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This fulfils the criterion that “the start of that therapy was concurrent with the
ACE inhibitor therapy”
For Reviewers
Do you agree that, based on the story above, Harry Peters is a potential subject
for the study being conducted by GHUH?
Please give reasons for your answer
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Clinical Care – Immunisation Use Case
Amrita Cheema is an 18-year-old girl about to embark on “gap year travel” before
she goes to university to study Politics with Spanish.  Her aim is to travel extensively
in continental South America, but most probably not to those countries bordering the
Caribbean (e.g. Colombia and Venezuela).
Amrita is making an initial visit to a specialist travel clinic to sort out vaccinations etc.
several months in advance of her departure, and is discussing the situation with
Nurse Peter Furman.  Peter uses the website from the National Travel Health
Network and Centre (NaTHNaC) [http://travelhealthpro.org.uk/country-information/]
to check the vaccination requirements and malaria prophylaxis requirements for
Brazil, Uruguay, Paraguay, Chile, Bolivia, Argentina and Peru.
In summary, for all of the countries, MMR and Dip/Tet/Polio are recommended.  In
addition, for most countries hep A, hep B and typhoid are recommended.  Yellow
fever vaccination is recommended for certain parts of several countries and for a
couple rabies and TB vaccination would be recommended for high-risk personnel.
Amrita agrees with Peter that she doesn’t fall into that high-risk category, but will
have a think about her likely itinerary and the need for yellow fever vaccination, but
all the others she should have.
Like most teenagers, Amrita is pretty hazy about which vaccinations she has actually
received, although she clearly remembers having the HPV vaccination (as this was
only given to girls) and “a set of vaccinations” just before taking her GCSEs.  Peter
therefore accesses Amrita’s Medication Profile to find out what her vaccination status
is.
Amrita has suffered from atopic eczema since she was a baby, so the initial view of
her Medication Profile shows the following:
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Peter notes this, as it may be relevant for vaccine reactions, but wants to move to a
specific screen for the Immunisation History:
From this, Peter can see Amrita is fully up to date with her childhood immunisation
schedule and therefore is covered for diphtheria, tetanus, polio, measles, mumps
and rubella.  This means that specifically for her travel, she needs to add in hepatitis
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A and B (which can be achieved using a single product with the two antigens) on a
three-dose schedule and typhoid vaccine.
For Reviewers
Do you think it is useful to have a specific Immunisation section within a
Medication Profile?
Is it acceptable to provide the “Dosage instructions” with reference to the type of
vaccination given (primary or booster)?
Do you think the Immunisation section within a Medication Profile should
amalgamate courses (e.g. all 3 doses of the HPV vaccine shown as one entry)?
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Clinical Research - Pharmacovigilance Use Case
June Stevens is a 56-year-old lady who has been admitted this autumn (2015) to
Good Health University Hospital (GHUH) for a knee replacement; her knee joint has
been steadily deteriorating and causing increasing pain since an accident 5 years
ago. June has been using regular analgesia for the knee pain for some time.
On admission, June’s Medication Profile is as shown below:
June has two children, and during both pregnancies she experienced some issues
with thromboembolism, and therefore for the orthopaedic surgery she requires
pharmacologic prophylaxis; in GHUH the medication of choice is enoxaparin given
subcutaneously 12 hours prior to surgery and then for 5-7 days post-surgery,
depending on the patient’s mobility.
Unfortunately, within about half an hour of receiving the pre-operative administration
of enoxaparin, June feels quite unwell; her tongue feels swollen and she is becoming
breathless, despite resting in the chair by her bed.   The duty doctor, Dr John Carter,
is called and diagnoses a hypersensitivity reaction, manifesting with angioedema.
June is immediately given oxygen, 500micrograms of adrenaline IM, 100mg
hydrocortisone (as sodium succinate) IV and 10 mg chlorphenamine IV.  Thankfully
this stabilises June’s condition and within 3 hours the angioedema has resolved.
However, her surgery is postponed.
In addition to the information as presented in the screen shot above, June’s
Medication Profile now has the following information:
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The “Further details” for the Cefuroxime courses give the following information
(shown for both – although each would be viewed separately):
At the ward round/review the next day, the team decide June has experienced a rare
but serious hypersensitivity reaction to the enoxaparin and record this in her
electronic health record
For Reviewers
Do you agree that, based on the Storyboard above, the display of the Medication
Profile information is accurate?
.
Please give reasons for your answer if possible
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The EHR system at GHUH encourages all clinical staff to engage in adverse reaction
reporting, and has an application that supports this.  It monitors EHRs for various
indicators of an adverse reaction, and if it detects a likely scenario, it actively asks
the clinician managing the patient if an ADR report should be filed, and if so, it
provides as much pre-filled information as possible to the clinician, including from
the Medication Profile of the patient.  Dr Carter accepts the request to complete an
ADR report for June and reviews the pre-filled information.
For the Medication sections, the following is presented, drawn from the Medication
Profile:
For Reviewers
Do you agree that, based on the story above, that the pre-populated Medication
information in the Adverse Drug Reaction report generated by the application and
presented to Dr Carter is accurate?
Please give reasons for your answer if possible
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Dr Carter decides to edit the form, particularly to add the indication (“Prescribed for”)
for the enoxaparin, since indication information is currently not given with
prescriptions, but may be recorded elsewhere in the patient’s notes.
In addition, Dr Carter is able to select the four items from June’s Medication Profile
to add to the “Treatment” section of the Suspect ADR Form – the adrenaline,
hydrocortisone, chlorphenamine and oxygen.  Rather than having to transcribe the
information, by selecting those items and using “drag and drop” functionality, the
Suspected ADR Form gets the full information from the Medication Profile directly.
For Reviewers
Do you think that if “indication” information were routinely present for medications,
even more information could have been populated “automatically” into the
Suspect ADR Form?
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Clinical Care – Decision Support Use Case
Luisa Schmitt is a 29-year-old lady living and working in mainland Europe, where the
healthcare culture does not have a single “gatekeeper” medical practitioner (a
general practitioner or family doctor); the patient is cared for by a set of specialist
practitioners depending on the patient’s healthcare needs.  Since being a teenager,
Luisa has unfortunately been susceptible to severe migraines.  She has had various
treatments over the years but now manages her condition by lifestyle management,
prophylactic propranolol and the use of zolmitriptan for symptomatic treatment of any
migraine that occurs.
In February 2015, Luisa suffers a severe urinary tract infection and visits her
gynaecologist, Dr. Hoffman, seeking treatment.  Luisa’s symptoms are such that Dr
Hoffman wishes to commence antibiotic treatment straight away and intends to
prescribe ciprofloxacin.   She uses her clinical system to issue the prescription.  Dr.
Hoffman is aware that Luisa has suffered from migraines since her teenage years,
as it was a consideration when selecting a suitable method of contraception for
Luisa, but she is not aware of the exact therapy that Luisa has.  The clinical system
has a medication decision support module, which references Luisa’s Medication
Profile, and therefore as soon as the ciprofloxacin has been selected, an alert is
displayed to Dr Hoffman, reminding her of the probable interaction between
zolmitriptan and ciprofloxacin, due to the enzyme inhibition effect of the ciprofloxacin.
A dosage reduction for the zolmitriptan is recommended.
Dr. Hoffman decides to review the detail of Luisa’s Medication Profile and receives
the following information:
Based on the information present in the alert, on viewing Luisa’s Medication Profile
and on further discussion with Luisa on prevalence and likelihood of a migraine
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occurring during or soon after this proposed course of therapy, Dr. Hoffman decides
to continue with the prescription of ciprofloxacin, but counsels Luisa that if a migraine
occurs, she should use only 2.5mg of zolmitriptan for symptomatic relief rather than
her normal 5mg dose.
Dr. Hoffman is also concerned that Luisa may experience a bout of vaginal
candidiasis as a result of the use of the broad spectrum antibiotic and the imbalance
in internal flora that this can cause.  Having already been alerted to the possibilities
of drug interactions occurring with Luisa’s anti-migraine treatment, she checks on
the use of itraconazole, and finds that could also be a problem; she therefore advises
Luisa to use local clotrimazole as a first line of therapy if thrush does develop.
For Reviewers
Do you think there is enough information in the Medication Profile to support Dr
Hoffman’s decision to prescribe ciprofloxacin for Luisa?
For medications that are used “as required”, do you think it is acceptable to
describe them as “Current Medications” and as a “Continuous course of therapy”
or do you think they should be described in a separate section?
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General Questions
Thank you very much for completing this evaluation.
There is no agreed definition for “Current Medication”.  Do you feel that for display
purposes, showing those medications the patient is currently prescribed or whose
course has completed within 30 days is reasonable?
Do you feel that differentiating between a continuous course of therapy and a
simple or “acute” course of therapy is useful for the Medication Profile?
Are there any specific comments not covered in the scenarios or in the questions
above that you would like to make?
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The Medication Profile
Julie M James
Centre for Health Informatics and Multi-professional Education
(CHIME)
University College London
Supervisors: Professor Dipak Kalra; Professor Jane Portlock
Abstract
Use of medicines is the commonest intervention used in the care of patients.
Information about the use of medicines by an individual over their lifetime, managed
as a coherent whole but presented as appropriate to particular contexts, is central to
providing good quality care.
Considerable investment continues to be made in specifying and implementing the
information structures underpinning electronic health systems to provide clinicians
with patient information to support their care provision, yet medication errors
continue to occur at rates that are not reducing.
At the same time, the quantity of healthcare information — which includes medication
information – is increasing, and there is growing interest in “secondary uses” of such
data, one of the largest of which is to support clinical research.    Unfortunately, for
both primary and secondary uses, the requirements for the actual data elements that
are needed for medication information are poorly specified, despite a variety of major
national and international initiatives.  The process for populating those data elements
with high quality, consistent, trustworthy information that can be presented efficiently
and clearly in order to service those use cases is even more poorly specified.
By gathering requirements from processes within clinical research and within patient
care alongside each other rather than separately, it is possible to generate an
integrated data element view of how a patient’s medication use over their lifetime
should be described and presented to support high quality patient care and clinical
research; this is termed the patient’s Medication Profile.
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Examination of the care processes that can provide the data to populate that
integrated view elicits the method and rules for the realisation of the Medication
Profile.
Layered formal information models are used to support the description of the data
elements of the Medication Profile (the static model) and the description of the
processes and rules to instantiate that model with data (the dynamic model).
These models are then evaluated against test scenarios to assess their success in
describing and presenting a patient’s Medication Profile to support both clinical care
and clinical research.
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Appendix 3: Evaluation coding example
Emergency Medication Supply Use Case
Question: Do you think there is enough information in the Medication Profile to
support Dr McMaster’s conclusions about Winston’s asthma in the past?
Verbatim:
I think that based on this information, you can conclude that Winston has asthma at
the time he used these medicines: these medicines are used for asthma and for
COPD, but regarding his age it is reasonable to conclude he has asthma. So I think
for the conclusion about his disease in the past this information is rather sufficient.
Although you preferably do not want to derive that from medication, but based on an
indication (e.g. ICPC or SNOMED code) in the EHR.
Coded as: “sufficient information provided” and “indication would be helpful” based
on highlighted words or phrases in the verbatim
Question: Is it correct to display no current medications for Winston in the
Medication Profile?
Verbatim:
Questionable.  An absolute answer depends on the formal definition of Current
Medications and on the presumption of how ubiquitous the clinical professions’
understanding of that definition is i.e. is the understanding of such definitions an
absolute requirement for being deemed competent to practice in an eHealth enabled
health care system?
If the system is able to reliably and repeatably infer Winston’s concordance based
on a health system wide reconciliation of prescribing and dispensing dates then
displaying “Patient’s behavioural current medications” can be considered correct.  If
the system cannot reliably and repeatably infer that concordance then the only view
that can be inferred is “Caring clinicians’ perceived current medications”.  Perhaps
both interpretations require explicit definition as separate parts of the data element.
Coded as: “agreed definition of ‘current’ needed” and “how to record/display/infer
compliance” based on highlighted words or phrases in the verbatim
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Appendix 4: The NHS Dose Syntax
Introduction
What is the “Dose Syntax”?
Whenever a medicine is used (prescribed, dispensed or administered) to provide
healthcare for a patient or group of patients, or reference to a medicine is made in
the care of patients, it is likely that there will information about the dosage of the
medicine.
This dosage information, which has been described as the “Dose Instruction” is
defined as “the full set of information that supports the correct administration of a
medication to a patient in order for it to have its therapeutic effect”.  Within this set of
information, there are a variety of different concepts represented, such as the
amount of medication to be administered, the frequency with which it is to be
administered etc.
In this era of distributed healthcare, with many different individuals and teams of
clinicians being involved in the care of a patient, it is vital that, as well as being able
to clearly and unambiguously describe the medicines themselves, there is a
requirement to clearly and unambiguously describe the Dose Instructions that
accompany the medicine in its use.  This is a requirement both for human
communication, and for electronic (machine-to-machine) communication and
information storage and retrieval.
In order to facilitate this communication, an Analysis of Dose Instructions was
undertaken, covering all domains (primary, secondary, tertiary care) in which
medications are used, including the core clinical specialties that have particular
dosage information requirements (chemotherapy, child health, anaesthesiology,
etc.).  The objective was to identify, define and describe the various concepts that
are used in Dose Instructions, to facilitate the clear and unambiguous description of
how a medicine is/was/should be administered, for all stages of the medication
process (prescribing, dispensing and administration).
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The Dose Syntax Model
Dose Instructions
A Dose Instruction is defined as “the full set of information that supports the correct
administration of a medication to a patient in order for it to have its therapeutic effect”.
Within this set of information, there are a variety of different concepts represented,
such as the amount of medication to be administered, the frequency with which it is
to be administered etc.  These are termed the component parts of the instruction,
and they themselves may have attributes, or sub-types, within them.
A single “dose instruction” may be complex, and therefore may be split into a number
of separate Dosage Instruction Clauses: each clause can then be split into its
Dose Instruction Components parts for further structuring.  The structured clauses
can be concatenated together again, using a mechanism to put the clauses and their
cd Simplified Class Model (informal data types)
DoseInstructions
DoseInstructionClause
+ sequence() : sequenceNumber
+ conjunction() : codedValue
Dose Quantity
+ value and units() : value (range)
+ value and units per() : value (range)
Dose Timing Route Site
Method
Additional Instruction
+ text() : string
+ value() : coded vocab
Device
+ text() : string
+ value() : coded vocab
Route of Administration
+ text() : string
+ value() : coded vocab
Site of Administration
+ text() : string
+ value() : coded vocab
Method of
Administration
+ text() : string
+ value() : coded vocab
Dose Quantiy Upper Bound
+ duration and units() : time (range)
+ quantity and units() : value (range)
Individual Dose
Timing
Course of
Therapy
Frequency Duration
Measured Time
+ point in time() : time
+ regularPattern value and units() : value (range)
+ regularPattern value and units per() : value (range)
Circumstantial TIme
+ text() : string
+ value() : coded vocab
Timing Pattern
Timing Description
Rate
+ value and units() : value (range)
+ value and units per() : value (range)
Objectives and Goals
+ text() : string
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0..1
0..1
0..1
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component structures together in the right order, to reproduce accurately the totality
of the information of the be a mechanism to put the clauses and their components
together in the right order instructions.
Dose Instructions Clause
A Dose Instructions Clause is a single statement that stands “on its own” to describe
a single set of dosage instruction information; it will contain a number of component
parts.  A single Dose Instructions Clause may form the complete Dose Instruction,
or two or more Dose Instruction Clauses may be concatenated together to give the
complete Dose Instruction, using Sequence Indication to ensure that the Clauses
are brought together in the correct order.
A Dose Instructions Clause that has a relationship to another Dose Instructions
Clause will have a Conjunction (“or”, “then” or “and”) and, if it is part of a sequence
(“then”) it will have an indication of where in that sequence it occurs.
Dose Instructions Components
Within any Dose Instructions Clause, the information contained within the Clause
can be divided into Component parts.  These Component parts form a finite set of
concepts, and are described in the sections below.  Rarely will all the Components
be present in even a complex Dose Instruction, but some, such as Dose Quantity,
are present in the majority of Dose Instructions.  Some Components have been
further sub-divided into sub-components or attributes of the particular component.
Dose Quantity
The Dose Quantity in a Dose Instruction or Dose Instruction Clause is the “amount”
of the described medication that is to be administered to the patient at a single point
in time (i.e. a single dosage administration act, which may itself be a Dose
Instructions Clause).
A Dose Quantity is usually expressed as a numerical value and an explicit unit of
measure; however sometimes the unit of measure is implicit (e.g. the “one” in “one
to be taken three times a day” is actually “one tablet” [or one capsule etc.]).   Note
that the expression of Dose Quantity value may be a range: e.g. “2-6 tablets”, “100-
200mg”, “one to two puffs”.
Note that the expression of some Dose Quantity information is such that it may
appear to be a “dose limit”; this should not be confused with the “Quantity Upper
Bound” as described below.  For example the statement of “up to three tablets” is
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actually a Dose Quantity range of “1-3 tablets”; it is describing the acceptable range
of the dose quantity for a single administration.
It is vital that the Dose Quantity component has consistency with the description of
the medicine to which it relates.  This is discussed in detail below.
Examples of Dose Quantity:
one tablet
two puffs (actuations)
25 - 50mg
one 5mL spoonful
750microgram/kg bodyweight
Dose Quantity Upper Bound
The Dose Quantity Upper Bound in a Dose Instruction or Dose Instruction Clause
describes the upper limit of the amount of a medicine that may be given in a specified
period of time; it is usually used when there is some degree of optionality in how the
medicine may be administered.
A common expression of Dose Instruction information that uses this Component in
its type/pattern is: “Take two tablets every 4-6 hours when required, to a maximum
of eight per day”.  The “eight tablets per day” is the Dose Quantity Upper Bound.
The Dose Quantity Upper Bound therefore has two distinct parts: the total amount
(dose quantity) of medicine that forms the limit or “upper bound” and the time period
that the amount can be administered in.  A Dose Instructions Clause may
occasionally have more than one Dose Quantity Upper Bound; if this is the case,
they will be stating the maximum cumulative dose for different periods of time, for
example: “maximum of 20mg in 24 hours, and 100mg in one week”.
Note: Conceptually it would be possible to specify a “lower bound dose quantity”
(for example: take a minimum of 300mg per day), however, in analysis, no actual
examples of this type of instruction have yet been found.
Examples of Dose Quantity Upper Bound:
Up to 6 tablets in 24 hours
No more than four sprays in one hour
Maximum of 500mg per day
Maximum of 250mg in one week
To a lifetime limit of 100microgram/kg bodyweight
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Dose Timing
The Dose Timing in a Dose Instruction or Dose Instructions Clause describes
“when” the medication is to be administered to the patient.
Description of “Timing” of medicines administration is possibly the most complex of
all the components of Dose Instructions.  In order to be comprehensive of the full
range of variables, such that as much information as is possible could be made
machine processable if required, it is necessary to analyse and document fully each
type of “Timing” description separately, even though these are often concatenated
and flow easily in human speech as if they are seamlessly one.  It is likely that, in
actual applications, some types of Timing information will be designated as too
complex to replicate fully in a machine readable way and therefore should continue
to be communicated only through text.  This is a legitimate decision, but it must be
made with full understanding of what is being set within any machine readable
boundary, and what is outside.  This understanding can only be obtained if the full
analysis is documented.
There are three paradigms to be considered in the understanding of the timing of
medicines administration: the “what is being timed”, which may be “individual dose
timing” or “course of therapy”, the type of “time pattern” – the “when” and “how long”
- being described, and the “timing description” being used to describe the actual time
information, which may be “measured time” or “circumstantial time”.
What is being timed: “Course of Therapy” Timing and “Individual Dose” Timing
When a medicine is used to provide healthcare to a patient, as a “therapy” (a
treatment, a patient management intervention), the medicine may be administered
once (only), or it may be administered a number of times, which may be either a
limited number of times, or it may be ad infinitum.  There is therefore a requirement
to describe the Timing of this “Course of Therapy”.
Similarly, there is a requirement to describe the Timing of each time a medicinal
product is administered, within a Course of Therapy; with is the Individual Dose
Timing; for example, a diuretic given regularly to treat hypertension is given “once
daily, in the morning” where the “once daily” is the Timing of each Individual Dose.
A single “one off” administration of a medication (such as an infusion of
streptokinase, or a pre-medication), in terms of this analysis, could be considered to
have a “course of therapy” component, but, because it is only a single administration,
its description is identical to the description of its individual dose timing.
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A Note on Vaccination: Vaccines are usually administered according to an agreed
schedule, with the Frequency of Individual Dose Timing being anything from one
month to 5-10 years.  It is a matter for national (public health) consideration to
determine how to describe each schedule, and it is important to have consistently
represented information for public health management.  For example: it is possible
to describe the course of therapy for the “triple” of diphtheria, tetanus and pertussis
as the initial three doses given at monthly intervals from age 2 months, with the pre-
school and school-leaving boosters being described as separate individual doses
and courses, or alternatively the full 18 year schedule be considered the course of
therapy.
Time Patterns: When and How Long - Frequency and Duration
For each of the Course of Therapy and the Individual Dose, there are two types of
Time Patterns that can be used to describe their timing; these may be used
separately or together, and are “Timing Frequency” and “Duration”.
Timing Frequency describes when the individual dose or course of therapy occurs,
Timing Duration describes for how long the individual dose or course of therapy
takes.
Timing Frequency, particularly for a series individual dosage administrations, may
be described using a timing pattern; for example, an instruction of “twice a day”
describes individual dosage administrations as happening “two times within a 24
hour period”, or “every 8 hours”, or at a specific time or times: “at 2pm and 6pm”.
However, for a single, non-repeating administration, the timing frequency may be a
single point in time, for example “at 8am” or “stat” or “2 hours before surgery”.
Timing Duration can be used both for an individual dose and for a course of therapy;
for individual doses, it is usually only relevant for infusion or nebulisation, most other
administrations are taken to be instantaneous; for example in the Dose Instructions
Clause “give 500mg over 15minutes every 6 hours” the “over 15 minutes” is the
duration of each individual dose of 500mg given.  Timing Duration is more commonly
used in description of Course of Therapy; for example the “for five days” of an
instruction “take two daily for 5 days”.
Timing Description: Measurable Time and Circumstantial Time
The nature of the timing of medicines administration may be described in relation to
“measurable time” in some way or another.  This may be described by reference to
a distinct point or points in time either within an unspecified day (e.g. at 6pm) or in a
partially specified day (e.g. at 6pm tomorrow) or within a fully specified day (e.g. at
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6pm on 14.2.2005).  Measurable time may also be specified in terms of patterns of
measurable time, as in “three times [within] a day”, in which “a day” is a pattern of
measurable time, i.e. 24 hours, or as “every 8 hours”.  Note that, for Dose
Instructions, most time patterns involve a 24 hour day, but weekly, monthly and
annual patterns are described; indeed, for vaccination, longer patterns (e.g. every 5-
10 years) may be described using this same method.
Alternatively, the “when” of medicines administration might be described in relation
to conditions or events or circumstances that will, have or do occur, and that form a
trigger to start, stop or in some other sense have influence over when a medicine is
administered.  For example: “starting one week before travel” – the event is that is
the timing trigger for medicines administration is “travelling” and the medicine
administration must commence one week before that event occurs.
In any one Dose Instruction or Dose Instructions Clause, the various components of
Dose Timing (individual dose or course of therapy; frequency or duration) may be
described using measurable time description, using circumstantial time description
or using a combination of the two.
Types or Patterns of Circumstantial Time
There are various types or patterns of Circumstantial Time used in the description of
Dose Timing that can be recognised and described.
Preconditions
A Precondition describes when an event will or will not occur, in relation to the
presence of a particular circumstance or event.  There is therefore an absolute
dependency on a certain event or activity or clinical condition occurring or taking
place to describe the “when” (either Frequency or Duration) of an Individual Dose or
Course of Therapy.
Many of the Individual Dose Frequency statements that use the Circumstantial Time
pattern of precondition are descriptions of clinical conditions that the medicines
administration is being used therapeutically for.  For example: “take two tablets to
relieve fever” implies that the medicine will only be administered if there is the
“precondition” of fever being present.  In these cases, the Precondition may “qualify”
(that is, be stated in addition to) a Dose Timing described using Measured Time.  For
example: “Give one tablet once daily, if the pulse rate is above 80 beats per minute”
states that that the medication must only be given at its Measured Time Frequency
of “once daily” when the Circumstantial Time clinical precondition of the patient
having “a measured pulse with a value of greater than 80 beats per minute” is met.
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A Precondition may have a Measured Time phrase within it, but that Measured Time
phrase does not describe either a Frequency or Duration but a “time interval”
between the precondition and the administration.  For example “Give two hours
before the procedure” is an Individual Dose Frequency described using the
Circumstantial Time pattern of precondition, whereby the medicines administration
has “the procedure (happening)” as the precondition, and the “time interval” being
“two hours before”.
Trigger Conditions
A Trigger describes when an administration may occur, in relation to the presence
of a particular circumstance or event.  In contrast to the “Precondition”, which
describes how the Dose Timing is controlled by the precondition, the “Trigger” allows
some optionality to be present.   Because the condition or event is a trigger that
“allows” rather than “requires” the medicine administration, it is often expressed with
the words “if” or “when” and therefore includes some very common instructions, such
as “Take two tablets every four to six hourly, when required for pain relief” as well as
rarer more complex examples.
Comment: There is a considerable element of judgement required to discern
whether a particular dosage phrase constitutes a precondition or a trigger.  A
precondition is “tighter” in that it “requires” the administration to start/stop/continue if
the related observation it is true, whereas the trigger is “allowing” the administration
to start/stop/continue if the related observation it is true.  Whether clinicians, patients
and systems can or should be able to truly differentiate this difference in clinical
practice is as yet unclear for dosage information.
Examples of Dose Timing Components:
Measured Time Examples:
Individual Dose Timing:
Frequency:
every 6 hours [q 6 h]
three times a day [t.d.s]
daily
twice a week
every 4-6 hours (frequency range)
not less than every 8 hours (minimum value of frequency range only)
up to four times a day (maximum value of frequency range only)
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Duration:
give 500mg over 30 minutes every 6 hours
30mg via syringe driver over 12 hours
mix into a bath of warm water and immerse body for 30 minutes
Course of Therapy Timing:
Frequency:
apply twice daily for 1 week; repeat at monthly intervals
one daily for the first 5 days of each month
Duration:
one to be taken three times a day for 5 days
apply sparingly for 7-10 days
take twice daily for 2 months
Circumstantial Time Examples:
Individual Dose Timing:
Frequency:
after each loose stool
before each nappy change
before sexual intercourse
when the cytotoxic infusion has been completed
Duration:
for the duration of each dressing change
Course of Therapy Timing:
Frequency:
for each acute attack of gout
Duration:
from one week before until four weeks after travelling
during an acute attack of gout
take one every 4 hours, for up to 10 doses
(although the Course of Therapy Duration could be
calculated as a Measured Time value, using the Measured Time information,
but described as it is, the Duration is bounded by “a number of doses having
been taken, which constitute the “circumstances” of the duration)
Combinations of Timing Descriptions:
Give one tablet once daily, if the pulse rate is above 80 beats per minute
(precondition on Individual Dose Frequency)
Inject 5mg subcutaneously every 6 hours when required to relieve migraine
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Objectives and Goals
The Objectives and Goals information in a Dose Instruction or Dose Instruction
Clause describes the Objective or Goal of that particular Dose Instruction or Dose
Instruction Clause.  The Objective or Goal information may relate to any of the other
components of the Dose Instruction Clause, but common patterns relate the
Objective or Goal to the Dose Quantity, Rate of Administration and/or the Dose
Timing components.
There are two distinct patterns for Objective and Goal information in Dose
Instructions; these are Maintenance Objective and Final Objective.
Maintenance Objective
A Maintenance Objective in a Dose Instructions Clause describes a requirement to
(achieve and) maintain a particular circumstance or condition.  There will be some
optionality in Dose Quantity, Rate of Administration or Dose Timing (usually a range
value in one of these components) and the Maintenance Objective gives the criteria
that should be used to determine the actual value of the component from within the
range.  For example, in the Dose Instructions Clause “Infuse 2-5micrograms/kg/min
to maintain systolic blood pressure at greater than 70mmHg” there is a range value
for the Rate of Administration component, with a Maintenance Objective stated as
“to maintain systolic blood pressure at greater than 70mmHg”; therefore the
instruction is to adjust the Rate of Administration within the stated range in order to
maintain the systolic blood pressure at a level that is greater than 70mmHg.
Final Objective
A Final Objective describes in a Dose Instructions Clause describes a requirement
to achieve a particular circumstance or condition, (at which point the administration
may cease).  There will be some optionality in Dose Quantity, Rate of Administration
or Dose Timing (usually a range value in one of these components) and the Final
Objective gives the criteria that should be used to determine the actual value of the
component from within the range.   For example, in the Dose Instructions Clause
“Take one tablet every morning until the bleeding stops” there is an implicit statement
about the Duration of the Course of Therapy (a Dose Timing component) in that the
therapy should continue “until the bleeding stops”; therefore the “Final Objective” is
“the bleeding stops”.
Examples of Objectives and Goals:
Maintenance Objective:
Dose Quantity:
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Give 1-4mg daily to keep the INR between 3-4
Rate of Administration:
Inhale at a rate of 1.5-4 litres/minute to maintain adequate peripheral
oxygenation
Dose Timing:
Inhale one puff up to six times a day to control the wheezing
Final Objective:
Dose Quantity:
Take 10-25mg four times a day until there is no breakthrough pain
Rate of Administration:
Infuse 100-250ml/hour until urine output is greater than 50ml/hour
The Route-Site-Method Complex
The “Route-Site-Method Complex” describes the “where” and “how” the prescribed
medication is to be administered to the patient.
In order to have its desired therapeutic effect, an allopathic medicine must in some
way come into contact with some or all of the body of the patient.  The Route-Site-
Method Complex component of a Dose Instruction or Dose Instructions Clause
describe the route into the body, where on the body the medicine makes it
entry/contact and/or the method of administration to be used.  This allows the
prescriber to give specific direction to the patient and/or parent/carer/healthcare
professional about “where” or “how” to administer their prescribed medication.
The Route-Site-Method Complex is can be further decomposed into the three
separate components of Route of Administration, Site of Administration and Method
of Administration; in any one Dose Instructions or Dose Instructions Clause, all, one,
two or none of the components may be used dependent on the medication
prescribed and the intent of the prescriber.
Examples of the Route-Site-Method Complex:
One tablet three times daily (none)
Inject (method) 100mg/5mL IV (route = intravenous)
Apply to the affected area (site) with gentle massage (site = “affected area”
and method = apply with gentle massage)
Instil (method) two drops into the left eye (site) twice a day
Inhale (method) two puffs four times a day
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Route of Administration
The Route of Administration describes which way that the administered medication
should take to get into the body or into contact with the body and constitutes part of
the “where” (the other part being site – see below).
There should be no implication that a route of administration is or can be taken as
synonymous with a description of the “final destination” for an administered
medication; the route of administration can only be a stylised description of the path
taken.
For example, an oral antibiotic may be used to treat a severe infection on a toe; the
oral route is used to get the medicine to be able to reach and treat the infection in
the toe.  For some specific routes of administration, there may be an incidental sense
of “final destination”, for example an ocular administration usually occurs when
treatment of an eye condition is required.  Note that this can in no sense be taken as
definitional: rectal administration of a medicine may be for a local effect (a steroid
foam for treatment of colitis) or for a systemic effect (metronidazole for treatment of
infection).  The route of administration of a medicine should only be a description of
the path taken; the end may or may not be implied.
Examples of routes of administration include: “oral”, “rectal”, “ocular”, “intravenous
(IV)”, “subcutaneous (SC)”.
Site of Administration
The Site of Administration describes the specific area of the body “where” the
medication is to be administered. The site can be seen as the particular anatomic
location where an administration activity happens (or has happened). It can be stated
specifically, for example including laterality (e.g. apply to the right eye; inject into the
left antecubital fossa vein) or stated more generally (e.g. apply to the affected
area(s)).
Site of Administration is a distinct and separate concept to Route of Administration,
Route of Administration being the “way in” to the body and the site the specific area
in/on the body where the “way in” is located.  In some Dose Instructions or Dose
Instructions Clauses, if the Site of Administration has been stated very explicitly, the
Route of Administration may be being implied rather than explicitly stated itself.  For
example, a Dose Instructions Clause that states “instil one drop into the right eye
twice a day” has a Site of Administration of “the right eye” which implicitly indicates
an ocular Route of Administration.
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Just as the Route of Administration is a description of the “path taken” and carried
no implication as to the sense of a description of a “final destination”; so the Site of
Administration is a description of where the administration happens, not the site of
action of the medication; although as for route, there are some examples where the
site of administration is also a description of the site of action (for example,
administration to the right ear is likely to imply a site of action in the right ear).
Method of Administration
The Method of Administration gives further information as to “how” the medication
should be administered.  A “method” can be defined as “a regular and systematic
way of accomplishing something”.  The “Method of Administration” is therefore the
particular way of carrying out or accomplishing a substance administration, in that it
further defines the process of the medication is to be administered to the patient,
whether that is by the patient or by the parent/carer/healthcare professional.
Method description is often an adjective that directly refines the action giving more
specific information as to “how” the prescriber intends that medication to be
administered; it can be also have a further qualifying description added to the original
method in order to fully define the exact method of administration required; for
example: “apply with gentle massage”.
In Secondary Care, standard charted dosage instructions do not usually have the
“method” concept made explicit.  However, if a dosage instruction is “written” as
opposed to the more common “charting”, there may be a method stated.  For
specialist parenteral administration, it is more common to have some “method”
information expressed, even if this is written as an annotation to a standard chart.
Method Qualifiers: As seen in the descriptions above, the Method of Administration
may be described or “qualified” by further information that gives more detail about
the administration; a method of administration is “application” (“apply” or “to be
applied”); this can be further qualified by various adverbs (liberally, sparingly, gently)
as required by the situation.  Due to the limited size of the vocabulary, however, pre-
co-ordinated concepts (“apply sparingly”, “inject using piggyback”) are used.
Rate of Administration
The Rate of Administration describes information about the “delivery speed” with
which a specified amount of a medication should be administered to a patient per
unit of time.  It is applicable for “continuous” medications only (e.g. liquids, inhaled
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gases etc.) since an instantaneous administration does not exist for long enough for
it to have a measurable speed at which it is given.
Certain medications, most notably parenteral infusions, may be given continuously
over an extended period of time.  The rate at which the medication is to be
administered may be specified as an alternative to a Dose Quantity and Timing, and
is usually used because the exact Dose Quantity to be given and/or duration of the
administration is not known.
Examples of Rate of Administration:
(to be given at) 2litres/minute
(to be given at) 5micrograms/kg/minute
(to be given at) 50ml/hour
Device Use Instructions
Device Use Instructions describe information about administration of a medicine that
involves the use of a device.
A number of medicines require their administration to the patient to be assisted by
the use of some kind of administration device.  This “device use” information is often
communicated as part of the Dose Instructions or in a Dose Instructions Clause.
In secondary care, particular named devices may be described as part of a dosage
instruction; for example, administration of a particular medication via one specific
lumen of a triple lumen sub-clavian catheter, or administration of an antibiotic through
a Hickman line.
This component must not be used for “recipe” information for extemporaneously
prepared medicines.
Examples of Device Use Instructions:
Via the nebuliser
Using the vaginal applicator
Additional Instructions/Information
The Additional Instructions/Information component of a Dose Instructions Clause
describes any other additional instructive information about the administration of the
medicine; it is usually non-quantitative in its nature.  It excludes any phrases relating
to use of a device in the administration of a medicine, to a “recipe” for
extemporaneous preparation of the medicine or to the active method of
administration of the medication.
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Additional Information/Instructions may give “negative” instructions or information,
for example “do not take at the same time as milk or antacids”.
Some Dose Instructions and Dose Instruction Clauses contain phrases of instructive
information, additional to the defined Dose Quantity, Dose Quantity Upper Bound,
Dose Timing, Objectives and Goals Information, Route-Site-Method Complex and
Device Use Instructions concepts.
Preparation Instructions form a particular subset of Additional
Instructions/Information.   A number of medicines require some form of manipulation
prior to their administration to the patient; this may be some form of preparation
instruction such as dissolution or shaking/agitation of a mixture.
Preparation Instructions:
Preparation Instructions describe manipulation of the medicine prior to its
administration, but the preparation is such that it does not affect the expression of
the quantity of the medication administered (for example the “dissolved in water”
manipulation does not affect the “two tablets” quantity of a dosage instruction that
reads “Take two tablets, dissolved in water, every morning”).
Examples of Additional Instructions/Information:
“as instructed on the pack”
“titrate according to response”
“with or after meals”
“do not take with milk”
“avoid alcohol while taking this medicine”
“dissolved in water”
“shaken well before use”
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